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Abstract 
Background 
Visual hallucinations occur in 70-90% of patients with dementia with Lewy bodies 
(DLB) and are related to decreased quality of life for patients. However, the 
underlying neuropathological changes that promote the manifestation of visual 
hallucinations in DLB are not known. Several hypotheses of visual hallucinations in 
DLB have either directly implicated the lateral geniculate nucleus (LGN), pulvinar and 
superior colliculus or suggested impairments in their putative functions.  
 
Methods 
Post-mortem LGN, pulvinar and superior colliculus tissue was obtained from DLB 
cases with a clinical history of visual hallucinations and compared to cognitively 
normal control and Alzheimer’s disease (AD) cases without visual hallucinations. 
Neuropathological lesions were quantified in individual cases using densitometry and 
neuronal and glial cell populations were quantified with stereology. RNA sequencing 
and subsequent bioinformatics analysis of biological pathway alterations was 
performed by a collaborator on pulvinar tissue from DLB and non-hallucinating 
control cases. The bioinformatics data was used to identify protein targets based on 
pathway alterations, which were then investigated using western blot analysis. 
 
Results 
Lewy body pathology and neuronal loss was specifically found in the pulvinar and 
superior colliculus of DLB cases, particularly in regions implicated in visual attention 
and target selection. In contrast, AD cases had more widespread degenerative 
changes. Molecular analysis of the pulvinar demonstrated reduced expression of 
several synaptic markers, concomitant with elevated expression of several astrocytic 
markers in DLB.  
 
Conclusion 
ii 
 
The relative specificity of changes in visual thalamic regions may contribute to the 
occurrence of visual hallucinations in DLB. Synaptic degeneration in the pulvinar 
likely further impedes visual attentional function in DLB. The present results may 
indicate DLB patients have impairments in directing visual attention to external stimuli, 
thus facilitating visual hallucinations by an over-reliance upon expectations and 
experience rather than stimulus-driven perception.  
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Chapter 1: Introduction 
1.1 Dementia 
People are living longer than at any previous point in human history, contributing to 
sustained global population ageing. According to the United Nations, there were 205 
million people aged over 60 years old in 1950. In 2009, this number had risen to 737 
million, and is projected to rise to up to 2 billion by 2050 (United Nations. Department 
of, 2010). The global elderly population is increasing, and will surpass child and 
adolescent numbers by 2045 (Sosa-Ortiz et al., 2012). As a result of this 
demographic shift, diseases for which increasing age is the greatest risk factor are 
expected to rise.   
Dementia refers to a group of conditions characterised by the progressive and 
irreversible decline in cognitive functions, with a corresponding impact upon 
autonomous living (American Psychiatric, 2013). Dementia can result from one of 
several conditions, including Alzheimer’s disease (AD), vascular dementia (VaD) and 
dementia with Lewy bodies (DLB), the primary focus of this project. Dementia 
disorders increase in incidence and prevalence with advancing age (World Health, 
2012). Global population ageing has contributed to an increased number of people 
diagnosed with dementia. In 2010 there were 36 million people living with dementia 
worldwide, by 2013 this rose to 44 million and is projected to reach 76 million by 
2030 (Prince et al., 2013). The rise in the global incidence and prevalence of 
dementia disorders has contributed to an increased financial burden on health 
services, as well as social costs to family members, who often provide care without 
financial compensation (Hurd et al., 2013; DaDalt and Coughlin, 2016).  
 
1.1.1. Epidemiology 
In higher-income countries, dementia occurs in 5-10% of those aged over 65 years 
old and the incidence of dementia increases with advancing age (Hugo and Ganguli, 
2014), ranging from 0.1% at 65 to 8.6% at 95 of age (Jorm and Jolley, 1998). 
Although prevalence is higher amongst females, incidence is not, suggesting that 
higher prevalence reflects longer life expectancy amongst females (Hugo and 
Ganguli, 2014). Clinically and pathologically, AD is the most prevalent form of 
dementia, accounting for 60-70% of all dementia cases (Jellinger et al., 1990; 
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Neuropathology Group. Medical Research Council Cognitive and Aging, 2001; 
Plassman et al., 2007). 
DLB is the second most prevalent primary degenerative dementia after AD 
(Heidebrink, 2002). The incidence of DLB is 3.8% of new dementia cases and its 
prevalence is 4.2% of dementia diagnoses in the community, 7.5% in secondary 
care (Vann Jones and O'Brien, 2014), and further increases up to three-fold when 
‘possible DLB’ is included (Boot, 2013). A prevalence study in 40 Swedish nursing 
homes found that 16% of residents had two or more core symptoms of DLB 
(Zahirovic et al., 2016). At autopsy, DLB accounts for 20% of all dementia cases 
suggesting an over-representation at autopsy or clinical under-diagnosis (McKeith, 
2000). DLB may be initially clinically under-recognised as it is characterised by motor 
and cognitive impairments, meaning patients can initially present to different medical 
specialists. DLB patients may, for example, be treated by a neurologist for motor 
symptoms or a dementia specialist (psychiatrist or geriatrician) for the cognitive 
aspects of the disorder. The medical specialist to whom DLB patients first present 
may influence their diagnosis as neurologists are more likely to underestimate the 
presence of dementia in patients with movement disorders (Hely et al., 2008), with 
dementia specialists often under-recognising motor features (Schneider et al., 2007).  
 
1.2 Dementia with Lewy bodies 
1.2.1 Overview of clinical diagnostic criteria for DLB 
DLB is characterised by three core clinical features: cognitive fluctuations, 
parkinsonism and visual hallucinations, in the presence of progressive cognitive 
decline (McKeith, 2006). Additionally, several suggestive and supportive features 
can aid clinical diagnosis of DLB. A diagnosis of ‘probable DLB’ may be made if two 
or more core features, or one core feature plus a suggestive feature, are present. 
‘Possible DLB’ may be diagnosed if one core or suggestive feature is present in 
isolation. Probable DLB cannot be diagnosed on the basis of suggestive features 
alone (McKeith et al., 2005). The consensus diagnostic criteria have high levels of 
specificity for DLB (~95%), but lower levels of sensitivity (32-83%) (McKeith et al., 
2000; Nelson et al., 2010).  
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1.2.2 Core clinical features of DLB 
Cognitive fluctuations are a core symptom of DLB and are defined as variations in 
cognitive ability and alertness over time (McKeith et al., 2004). This may be 
observed as changes in responsiveness to an individual’s surroundings, marked by 
periods of reduced attentiveness or awareness to external stimuli (McKeith, 2006).  
The fluctuating nature of this phenomenon means that the individual experiences 
transient periods of normal, or near-normal, functioning (McKeith et al., 1996). 
Although cognitive fluctuations may also occur in AD and VaD they tend to occur in 
more severe dementia, whilst DLB patients show the greatest variations in attention, 
independent of dementia severity and parkinsonism (Walker et al., 2000b). DLB 
patients typically have spontaneous episodes of interruptions in awareness or 
attention whilst AD patients describe difficulties in dealing with the cognitive 
demands of their situation (Bradshaw et al., 2004). Ratings of cognitive fluctuations 
based on clinician impression are also higher in DLB compared to AD patients 
(Walker et al., 2012). DLB patients have impaired performance on cognitive reaction 
time tasks, identified as predictors of other measures of cognitive fluctuations 
(Walker et al., 2000a), in comparison to AD, Parkinson’s disease (PD) and older 
cognitively normal individuals (Ballard et al., 2002).  
Parkinsonian extra-pyramidal symptoms also represent a core symptom of DLB and 
consist of slowness of movement (bradykinesia), tremor in the absence of voluntary 
muscle contraction (rest tremor), mask-like face, rigidity, stooped posture and 
shuffling gait (McKeith et al., 2005). Parkinsonian signs are the predominant clinical 
features of PD (Gibb and Lees, 1988) and occur in approximately 68% of DLB 
patients (Aarsland et al., 2001). The phenotypic similarities between PD and DLB 
likely result from both being pathologically characterised by the intracytoplasmic 
aggregation of the protein α-synuclein into deposits termed Lewy bodies within 
vulnerable neurons (Spillantini et al., 1997; Attems et al., 2013). PD dementia is 
differentiated from DLB on the basis of motor symptoms preceding cognitive 
symptoms by one year or more (McKeith, 2006), though this arbitrary distinction has 
been challenged (Berg et al., 2014). However, DLB patients may have subtle 
differences in motor symptoms, specifically less rest tremor and more rigidity than 
PD patients (Gnanalingham et al., 1997). PDD patients have more severe motor 
symptoms than DLB, as assessed by Hoehn and Yahr staging, a clinical rating scale 
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of the severity of parkinsonian features (Petrova et al., 2015). Another study has 
found greater rigidity, gait impairment, bradykinesia and tremor during voluntary 
muscle contraction (action tremor) but no difference in rest tremor or abnormal 
posture in DLB compared to PD cases (Aarsland et al., 2001). Overall, DLB cases 
have a motor phenotype where gait and postural difficulties, rather than tremor, are 
the most prominent features (Burn et al., 2003). Gait and postural predominant motor 
phenotypes in DLB indicate involvement of non-dopaminergic neurotransmitter loss 
in motor impairment, with cholinergic loss implicated (Burn et al., 2003; Burn et al., 
2006). AD patients can also experience parkinsonian symptoms. However, 
neuropathological examination has shown AD cases with extrapyramidal features 
more frequently have pathological similarities to PD and DLB than those who do not 
(Tosto et al., 2015). Motor symptoms in DLB may contribute to the greater functional 
impairment found in DLB compared to AD patients (McKeith et al., 2006).   
A third core clinical feature of DLB is recurrent complex visual hallucinations which 
occur in 60-80% of patients (Burghaus et al., 2012). Whilst visual hallucinations are 
sometimes found in other neurodegenerative disorders, such as AD and PD, they 
are more prevalent (Ballard et al., 1997; Fenelon et al., 2000), appear earlier 
(Fenelon et al., 2000), are more severe (Chiu et al., 2016), and are more likely to 
persist over time (Ballard et al., 1997) in DLB. Hallucinations in DLB patients are 
typically complex, involving objects, such as people, animals, insects or disembodied 
faces, whilst in AD they are simple and brief, such as seeing shadows (Mosimann et 
al., 2006). There may be gender differences in the content of hallucinations, with 
men more likely to hallucinate machines, and women more likely to hallucinate family 
members or children (Urwyler et al., 2016). Hallucinations may be frightening 
(Burghaus et al., 2012) and DLB patients have less insight into the unreality of these 
perceptions compared to non-demented PD patients (Bertram and Williams, 2012). If 
they hallucinate, DLB and AD patients have a similar level of reduced insight into the 
unreality of their perceptions (Ballard et al., 1997). Hallucinations in DLB are related 
to decreased quality of life and are associated with higher rates of institutionalisation 
(Bostrom et al., 2007). Additionally, visual hallucinations contribute to increased 
distress amongst caregivers of DLB patients (Ricci et al., 2009). Other visual 
symptoms, such as abnormalities in saccadic and pursuit eye movements, pupil 
reactivity and visual perception are also frequently observed in DLB (Armstrong, 
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2012), and may result from shared visual system pathology with that inducing visual 
hallucinations (Diederich et al., 2014). Despite the prevalence and impact of visual 
hallucinations on DLB patients, the underlying pathological changes promoting their 
occurrence are unknown (Diederich et al., 2014), thus limiting the development of 
targeted treatments. 
 
1.2.3 Suggestive clinical features of DLB  
In addition to the three core features, rapid eye movement (REM) sleep behaviour 
disorder, neuroleptic sensitivity and low dopamine transporter uptake in the basal 
ganglia on single-photon emission computerised tomography (SPECT) or positron 
emission tomography (PET) are considered suggestive symptoms of DLB (McKeith 
et al., 2005). 
REM sleep behaviour disorder is characterised by an individual abnormally acting 
out dreams by vocalising and moving, often against a perceived attacker (Boeve, 
2013). REM sleep behaviour disorder is more commonly found in synucleinopathies 
than in AD or mild cognitive impairment (MCI, an intermediate state between normal 
cognitive functioning and AD (Morris and Cummings, 2005)) (Boeve et al., 2001). 
REM sleep behaviour disorder is also found in progressive supranuclear palsy (PSP), 
a disorder marked by parkinsonism without α-synuclein pathology (Munhoz and 
Teive, 2014) but is strongly associated with α-synuclein pathology when it precedes 
the onset of other neurological symptoms (Boeve et al., 2013). As PSP is a 
tauopathy rather than an α-synucleinopathy, the topography of pathological changes 
may be important in eliciting REM sleep behaviour disorder (Munhoz and Teive, 
2014).  
Neuroleptic sensitivity is characterised by the exacerbation of parkinsonian motor 
features and/or impaired consciousness following administration of neuroleptic drugs 
(McKeith et al., 2005). Neuroleptic medications are a class of pharmaceuticals that 
inhibit dopaminergic D2 receptors primarily used in the treatment of schizophrenia 
(Madras, 2013). The proposed efficacy of neuroleptics in schizophrenia is based on 
a hypothesised increase in D2 receptors in the striatum of schizophrenic patients, 
with pharmacological antagonism reducing dopaminergic activity to normal levels 
(Nordstrom et al., 1995; Corripio et al., 2011). D2 receptors are reduced in the 
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striatum of DLB patients, thus administration of neuroleptic agents may further 
exacerbate striatal dopaminergic deficits (Walker et al., 1997; Piggott et al., 1999). 
Approximately 50% of DLB patients have a severe adverse reaction to neuroleptics, 
and a greater proportion have milder adverse reactions (McKeith et al., 1992; 
Aarsland et al., 2005). As a result of early reports on the sensitivity of DLB patients 
to neuroleptics (e.g. (McKeith et al., 1992)), there are few modern studies on rates of 
neuroleptic sensitivity in DLB. Some studies have assessed the efficacy of atypical 
antipsychotics, that interact with the serotonergic system and have a more transient 
effect on D2 receptors, for treating psychotic symptoms in DLB (Kusumi et al., 2015). 
Despite early promise from a positive case report (Allen et al., 1995), a randomised 
controlled trial suggested that risperidone, an atypical antipsychotic, is poorly 
tolerated by the majority of DLB patients and can lead to a worsening of scores on 
some neuropsychological tests (Culo et al., 2010).   
Neuroimaging of the dopamine transporter (DAT) with PET or SPECT shows 
reduced binding in the nigrostriatal dopaminergic system in DLB (Piggott et al., 1999; 
McKeith et al., 2005). A large multicentre trial has shown that SPECT imaging of 
DAT is a reliable method for segregating DLB from AD (McKeith et al., 2007). As 
there is some overlap in clinical presentations between AD and DLB, particularly in 
early stages (McKeith et al., 2016), additional tools to differentiate these two 
diseases are of particular importance.  
 
1.2.4 Supportive clinical features of DLB  
Supportive features incorporate symptoms often occurring in DLB but lack the 
specificity to include them in a scheme designed to improve diagnostic accuracy 
(McKeith et al., 2005). Supportive features of DLB include repeated falls and 
syncope, transient loss of consciousness, severe autonomic dysfunction, non-visual 
hallucinations, delusions, depression, medial temporal preservation on structural 
magnetic resonance imaging (MRI), reduced occipital perfusion, low uptake of l-
metaiodobenzylguanidine (l-MIBG) on cardiac scintigraphy and low wave activity on 
electroencephalogram with transient, sharp waves in the temporal lobe (McKeith et 
al., 2005).   
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1.2.5 Non-hallucinatory visual features of DLB  
Although visual hallucinations are a core clinical feature (McKeith et al., 2005), other 
visual deficits commonly occur in DLB (Armstrong, 2012). Visual acuity does not 
differ significantly in DLB patients compared to age-matched controls, though 
impairments have been found in other visual functions such as eye movement 
difficulties, visuospatial perception and visual attention (Metzler-Baddeley et al., 
2010). Although visual perceptual and oculomotor difficulties are commonly 
encountered amongst DLB patients, they are not considered to be core or supportive 
features necessary for rendering a clinical diagnosis (McKeith et al., 2005).   
Eye movement deficits occur in several neurodegenerative dementia disorders, 
prominently in PSP, but are thought to be more significant in DLB and PDD than AD 
(Armstrong and Kergoat, 2015). Saccades are fast eye movements that serve to 
move the eye so that the fovea centralis, the retinal area corresponding to the central 
visual field, is centred upon the region of the visual field to which the observer 
wishes to attend (Schall, 1995). Saccadic eye movements take longer to execute 
and are more likely to fall short of their target in DLB compared to control and AD 
patients (Mosimann et al., 2005).  
Complex visual functions are thought to be particularly impaired in DLB (Armstrong, 
2012). DLB patients perform poorly on tasks involving size or length estimation of 
observed objects, overlapping figures and spatial localisation, indicating visuospatial 
dysfunction (Mosimann et al., 2004). When presented with a battery of cognitive 
tasks, DLB patients consistently show poorer performance on sub-scales with a 
substantial visuospatial component than AD or PD (Scharre et al., 2016). Despite not 
being a core clinical feature, visuospatial impairment is often a presenting feature of 
DLB and may be useful in the differentiation from AD (Tiraboschi et al., 2006; 
Yoshizawa et al., 2013).  
Visual attention is also impaired in DLB (Collerton et al., 2003). DLB patients perform 
more poorly on tests of attentional/executive function, including the trail-making and 
Stroop tasks, than PDD (Mondon et al., 2007). DLB patients show impaired filtering 
of distracting visual information (Perriol et al., 2005) and make more frequent 
saccades to distractors during pursuit eye movements (Henderson et al., 2011). The 
manifestation of visual hallucinations has been related to visual attentional deficits 
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(Cagnin et al., 2013), and focused attention upon hallucinated objects has been 
demonstrated to promote their cessation in PD (Diederich et al., 2003).    
 
1.2.6 Phenotypic overlaps between DLB and other parkinsonian motor disorders 
PD is a movement disorder characterised by slowness of movement, rigidity, and 
rest tremor, typically referred to as a parkinsonian motor phenotype (Postuma et al., 
2015). A spectrum of cognitive features occur in PD, ranging from subtle cognitive 
impairment to PDD (Litvan et al., 2012). Approximately 20% of PD patients 
experience complex visual hallucinations, though approximately 40% experience 
‘simple’ hallucinations involving the perception of movement or a presence in the 
peripheral visual field (passage and presence hallucinations, respectively) (Fenelon 
et al., 2000). Subtle features of impaired cognition are a risk factor for PDD, which 
occurs in up to 80% of PD patients (Aarsland et al., 1996; Aarsland et al., 2003). 
PSP is a progressive parkinsonian disorder characterised by postural instability with 
falls and slow vertical saccadic eye movements (Respondek et al., 2013). 
Corticobasal degeneration (CBD) has a variable presentation, with asymmetrical 
rigidity, dysfunctional voluntary movement and unintentional movements (Armstrong 
et al., 2013). Both PSP and CBD are pathologically characterised by tau pathology, 
as further described in section 1.3.2. PSP and CBD patients rarely experience visual 
hallucinations (Armstrong and Kergoat, 2015). 
Multiple systems atrophy (MSA) is characterised by autonomic dysfunction, 
particularly urinary incontinence and erectile dysfunction in males, in addition to 
either parkinsonism non-responsive to levodopa and/or a syndrome of unsteadiness 
and discoordination, termed ataxia (Gilman et al., 2008). MSA is pathologically 
characterised by the presence of Papp-Lantos bodies, as further described in section 
1.2.8. The topography of Papp-Lantos bodies is related to several distinct clinical 
phenotypes of MSA (Kim et al., 2015). Visual hallucinations may occur in 5-9% of 
MSA patients but their presence is considered to be more strongly predictive of DLB, 
PD or PDD (Bertram and Williams, 2012). 
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1.2.7 Cognitive profile of DLB vs other neurodegenerative diseases 
Even at early stages, DLB patients typically have greater impairments in visuo-
spatial processing than AD (Yoshizawa et al., 2013). In contrast to PD, PDD and 
MSA, DLB patients have more severe impairment on attentional/executive 
functioning tasks, particularly those with a high visuo-spatial processing component 
(Kao et al., 2009; Petrova et al., 2015). Although encoding and retrieval of memory is 
more impaired in AD (Yoshizawa et al., 2013), DLB patients have more memory 
domain impairments than MSA or PD (Kao et al., 2009). The overall cognitive profile 
of DLB patients suggests prominent attentional and executive dysfunction, 
particularly tasks with a substantial visuo-spatial component, and relative 
preservation of memory when compared to AD.   
 
1.2.8 α-synuclein pathology 
Many neurodegenerative dementia disorders are characterised by aberrant 
misfolding and aggregation of highly-expressed tissue proteins (Taipa et al., 2012). 
DLB cases have midbrain, limbic and neocortical neuronal cytoplasmic inclusions 
consisting of ubiquitinated α-synuclein termed Lewy bodies (Perry et al., 1990b; 
Spillantini et al., 1997). Lewy bodies are also the characteristic neuropathological 
feature of PD and PDD and, as a result, the three conditions are collectively 
considered to lie on the Lewy body disease spectrum (Kovari et al., 2009; Attems et 
al., 2013). Mild Lewy body pathology is occasionally found in aged cases without 
cognitive or motor impairment, and may be more prevalent with increasing age in 
such individuals (Saito et al., 2004). 
α-synuclein is thought to be central to the pathogenesis of Lewy body disease (Kalia 
and Kalia, 2015) due to the involvement of α-synuclein mutations in familial PD 
(Polymeropoulos et al., 1997) and its presence within Lewy bodies (Spillantini et al., 
1997). In Lewy bodies, α-synuclein is aggregated into insoluble assemblies (Baba et 
al., 1998) which are thought to follow a stereotypical temporal and topographic 
course, originating in the brainstem and spreading to the neocortex through the 
limbic system (Braak et al., 2003; McKeith et al., 2005). Limbic or neocortical Lewy 
body pathology is necessary for a pathological diagnosis of DLB (McKeith et al., 
2005).  
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α-synuclein-positive inclusions in astrocytes and oligodendrocytes have also been 
described in brainstem and midbrain regions in PD (Wakabayashi et al., 2000; Seidel 
et al., 2015). More recently, an antibody against aggregated α-synuclein has 
demonstrated astrocytic and ‘dot-like’ profiles in cortical regions in DLB (Kovacs et 
al., 2012). However, the role of glial α-synuclein pathology in the aetiology of Lewy 
body disease, and its relationship to clinical features, is not yet known. 
Neuropathological staging schemes have been devised to chart the topographical 
distribution of Lewy body pathology in PD/PDD (Braak et al., 2004) and DLB 
(McKeith et al., 2005). Both the PD and DLB schemes describe Lewy body 
pathology spreading in a stereotypical manner, originating in the brainstem before 
affecting limbic regions and, ultimately, vulnerable regions of the neocortex (Braak et 
al., 2004; McKeith et al., 2005). Based purely on the topography of Lewy body 
pathology, DLB and PDD are indistinguishable (Ruffmann et al., 2016). However, 
Lewy body pathology is higher in the neocortex than the brainstem of individuals who 
present with dementia; in contrast, brainstem pathology is greater than neocortical 
pathology in individuals who present with parkinsonism (Yamamoto et al., 2005). A 
diagnosis of DLB or PDD is based upon the sequence of symptom onset, with the 
requirement that parkinsonism precedes cognitive symptoms by one or more years 
to qualify for a diagnosis of PDD (McKeith et al., 2005). Why some Lewy body 
disorders present with cognitive or motor symptoms has not been satisfactorily 
explained in the literature. However, it is possible the initial sequence of Lewy body 
deposition is different between DLB and PDD patients, but the same distribution is 
observed at terminal stages.  
The stereotypical spread of Lewy body pathology in DLB, PD and PDD has 
prompted speculation that aggregated α-synuclein may spread through the brain in a 
manner reminiscent of the mode of transmission described previously for prion 
protein in transmissible spongiform encephalopathies such as variant Creutzfeldt-
Jakob disease, kuru and bovine spongiform encephalopathy (Prusiner and 
Kingsbury, 1985; Seidel et al., 2015). This hypothesis suggests misfolded species of 
α-synuclein protein, when introduced to normal physiological α-synuclein, have the 
capacity to induce misfolding into the pathogenic conformation, gaining toxic 
qualities (Goedert, 2015).  
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α-synuclein aggregates within oligodendroglia, termed Papp-Lantos bodies or glial 
cytoplasmic inclusions, are the characteristic neuropathological feature of MSA 
(Barker and Williams-Gray, 2016). Why α-synuclein affects oligodendroglia rather 
than neurons in MSA, and its role in neurodegeneration, remains unknown (Burn and 
Jaros, 2001). Lewy bodies and occasional α-synuclein-positive neuroaxonal 
spheroids have been previously described in neurodegeneration with brain 
accumulation type 1 (NBIA1, formerly Hallervorden-Spatz disease) (Wakabayashi et 
al., 1999; Galvin et al., 2000; Neumann et al., 2000; Saito et al., 2000). However, the 
underlying pathophysiology of NBIA1 is not well understood, thus limiting knowledge 
on whether α-synuclein is a primary pathology and how it contributes to the disease 
process (Jellinger, 2003). 
 
1.2.9 Concomitant pathologies in DLB 
The aged brain often manifests more than one type of age-related 
neurodegenerative pathology (Kovacs et al., 2008; Jellinger and Attems, 2015). 
However, the presence of multiple pathologies within an aged brain does not, by 
necessity, mean that the individual has more than one type of dementia (i.e. mixed 
dementia). A diagnosis of mixed dementia is typically only given when the full 
pathological diagnostic criteria for more than one disorder have been met (Jellinger 
and Attems, 2007).  
Intermediate AD-type pathology, in the form of neurofibrillary tangles and amyloid-β 
plaques (as discussed in section 1.3.2), is often observed, but not invariant, in DLB 
brains (McKeith et al., 1996). Rather than being incidental, AD-type pathology may 
contribute to the disease process and exacerbate cognitive decline in DLB (Howlett 
et al., 2015). However, the presence of neurofibrillary tangles and/or amyloid-β 
plaques is not necessary for a neuropathological diagnosis of DLB (McKeith et al., 
2005). Imaging of amyloid-β using positron emission tomography intra vitam is an 
attractive method to assess changes previously only identifiable post-mortem. 
However, amyloid-β imaging has not been consistently demonstrated to improve 
accuracy of DLB diagnosis (Donaghy et al., 2015). Imaging suggests amyloid-β is 
higher in DLB than PDD (Gomperts, 2014), and may be useful in identifying PD 
patients at risk of cognitive decline (Donaghy et al., 2015). Furthermore, elevated 
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expression of amyloid-β in cerebrospinal fluid has been identified as a predictor of 
cognitive decline in PD (Yarnall et al., 2014), and may predict more rapid cognitive 
decline in DLB (Abdelnour et al., 2016). It is unclear how amyloid-β may contribute to 
elevated rates of cognitive decline, but it has been demonstrated to enhance the 
aggregation of α-synuclein in vivo, suggesting it may accelerate the progression of 
Lewy body disease (Masliah et al., 2001).  
Vascular pathologies increase in frequency with ageing, and may also be found in 
DLB. DLB cases have significantly more severe cerebrovascular lesions than PD 
cases, ranging from nothing to mild/moderate lacunes and/or white matter lesions 
(Jellinger and Attems, 2008). Cerebral amyloid angiopathy (CAA) has been 
demonstrated to be significantly higher in DLB than PD cases, and correlates with 
the global burden of tau and α-synuclein. However, one study investigating 
cerebrovascular lesions reported no significant difference in the severity of white 
matter changes or cortical micro-infarcts, but did find increased total mini-bleeds, in 
DLB compared to control cases (De Reuck et al., 2013).  
TAR DNA-binding protein (TDP)-43 pathology, the characteristic neuropathological 
feature of amyotrophic lateral sclerosis and a subtype of frontotemporal dementia, 
has been reported in aged individuals without cognitive impairment, AD and DLB 
cases (Higashi et al., 2007). In AD cases, TDP-43 follows a distinct topographical 
sequence of deposition (Josephs et al., 2014; Josephs et al., 2016), which has also 
been observed in normal ageing and DLB (McAleese et al., 2016). However, TDP-43 
pathology in DLB, whilst variable, is not significantly more advanced than that 
observed in aged control cases and seems to show a greater association with AD-
type than α-synuclein pathology (McAleese et al., 2016). However, one study has 
demonstrated significant relationships between α-synuclein and TDP-43 burden 
within the amygdala (Yokota et al., 2010).   
 
1.3 Alzheimer’s disease 
1.3.1 Clinical features  
AD is clinically characterised by progressively declining cognition which substantially 
impairs the ability to conduct normal daily activities (McKhann et al., 2011). Although 
commonly considered to be an amnestic disorder, there are non-amnestic 
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presentations that can result from AD pathology, such as posterior cortical atrophy 
(Alladi et al., 2007) and logopenic progressive aphasia (Rabinovici et al., 2008). 
Amnestic AD is the most common presentation of AD, and is characterised by 
impairment in the learning and recall of recently acquired information due to deficient 
episodic memory (McKhann et al., 2011; Dubois et al., 2014). 
  
1.3.2 Amyloid-β and tau pathology 
AD-type pathology consists of senile plaques, neurofibrillary tangles, neuropil 
threads and neuritic plaques (Hyman et al., 2012). Neurofibrillary tangles and 
neuropil threads consist of microtubule-associated protein tau, a protein normally 
localised to axons that binds to, and stabilises, the microtubule network (Mandelkow 
and Mandelkow, 2012). Under pathological conditions, tau becomes abnormally 
phosphorylated, detaches from microtubules and accumulates in vulnerable neurons 
(Bancher et al., 1989; Mandelkow and Mandelkow, 2012). Variants of tau pathology 
are found in several disorders known as tauopathies, which include AD, PSP and 
CBD (Irwin, 2016). As with Lewy body pathology, staging schemes have been 
developed to chart the temporal sequence of these pathologies in AD. Tau 
neurofibrillary tangles are thought to originate in the transentorhinal cortex, prior to 
spreading to the fusiform and lingual gyri, and ultimately affecting wider neocortical 
regions (Braak et al., 2006).  
Amyloid-β is a peptide cleaved from the amyloid precursor protein by β- and γ-
secretases and accumulates in the parenchyma into neurotoxic plaques (Kuruva and 
Reddy, 2016). Senile plaques largely consist of extracellular deposits of amyloid-β 
peptide and originate in cortical regions prior to deposition in sub-cortical structures, 
ultimately affecting midbrain and brainstem regions (Thal et al., 2002). The presence 
of focal amyloid-β deposits with a distended halo of tau-positive neurites, termed 
neuritic plaques, are necessary for a neuropathological diagnosis of AD (Attems et 
al., 2013). 
Stereological studies have typically reported neurofibrillary tangles to be a more 
robust correlate of neuronal loss than amyloid-β plaques (Erskine and Khundakar, 
2016). However, it is thought that both pathologies interact to elicit the neuronal 
dysfunction and death that contributes to the clinical phenotype of AD (Attems et al., 
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2013).  AD-type pathology is frequently observed in aged, cognitively intact 
individuals. A post-mortem study of 39 cognitively intact, elderly subjects identified 
only one case without neurofibrillary tangle pathology. However, tau pathology was 
milder in cognitively intact individuals than AD, predominantly corresponding to the 
first three stages of the Braak staging scheme (Knopman et al., 2003). Therefore, 
although AD-type pathology may be encountered in the cognitively intact elderly, it is 
typically less severe than in individuals with AD. 
 
1.3.3 Concomitant pathologies in AD 
Vascular pathologies, such as atherosclerosis, small vessel disease and CAA, occur 
commonly with ageing, particularly alongside AD-type pathology (Grinberg and Thal, 
2010; Attems et al., 2013). Rather than incidental findings, vascular pathologies may 
contribute to cerebral hypoperfusion in AD (Love and Miners, 2016), and hasten the 
rate of cognitive decline (Pachalska et al., 2015).   
TDP-43 pathology has been identified in AD, where it follows a distinct sequence of 
deposition and is related to an accelerated rate of cognitive decline (Josephs et al., 
2014; Josephs et al., 2016). TDP-43 pathology shows a greater association with AD 
than with DLB or normal ageing (McAleese et al., 2016). 
 
1.4 The molecular function of α-synuclein  
1.4.1 Synaptic function 
Synapses are the primary medium for neuronal communication and comprise the 
axon of the presynaptic neuron, the dendrite of the postsynaptic neuron and the 
space between them, termed the synaptic cleft (Hudspeth et al., 2013). The majority 
of synapses within the human central nervous system are chemical synapses, which 
facilitate neuronal communication via neurotransmitters (Sudhof, 2013). Prior to 
release into the synaptic cleft, neurotransmitters are stored in synaptic vesicles 
(Hudspeth et al., 2013), which are required to quickly fuse with a special area of the 
plasma membrane, termed the ‘active zone’, in response to the influx of calcium ions 
into the presynaptic neuron as the result of action potential generation (Sudhof, 
2013). Synaptic vesicle exocytosis is mediated by the N-ethylamide sensitive factor 
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attachment protein receptor (SNARE) family which include synaptobrevin, syntaxin-1 
and synaptosomal-associated protein 25 (SNAP-25) (Rizo and Xu, 2015).  
The SNARE family of proteins facilitate the exocytotic release of neurotransmitters 
into the synaptic cleft by mediating the fusing of the presynaptic vesicle to the cell 
membrane. SNARE proteins carry out this function by assembling into a stable four-
helix bundle known as the SNARE complex, which provides energy for the synaptic 
vesicle (Weber et al., 1998). The SNARE complex interacts with a variety of other 
proteins to facilitate synaptic vesicle exocytosis (Sudhof, 2013), including 
chaperones such as α-synuclein, which are thought to support exocytosis by 
maintaining the SNARE complex assembly (Burre et al., 2010; Sharma et al., 2011).   
  
1.4.2 α-synuclein structure 
α-synuclein, the major protein component of Lewy bodies, is thought to 
predominantly exist as an unfolded monomeric protein with a propensity to 
aggregate (Spillantini et al., 1997; Tofaris and Spillantini, 2007). However, the N-
terminal region of α-synuclein adopts a helical conformation in the presence of lipid 
membranes (Eliezer et al., 2001), which may facilitate membrane binding to aid ion-
channel formation, a putative role for α-synuclein (Zakharov et al., 2007). When 
isolated from red blood cells α-synuclein has been reported to exist as a tetramer 
with a helically folded structure that is resistant to aggregation (Bartels et al., 2011). 
However, the tetrameric structure of α-synuclein has been contested by other studies 
which have reported α-synuclein to be an unfolded monomer when isolated from 
human and murine brain, or human-derived neuronal cell lines (Fauvet et al., 2012).  
 
1.4.3 α-synuclein aggregation 
The factors predisposing α-synuclein aggregation in Lewy body disease are not well 
understood but the monomeric form may be particularly vulnerable to assemble into 
the β-pleated sheet rich structures comprising Lewy bodies and neurites (Bartels et 
al., 2011; Eugene et al., 2014). The ratio of different α-synuclein conformations may 
be perturbed in Lewy body disorders, leading to a relative increase in aggregation-
prone monomeric α-synuclein (Gurry et al., 2013). Polymorphisms in the α-synuclein 
promoter have been identified as a potential risk factor for idiopathic PD (Kruger et 
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al., 1999). This is consistent with the suggestion that increased expression levels of 
α-synuclein may promote self-aggregation into an intermediate stage characterised 
by oligomeric species before further aggregation into the fibrils comprising Lewy 
bodies and neurites (Giasson et al., 1999; Conway et al., 2000a; Conway et al., 
2000b). However, whilst most oligomers likely aggregate further into fibrils, some 
oligomers stabilise and aggregate into ‘stacks’ of oligomers (Paslawski et al., 2014). 
Oligomers are thought to be more neurotoxic than fibrillar or monomeric forms of α-
synuclein, and may be a major causative agent in the neuronal dysfunction that 
characterises α-synucleinopathies (Winner et al., 2011; Cremades et al., 2012).  
Aggregation of α-synuclein is thought to be an important pathogenic event in the 
natural history of Lewy body disorders (Bendor et al., 2013); however, it is not clear 
whether aggregation elicits toxic effects through a loss- or gain- of function (Cookson, 
2006). α-synuclein aggregates may induce a loss of function by binding the 
membrane-bound monomeric form, removing it from the membrane, thus inhibiting 
its normal function (Chaudhary et al., 2014). However, α-synuclein aggregation may 
lead to a gain of cytotoxic function as oligomeric α-synuclein interacts with cellular 
membranes and induces the influx of substances from the extracellular milieu into 
the neuron, critically impairing neuronal functioning (Danzer et al., 2007). Additionally, 
fibrillar α-synuclein may inhibit microtubule formation by inducing the fibrillisation of 
tau protein, potentially inhibiting the microtubule transport network (Oikawa et al., 
2016). Neuronal dysfunction as a result of α-synuclein aggregation may result from 
both a loss of normal function and a gain of toxic function, with aggregation impeding 
the normal physiological role of α-synuclein but also leading to the creation of 
aggregates with cytotoxic qualities.  
 
1.5 Human visual system and visual thalamic structures 
1.5.1 An overview of the human visual system 
Visual perception begins in the eye, where light is transduced by the photoreceptors 
of the retina and transmitted along the optic nerve (Masland, 2012). Retinal ganglion 
cells (RGC), whose axons comprise the optic nerve, transmit the neural 
representation of the observed visual field to the lateral geniculate nucleus (LGN) of 
the thalamus, the primary subcortical relay centre between the retina and visual 
cortex (Reese, 2011) (Fig. 1.1). The visual cortex then sends ascending visual 
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information to one of two parallel post-striate pathways: one projecting dorsally, 
which is involved in spatial and movement perception, and one projecting ventrally, 
which is implicated in object perception (Ungerleider LG, 1982) (Fig. 1.2). 
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Figure 1.1: The afferent visual pathways.   
The primary visual pathway (blue) projects from the retina to the lateral geniculate nucleus (LG) prior 
to the primary visual cortex (V1). The secondary visual pathway (red) projects from the retina to the 
superior colliculus (SC) and the pulvinar (PL).  
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An additional ‘secondary’ visual pathway originates in the retina, running parallel to 
the ‘primary’ retina-LGN-primary visual cortex pathway. The secondary visual 
pathway projects from the retina to the superior colliculus and then innervates the 
pulvinar nucleus of the thalamus (Fig. 1.1) (Diederich et al., 2014). From the pulvinar, 
one pathway continues to visual area V5/MT and is thought to serve motion 
processing (Stepniewska et al., 1999; Stepniewska et al., 2000). Another pathway 
from the pulvinar projects to widespread targets, including the cingulate gyrus, 
amygdala and insular cortex (Romanski et al., 1997), and is thought to integrate 
sensory inputs with limbic influences (Benarroch, 2015).  
The primary and secondary visual pathways are not completely segregated. The 
superior colliculus of the secondary visual pathway has reciprocal connectivity with 
the LGN and visual cortex (Krauzlis et al., 2013). Similarly, the pulvinar directly 
innervates the primary visual cortex, and can modulate its activity (Zhou et al., 2016). 
Therefore, the two subcortical visual pathways could be considered to be separate 
but synergistic.  
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Figure 1.2: The human post-striate visual systems.   
Two streams are demonstrated projecting from the primary visual cortex (V1). One stream travels 
ventrally along the occipito-temporal region (green arrow; ventral stream), from V1 to the association 
visual cortical areas V2 and V4, before projecting down the inferior temporal lobe. Another stream 
projects dorsally along the occipito-parietal region (red arrow; dorsal stream), from V1 to the V5/MT 
area, travelling further to the inferior parietal lobule. 
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1.5.2 The lateral geniculate nucleus 
The LGN is a laminar structure on the inferolateral aspect of the thalamus, 
enveloped by the optic tract (Jones, 2007). The LGN is composed of six laminae, 
each containing lamina-specific cell types: the magnocellular laminae comprising 
larger cells and parvocellular laminae containing smaller cells (Clark, 1932). The two 
ventral laminae are composed of magnocellular neurons, whilst the remaining four 
dorsal laminae are parvocellular. Laminae four and six are innervated by processes 
originating in the contralateral retina, whilst afferent input to laminae 3 and 5 
emanates from the ipsilateral retina (Steriade M, 1997). As each retina encodes 
information from both the right and left visual hemi-fields, each LGN processes 
information from the contralateral visual hemi-field from both eyes (Jones, 2007). A 
third cell type, koniocellular, exist in the LGN and are present on the ventral surface 
of each lamina and within intralaminar regions (Hendry and Reid, 2000).  
The primary innervation of the LGN comes from the retina through RGC and its main 
efferent connection is with the primary visual cortex through the optic radiations 
(Steriade M, 1997). However, input also comes to the LGN from the midbrain 
superior colliculus and is thought to suppress LGN activity during fast saccadic eye 
movements, a phenomenon known as ‘saccadic suppression’ (Harting et al., 1991). 
The LGN also receives modulatory inputs from the thalamic reticular nucleus, a top-
down regulator of thalamic activity that forms part of activity-dependent inhibitory 
loops with efferent targets of the LGN (Crick, 1984). The LGN also has considerable 
reciprocal connectivity with the targets of its efferent projections, especially the 
primary visual cortex, which sends feedback modulation to the LGN and reticular 
thalamus (Jones, 2007). LGN excitability is modulated by inputs from the brainstem 
reticular formation through pontogeniculo-occipital waves, which occur during sleep 
and can create spurious visual activity in the absence of visual input (Steriade, 1996).  
The segregation of the LGN into magnocellular and parvocellular laminae reflects the 
organisation of the primate visual system into functionally distinct but mutually 
complimentary and interacting pathways. Studies of non-human primates have 
demonstrated that parvocellular neurons, which are predominantly innervated by 
RGC from the fovea centralis of the retina, have lower contrast sensitivity but higher 
spatial frequency than magnocellular neurons, which are rarely innervated by RGC 
from the fovea centralis (Derrington and Lennie, 1984). Parvocellular neurons 
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receive inputs from retinal cells that respond to red-green colour, whereas 
magnocellular neurons receive input from retinal cells that are achromatic (Martin et 
al., 2011). The differences in response properties between magnocellular and 
parvocellular neurons reflect differences in their functional roles in visual perception: 
the magnocellular pathway is implicated in spatial and motion perception and the 
parvocellular pathway is involved in form recognition (Merigan and Maunsell, 1993). 
A neuroimaging study has indicated that similar functional distinctions exist between 
magnocellular and parvocellular laminae in the human LGN (Zhang et al., 2015). 
Unlike magnocellular and parvocellular neurons, koniocellular cells of the LGN 
survive following ablation of the primary visual cortex (Cowey and Stoerig, 1989) as 
they directly innervate the cortical motion processing region V5/MT (Sincich et al., 
2004). Koniocellular neurons show slower rhythmic patterns of activity than 
magnocellular or parvocellular neurons (Cheong et al., 2011) and are innervated by 
retinal cells that are sensitive to the blue-yellow colour spectrum (Jeffries et al., 
2014). Koniocellular neurons are a heterogenous neuronal class suggesting that 
individual sub-classes are implicated in divergent physiological processes (Xu et al., 
2001). Koniocellular neurons project to the visual area V5/MT indicating a role in the 
perception of movement (Diederich et al., 2014). However, the pathway in which 
koniocellular neurons participate may also aid visuo-spatial attention (Jayakumar et 
al., 2013), as visual attention can be better directed by blue-yellow than red-green 
stimuli (Li et al., 2007).     
 
1.5.3 The pulvinar nucleus 
The pulvinar is a large nucleus at the posterior part of the thalamus, lying on the 
superior aspect of the LGN (Jones, 2007). The pulvinar has four morphologically and 
physiologically distinct regions: anterior, medial, lateral and inferior (Burton and 
Jones, 1976). However, these regions can be further sub-divided on the basis of the 
neurochemical composition of individual neurons (Jones and Hendry, 1989). 
Although the pulvinar is often considered to be a predominantly visual structure, the 
anterior and medial aspects do not project to regions that are specifically involved in 
visual perception (Jones, 2007). The anterior pulvinar projects to somatosensory 
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regions whilst the medial pulvinar may support vision through its interaction with 
regions involved in sensory processing and attention (Benarroch, 2015). 
The primary pulvinar inputs relating to visual perception originate in the visual 
regions of the midbrain, such as the superior colliculus (Lysakowski et al., 1986). 
The superior colliculus is thought to primarily innervate the inferior pulvinar due to its 
degeneration following collicular lesions (Benevento and Fallon, 1975) but functional 
studies also show innervation of the medial and lateral pulvinar, with both regions 
sending afferent fibres to the medial temporal region (area V5/MT) of the dorsal 
visual stream (Benevento and Standage, 1983; Berman and Wurtz, 2010). Some 
retinal innervation of the inferior pulvinar is also present (Nakagawa and Tanaka, 
1984), though these afferents are relatively small and proximal to the LGN (Jones, 
2007). Cortical regions directly connected to each other are typically also connected 
through the pulvinar, contributing to its putative role in modulating cortico-cortical 
interactions (Benarroch, 2015). Of particular relevance to the visual system, the 
secondary visual area V2 (Ungerleider et al., 2014) and the fourth visual area V4 
(Gattass et al., 2014) innervate relay neurons in the inferior and lateral pulvinar.  
Thalamocortical output from the pulvinar generally innervates primary and 
association sensory cortices (Jones, 2007), suggesting a role as an association 
nucleus (Benarroch, 2015). The lateral pulvinar projects to the primary visual cortex, 
innervating laminae 1, 2 and 3, and the association visual cortex. These connections 
may be directly reciprocal (Ogren and Hendrickson, 1976), though the descending 
pathway may be routed through the reticular thalamic nucleus (Jones, 2007). The 
inferior pulvinar also innervates the primary and association visual cortices, as well 
as area V5/MT in the dorsal visual stream (Cusick et al., 1993). 
Functionally, the pulvinar is hypothesised to play a role in visual attention (Jones, 
2007).  Physiological studies have shown changes in the excitability of pulvinar 
neurons based on the behavioural relevance of stimuli in the visual field (Kastner et 
al., 2004). Lesions of the pulvinar often lead to deficits of visual attention, such as 
spatial neglect, a phenomenon where an individual cannot perceive a region of the 
visual field (Karnath et al., 2002). Pulvinar lesions can induce difficulties in localising 
stimuli, including spatially combining separate visual features, indicating a role in 
visuospatial perception (Ward et al., 2002).  
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1.5.4 The superior colliculus 
The superior colliculus is a laminar structure on the dorsal aspect of the midbrain 
(May, 2006). Although the superior colliculus has traditionally been considered an 
important structure for oculomotor functions (Gandhi and Katnani, 2011), it is 
becoming increasingly clear that it contributes to more complex components of visual 
perception, such as visual target selection (Krauzlis et al., 2013) and attention 
(Muller et al., 2005). Anatomically, the superior colliculus has alternative strata 
consisting of white and grey matter, broadly arranged into three grey matter laminae: 
stratum griseum superficiale (SGS; superficial grey lamina), stratum griseum 
intermedium (SGI, intermediate grey lamina) and stratum griseum profundum (SGP, 
deep grey lamina) (Krauzlis et al., 2013).  
The SGS is an exclusively visual lamina of the superior colliculus and receives direct 
retinal input (Perry and Cowey, 1984). Modulatory cholinergic afferents to the SGS 
have been described in cats, emanating from the parabigeminal nucleus (Sherk, 
1979). The efferent projections from the SGS innervate primary visual pathway 
structures, such as the LGN and primary visual cortex (Benevento and Fallon, 1975), 
where they are thought to suppress activity during eye movements (Wurtz et al., 
2011). The SGS may also contribute to non-conscious motion perception, through its 
connectivity with area V5/MT in the dorsal visual stream through the inferior pulvinar 
(Stepniewska et al., 1999; Stepniewska et al., 2000). 
The SGI and SGP are considered to be functionally and anatomically independent 
from the SGS (Krauzlis et al., 2013). In contrast to the predominantly retinal input of 
the SGS, the SGI and SGP receive afferents from wide-ranging cortical and sub-
cortical regions. Inputs to the SGI and SGP include motor and association sensory 
cortices, the hypothalamus, zona incerta, substantia nigra pars reticulata, locus 
coeruleus, dorsal raphe, pedunclopontine and deep cerebellar nuclei (Sparks and 
Hartwich-Young, 1989). Functionally, the SGI and SGP have traditionally been 
viewed as having a predominantly motor function (Gandhi and Katnani, 2011). 
However, these laminae, which contain retinotopic maps of the visual field, are also 
thought to support the selection of visual targets (Sparks, 1999). Neurons within the 
retinotopic area corresponding to the target of an upcoming saccade show 
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heightened activity prior to the initiation of the saccade, suggesting the SGI and SGP 
are involved in the selection of saccadic targets (Glimcher and Sparks, 1992). 
Outputs from the SGI to the mediodorsal nucleus of the thalamus, which projects to 
the frontal eye fields, may serve to stabilise the visual field during saccadic eye 
movements (Wurtz et al., 2011). Auditory and somatosensory maps have been 
demonstrated in the deeper laminae of the cat superior colliculus, in addition to multi-
sensory neurons that respond to input from more than one sensory modality, 
indicating a role in the integration of sensory inputs (Wallace et al., 1993).  
 
1.6 Visual hallucinations 
1.6.1 Cortical release hypothesis 
Charles Bonnet syndrome (CBS) is a hallucinatory disorder defined by the presence 
of visual hallucinations in a cognitively intact elderly individual (Ffytche, 2005). Visual 
hallucinations are a common feature of eye disease, occurring in up to 40% of cases, 
particularly when visual dysfunction has occurred in late life (ffytche, 2009). The 
association between eye disease and hallucinations prompted the development of 
the ‘cortical release’ hypothesis of visual hallucinations (Manford and Andermann, 
1998). This suggests impairments between the retina and the primary visual cortex 
may be important in the manifestation of complex visual hallucinations. This 
phenomenon is postulated to result from a reduction in inhibition, particularly in 
association visual areas, as a compensatory mechanism for impaired or degraded 
visual input. This hypothesis is supported by the observation that complex visual 
hallucinations occur in epileptiform disorders, which are also marked by altered 
excitatory/inhibitory activity, particularly when the focus of aberrant activity is the 
visual association regions (Josephson and Kirsch, 2006).  
The cortical release hypothesis suggests reduced inhibition occurs as a response to 
reduced input to the visual cortex. Lesions of the LGN have been demonstrated to 
induce defects in acuity in the visual field corresponding to the area lesioned, though 
normal functioning usually resolves in the case of small focal lesions (Gunderson 
and Hoyt, 1971), (Luco et al., 1992). However, although one study has demonstrated 
visual acuity deficits as a function of disease duration in individuals with Lewy body 
disease (Archibald et al., 2011), another study has not demonstrated visual 
impairments exceeding those observed in neurologically unimpaired controls 
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(Metzler-Baddeley et al., 2010). Visual acuity impairments in PD are related to the 
onset of minor hallucinatory phenomena, such as passage and presence 
hallucinations, where an individual may erroneously perceive movement or a 
presence in their peripheral visual field (Urwyler et al., 2014). No difference has been 
found in visual acuity on ophthalmological assessment between hallucinating and 
non-hallucinating PD patients (Gallagher et al., 2011). Visual hallucinations have 
been previously described in non-demented PD cases with normal visual acuity but 
deficient colour vision and contrast sensitivity (Diederich et al., 1998). This could 
suggest that higher visual functional impairment, rather than ocular dysfunction, 
contributes to visual hallucinations in some cases. 
If ocular changes are not responsible for visual cortical compensation, this may 
suggest that visual cortical input is altered through another mechanism, if cortical 
release underlies the manifestation of visual hallucinations in DLB. The LGN and 
pulvinar may be functionally altered in Lewy body disease, creating conditions that 
contribute to cortical release (Manford and Andermann, 1998). Brainstem regions 
modulating visual thalamic activity, such as the dorsal raphe and pedunculopontine 
nucleus, can alter visual thalamic activity between sleep-wake cycles (Monti, 2011). 
Degeneration of brainstem regions projecting to the visual thalamus may alter 
activity in the LGN and pulvinar, which has a corresponding effect upon activity in the 
association visual cortex (Manford and Andermann, 1998). One study has 
demonstrated an absence of visual acuity deficits but a relationship between visual 
hallucinations and sleep-wake cycle dysfunction (Gallagher et al., 2011). This may 
suggest shared mechanisms, such as brainstem degeneration, underlying both sleep 
dysfunction and visual hallucinations.  
 
1.6.2 Perception and attention deficit 
Normal object perception is thought to be the result of the complex interplay between 
external ‘bottom-up’ visual input, and internal ‘top-down’ representations of objects 
and scenes, termed ‘proto-objects’, formed as a result of visual experience, and 
deployed on the basis of expectations (Wolfe et al., 2003). Competition is thought to 
exist between both bottom-up visual input and top-down expectations to bias 
perception. The perceptual and attention deficit (PAD) model suggests that 
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dysfunctional sensory input processing biases toward top-down expectations and 
contributes to the selection of incorrect proto-objects (Collerton et al., 2005b). 
Crucially, scene perception remains intact, so the perceived proto-object is 
congruous with the observed scene but incorrect. Under normal conditions, attention 
affixes proto-objects into the observed visual scene, and this process is also thought 
to be perturbed in the PAD model (Lu and Dosher, 1998). Therefore, under the PAD 
model, impairments in object perception contribute to incorrect proto-object selection, 
and attentional dysfunction fixes incorrect, though contextually congruous objects, 
into the subjective visual scene, which are perceived as visual hallucinations 
(Collerton et al., 2005a). The authors of the PAD hypothesis have tested this model 
by assessing perception and attention in patients with a dementia diagnosis and 
controls (Makin et al., 2013). They found attention, but not visual acuity, was 
significantly deficient in dementia cases with visual hallucinations, offering some 
support for the PAD hypothesis. Lower scores of sustained attention in hallucinating 
PD patients (Meppelink et al., 2008) and the disappearance of visual hallucinations 
following focused attention (Diederich et al., 2003) further indicate a role for attention 
in the aetiology of visual hallucinations in Lewy body disease.    
The PAD hypothesis and subsequent experimental work have implicated 
dysfunctional attentional processes in the aetiology of complex visual hallucinations 
(Collerton et al., 2005b; Meppelink et al., 2008; Makin et al., 2013). Therefore, 
dysfunction or degeneration of regions implicated in visual attentional mechanisms 
may contribute to the manifestation of visual hallucinations in DLB. The LGN 
receives widespread inputs from regions that modulate visual activity, such as the 
superior colliculus and thalamic reticular nucleus (Jones, 2012). As it is an early 
relay structure for afferent visual processing, the LGN is ideally placed to modulate 
visual input in response to attentional and behavioural demands. Increased activity 
has been reported in the LGN as a consequence of focused attention, indicating that 
attention modulates activity in the LGN (O'Connor et al., 2002). However, attention-
mediated activity changes in the LGN are likely the result of modulatory feedback 
from the primary visual cortex to the reticular thalamic nucleus, which gates LGN 
activity patterns (Montero, 2000; Jones, 2012).  
The pulvinar is thought to have an important role in visual attentional mechanisms 
(Jones, 2012; Benarroch, 2015) and its widespread cortical connections are thought 
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to underlie its putative function in modulating cortico-cortical activity based on 
attentional demands (Saalmann et al., 2012). Lesions of the pulvinar lead to deficits 
in filtering distracting visual stimuli (Fischer and Whitney, 2012) and in attending to 
specific features of an observed stimulus (Ward et al., 2002). Taken together, this 
indicates a functional role for the pulvinar in visual attention.  
The Sprague effect, where spatial neglect occurs as a result of lesions to the 
occipital or parietal lobe, is recovered following superior colliculus lesioning, 
suggesting its contribution to visual attention (Sprague, 1966; Weddell, 2004). Like 
the LGN, the superior colliculus shows increased activity when the observer is 
attending to a visual stimulus, albeit with substantially higher attention-mediated 
activity than the LGN (Schneider and Kastner, 2009). Stimulation of collicular regions 
bias eye and head/neck movements toward spatial locations corresponding to the 
retinotopic area stimulated, indicating a role in target selection (Corneil et al., 2002; 
Gandhi and Katnani, 2011). Microstimulation of the superior colliculus can also 
spatially focus attention without eye movements toward the area of attention, a 
phenomenon known as covert attention (Muller et al., 2005).  
Perception and attentional deficits in DLB are thought to be the result of cholinergic 
dysfunction (Collerton et al., 2005b). Post-mortem studies have demonstrated 
cholinergic deficits in DLB, often exceeding those found in AD (Perry et al., 1990a; 
Perry et al., 1994; Tiraboschi et al., 2002), and these have been suggested to 
contribute a vulnerability to visual hallucinations (Perry and Perry, 1995). The major 
cholinergic nuclei, such as the nucleus basalis of Meynert (Lippa et al., 1999; Kim et 
al., 2011; Grothe et al., 2014) and pedunculopontine nucleus (Schmeichel et al., 
2008; Hepp et al., 2013), typically manifest Lewy body pathology in DLB. A 
physiological study that measured activity as an analogue of cholinergic activity has 
demonstrated changes in DLB which are commensurate with visual hallucination 
frequency and severity (Marra et al., 2012). An imaging study targeting cholinergic 
receptors in vivo has also suggested alterations in cholinergic uptake associated with 
visual hallucinations (O'Brien et al., 2008). A relationship between cholinergic 
dysfunction and visual hallucinations is further implied by reports of 
acetylcholinesterase inhibitor efficacy in their treatment (Burghaus et al., 2012).   
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1.6.3 ‘Blind’ to blindsight 
Blindsight is the ability of blind individuals to utilise facets of observed visual scenes 
without conscious awareness of perception (Barbur, 2004). Specifically, individuals 
with blindsight often accurately locate or identify presented stimuli within their 
peripheral visual field, react to moving stimuli and perform eye movements to follow 
and move between presented objects, despite an inability to consciously perceive 
them (Stoerig and Cowey, 1997). More recent work indicates that emotion-laden 
images may be perceived in an analogous manner termed ‘affective blindsight’ 
(Tamietto and de Gelder, 2010). PD patients often inappropriately guess objects in 
their peripheral visual fields, have difficulty perceiving motion, exhibit eye movement 
deficiencies and have impairments in recognising emotional facial stimuli, suggesting 
they have the converse of blindsight (Diederich et al., 2014). The ‘blind’ to blindsight 
syndrome is thought to contribute to the occurrence of presence and passage 
hallucinations, simple hallucinations where an object or movement is incorrectly 
perceived in the peripheral visual field. Deficient blindsight pathways in Lewy body 
disease may also force reliance upon the longer-latency primary visual pathway for 
information normally carried along the faster secondary visual pathways (Diederich 
et al., 2014). It is possible that slowed transfer of supportive visual information could 
lead to an over-reliance upon top-down processing in visual perception, particularly 
in circumstances of changing visual conditions, and bias the individual towards 
expected, rather than experienced, visual stimuli. This could contribute toward visual 
hallucination if top-down processes are also dysfunctional.  
The hypothesis that Lewy body disorder patients are ‘blind’ to blindsight suggests 
brain structures with functional roles in motion perception, eye movements and 
perception of emotional stimuli will be pathologically dysfunctional. Four brain 
structures, the LGN, pulvinar, superior colliculus and amygdala, have been directly 
implicated in these functions and in blindsight pathways hypothesised to be 
dysfunctional in Lewy body disease (Diederich et al., 2014). Koniocellular neurons of 
the LGN directly innervate the cortical motion perception area, V5/MT, in a pathway 
thought to contribute to the blindsight phenomenon (Sincich et al., 2004; Schmid et 
al., 2010). However, magnocellular and parvocellular neurons of the LGN, which are 
not part of putative blindsight pathways and primarily innervate the primary visual 
cortex, also show sensitivity to motion (Lee et al., 1979).  
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The SGS of the superior colliculus is thought to have a role in motion perception as it 
contains motion sensitive neurons (Inayat et al., 2015). Additionally, the SGS 
receives direct retinal input and projects to the motion area V5/MT through the 
inferior aspect of the pulvinar, in a pathway with a putative role in the non-conscious 
perception of motion (Lanyon et al., 2009) and may, therefore, contribute to motion 
perception deficits in Lewy body disorders (Diederich et al., 2014). The SGI of the 
superior colliculus also has an important role in selecting the targets of upcoming 
saccadic and pursuit eye movements (Glimcher and Sparks, 1992; Krauzlis and Dill, 
2002), which are deficient in Lewy body disorders (Mosimann et al., 2005; Diederich 
et al., 2014). In particular, DLB patients have increased saccadic latency and a 
tendency to perform saccades that fall short of their target (Mosimann et al., 2005), 
an identical pattern of deficits to that observed when the SGI of non-human primates 
is chemically inactivated (Aizawa and Wurtz, 1998).  
In addition to the role of the pulvinar in relaying motion information from the superior 
colliculus to V5/MT, the medial aspect of the pulvinar has substantial connectivity 
with the amygdala (Romanski et al., 1997), in which high levels of Lewy body 
pathology have been associated with visual hallucinations (Harding et al., 2002). PD 
patients show impaired perception of fear in observed faces (Sprengelmeyer et al., 
2003), and lesions specifically affecting the medial pulvinar lead to impaired fear 
perception, particularly in observed faces (Ward et al., 2007), indicating the medial 
pulvinar may contribute to affective blindsight (Diederich et al., 2014).  
 
1.6.4 Difficulty in engaging the dorsal attentional network  
Dysfunctional connectivity and activity across brain networks has been proposed as 
a contributor to the occurrence of visual hallucinations across numerous disease-
states (Onofrj et al., 2013). This hypothesis, when specifically applied to DLB/PD, 
has indicated dysfunction contributing to altered activity in response to observed 
visual stimuli and may lead to the manifestation of visual hallucinations. Under 
normal conditions, the ventral attentional network monitors incoming sensory 
information and engages the dorsal attentional network, which directs attention to 
visual stimuli, on the basis of salience and behavioural relevance (Corbetta and 
Shulman, 2002; Asplund et al., 2010). In DLB/PD, it has been suggested that the 
31 
 
brain has difficulty in activating the dorsal attentional network in response to 
ambiguous visual stimuli (Shine et al., 2014). This leads to an overreliance on the 
default mode network, which is involved in self-referential thought that manipulates 
and retrieves memories (Mazoyer et al., 2001). The default mode network has 
previously been related to ‘mind wandering’ and may bias perceptual systems 
toward ‘top-down’ influences based on memory or experience of visual perception 
(Shine et al., 2014).  
In DLB/PD patients, a dysfunctional default mode network may lead to difficulty in 
engaging the dorsal attentional network. The dorsal attentional network involves 
dorsolateral prefrontal, posterior parietal and striatal regions interconnected with the 
superior colliculus (Bisley and Goldberg, 2010). The dorsal attentional network is 
implicated in directing attention toward stimuli on the basis of salience of behavioural 
goals (Shine et al., 2014). The superior colliculus has an important role in target 
selection, orienting and visual attention (Krauzlis et al., 2013), suggesting the pattern 
of deficient activity is consistent with known roles of the superior colliculus. The 
pulvinar has not been directly implicated in the shifting between default mode 
network and dorsal attention network. However, the pulvinar has a strong influence 
on visual cortical activity in response to observed stimuli, and can influence 
attention-mediated enhanced cortical activity (Purushothaman et al., 2012; Zhou et 
al., 2016). This role is functionally similar to that suggested for the dorsal attentional 
network and may indicate interaction with the pulvinar.  
 
1.7 The thalamus and superior colliculus in neurodegenerative disorders 
1.7.1 Thalamic pathology in Lewy body disorders 
The thalamus consists of over 40 anatomically and physiologically distinct sub-nuclei 
and is a central hub for relaying and modulating activity across the brain (Jones, 
2012). Dysfunction in highly-interconnected hubs, such as the thalamus, has 
previously been implicated in dysfunctional network activity in dementia disorders 
(Pievani et al., 2011). As a result, the thalamus has been the subject of several 
studies aiming to elucidate its pathological vulnerability and relevance to the clinical 
features of dementia. 
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Neuropathological studies have demonstrated that Lewy body pathology is most 
frequently encountered in the central lateral, central medial, limitans-suprageniculate, 
paracentral, paraventricular and reuniens nuclei in PD (Rub et al., 2002). However, 
cell counting methods across all thalamic nuclei have demonstrated no neuronal loss 
in any region in PD but significant loss in the anterodorsal nucleus in AD compared 
to control cases (Xuereb et al., 1991). Neuronal loss has not been demonstrated in 
the limbic thalamic nuclei but has been reported in the intralaminar nuclei in PD and 
PSP compared to control cases (Henderson et al., 2000). Reductions in neuronal 
number were reported in the parafascicular and centre-median nuclei in PD and PSP 
when compared to control (Henderson et al., 2000). Examination of the intralaminar 
nuclei in DLB and PDD has demonstrated the paraventricular, central lateral and 
central medial nuclei are most severely affected by Lewy body pathology in DLB and 
PDD (Brooks and Halliday, 2009). However, neuronal loss was only observed in the 
parataenial, central lateral and centre-median/parafascicular nuclei of DLB, PD and 
PDD cases compared to control.  
Autoradiographic studies have been used to investigate the expression of post-
synaptic receptors or pre-synaptic transporters, which may indicate neurochemical 
abnormalities in the thalamus across disease states. Nicotinic cholinergic (alpha 3 
and alpha 6) receptor expression labelled by the [(125)I]alpha-conotoxin MII ligand is 
reduced in the centre-median, parafascicular and ventral lateral nuclei in DLB (Ray 
et al., 2004; Bohr et al., 2005). The LGN and pulvinar were not analysed in this study 
as they were only present on sections from a small number of cases but, when 
present, the LGN had among the highest levels of receptor expression. Studies 
employing a different cholinergic receptor ligand (α-bungarotoxin, labelling alpha 7, 8 
and 9 receptors) have demonstrated cholinergic receptor reductions in the reticular 
thalamic nucleus, a key regulator of thalamic activity in DLB, which exceed those 
found in schizophrenia cases (Court et al., 1999). Muscarinic M2 and M4 cholinergic 
receptors labelled by the ligand [3H]AFDX384 were specifically reduced in the 
mediodorsal nucleus in DLB compared to control cases (Warren et al., 2007). The 
LGN and pulvinar were not assessed in this study but the mediodorsal nucleus is a 
key target of the cholinergic pedunculopontine nucleus, where atrophy has been 
identified in hallucinating PD cases compared to those without hallucinations 
(Janzen et al., 2012). Acetylcholine may contribute to enhanced cortical neuronal 
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activity, thus increasing the probability that signals are differentiated from noise. 
Cholinergic reductions may create ambiguity in discriminating signals from 
background neural activity, which may corrupt and alter information transfer 
throughout the cortex, and may therefore contribute to the development of visual 
hallucinations (Perry and Perry, 1995). Autoradiographic studies of dopaminergic D2 
receptors in the thalamus have identified changes in the lateral dorsal and 
ventrointermedius nuclei in DLB cases with extrapyramidal features but these 
changes were unrelated to visual hallucinations  (Piggott et al., 2007).  
 
1.7.2 Neuroimaging studies in the thalamus in DLB 
Until recently, neuroimaging studies have mostly studied the thalamus as a unitary 
structure due to inability to resolve small thalamic sub-nuclei. One study that 
employed PET with ligands to detect glucose metabolism has demonstrated no 
change to glucose metabolism in the thalamus in DLB (Ishii et al., 1998). Structural 
MRI has demonstrated bilateral reductions in thalamic volume in DLB compared to 
control cases (Beyer et al., 2007). Diffusion tensor MRI, a neuroimaging technique 
that detects tissue damage through increased diffusivity of tissue, has found 
increased mean diffusivity in DLB but this was not significantly different from AD 
(Watson et al., 2012). 
SPECT imaging has been employed to assess regional perfusion changes in DLB as 
a method to clinically differentiate from AD. These studies have validated previous 
findings of occipital hypoperfusion in DLB but have also demonstrated this occurs 
alongside thalamic hyperperfusion in comparison to AD cases (Sato et al., 2007; 
Shimizu et al., 2008). Compared to controls, DLB patients have reduced perfusion in 
the thalamus at early stages of the disease (Chang et al., 2008). This may indicate 
that physiological changes in the thalamus and occipital lobe act in concert to 
contribute to visual manifestations in DLB.   
     
1.7.3 Pathological and neuroimaging studies in the thalamus in Alzheimer’s disease 
MRI data in familial AD has shown volumetric losses in the thalamus when it is 
assessed as a unitary structure (de Jong et al., 2008). Total thalamic volume loss 
has also been demonstrated on MRI in sporadic cases that have been clinically 
34 
 
assessed as having prodromal AD (Eustache et al., 2016), and in amnestic MCI 
cases, compared to controls (Yi et al., 2016). The anterior nuclei of the thalamus are 
particularly vulnerable to AD-type histopathological changes, with the anterodorsal 
nucleus showing complete loss of neurons in some cases (Braak and Braak, 1991; 
Xuereb et al., 1991). The dorsomedial nucleus also shows neuronal loss and AD-
type pathology in AD (Paskavitz et al., 1995).  
On histological examination, the LGN shows widespread amyloid-β deposition, in the 
absence of neurofibrillary and neuritic plaque pathology, in AD cases (Price et al., 
1991; Leuba and Saini, 1995). However, another study reported very low levels of 
tau pathology in the LGN (Dugger et al., 2011). Cytochrome oxidase levels are also 
reduced on histological analysis of the LGN in AD, and this has been suggested to 
contribute to visual dysfunction in AD (Wong-Riley et al., 1997).  
The pulvinar has widespread plaque and tangle pathology in AD cases compared to 
controls (Kuljis, 1994). Although psychotic symptoms are relatively uncommon in AD 
compared to DLB, AD patients with psychotic features have reduced pulvinar 
perfusion on SPECT compared to AD patients without psychotic features (Mega et 
al., 2000). AD cases may have increased iron in the pulvinar as demonstrated by 
T2*-weighted MRI but its contribution to the clinical phenotype requires further 
investigation (Moon et al., 2012; Langkammer et al., 2014). 
The superior colliculus exhibits lower levels of tau pathology than the inferior 
colliculus in AD, and is milder than that observed in the superior colliculus in PSP 
(Dugger et al., 2011). Another study has described tau and amyloid-β pathology 
across all laminae of the superior colliculus, though amyloid-β was relatively more 
severe than tau pathology (Leuba and Saini, 1995). 
 
1.8 The visual system in Lewy body disorders 
1.8.1 The retina 
An early case report of the retina in a DLB patient showed reduced density of cone 
cells and pale inclusion bodies in the outer plexiform lamina, which were not 
immunoreactive for any known markers of Lewy bodies in the brain, with α-synuclein 
homologues β-synuclein and γ-synuclein expressed in different laminae to those 
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observed in control retinae (Maurage et al., 2003). A later study using six PD/PDD 
cases failed to demonstrate retinal pathology beyond diffuse cytoplasmic α-synuclein 
immunoreactivity within isolated cells (Ho et al., 2014). Retinal α-synuclein 
immunoreactivity was not considered to be typical of Lewy body pathology observed 
in the brain. However, another study demonstrated sparsely distributed fibres in the 
inner retinal surface of 7/9 PD and 1/3 DLB cases, with no immunoreactivity 
observed in cases without α-synucleinopathy (Beach et al., 2014). A further study in 
three PD cases reported lamina-specific deposition of α-synuclein-immunoreactive 
intracellular inclusions present in the nuclear, plexiform and the ganglion cell laminae 
of the inner retina, and these were morphologically similar to Lewy bodies in the 
brain (Bodis-Wollner et al., 2014).  
Visual acuity has been assessed using the Snellen chart in probable DLB patients 
and demonstrated no significant difference compared to control or PD, irrespective of 
visual hallucination status (Devos et al., 2005). However, in the same study, 
electroretinograms demonstrated photoreceptor abnormalities in the retina of DLB 
patients, which the authors speculate are more likely to contribute to simple than 
complex visual hallucinations. Another study demonstrated no change in visual 
acuity in PD patients diagnosed less than three years previously compared to 
controls (Nowacka et al., 2015). Retinal functional abnormalities have been 
speculated to result from dopaminergic reductions, possibly as a result of diminished 
dopaminergic input to the retina (Nowacka et al., 2015). Retinal dopaminergic 
deficits have been suggested to be due to the presence of dopaminergic neurons 
and fibres, predominantly in the inner retinal laminae (Frederick et al., 1982), and the 
descriptions of α-synuclein pathology occurring within these strata in Lewy body 
disorders (Bodis-Wollner et al., 2014).     
Optical coherence tomography (OCT), a technique for obtaining high-resolution 
images of the eye, has been used to determine thinning of the retinal nerve fibre 
lamina in DLB, PDD and AD as an analogue of neuronal or axonal loss in the retina 
(Moreno-Ramos et al., 2013). This study reported significant retinal nerve fibre 
thinning in all disease groups compared to control and this was related to general 
cognitive decline, as determined by lower mini-mental state examination (MMSE) 
score (Moreno-Ramos et al., 2013). A further study using OCT to determine the 
thickness of individual retinal laminae in a larger cohort of 101 PD compared to 46 
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control eyes has described volumetric reductions in the total macula, inner plexiform 
lamina, inner nuclear lamina and outer nuclear lamina (Chorostecki et al., 2015). 
However, PD patients had volumetric increases in the outer plexiform lamina. Not all 
studies employing OCT have demonstrated retinal lamina thinning. One study using 
recently diagnosed PD patients failed to replicate findings of reduced retinal and 
retinal nerve fibre lamina thickness (Nowacka et al., 2015). OCT studies of the retinal 
vasculature have demonstrated venous morphological changes but no arterial 
abnormalities in PD (Kromer et al., 2016).  
 
1.8.2 The LGN 
The LGN has been pathologically investigated only once in DLB, with an absence of 
Lewy pathology reported in 19 cases, irrespective of visual hallucination status 
(Yamamoto et al., 2006). However, all DLB cases were qualitatively assessed as 
having very mild or mild neuronal loss in the LGN. Another study reported α-
synuclein immunoreactivity in the form of neurites and dot-like structures present in 
15/16 PD cases (Rahimi et al., 2015). No study has yet determined whether 
neuronal loss occurs in the LGN in DLB using quantitative methods.  
No imaging or physiological studies have been carried out in the LGN in DLB. 
However, in PD, the magnocellular visual pathway showed greater impairment on 
assessment of event-related potentials compared to controls than the parvocellular 
pathway (Arakawa et al., 1999). Another study employed a psychophysical approach 
to determine the functional integrity of magnocellular, parvocellular and koniocellular 
pathways, based on assessment of their known visual functions (Silva et al., 2005). 
This study reported impaired performance on a contrast sensitivity task to evaluate 
magnocellular performance in PD patients compared to controls. PD patients were 
also impaired on tasks forcing them to use chromatic information to determine a gap 
in a ring with red/green and blue/yellow spectra, as markers of parvocellular and 
koniocellular pathways, respectively. The patterns of impairment were independent 
of one another, and only magnocellular task performance was related to age. 
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1.8.3 The occipital lobe  
The primary visual cortex within the occipital lobe was initially described as being 
frequently spared Lewy pathology in DLB (Perry et al., 1990b). Subsequent studies 
have reported low (Yamamoto et al., 2006; Yamamoto et al., 2007; Mukaetova-
Ladinska et al., 2013) or absent (Khundakar et al., 2016) Lewy pathology in the 
primary visual cortex in DLB. Occipital visual association cortices are typically 
reported to have more severe α-synuclein pathology than the primary visual cortex 
(Yamamoto et al., 2006; Mukaetova-Ladinska et al., 2013). Qualitative assessment 
reported very mild or mild neuronal loss (Yamamoto et al., 2006), whilst a 
quantitative study found no significant change in neuronal number in any primary 
visual cortical lamina in DLB (Khundakar et al., 2016). α-synuclein pathology has 
been reported in lamina 6 of the visual cortex in 7/16 PD cases, and was more 
severe than the Lewy pathology in the LGN reported in the same study (Rahimi et al., 
2015). The synaptic proteins synaptophysin, SNAP-25, syntaxin and γ-synuclein 
were found in one study to be significantly reduced in the visual cortex in DLB, as 
determined by enzyme-linked immunosorbent assay (ELISA), and this was related to 
cholinergic activity, as determined by a choline acetyltransferase activity assay 
(Mukaetova-Ladinska et al., 2013).           
An increase in α4β2 nicotinic cholinergic receptor binding has been reported in the 
occipital lobe of hallucinating DLB cases and this increase was especially marked in 
patients that had recently hallucinated (O'Brien et al., 2008). Cholinergic receptor 
upregulation in DLB may be due to hyperactive cholinergic afferents from the LGN 
as a result of heightened excitation. A study employing transcranial magnetic 
stimulation to generate phosphenes, the elicitation of basic perceptual phenomena 
as a result of occipital stimulation, has reported the threshold of stimulation 
necessary to induce their occurrence is lower in DLB cases with more severe visual 
hallucinations, indicating occipital hyperexcitation (Taylor et al., 2011). 
Transcriptomic and proteomic assessment of post-mortem visual cortex tissue 
obtained from hallucinating DLB patients has suggested an altered gene expression 
profile and proteomic changes indicating impaired gamma-aminobutyric acid (GABA) 
-ergic transmission (Khundakar et al., 2016). Changes to GABA, the major inhibitory 
neurotransmitter (Jembrek and Vlainic, 2015), may alter the excitability of the 
primary visual cortex in DLB (Desgent and Ptito, 2012).  
38 
 
Structural MRI studies have demonstrated atrophy in the occipital lobe in DLB cases 
compared to PDD and control (Beyer et al., 2007). However, another study failed to 
find occipital changes in DLB compared to PDD (Burton et al., 2004). However, this 
study considered visual hallucinations necessary for a diagnosis of PDD, thus 
increasing phenotypic similarities between the DLB and PDD groups (Watson et al., 
2009). Another study with a large cohort and carefully matched participants failed to 
show significant occipital atrophy in DLB compared to control (Whitwell et al., 2007).     
Arterial spin-labelling MRI and PET/SPECT studies have consistently reported 
occipital hypoperfusion in DLB patients (Donnemiller et al., 1997; Lobotesis et al., 
2001; Colloby et al., 2002; Ceravolo et al., 2003; Sato et al., 2007; Shimizu et al., 
2008; Armstrong, 2012; Taylor et al., 2012; Robertson et al., 2016). Bilateral 
perfusion deficits have been related to the occurrence of visual hallucinations 
(Pasquier et al., 2002; Nagahama et al., 2010) and have been suggested to relate to 
visuospatial deficits in DLB (Colloby et al., 2002). A study using ELISA to quantify 
molecular markers of occipital microvasculature and perfusion in tissue obtained 
from the primary and secondary visual cortices has demonstrated specific reductions 
in the vascular endothelial growth factor (VEGF) and myelin-associated glycoprotein 
(MAG), putative markers of microvasculature and hypoperfusion, respectively, in 
DLB compared to control and AD cases (Miners et al., 2014b). VEGF and MAG were 
significantly positively correlated with each other and negatively correlated with total 
α-synuclein and phosphorylated α-synuclein. Therefore, hypoperfusion in the 
occipital lobe in DLB may occur due to microvascular changes as a result of α-
synuclein pathology. Although previous studies have demonstrated an absence, or 
very low levels, of Lewy body pathology in DLB (Khundakar et al., 2016), the 
sensitivity of ELISA may have detected low levels of pathology that cannot be 
observed by immunohistochemical methods.     
PET studies have reported glucose hypometabolism in the occipital lobe in DLB 
compared to control and AD (Imamura et al., 1997; Ishii et al., 2015), and MSA 
patients (Claassen et al., 2011). Occipital hypoperfusion has been reported to be a 
marker of prodromal DLB, though this was based on a study which assessed a 
relatively small number of patients (Fujishiro et al., 2013). A study using autopsy-
confirmed cases demonstrated occipital hypometabolism as a unique feature of DLB, 
particularly in the primary visual cortex, and was able to identify cases clinically 
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diagnosed as AD but retrospectively diagnosed with DLB following neuropathological 
assessment (Minoshima et al., 2001). Occipital hypometabolism, in combination with 
preserved glucose metabolism in temporal and parietal cortices, may contribute to 
the manifestation of visual hallucinations in DLB (Imamura et al., 1999). The number 
of times non-demented PD patients experience pareidolia, the misidentification of 
visual stimuli, has been significantly correlated with hypoperfusion of the occipital, 
temporal and parietal cortices (Uchiyama et al., 2015). The authors suggest 
paradoelia is a marker for visual hallucinations, thus indicating that posterior cortical 
hypometabolism may create a vulnerability to hallucinogenesis. However, no 
difference in occipital glucose metabolism was previously found between 
hallucinating and non-hallucinating DLB cases (Metzler-Baddeley et al., 2010). 
Studies employing diffusion tensor imaging (DTI) have reported white matter 
damage in the occipital lobe in DLB, particularly in occipito-parietal tracts (Watson et 
al., 2012), which exceeds that observed in AD and control patients (Nedelska et al., 
2015). DLB patients have a similar pattern of global white matter impairment to that 
observed in PDD but the association visual areas of the lateral occipital cortex are 
more severely affected in DLB than in PDD (Lee et al., 2010). The authors speculate 
this may contribute to the greater vulnerability to visual hallucinations in DLB than 
PDD. However, another study has reported that occipital white matter damage is 
associated with an absence of visual hallucinations in DLB (Barber et al., 1999). 
 
1.8.4 The pulvinar 
Neuropathological examination of the pulvinar, association visual cortex and inferior 
temporal cortex, components of the secondary visual pathway, has demonstrated 
Lewy body pathology is more severe than that observed in the primary pathway 
routed through the LGN and primary visual cortex (Yamamoto et al., 2006). The 
pulvinar has been demonstrated to exhibit variable Lewy body pathology in DLB, 
ranging from absent to severe, which is independent of disease duration and 
concomitant AD-type pathology. In a comprehensive study of the pulvinar in PD, no 
sub-region of the pulvinar was found to exhibit neuronal or volumetric reductions 
compared to control or AD cases (Xuereb et al., 1991). An ELISA study has 
demonstrated a reduction in the expression of kallikrein related peptidase 6 (KLK6) 
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in the pulvinar in DLB compared to control cases (Miners et al., 2014a). KLK6 is a 
protease with a putative function in the cleavage of α-synuclein within its most 
fibrillogenic region, suggesting it may inhibit aggregation of α-synuclein (Kasai et al., 
2008). However, there was no relationship between KLK6 levels and α-synuclein 
pathology (Miners et al., 2014a). 
DTI MRI has been used to assess thalamic sub-nuclei on the basis of connectivity. 
DLB patients have increased mean diffusivity, as a putative marker of tissue damage, 
in thalamic regions projecting bilaterally to the prefrontal and parieto-occipital 
cortices (Delli Pizzi et al., 2015b). Using the same approach but specifically framed 
around visual hallucinations, the same research team have demonstrated increased 
mean diffusivity in posterior thalamic regions projecting to occipital and parietal 
cortical regions, which is significantly related to the severity and frequency of visual 
hallucinations in DLB (Delli Pizzi et al., 2014). The anatomy of the posterior thalamus 
does not map perfectly onto sub-regions delineated as a result of connectivity 
studies (Shipp, 2003). However, posterior thalamic projections to occipital and 
parietal regions reflect known pathways emanating from the pulvinar in non-human 
primates (Soares et al., 2001; Kaas and Lyon, 2007). Neuroimaging analysis of 
connectivity has demonstrated disconnect between the thalamus and occipital cortex 
in DLB (Caminiti et al., 2016), which could have relevance to the LGN and pulvinar 
as both are strongly interconnected with the occipital lobe (Jones, 2012).  
 
1.8.5 The superior colliculus  
Neuropathology in the superior colliculus has only been investigated in DLB in one 
study, which found moderate Lewy body pathology (Sierra et al., 2016). However, 
this study did not assess neuronal density or the vulnerability of individual laminae to 
Lewy body pathology, nor were the findings related to visual hallucinations.    
Structural connectivity studies have reported decreased white matter integrity in the 
anterior thalamic radiation, which is related to microstructural damage in the 
mediodorsal thalamic nucleus (Delli Pizzi et al., 2015a). The mediodorsal thalamus 
receives input from the superior colliculus (Erickson et al., 2004) in a pathway that 
ultimately projects to the frontal eye fields (Sommer and Wurtz, 2004), perhaps 
indicating that this pathway is dysfunctional in DLB. 
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1.8.6 Brain regions beyond the primary and secondary visual pathways 
A DTI study of white matter pathways has demonstrated increased diffusivity of the 
inferior longitudinal fasciculus, a white matter tract projecting from the occipital lobe 
to the temporal cortex, associated with visual hallucinations in DLB (Kantarci et al., 
2010).  Consistent with the proposal that occipito-temporal abnormalities may 
contribute to visual hallucinations, hypometabolism in the right occipito-temporal 
junction is greater in DLB patients with visual hallucinations compared to those 
without (Perneczky et al., 2008).  
SPECT studies of cerebral perfusion have demonstrated hypoperfusion in the right 
inferior temporal lobe and bilateral perfusion in the anterior cingulate (Heitz et al., 
2015), and the left midcingulate gyrus (Blanc et al., 2014), are significantly correlated 
with the intensity of visual hallucinations in DLB. A combined study using MRI and 
PET has reported atrophy and reduced perfusion of the right anterior insula is 
significantly related to the intensity of visual hallucinations (Blanc et al., 2014).  
Temporal lobe Lewy body pathology burden has been correlated with the presence 
of visual hallucinations, especially in the amygdala and parahippocampal gyrus 
(Harding et al., 2002). In the temporal lobe, hallucinating PD cases have higher 
densities of Lewy bodies in the middle temporal gyrus, entorhinal cortex and anterior 
cingulate compared to those with no history of visual hallucinations (Gallagher et al., 
2011). 
Higher Lewy body pathology has also been found in the amygdala, frontal, temporal 
and parietal cortices in PD patients with visual hallucinations compared to those 
without hallucinations (Papapetropoulos et al., 2006). However, the group with visual 
hallucinations predominantly had neocortical Lewy body pathology, compared to the 
non-hallucinating group who generally had brainstem and transitional types. As 
visual hallucinations typically occur later in the time course of PD (Fenelon et al., 
2000; Richard et al., 2002), and neocortical Lewy body pathology is thought to be the 
final stage of α-synuclein deposition (Braak et al., 2004; McKeith, 2006), these 
findings may simply reflect changes resulting from longer disease duration.  
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Visual hallucinations in DLB have been related to reduced nicotinic α-bungarotoxin 
binding in the temporal lobe, possibly due to the loss of alpha 7 nicotinic receptor 
markers (Court et al., 2001). Increased binding of ligands for M2 and M4 muscarinic 
receptors in the cingulate has been related to the presence of visual hallucinations 
and may be involved in their pathophysiology (Teaktong et al., 2005).  
 
1.9 Summary and overview 
DLB is a common neurodegenerative dementia disorder marked by the presence of 
complex and recurring visual hallucinations (McKeith, 2006). Despite being a core 
symptom of DLB, there is a paucity of evidence regarding the pathological aetiology 
of visual hallucinations (Burghaus et al., 2012). There is some evidence to support 
the hypothesis that cortical excitability changes could contribute to visual 
hallucinations in DLB (Ffytche, 2005; Taylor et al., 2011; Makin et al., 2013). The 
visual thalamus contains nuclei involved in ascending connections to the cortex 
through the LGN, as well as structures involved in visual attentional functions such 
as the pulvinar. The superior colliculus is proximal to the LGN and pulvinar, 
functionally interacting with both, and has previously been directly related to 
processes implicated in visual hallucinations in DLB (Diederich et al., 2014; Shine et 
al., 2014). A number of hypotheses directly implicate subcortical visual thalamic 
structures, or predict dysfunctional activity consistent with the known function of 
these structures, in the manifestation of visual hallucinations in DLB. The present 
study therefore quantitatively assessed cellular populations in structures within, or 
interacting with, the visual thalamic circuitry. Additionally, proteomic assessment was 
conducted on the pulvinar to evaluate whether it manifests changes at the molecular 
level. The overall goal of this study was thus to evaluate whether subcortical visual 
structures manifest changes that could create a vulnerability to visual hallucination in 
DLB.   
 
1.10 Research aims 
The present study aimed to assess the vulnerability of the visual thalamic structures 
to neurodegenerative changes in DLB. Such changes, if present, may provide 
insights into the pathological aetiology of visual hallucinations in DLB. 
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The hypothesis for this study was that some or all assessed subcortical visual 
structures, the LGN, pulvinar and superior colliculus, possess a distinct pattern of 
neurodegenerative pathology and/or alterations to neuronal/glial populations in DLB 
compared to AD and control cases. Additionally, the pulvinar nucleus was 
hypothesised to have an altered gene and protein expression profile that may create 
a vulnerability to visual hallucinations in DLB compared to control cases. 
This study aimed to: 
1) Assess the burden of α-synuclein, tau and amyloid-β pathology in the sub-
regions of the LGN, pulvinar and superior colliculus in DLB, AD and control 
cases using quantitative histological techniques. 
2) Calculate neuronal and glial cell populations in the sub-regions of the LGN, 
pulvinar and superior colliculus in DLB, AD and control cases using three-
dimensional stereological analysis. 
3) Identify proteins to target based on gene expression analysis using RNA 
sequencing data from pulvinar tissue in DLB compared to control cases. 
4) Assess targeted proteins in the pulvinar in DLB compared to control cases, 
using molecular techniques. 
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Chapter 2: Methods 
2.1 Introduction 
This chapter describes the sampling and staining of histological specimens and the 
biochemical assay protocols performed on fixed and frozen brain tissue. These will 
be separated into histopathological analysis using fixed human tissue and 
biochemical analysis using frozen human tissue. Histopathological analysis 
incorporates the dissection methods and storage of fixed tissues, the histological and 
immunohistochemical methods to stain tissues and the stereological and 
densitometric analyses to assess pathological and morphological changes. 
Biochemical analyses will outline the acquisition of frozen tissue specimens, the 
RNA isolation techniques for RNA sequencing, the bioinformatics techniques used to 
assess pathway changes and the proteomic assays used to quantify protein 
expression in tissue.  
 
2.2 Study cohort 
DLB and AD cases were selected for inclusion in the present study on the basis of 
fulfilling clinical and neuropathological criteria for DLB or AD, respectively (McKeith 
et al., 2005; Montine et al., 2012). AD cases were included as a group with well-
defined cognitive impairment and neurodegenerative pathology but an absence of 
complex visual hallucinations (Burghaus et al., 2012). Clinico-pathological diagnosis 
was reached following a case note review by senior clinicians and consideration of 
neuropathological findings by a senior neuropathologist. In most cases, DLB cases 
were included on the basis of a clinical history of recurrent complex visual 
hallucinations. Control cases were included on the basis of an absence of 
neurological and psychiatric disorders during life and absent or low 
neurodegenerative pathology on post-mortem assessment. The individual 
characteristics of the individual study cohorts are detailed in each chapter.   
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2.3 Tissue acquisition and preparation 
2.3.1 Tissue preparation at the Newcastle Brain Tissue Resource 
All brain tissue was acquired from the NBTR, a United Kingdom Human Tissue 
Authority approved research tissue bank. Ethical approval was granted by the Local 
Research Ethics Committee of Newcastle and North Tyneside Health Authority (ref: 
08/H0906/136). Tissue was obtained at autopsy, with the interval from death to 
freezing and fixation noted. Tissue from the left hemisphere was sliced coronally at 
approximately 1 cm intervals, prior to rapid freezing at -80°C between copper blocks. 
The right hemisphere was fixed in 10% neutral-buffered formalin for five weeks 
before dissection into 7 mm coronal sections. From the 7 mm coronal slices, a pre-
defined number of sections were sub-dissected into blocks used for diagnosis and 
research (Fig. 2.1). All fixed brain tissue sections were then processed by paraffin 
wax embedding, including the remaining tissue following sub-dissection of diagnostic 
tissues. 
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Figure 2.1: Brain map of dissection protocol at NBTR.   
Brain regions with letters indicate the code for the individual blocks that are used for neuropathological diagnosis. The LGN and pulvinar were typically found, 
in entirety, between coronal levels 18 and 21. Purple and cyan coloured blocks indicate blocks that are obtained for diagnostic and research purposes, 
respectively. Blocks J and AH from the NBTR dissection protocol were usually sampled for analysis.  
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2.3.2 The lateral geniculate nucleus 
The LGN is a small structure located on the ventrolateral aspect of the surface of the 
posterior thalamus and is easily identified on coronal sections by its distinctive shape 
and laminar structure (Fig. 2.2A). The LGN was serially sectioned from the start of 
the first tissue block on which it was not present based on gross examination, 
typically corresponding to coronal levels 16-17 or block F on the NBTR brain 
dissection protocol, until its disappearance (Fig. 2.1).  
 
2.3.3 The pulvinar nucleus 
The pulvinar is the largest of the thalamic nuclei and occupies the majority of the 
posterior aspect of the thalamic complex (Jones, 2012) (Fig. 2.2B). The pulvinar was 
identified at its anterior pole, situated on the lateral posterior aspect of the 
centromedian thalamic nucleus (Fig. 2.2A) (Popken et al., 2002; Mai et al., 2016). 
Sectioning commenced from the presence of the centromedian nucleus without any 
pulvinar present, to ensure that the complete antero-posterior extent of the pulvinar 
was sampled through the z-axis. On the NBTR brain dissection protocol, sectioning 
typically commenced at coronal level 16-17 (block F; Fig. 2.1).      
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Figure 2.2: Coronal brain sections illustrating the LGN and pulvinar.   
Sections are stained with Loyez’s haematoxylin and illustrate the anatomical location of the LGN and 
pulvinar. A demonstrates the LGN (yellow) and the centromedian thalamic nucleus (red). B illustrates 
the pulvinar complex (red). Images courtesy of (Mai et al., 2016), plates 44 and 46.  
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2.3.4 The superior colliculus 
Under the NBTR brain dissection protocol, the midbrain was cut from the cerebrum 
at the level of the third cranial nerve, along a line from the junction of the mammillary 
body running posteriorly to the upper part of the superior colliculus. The superior 
colliculus was identified based on its location on the dorsal aspect of the midbrain, 
proximal to the periaqueductal grey (Krauzlis et al., 2013) (Fig. 2.3). 
 
 
Figure 2.3: Left upper midbrain stained with Loyez’s haematoxylin. 
The superior colliculus is outlined in red. This is a photomicrograph of a control case. 
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2.3.5 Cutting and preparation of tissues 
Blocks containing the entire structure of interest were sectioned on a HM340E rotary 
microtome with a z-axis monitor (Thermo Scientific, Waltham, MA, USA), with 5x 30 
μm and 10x 10 μm sections taken at every 0.5 mm interval (Fig. 2.4). 
  
 
Figure 2.4: Sampling strategy used for stereological analysis. 
From a random starting point, 5x 30 μm sections (red) and 10x 10 μm (green) were taken, the tissue 
(blue) was then cut through for approximately another 250 μm, until 500 μm from the initial start of that 
interval was reached. 
 
 
Sections were mounted onto Histobond (CellPath, Newtown, UK) charged slides 
using a water bath and dried for 48 hours at 30 °C. Once dried, sections were stored 
at room temperature prior to staining.   
 
2.3.6 Histological staining with cresyl violet 
Cresyl violet staining was conducted on 30 μm sections at intervals using the 
sampling scheme noted in Fig. 2.4. Sections were first heated in a 60°C oven for 30 
minutes prior to dewaxing by immersion in absolute xylene, then rehydrated through 
a graded series of ethanol solutions from absolute ethanol to 95% ethanol. Sections 
were then placed in 1% hydrochloric acid in 70% ethanol for five minutes then 
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washed in distilled water, prior to incubation in pre-heated 60°C cresyl fast violet 
solution in a 60°C oven for five minutes and removed from the oven to cool for a 
further five minutes in solution. Sections were differentiated in 95% ethanol solution 
until pallor of the internal capsule was evident on thalamic sections or the red 
nucleus and periaqueductal grey were visible on upper midbrain sections, before 
being dehydrated through a graded series of progressively less dilute ethanol 
solutions, cleared in xylene and mounted using DPX (CellPath, Newtown, UK).   
 
2.3.7 Immunohistochemistry 
Immunohistochemistry was conducted on 6-10 μm formalin-fixed tissue sections. 
Paraffin-embedded sections were first heated in a 60°C oven for 30 minutes prior to 
dewaxing by immersion in absolute xylene. Sections were then rehydrated through a 
graded series of progressively more dilute ethanol solutions, beginning with absolute 
ethanol and progressing through 95%, 90%, 70%, 50% and 30% solutions until 
water. Antigen retrieval protocols were conducted on tissue sections to unmask 
epitopes that have been cross-linked as a result of tissue fixation. The optimal 
technique used to unmask the epitopes was empirically determined and differed for 
the individual antibodies employed. Antigen retrieval using citrate buffer used 
trisodium citrate pH 6.0 pre-heated for 10 minutes at full power in an 800 watt 
microwave (SLS, Hessle, UK), then heated on full power in the microwave with the 
slides for 10 minutes and cooled in the solution for 20 minutes at room temperature. 
The formic acid method involved immersing slides in room temperature absolute 
formic acid for a pre-determined period of time. Ethylenediamine tetra-acetic acid 
(EDTA) pH 8.0 antigen retrieval was performed in a pressure cooker. EDTA buffer 
was heated in a pressure cooker until boiling and sections were then placed in 
boiling EDTA for two minutes. Sections were then washed in flowing water. Trypsin 
antigen retrieval used trypsin working solution pH 7.8 consisting of 0.5% trypsin in 
water mixed with 1% calcium chloride in water and diluted to 0.05% trypsin with 
water. Trypsin working solution was heated to 37ºC and sections were placed into 
the solution and incubated for 15 minutes at 37ºC, prior to washing in running water.  
Endogenous peroxidase activity in tissues was blocked in 3% hydrogen peroxide in 
water for 20 minutes. Sections were thoroughly washed after quenching, firstly in 
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water and then in three washes of 10 mM tris-buffered saline and Tween20 pH 7.6 
(TBST).  
Tissue sections were outlined using an ImmEdge hydrophobic barrier pen (Vector 
Laboratories, Burlingame, CA, USA) and primary antisera, suspended in TBST, were 
pipetted onto the section and incubated for one hour at room temperature. Following 
three washes in TBST, the universal probe from the Menarini MenaPath kits 
(Menarini, diagnostics, Berkshire, UK) was placed onto the section for 30 minutes 
incubation at room temperature. Sections were then washed three times in TBST 
before polymer solution conjugated to horseradish peroxidase (Menarini MenaPath) 
was placed onto sections and incubated for 30 minutes, prior to three washes in 
TBST. To visualise antibody binding, 3, 3’ diaminobenzidine (DAB) chromogen in 
DAB substrate buffer (Menarini MenaPath) was made up as per manufacturer’s 
instructions and applied to sections for four minutes. Sections were then washed in 
running water for ten minutes. 
Sections were counterstained by placing them in Mayer’s haematoxylin solution for 
30 seconds. They were then washed in water, differentiated with 1% hydrochloric 
acid in 70% ethanol, and blued with 1% ammonia in water.  
Sections were then dehydrated through a series of progressively more concentrated 
ethanol solutions until absolute ethanol, before clearing in xylene and being mounted 
with DPX (CellPath, Newtown, UK). Sections were carefully checked by the unaided 
eye and under a microscope to ensure quality and consistency of staining.    
 
2.4 Stereological analysis 
2.4.1 Introduction to stereology 
Stereological methods enable one to estimate three-dimensional attributes of a 
structure, such as volume, based on its two-dimensional profile on sections taken at 
uniform intervals throughout the entire structure (Mouton, 2013). This differs from 
traditional neuropathological methods, which typically use a single section from a 
brain structure and calculate the density of a particular object within a defined region 
of interest. This approach assumes that a section obtained from an arbitrary point 
within a brain structure is representative of the whole region, and that objects within 
the structure are expressed in a homogeneous distribution throughout. Neuronal 
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counts within a single structure are dependent upon the structure being cut at the 
same plane in every case, to ensure a similar area is sampled in every case. 
To overcome issues with two-dimensional analysis of the brain, stereological 
protocols enable greater inference to be drawn regarding three-dimensional 
characteristics of individual structures (Mouton, 2011). Using this method, 
assumptions regarding the homogeneous distribution of particles within a structure 
and sectioning on the same plane do not have to be made as the whole structure is 
sampled. For small structures, such as those to be assessed in the present project, 
this typically involves serially sectioning the entire structure from its anterior to 
posterior pole (Mouton, 2013). As a result, this is a labour-intensive approach 
typically only employed in a research setting and is often at odds with the efficient 
reporting of cases conducted in a brain storage facility. However, several studies 
have been conducted using stereological methodology to investigate changes to 
neuronal populations that occur in various dementias (Erskine and Khundakar, 2016). 
Previously, stereological studies have demonstrated important relationships between 
neuronal loss and cognitive decline in AD (Gomez-Isla et al., 1996; von Gunten et al., 
2006).  
In the present studies, stereological methodology has been employed to investigate 
whether total neuronal or glial number differs in the subcortical visual structures 
across the individual experimental groups. Total cell number is estimated by 
determining volume on the basis of the two-dimensional profile of the structure of 
interest obtained at known intervals analysed serially throughout the entire structure. 
As a result of the whole structure being evaluated, it is not affected by artefacts such 
as the plane on which the object is cut or the distribution of the sampled object within 
the structure (Mouton, 2011). Cellular density is calculated by counting the object of 
interest within randomly sampled areas of the region of interest, inside a frame of 
known size. Total number is then estimated as a product of the mean density of the 
cellular population of interest per area, and the total volume of the structure.      
 
2.4.2 Sampling method 
Stereologer software (Stereologer, Bethesda, MD, USA) was used on a computer 
coupled to a Zeiss AxioVision Z.1 microscope (Zeiss, Oberkochen, Germany) with a 
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motorised stage. As outlined in section 2.3.5 on cutting and preparation of tissues, 
the LGN and pulvinar were serially sectioned, beginning at a random point within the 
first interval, and then at systematic 0.5 mm intervals through the antero-posterior 
extent of the structure (z-axis) until the posterior pole, as outlined in Fig. 2.4. As the 
starting point was random, and the intervals between sampled sections were uniform, 
this meant that the every part of the structure had an equal probability of being 
sampled for analysis. On the basis of this sampling method, the entire structure was 
sampled throughout its z-axis. 
On each coronal section, a region of interest corresponding to the boundary of the 
structure (x-y axis), was drawn at low magnification (Fig. 2.5A). Within the delineated 
region of interest, a systematic, randomly-oriented point grid was superimposed over 
the observed image (Fig. 2.5B). The imposition of a randomly-oriented point grid 
means that every area within the region of interest has an equal probability of being 
sampled for analysis. As a result of this sampling method, a representative sample of 
the coronal profile of each structure was obtained across its x-y axis on each section. 
This meant that the structure was sampled in a systematic and random manner 
through its x-y and z axis.   
The number of sections analysed per case, and the interval between the individual 
points on the grid, were empirically determined for each structure based on an initial 
pilot study, prior to the collection of data. Initial pilot studies consisted of analysis of a 
minimum of two complete cases. On the completion of the pilot cases, coefficient of 
error (CE) values were calculated with the aim of assessing whether each case had 
been sampled to a sufficient degree to ensure that sampling error was within 
acceptable boundaries. CE values were determined by the Gundersen-Jensen 
method (Gundersen and Jensen, 1987), as described by the following equation: 
𝐶𝐶𝐶𝐶2 = �Σ (𝐼𝐼2)(Σ 𝐼𝐼)2 + Σ (𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉2)Σ (𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉2) − 2Σ(1 ⋅ 𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉)(Σ 𝐼𝐼 ⋅ Σ 𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉)� ⋅ � 𝑛𝑛𝑛𝑛 − 1� 
Where 𝐼𝐼 = objects counted, 𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉 = reference area x (sampling frame density)2 x 
section depth, and 𝑛𝑛 = number of fields. 
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CE values between 0.01 and 0.15 are considered to contain acceptable levels of 
error (Herculano-Houzel et al., 2015). 
 
2.4.3 Estimation of the volume of structures 
The present series of studies were designed to estimate the total number of neurons 
within the specified brain regions across different disease states. Therefore, in each 
individual case, the parameters to be assessed were the total volume of the structure 
and the mean number of neurons within a defined volume of tissue. The product of 
the mean number of neurons per volume, combined with the total volume of the 
structure, gives an estimation of the total number of neurons within each structure 
per case.  
A systematic and random counting grid was superimposed onto the image, as 
outlined in the previous section, and Cavalieri’s method was used to determine the 
volume of the structure. Cavalieri’s principle allows estimation of the total volume of 
a structure of interest based on the intersection distance (T), the area per point on 
the counting grid (a) and the sum of the number of counted points (p): 
𝑉𝑉 ≔ 𝑇𝑇 ∙ 𝑎𝑎 ∙ Σ𝑝𝑝 
As outlined in section 2.4.2 on the sampling of tissues, a region of interest was 
drawn around the border of the structure in the x-y axis at low magnification of 2.5x 
objective. A counting grid was then super-imposed over this image on the screen of 
the computer coupled to the microscope. The distance between points on the 
counting grid was empirically determined, based on the result of pilot studies. All 
points within the defined region of interest were clicked to count them as within the 
region of interest. This was repeated for every section at equally-spaced intervals for 
the entirety of the structure through the z axis per case. On the basis of the 
information input to the programme, the software calculated an estimate of the total 
volume of the structure, according to the Cavalieri principle.  
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2.4.4 Estimation of neuronal number 
To determine the mean density of cells within a given structure, the x-y axis was 
randomly sampled, as outlined in section 2.4.2 on the sampling of tissues. Similar to 
the point-grid that was used for determination of volume using the Cavalieri method, 
a grid of randomly-oriented points was used to sample the x-y axis. In this instance, 
each point corresponded to an area that was then viewed at high magnification. The 
number of points per area of tissue was empirically determined on the basis of pilot 
studies. Within each area viewed at high magnification, a frame of known size was 
superimposed onto the observed image (Fig. 2.5C). The frame size employed for 
each structure was empirically determined based on pilot studies. The thickness of 
the section was determined, then the number of cells within each frame was counted, 
excluding cells that transected the border of the frame on its left and bottom border. 
The known size of the frame and the thickness of the section enabled the volume of 
tissue sampled to be determined and, therefore, the mean density of cells per 
volume were calculated. This procedure was repeated for every section at equally-
spaced intervals for the entirety of the structure through the z axis, yielding the 
numerical density, i.e. the mean number of cells in a given volume of tissue.  
The numerical density was calculated per case as follows: 
𝑁𝑁𝑁𝑁 = ∑ 𝑄𝑄−𝑝𝑝−
𝑃𝑃 ⋅ 𝑉𝑉
 
Where 𝑁𝑁𝑁𝑁 = numerical density,  𝑝𝑝− = disector samples, 𝑄𝑄− = Q-weighted number 
of objects counted, 𝑃𝑃 = total number of disectors, and 𝑉𝑉 = disector volume. 
Although point grids were used to determine volume and to select regions in which to 
count cells at high magnification, these two steps were conducted sequentially by the 
software programme. Therefore, it was possible for the interval between points for 
determination of volume to be different from the interval used for selecting the frame 
in which to count cells at high magnification. For each parameter, the interval 
between points in counting grids was kept the same for all cases per structure.  
An overall estimate of the number of cells present within a structure of interest was 
determined automatically by the Stereologer software by calculating the mean 
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number of cells in a given area, with consideration of the volume estimate provided 
by the Cavalieri method.  
In practice, a series of sections for each structure per case was obtained. On each 
section, a region of interest was drawn around the structure at 2.5x objective (Fig. 
2.5A). A grid of points was then superimposed over the region of interest, points on 
the region of interest had to be clicked to turn green, thus providing data to 
determine volume using the Cavalieri principle (Fig. 2.5B). As before, another point 
grid was superimposed, the size of which was empirically determined by pilot studies, 
to sample the x-y axis to determine areas that will be viewed at 63x objective to 
determine cellular density (Fig. 2.5B). Neurons were then counted within disector 
frames of known dimensions at 63x oil immersion objective (Fig. 2.5C). At each point, 
the top and bottom of the section were established through the z-axis, thus 
determining the thickness of the section. Cells were counted if their nucleolus was 
present within the frame, or if they were on the right or top border of the frame (Fig. 
2.5C). Neurons were differentiated from glia based on the presence of Nissl 
substance within the cytoplasm, a pale nucleus and a single, identifiable, nucleolus 
(Khundakar et al., 2009).  
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Figure 2.5: Stereological methods.   
A region of interest was drawn around the structure to be assessed, in this instance the magnocellular laminae of the LGN (A). A point grid was superimposed 
over the structure, points were clicked to turn green if they were within the region to be sampled (B). The points clicked were used to determine volume using 
the Cavalieri method, and neurons were counted within randomly-sampled frames in the x-y axis. Randomly sampled points within the region of interest were 
viewed at high magnification, and neurons were counted within a disector frame of known dimensions (C). 
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2.5 Densitometric analysis of immunoreactivity 
Densitometric analysis assessed the percentage area stained by an antibody in a 
particular region of interest.   
For the LGN, images of the entire the region of interest on coronal sections 
throughout the z-axis of the structure were captured on a microscope using a 
camera coupled to a computer. The images were imported into NIS elements (Nikon, 
Tokyo, Japan) or ImagePro (Media Cybernetics Plus v.4.1 (Bethesda, MD, USA) 
image analysis software and standardised red-blue-green (RGB) thresholds were 
determined separately for each antibody. To exclude intracellular amyloid-β from 
analysis of 4G8 antibody, size restrictions were also employed based on empirical 
observations of size. Intracellular amyloid-β was not counted as it is present in most 
cells and may then be affected by factors such as neuronal loss. This allowed 
analysis of the immunopositive signals without detection of non-specific background 
staining, as it did not reach the intensity threshold for detection. The percentage area 
stained was recorded for every image taken and a mean generated across all 
images per case.  
For the pulvinar and superior colliculus, the Stereologer programme was used to 
draw a region of interest at 2.5x objective, from which randomly sampled points were 
analysed on higher-magnification, either 10x, 20x or 40x objective, dependent upon 
the size and distribution of the objects being analysed. For consistency, the objective 
at which objects were analysed was the same for each antibody per region across all 
cases. The randomly sampled frames were photographed, using the microscope 
camera, and imported to ImagePro or NIS elements analysis software to conduct 
analysis of the percentage area stained (Fig. 2.6). RGB thresholds were empirically 
determined and applied per antibody. Size thresholds were employed for 4G8 
amyloid-β analysis to prevent counting of intracellular amyloid-β.  
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Figure 2.6: Densitometric analysis of immunoreactivity.   
Images of sections stained with α-synuclein at 20x magnification have a region of interest drawn around the disector frame. A colour threshold is then applied 
which detects immunoreactivity labelled by the DAB chromogen within the region of interest only but does not detect non-specific background staining. 
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2.6 Molecular techniques 
2.6.1 RNA isolation and sequencing 
Frozen tissue was placed in 5-10 volumes of pre-cooled RNAlater solution (Ambion, 
Warrington, UK) and stored at -80°C. Tissue was removed from RNAlater and 
rapidly homogenised in TRI-reagent (Ambion, Warrington, UK) and stored at -80°C. 
RNA was extracted using a spin column method as per manufacturer’s instructions 
(Ribopure, Ambion, Warrington, UK), and 1 μg of RNA DNase-treated (Turbo-DNase 
free, Ambion, Warrington, UK). The RNA concentration was determined using a 
Nanodrop ND 1000 Spectrophotometer (Nanodrop Technologies, DE, USA) and 
RNA integrity number examined with an Agilent 2100 Bioanalyzer RNA 6000 Nano 
Assay (Agilent Technologies, Stockport, UK) according to manufacturer’s 
instructions. 
 
2.6.2 Western blotting 
Frozen tissue was brought to -20°C in a freezing cabinet and relevant regions 
removed. Approximately 20 mg tissue was homogenised using a rotor-stator type 
homogeniser in ice cold lysis buffer containing 0.2 M tetraethyl ammonium 
bicarbonate, pH 7.2 (TEAB; Sigma-Aldrich, MO, USA), 1 mM EDTA and protease 
inhibitor tablets (Complete, Roche, Burgess Hill, UK). Samples were made to 0.02% 
sodium dodecyl sulphate and sonicated on ice in a sonicating water bath for 20 
minutes and with a sonic probe for five seconds. Protein quantification was then 
performed using Bradford assay (Sigma-Aldrich, MO, USA). 
Samples were prepared for sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) by adding sample buffer (Novex NuPAGE LDS sample 
buffer, Invitrogen, Waltham, MA, USA), a reducing agent (NuPAGE sample reducing 
agent, Invitrogen, Waltham, MA, USA) and made up to 1 µg/µl with TEAB. Prepared 
samples were then denatured by heating at 70 ºC to reveal primary protein structure. 
Prepared tissue samples were then loaded onto NuPAGE 12% Bis-Tris gel 
(Invitrogen, Waltahm, MA, USA), 10 µg per well, with 1x SDS NuPAGE MOPS 
Running Buffer containing NuPAGE Antioxidant (Invitrogen, Waltham, MA, USA). 
Proteins were transferred to a nitrocellulose membrane using an iBlot transfer device 
(Invitrogen, Waltham, MA, USA) and stained with Ponceau S solution (Sigma-Alrich, 
MO, USA) to ensure successful transfer and equal protein loading. Membranes were 
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destained with 1x TBST (Sigma-Aldrich, MO, USA) and stored in TBST at 4°C 
overnight.  
Membranes were incubated in 5% dried milk (Marvel, Premier Foods, Griffiths Way, 
UK) in TBST for 60 minutes at room temperature to block non-specific protein 
binding sites. Primary antibody incubation was conducted for one hour at room 
temperature diluted in 5% dried milk in TBST with agitation. Membranes were 
washed in TBST for 10 minute intervals two times, and then incubated for a further 
30 minutes with horseradish peroxidase conjugated secondary antibodies at room 
temperature under agitation. Membranes were washed for 15 minutes four times in 
TBST prior to visualisation with Enhanced Chemiluminescence (GE, Amersham, 
Buckinghamshire, UK) and detected using x-ray film (Fuji, Fisher Scientific, 
Loughborough, UK). Size and intensity of protein bands was quantified using ImageJ 
software (NIH, Bethesda, MA, USA) with target protein expression normalised to 
glyceraldehyde 3-phosphate dehydrogenase-horseradish peroxidase conjugate 
(GAPDH-HRP conjugate; 1:4000, Santa Cruz, TX, USA) expression. Although 
concerns have been raised about the reliability of using highly-expressed 
housekeeping proteins as western blot loading controls (Goasdoue et al., 2016), 
GAPDH has been demonstrated to be less variable across different biological 
conditions than other commonly used loading controls such as β-tubulin and β-actin 
(Goasdoue et al., 2016; Lee et al., 2016). 
 
2.7 Statistical analysis 
All data were assessed for normality by the Shapiro-Wilk test and inspection of 
histograms and Q-Q plots. Homogeneity of variance was assessed by Levene’s f-
test. Homogeneity of regression slopes was determined by inspection of co-
regression of variables on a scatterplot.  
If all assumptions were met, analysis of covariance (ANCOVA) was employed for all 
variables, using age and post-mortem interval as covariates. This enabled the effects 
of age and different degrees of post-mortem autolysis to be statistically controlled 
and has been used in similar stereological studies (Dorph-Petersen et al., 2009). If 
all parameters excluding homogeneity of regression slopes were satisfied, analysis 
of variance (ANOVA) was used. This allows significant main effects to be identified in 
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data but does not enable one to control for covariates influencing the main effect. If 
data were not normally distributed, non-parametric Kruskal-Wallis tests were used. 
Post-hoc analysis of ANCOVA was conducted using pairwise comparisons. For 
ANOVA, Tukey’s honest significant difference (HSD) test was used. Kruskal-Wallis 
tests were followed by Mann-Whitney U tests. Corrections for multiple comparisons 
were not employed on Mann-Whitney tests. By convention, the Bonferroni correction 
(α/n, where n is the number of independent tests performed) is employed to 
attenuate for multiple comparisons. This correction is one of the most conservative 
multiple comparisons adjustments, as the α value falls markedly with higher numbers 
of tests, leading to increased probability of performing a type two error (i.e. a false 
negative) (Streiner and Norman, 2011). The premise of multiple comparisons testing 
has been criticised on the basis that it assumes chance is the first order explanation 
for observations, undermining the key tenet of empirical research that assumes 
regularities of nature which may explain observations (Rothman, 1990). Additionally, 
the relatively small samples employed in the present series of studies would likely 
mean that these studies would be under-powered to detect a significant difference if 
multiple comparisons corrections were employed. However, to determine the 
importance of statistically significant alterations, and to guard against potential type 
one errors (i.e. false positives), effect sizes were calculated using Cohen’s d and 
considered for all observed changes.      
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Chapter 3:   Histological studies in the lateral geniculate nucleus 
3.1 Introduction 
Although visual hallucinations are a core clinical diagnostic feature of DLB, the 
pathological changes that give DLB patients a vulnerability to hallucination remain 
largely unknown (McKeith et al., 2005; Diederich et al., 2014). Physiological studies 
have demonstrated thinning of the retinal nerve (Moreno-Ramos et al., 2013) and 
electroretinogram alterations in DLB (Devos et al., 2005). Neuropathological studies 
have also demonstrated sparse neuritic α-synuclein pathology in the retina of nine 
PD and three DLB patients (Beach et al., 2014) though another study, using six PD 
cases, has noted that retinal α-synuclein differs from Lewy pathology in the brain (Ho 
et al., 2014). However, this has been contested with another study reporting retinal 
α-synuclein pathology to be similar to that observed in the brain (Bodis-Wollner et al., 
2014). Despite the high prevalence of visual perceptual abnormalities, the afferent 
visual system remains relatively under-studied in DLB. 
The LGN relays incoming visual information from the retina to the primary visual 
cortex (Jones, 2012). Although it is a crucial structure for visual sensation, few 
studies have assessed how the LGN is affected by neurodegenerative disease. 
Sparse tau pathology has been recorded in AD and PSP (Dugger et al., 2011), whilst 
amyloid-β pathology has been observed in the LGN in AD and some aged control 
cases (Leuba and Saini, 1995). Two studies have used qualitative methods to 
investigate the LGN in Lewy body diseases. One study found cell loss but an 
absence of Lewy body pathology in DLB (Yamamoto et al., 2006) and another 
described α-synuclein pathology in the LGN and visual cortex in PD (Rahimi and 
Kovacs, 2014). The role of the LGN in visual hallucinations in DLB has not yet been 
investigated using quantitative neuropathological techniques, despite an opinion 
paper expressing the need for such studies (Diederich et al., 2014). The aim of the 
present study, therefore, was to investigate whether pathological abnormalities exist 
in the LGN that may contribute to the generation of complex visual hallucinations in 
DLB.  
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3.1.1 Aims 
Using post-mortem LGN tissue taken from DLB patients who had experienced visual 
hallucinations, compared with aged cognitively normal controls and disease-control 
AD patients with no visual hallucinations, this study aimed to:  
1) Use stereological methods to estimate the total number of neurons and glial 
cells in the LGN. 
2) Quantify the burden of neurodegenerative pathological lesions, labelled by 
antibodies against amyloid-β, phosphorylated tau and α-synuclein. 
3) Assess whether there are changes to sub-populations of neurons labelled by 
antibodies against the calcium-binding proteins calbindin, calretinin and 
parvalbumin, and the GABA-ergic neuron marker glutamic acid decarboxylase 
65/67 (GAD65/67).  
 
3.2 Methods 
3.2.1 Tissue acquisition 
The LGN lies on the bank of the lateral ventricle, on the ventral surface of the 
posterior thalamus (Jones, 2007). The LGN is easily identified in coronal sections, 
even to the unaided eye, due to its distinctive striated architecture (Fig. 3.1) (Jones, 
2012).  
Three groups were included in the LGN study: DLB patients who had experienced 
complex visual hallucinations during life, AD patients who had not experienced 
complex visual hallucinations during life and aged controls showing none, or very low, 
age-associated neurodegenerative pathology and no clinical history of psychiatric 
disease. Cases with severe degenerative opthalmological conditions, such as 
glaucoma and macular degeneration, were excluded due to previously documented 
degeneration of the LGN in these disorders (Hernowo et al., 2011; Zikou et al., 2012). 
Within these criteria, cases were included based on whether the LGN was complete 
both coronally and along its antero-posterior extent. The cases meeting the criteria 
consisted of six DLB, seven AD and seven control cases (Table 3.1).  
From a random starting point, fixed tissue blocks containing the entire LGN were 
serially sectioned from the anterior to the posterior pole to ensure that the entire 
structure was sampled. 30 μm sections were obtained at each 1 mm interval and 
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stained with cresyl violet for stereological analyses. 10 μm sections were obtained at 
approximately alternate intervals to those obtained for stereology were stained with 
antibodies against a range of protein targets (Table 3.2) using Menarini MenaPath 
Polymer kits (Menarini, Berkshire, UK), as described in Methods.  
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Table 3.1: Demographic information for cases used in the LGN study.  
‘PM interval’ represents the interval between death and post-mortem examination, ‘Braak NFT’ represents global neurofibrillary pathology stage as outlined in 
(Braak et al., 2006), ‘McKeith LB’ represents global Lewy body pathology stage, as outlined in (McKeith et al., 2005), ‘clinico-path diagnosis’ represents the 
overall diagnosis, as decided upon by case-note review and neuropathological examination by senior clinicians, in accordance with consensus criteria 
(McKeith et al., 2005; Montine et al., 2012). 
Case ID Gender Age at 
death 
(years) 
PM 
interval 
(hours) 
Braak 
NFT 
McKeith LB Clinico-path 
diagnosis 
Hallucinations 
C1 F 78 23 2 None Control None reported 
C2 F 74 45 2 None Control None reported 
C3 F 85 99 2 None Control None reported 
C4 M 77 83 2 None Control None reported 
C5 M 73 25 0 None Control None reported 
C6 M 80 16 2 Brainstem Control None reported 
C7 M 85 57 2 None Control None reported 
Mean±SD  81.4±8. 43.6±33 1.8±1    
D1 M 84 56 2 Neocortical DLB Complex visual hallucinations 
D2 M 89 88 3 Neocortical DLB Complex visual hallucinations 
D3 M 71 8 3 Neocortical DLB Complex visual hallucinations 
D4 M 71 68 3 Neocortical DLB Complex visual hallucinations  
D5 M 78 83 1 Neocortical DLB Complex visual hallucinations 
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D6 F 78 96 3 Neocortical DLB Complex visual hallucinations 
Mean±SD  78.5±7 66.5±32 2.5±1    
A1 M 76 6 6 None AD None reported 
A2 M 91 22 5 None AD None reported 
A3 F 85 32 5 None AD None reported 
A4 F 77 63 6 None AD None reported 
A5 F 81 73 5 None AD None reported 
A6 F 93 34 5 None AD None reported 
A7 F 86 51 6 None AD None reported 
Mean±SD  84.1±7 40.1±24 5.4±1    
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3.2.2 Stereology 
The LGN has a distinctive laminar structure that enables delineation of functionally 
and anatomically distinct sub-populations of cells. The LGN is typically divided, 
based on laminae and cellular populations, into two ventral ‘magnocellular’ and four 
dorsal ‘parvocellular’ laminae (Dorph-Petersen et al., 2009). Magnocellular neurons 
are optimised for detecting motion and rapidly changing visual information, in 
contrast to parvocellular neurons, which are better suited to detailed form and colour 
processing (Jones, 2012; Denison et al., 2014). As a result of the functional 
differences between magnocellular and parvocellular neurons, separate stereological 
counts were made of both populations to help interpret the likely physiological effects 
of any specific changes. As shown in Fig. 3.1, neuronal and glial populations were 
determined by their anatomical location within laminae of LGN. However, as noted 
previously (Hickey and Guillery, 1979), some magnocellular neurons are present 
outside the two ventral laminae. Therefore, these ‘islands’ of magnocellular neurons 
were identified based on staining intensity and size (as in (Dorph-Petersen et al., 
2009)) and included in estimations of magnocellular neuron number, as in Fig. 3.1.  
 
Figure 3.1: Anatomy of the LGN.  
This section is taken from approximately the midpoint through the coronal plane and stained with 
cresyl violet. Lamination is evident on the photomicrograph and the schematic illustrates how the LGN 
was divided into magnocellular (black) and parvocellular (grey). Bar = 1 mm.  
A third sub-type of LGN neuron, koniocellular cells, are distributed on the ventral 
aspect of some laminae, rather than being lamina-specific (Jones, 2012). A previous 
report suggested that koniocellular neurons are labelled by calbindin antibodies 
(Munkle et al., 2000). However, no specific labelling was located in the LGN using 
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various methods of epitope unmasking and antibody titrations with two calbindin 
antibodies (Sigma Aldrich, MO, USA and Merck Millipore, Germany).  
Stereological methodology was used to estimate the total number of neurons and 
glia within the LGN, as outlined in section 2.4. Cell counts were conducted at 63x oil-
immersion objective using the optical disector probe. Glial cell counts were 
calculated in both LGN sub-regions in disector frames of 1900 μm2, with neuron 
counts calculated in disector frames of 3500 μm2. Section thickness did not 
significantly vary across disease groups in the magnocellular or parvocellular 
laminae. Mean CE values suggested that the analysis reached an acceptable level 
of accuracy, as all cases had CE values <0.10. A mean of 7 (range of 5-9) sections 
were analysed per case. 
 
3.2.3 Densitometry 
Sections from alternate intervals to those used for stereological analysis were 
stained with AT8, 4G8 and 5G4 antibodies to label phosphorylated tau, amyloid-β 
and aggregated α-synculein, respectively. To determine the percentage area 
immunoreactive for individual antibodies, images were taken of the entire LGN using 
a Nikon 90i microscope (Nikon, Tokyo, Japan) with a 20x magnifying objective and 
DsFi1 camera (Nikon, Tokyo, Japan). Images were then imported into NIS elements 
software and RGB thresholds determined individually for AT8, 4G8 and 5G4 
antibodies, as described previously (Mandler et al., 2014). As in section 2.5, 
individual thresholds were set based on colour and intensity to ensure that non-
specific background staining was not included. Size thresholds were employed for 
sections stained with the 4G8 antibody to ensure that intracellular amyloid-β was not 
included in analyses.     
To determine the percentage area immunoreactive for GAD65/67, calretinin and 
parvalbumin, sampled images were taken of the entire the LGN from sections 
throughout the structure, using a Zeiss AxioPlan 2 microscope (Zeiss, Oberkochen, 
Germany) with a 20x magnifying objective and 3-chip CCD true colour camera (JVC, 
Yokohama, Japan). Images were imported into the ImagePro Plus v.4.1 image 
analysis system and RGB thresholds determined individually for each antibody, as 
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described previously (Perry et al., 2012). Individual thresholds were set based on 
colour and intensity to ensure that non-specific background staining was not included.   
Cholinergic dysfunction is well described in DLB and may contribute to visual 
hallucinations (Perry and Perry, 1995). The LGN receives cholinergic afferents which 
directly modulate its excitability (Kodama and Honda, 1996), suggesting cholinergic 
dysfunction may alter visual system activity and potentially contribute to visual 
hallucinations. The LGN was stained with antibodies against choline 
acetyltransferase, a cholinergic marker, and the cholinergic pre-synaptic transporter 
to determine whether changes were observed in DLB compared to control and AD. 
However, no immunoreactivity was observed in the LGN with either antibody, despite 
numerous titrations and epitope retrieval steps being used. Choline acetyltransferase 
immunoreactivity was observed in the corpus striatum as expected but not 
immunoreactivity was observed in the LGN, implying that the antibody worked but 
the epitope recognised by the antibody was not present within the LGN. In the case 
of the vesicular cholinergic transporter, no immunoreactivity was visible anywhere, 
implying the antibody did not work. 
 
3.2.4 Statistical analyses 
Inspection of Q-Q plots, and Shapiro-Wilk and Levine’s F tests suggested that LGN 
stereological data were normally distributed and had homogeneity of variance. 
Additionally, visual inspection of regression lines of stereological data with age and 
PM interval indicated that homogeneity of regression slopes could also be assumed. 
Therefore, ANCOVA was conducted on LGN stereological data, followed by post-hoc 
pairwise comparisons. However, neuropathological and densitometric data were not 
normally distributed, so Kruskal-Wallis and post-hoc Mann-Whitney tests were 
conducted.  
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Table 3.2: Antibodies used in the LGN study. 
Antibody Manufacturer Dilution Antigen retrieval 
5G4 α-synuclein Analytik Jena, 
Germany 
1:4500 Formic acid + 
citrate pH 6.0 
AT8 phospho-tau Autogen, MA, USA 1:4000 Citrate pH 6.0 
4G8 amyloid-β Covance, NJ, USA 1:15000 Formic acid 
GAD65/67 Sigma Aldrich, MO, 
USA 
1:12000 Citrate pH 6.0 
Parvalbumin Sigma Aldrich, MO, 
USA 
1:8000 Citrate pH 6.0 
Calretinin Sigma Aldrich, MO, 
USA 
1:1000 Citrate pH 6.0 
 
3.3 Results 
3.3.1 Demographics 
There was no significant difference in age at death (F=0.92, p=0.415), post-mortem 
delay (F=1.486, p=0.253) or gender (χ²=3.935, p=0.140) between experimental 
groups (Table 3.1).  
 
3.3.2 Stereology 
Stereological data are summarised in Fig. 3.2. A significant main effect of diagnosis 
on parvocellular neuron number was found (F=5.845, p=0.013), with a significant 
decrease in AD cases compared to DLB (p=0.004, d=1.18) and a trend towards a 
significant reduction in AD compared to control (p=0.064, d=0.80). A significant main 
effect of diagnosis on parvocellular glia cell number was found (F=4.118, p=0.038), 
with a significant decrease in AD cases compared to DLB (p=0.012, d=1.17). No 
significant main effect of diagnosis on neuronal or glial cell number was found in the 
magnocellular laminae. 
There was no significant main effect of diagnosis on the ratio of glial cells to neurons 
in the parvocellular laminae of the LGN. However, a significant main effect of 
diagnosis on the ratio of glial cells to neurons was found in the magnocellular 
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laminae (F=7.733, p=0.005), with the ratio of glial cells to neurons increased in 
magnocellular laminae in AD compared to control (p=0.001, d=1.67) and in AD 
compared to DLB (p=0.035, d=1.15).  
Braak stage was negatively correlated with the number of parvocellular neurons 
(rho=-0.473, p=0.035; Fig. 3.3) and the number of magnocellular neurons (rho=-
0.444, p=0.050; Fig. 3.3) across all subjects.  
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Figure 3.2: Dot plots illustrating stereological estimates in the LGN.  
Lines demonstrate the mean; *p<0.05 compared to DLB, **p<0.05 compared to control and DLB. 
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Figure 3.3: Scatterplots demonstrating correlations between Braak stage and stereological and densitometric data. 
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3.3.3 Densitometry 
An absence of Lewy body pathology was found in all cases (Fig. 3.4A), despite 
immunoreactivity in the insula, present on the same slides of the cases with DLB (Fig. 
3.4B) but not AD or control. Tau pathology was absent in most cases, except for 
occasional sparse AT8-immunoreactive neuropil threads, which were seen in the AD 
cases with a Braak neurofibrillary pathology stage of 6 (Fig. 3.4C and 4D). 4G8 
immunoreactivity, as an indicator of amyloid-β pathology, was present in all cases 
but to varying degrees (Fig. 3.4E and 3.4F). A significant main effect of diagnosis on 
amyloid-β percentage area stained was found (χ²=9.599, p=0.008), with a significant 
7.9 fold increase found in AD cases, when compared to control (U=4.0, p=0.004, 
d=1.49). No significant difference was found between DLB and control subjects or 
between AD and DLB. 
GABAergic interneurons were identified in the LGN by staining for GAD65/67. The 
distribution and morphology of the GAD65/67-labelled cells was consistent with 
those identified in a previous study of interneuron populations in the human LGN 
(Zinner-Feyerabend and Braak, 1991) (Fig. 3.5A). The percentage area of 
GAD65/67 immunostaining did not differ significantly between DLB, control and AD. 
Within cases, there was no significant difference in GAD65/67 density across 
sections.  
Calcium-binding proteins were used to identify neuronal sub-populations present 
within the LGN (Munkle et al., 2000). Calcium-binding proteins were used to identify 
neuronal sub-populations up-regulated following diminished visual input (Arai et al., 
1992; Gonzalez et al., 2006), and project to the visual cortex (Yucel et al., 2000). As 
described in a previous study (Munkle et al., 2000), parvalbumin staining was 
widespread within the LGN, with some neurons intensely labelled, and a proliferation 
of dark terminal-like boutons (Fig. 3.5B). Percentage area of parvalbumin 
immunostaining did not significantly differ between DLB, control and AD (Fig. 3.6).  
Calretinin showed a homogeneous pattern of staining, with magnocellular neurons 
stained more intensely than parvocellular neurons (Fig. 3.4C and 3.4D), as 
demonstrated previously (Munkle et al., 2000). No significant main effect of 
diagnosis on percentage area stained for calretinin was found between DLB, control 
and AD (Fig. 3.6). Parvalbumin and calretinin expression did not significantly differ 
across sections from within individual cases. 
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GAD65/67 immunoreactivity was negatively correlated with Braak stage (rho=-0.440, 
p=0.046; Fig. 3.3). Parvalbumin percentage area stained was negatively correlated 
with Braak stage (rho=-0.562, p=0.008; Fig. 3.3). Calretinin was not significantly 
correlated with any neuropathological variables.  
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Figure 3.4: Neuropathology in the LGN.  
Photomicrographs demonstrating the absence of α-synuclein staining in the LGN of a DLB case (A), 
in contrast to the insula (B), on the same slide of the same case, with Lewy bodies and neurites 
observed (B, inset); absence of tau pathology in a Braak stage 5 AD case (C), sparse tau pathology in 
a Braak stage 6 case (D); amyloid-β pathology in a DLB (E) and AD (F) case. Scale bar = 100 μm, 
inset images are x4 the original image. 
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Figure 3.5: Neuronal subpopulations in the LGN.  
Photomicrographs illustrating the distribution of GAD65/67 immunoreactive cells in the LGN (A) with 
interneuronal morphologies (A inset), consistent with (Zinner-Feyerabend and Braak, 1991); 
parvalbumin immunostaining showing numerous stained processes and synapses, in addition to 
intensely labelled cells (inset; B), consistent with (Munkle et al., 2000); calretinin immunostaining 
revealing more intense staining of magnocellular (C) than parvocellular (D) neurons in one case, 
consistent with (Munkle et al., 2000). A+B scale bars = 100 μm, C+D scale bars = 50 μm. Inset 
images are x4 the original image. 
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Figure 3.6: Bar charts illustrating densitometric data in the LGN.  
Bars symbolise means and standard deviation; *p<0.05 compared to control.  
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3.4 Discussion 
The present results suggest the number of neuronal and glial cells does not 
significantly differ from that of aged controls in the LGN of DLB patients. However, 
the severity of gliosis was higher in AD cases, compared to DLB and control subjects. 
These changes were accompanied by increased amyloid-β pathology in AD cases 
and a moderate loss of parvocellular neurons and glia in AD, when compared to DLB 
cases. 
Although the LGN is a vital part of the afferent visual pathway (Jones, 1998), and 
visuoperceptual changes are a frequent occurrence in DLB (Armstrong, 2012), few 
studies have investigated how the LGN is affected in DLB. The only pathological 
studies conducted in LGN in DLB have focused on the magnitude of 
neuropathological lesions, and one study on neuronal loss, but based entirely on 
qualitative assessment (Yamamoto et al., 2006; Rahimi and Kovacs, 2014).  
The present study found cellular populations of the LGN apparently spared in DLB 
and not subject to substantial neurodegeneration. In contrast, AD cases exhibited 
increased gliosis and moderate cell loss. Previous work has shown there are retinal 
abnormalities in Lewy body diseases (Maurage et al., 2003; Devos et al., 2005; 
Moreno-Ramos et al., 2013; Beach et al., 2014). However, the relative sparing of the 
LGN in DLB demonstrated in the present study is unprecedented. Whilst this finding 
implies the manifestation of visual symptoms in DLB is likely the result of 
degenerative changes elsewhere in the brain, one may speculate that the relative 
intactness of the LGN, in the context of degeneration elsewhere, may be an 
important factor the pathophysiology of visual hallucinations in DLB.  
In DLB, retinal changes may lead to an incomplete representation of the visual scene 
being relayed to the LGN. As the LGN is seemingly intact, it may then relay the 
incomplete visual scene to higher visual structures. In a somewhat analogous 
fashion to the ‘filling in’ of the blind spot created by the optic nerve emanating from 
the retina, this incomplete or distorted visual information may then require 
completion by higher visual structures. Pathological alterations to higher visual 
structures involved in the process of ‘filling in’ may mean that the process of 
correcting for the missing information is not carried out correctly. This could result in 
the generation of images that are additional to the input that has been conveyed to 
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the brain, i.e. hallucinations, perception without sensory input. In AD cases, the mild 
degeneration of the LGN may be commensurate with retinal and/or cortical changes, 
thus preventing incomplete visual information being faithfully relayed to the higher 
visual system.  
Consistent with the findings of the present study, Lewy body pathology has 
previously been described as absent from the LGN in DLB (Yamamoto et al., 2006). 
However, another study in PD has shown that the LGN is frequently affected by α-
synuclein pathology, albeit to a minor degree (Rahimi and Kovacs, 2014). Whilst a 
different clinical entity from DLB, there are some similarities between the two 
conditions in terms of the neuropathological lesions present (Spillantini et al., 1997). 
It is not clear why α-synuclein pathology was identified in PD but not in DLB. One 
explanation may be that as DLB typically has a shorter disease duration than PD, 
there is a shorter period of time for pathology to spread to the LGN. Impaired 
antigenicity or a dysfunctional antibody may be ruled out, considering the strong 
immunostaining observed in the insula on the same slides of the same cases (Fig. 
3.4B).  
It is possible the difference in vulnerability of the LGN to α-synuclein pathology 
reflects idiosyncratic differences between PD and DLB. The LGN has substantial 
connectivity with the pedunculopontine nucleus of the brainstem (Rye, 1997), a 
structure more severely affected by Lewy body pathology in PD compared to DLB 
(Hepp et al., 2013). An emerging view suggests misfolded α-synuclein spreads 
throughout the brain in a transsynaptic manner, reminiscent of prion protein (Herva 
and Spillantini, 2015; McCann et al., 2016). Thus the presence of α-synuclein 
pathology in the LGN in PD may be the result of a greater pathological burden at 
brainstem sites interconnected with the structure. The LGN receives input from brain 
regions other than the pedunculopontine nucleus but brainstem sites may be of 
particular relevance in this regard as the brainstem is thought to be a key 
predilection site for α-synuclein pathology in the brain in PD (Braak et al., 2003).  
Although previous studies in neurodegenerative diseases disagree on whether the 
LGN is affected by neurofibrillary pathology (Leuba and Saini, 1995; Dugger et al., 
2011), the present study did show some sparse neuropil threads in three cases that 
had been neuropathologically classified as having the highest global burden of 
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neurofibrillary pathology.  Additionally, Braak neurofibrillary pathology stage was 
related to the amount of amyloid-β in the LGN and inversely related to the number of 
neurons within the LGN. The primary cortical target of the LGN, the primary visual 
cortex, is affected at the most advanced stage of tau pathology (Braak et al., 2006). 
This raises the possibility that degeneration of the LGN observed in Braak stage 6 
AD cases is the result of degeneration of the primary visual cortex (Hof and Morrison, 
1990), and the reciprocal connectivity between both structures (Jones, 1998). The 
primary visual cortex is not typically affected by tau pathology in DLB (Perry et al., 
1990b; Khundakar et al., 2016). Therefore, the sparing of the LGN may reflect the 
preservation of its primary afferent target. Tau pathology is observed in the visual 
cortex during in the most advanced stages of AD (Braak et al., 2006) and the 
degeneration observed in the LGN is relatively mild, which raises the suggestion this 
may represent a late event in the progression of AD. If changes to the LGN occur at 
late stages of AD it is difficult to estimate how much of an influence this has upon the 
clinical phenotype. 
As reported in a previous study (Leuba and Saini, 1995), increased amyloid-β was 
found in the LGN of AD cases. DLB typically had comparable amyloid-β pathology to 
control, though two DLB cases did exhibit high amyloid-β expression. Though 
possibly coincidental, the two DLB cases with high amyloid-β pathology were the 
oldest in the DLB group. As amyloid-β turnover is increasingly impaired with 
advancing age (Patterson et al., 2015), it is possible that this is an age-related 
phenomenon in DLB. 
This study showed no significant changes in GAD65/67, parvalbumin and calretinin 
immunoreactivity between groups. However, significant correlations were observed 
between Braak stage and several variables, including the percentage area stained 
for calcium-binding protein parvalbumin and amyloid-β peptide, and cell numbers 
from stereology. Whilst these findings may reflect the relationship of these variables 
to global tau pathology burden, they may also reflect the composition of the groups 
used. Control cases all had Braak stage 0-2, AD cases had Braak stage 5-6 and 
DLB cases were between both. Therefore, based on the present data, it is not 
possible to establish whether the correlations reflect increasing global tau burden or 
simply the distinct conditions of each group, or both.   
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Two previous studies using stereological approaches to estimate the number of 
neurons have been conducted in the LGN in tissue from people who had 
schizophrenia and were generally of lower age (Selemon and Begovic, 2007; Dorph-
Petersen et al., 2009). Whilst the numerical estimates presented here are broadly 
similar to one study (Dorph-Petersen et al., 2009), they are over three times smaller 
in magnitude than reported in another (Selemon and Begovic, 2007). The slight 
disparity in numerical estimates in the present study compared to Dorph-Peterson 
and colleagues (Dorph-Petersen et al., 2009) is possibly due to slight variations in 
the sampled region of interest within the LGN. Dorph-Peterson and colleagues 
included the intralaminar regions in their analysis of the LGN, which would have 
increased the volume of the structure. Though these laminae contain fewer neurons 
than the magnocellular or parvocellular laminae, counting them would likely have 
increased the estimated number of neurons by increasing the volume estimate of the 
region of interest, whilst only moderately reducing the measures of neuronal density. 
This is especially true of the magnocellular laminae, which have much wider 
intralaminar laminae and contain more intralaminar neurons than parvocellular 
intralaminar regions (Percival et al., 2014). Correspondingly, a greater magnitude of 
difference was found between magnocellular compared to parvocellular counts in the 
present study and that by Dorph-Peterson and colleagues (Dorph-Petersen et al., 
2009). 
As described earlier, greater differences were found between the present results and 
those reported by Selemon and colleagues, who recorded greater numbers of 
neurons in the LGN than the present study (Selemon and Begovic, 2007). The 
previous study (Selemon and Begovic, 2007) calculated the volume of the LGN 
using the thickness of sections without adjusting for shrinkage as a result of staining. 
In contrast, the present study, and that by Dorph-Peterson and colleagues (Dorph-
Petersen et al., 2009), measured section thickness after the staining of tissue 
sections. It is possible, therefore, that the Selemon study over-estimated the volume 
of the LGN in their study, which would correspondingly overestimate neuronal 
number.  
AD patients have previously been shown to exhibit a pattern of perceptual deficits, 
when tested using electroretinograms and visual evoked potentials, suggesting 
magnocellular pathway dysfunction (Sartucci et al., 2010). It is possible that the 
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magnocellular gliosis observed in the present study is the neuropathological 
analogue of these symptoms. However, as perceptual data from the cohort during 
life is incomplete or absent, it is not possible to establish the relationship between 
these phenomena by relating the neuropathological findings from the present study 
to physiological data from life. 
This study was limited by a relatively small sample size, which was the result of 
tissue availability and sampling restrictions, limiting the power of the study. As some 
changes in the AD group were approaching statistical significance, such as 
magnocellular neuron number, it is possible that a larger sample size may have 
yielded a significant result. However, the DLB group showed no indication or trend 
towards reductions in any of the assessed variables. Therefore, if the DLB group are 
representative of DLB cases generally, it is less likely that a larger group would have 
yielded a significant difference from controls. Small group sizes are a persistent 
feature of human post-mortem studies, especially those which employ correctly 
applied stereological methodology, which necessitates whole, intact structures 
(Erskine and Khundakar, 2016). This study was conducted using the most unbiased 
approach possible. However, shrinkage following formalin fixation is well-understood 
(Haug et al., 1984) and it is impossible to exclude the possibility that bias was 
unwittingly introduced by a differential rate of shrinkage across disease groups. 
In summary, the present study has shown that the LGN is relatively preserved in 
hallucinating DLB cases, in comparison to mild increases in pathology and 
degeneration observed in non-hallucinating AD cases. The preservation of the LGN 
may contribute to the phenomenon of visual hallucinations in DLB by faithfully 
relaying the features of a fragmented or distorted visual scene. However, it is unlikely 
that the preservation of the LGN is itself sufficient to cause hallucinations, which 
likely result from dysfunction in other areas of the visual system. Changes to the 
LGN in AD are speculated to be a late feature of neuropathological change, so it is 
difficult to assess the importance of the present findings in understanding clinico-
pathological correlative relationships in AD.   
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Chapter 4: Histological studies in the pulvinar nucleus 
4.1 Introduction 
The pulvinar nucleus of the thalamus is thought to play an important role in visual 
attentional mechanisms (Benarroch, 2015; Zhou et al., 2016). Pulvinar lesions can 
cause deficits in filtering distracting stimuli (Fischer and Whitney, 2012) and feature 
binding of visual objects (Ward et al., 2002). The pulvinar, which has widespread 
cortical connections, is thought to play a general role in modulating cortico-cortical 
activity based on attentional demands (Saalmann et al., 2012). The widespread 
cortical connections of the pulvinar seem to mirror the connectivity of cortico-cortical 
pathways, suggesting that the pulvinar plays a crucial role in modulating activity 
across the cortex (Benarroch, 2015). The pulvinar is traditionally parcellated into four 
anatomical sub-regions based on histological staining: anterior, medial, lateral and 
inferior (Munkle et al., 2000). However, these histological sub-regions do not map 
perfectly onto sub-regions that have been segregated based on functionality or 
connectivity (Shipp, 2003).  
Recent evidence has suggested degeneration of particular sub-regions of the 
pulvinar, as assessed by mean diffusivity on functional MRI, predicts clinical markers 
of visual hallucination frequency and severity (Delli Pizzi et al., 2014). Despite such 
findings, no neuropathological studies have investigated the role of different pulvinar 
sub-regions in visual hallucinations in DLB. Therefore, the present study aimed to 
assess potential degenerative morphometric and/or neuropathological changes to 
the pulvinar nucleus that may contribute a vulnerability to visual hallucinations, using 
unbiased stereological and quantitative neuropathological methods.  
 
4.1.1 Aims 
Using post-mortem pulvinar tissue taken from hallucinating DLB patients, compared 
with aged cognitively normal individuals and disease-control non-hallucinating AD 
patients, this study aimed to:  
1) Use stereological methods to evaluate the number of neurons and glia in the 
sub-regions of the pulvinar.  
2) Quantify and compare the burden of neuropathological lesions in the different 
sub-regions of the pulvinar. 
88 
 
3) Quantify and compare the degree of astrogliosis and microgliosis in the sub-
regions of the pulvinar, based on indications from RNA sequencing results in 
Chapter 5.  
 
4.2 Methods 
4.2.1 Tissue acquisition  
The pulvinar is the most posterior of the thalamic nuclei and protrudes into the lateral 
ventricle (Jones, 2007). In the fixed tissue dissection protocol used at NBTR, two or 
three blocks corresponding to the posterior thalamus typically contain the extent of 
the pulvinar through the z-axis.  
Three groups of cases were included in this study: DLB patients who had 
experienced complex visual hallucinations during life, AD patients without a clinical 
history of visual hallucinations and aged control subjects with low or absent levels of 
neurodegenerative pathology and no history of psychiatric disorders. Cases were 
included based on whether the pulvinar was intact along its antero-posterior extent. 
The cases meeting these criteria consisted of eight DLB, eight AD and eight control 
subjects (Table 4.1).  
From a random starting point, fixed tissue blocks containing the entire pulvinar were 
exhaustively serially sectioned, with 30 μm sections obtained at each 1 mm interval 
and stained with cresyl fast violet for stereological analyses. 10 μm sections were 
stained with antibodies against a range of protein targets (Table 4.2) using Menarini 
Menapath Polymer detection kits (Menarini, Berkshire, UK), as described in Methods. 
Protein targets included cluster of differentiation 68 (CD68) and glial fibrillary acidic 
protein (GFAP), putative markers of activated microglia and astrocytes, respectively. 
This was due to RNA sequencing data (detailed in Chapter 5) suggesting changes 
indicative of gliosis.   
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Table 4.1: Demographic information for cases used in the pulvinar study. 
‘PM interval’ is the interval between death and post-mortem examination, ‘Braak NFT’ represents global neurofibrillary pathology stage as outlined in (Braak 
et al., 2006), ‘McKeith LB’ represents global Lewy body pathology stage, as outlined in (McKeith et al., 2005), ‘clinico-path diagnosis’ represents the overall 
diagnosis, as decided upon by case-note review and neuropathological examination by senior clinicians, in accordance with consensus criteria (McKeith et al., 
2005; Montine et al., 2012). 
Case ID Gender Age at death 
(years) 
PM 
interval 
(hours) 
Braak 
NFT 
McKeith LB Clinico-path 
diagnosis 
Hallucinations 
C1 F 78 23 2 None Control None reported 
C4 M 77 83 2 None Control None reported 
C5 M 73 25 0 None Control None reported 
C6 M 80 16 2 Brainstem Control None reported 
C7 M 85 57 3 None Control None reported 
C8 F 99 5 2 None Control None reported 
C9 F 65 47 1 Amygdala Control None reported 
C10 F 76 86 2 None Control None reported 
Mean±SD  79.1±10 42.8±31 1.8±1    
D2 M 89 88 3 Neocortical DLB Frequent complex visual 
hallucinations 
D6 F 78 96 3 Neocortical DLB Frequent complex visual 
hallucinations 
D7 F 73 99 3 Neocortical DLB Infrequent complex visual 
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hallucinations 
D8 M 81 81 3 Neocortical DLB Frequent complex visual and 
auditory hallucinations 
D9 M 77 46 3 Neocortical DLB Infrequent complex visual 
hallucinations 
D10 F 81 44 4 Neocortical DLB Frequent complex visual 
hallucinations 
D11 F 91 10 3 Neocortical DLB Frequent complex visual 
hallucinations 
D12 M 73 47 2 Neocortical DLB Frequent complex visual 
hallucinations 
Mean±SD  80.4±7 63.9±32 3.1±1    
A1 M 76 6 6 None AD None reported 
A2 M 85 32 5 None AD None reported 
A5 F 81 73 5 None AD None reported 
A8 M 89 61 6 None AD None reported 
A9 M 68 24 6 None AD None reported 
A10 F 86 123 6 Brainstem AD None reported 
A11 F 95 23 6 Amygdala AD None reported 
A12 M 85 39 6 None AD None reported 
Mean±SD  83.1±8 47.6±37 5.8±1    
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4.2.2 Stereology 
The primate pulvinar has traditionally been parcellated into four cytoarchitectonically 
defined regions: the anterior, medial, lateral and inferior pulvinar nuclei (Hirai and 
Jones, 1989). GAD65/67 immunohistochemistry was used to delineate the pulvinar 
into sub-regions, based on a previous report (Popken et al., 2002) (Fig. 4.1). The 
inferior pulvinar was incomplete on all sections due to its location at a point where 
the upper midbrain is dissected from the diencephalon, thus precluding stereological 
analysis of this sub-region. The lateral pulvinar was differentiated from other 
structures based on its striated appearance (Fig. 4.1) (Jones, 2012). 
The border between the anterior and medial pulvinar could not be reliably identified 
through the z-axis. As stereological protocol requires the entire structure to be 
sampled for analysis, the anterior and medial pulvinar were grouped together and 
will subsequently be referred to as the ‘anteromedial pulvinar’ when referring to 
stereological analyses.  
Stereological methods were used to estimate the total number of neurons and glia 
within the pulvinar nuclei. Cell counts were conducted at 63x oil-immersion objective 
using the optical disector probe. Glial cell counts were calculated in both pulvinar 
sub-regions in disector frames of 1900 μm2, with neuron counts calculated in 
disector frames of 3500 μm2. Section thickness did not vary across disease groups 
in anteromedial or lateral pulvinar. CE values had acceptable levels of accuracy, with 
CE values <0.10. A mean of 9 sections (range 7-12) were analysed for the 
anteromedial pulvinar and a mean of 8 sections (range 6-9) for the lateral pulvinar.    
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Table 4.2: Antibodies used in the pulvinar study. 
Antibody Manufacturer Dilution Antigen retrieval 
5G4 α-synuclein Analytik Jena, 
Germany 
1:4500 Formic acid + 
citrate pH 6.0 
AT8 phospho-tau Autogen, MA, USA 1:4000 Citrate pH 6.0 
4G8 amyloid-β Covance, NJ, USA 1:15000 Formic acid 
GAD65/67 Sigma Aldrich, MO, 
USA 
1:12000 Citrate pH 6.0 
GFAP Dako, Denmark 1:10000 Citrate pH 6.0 
CD68 Dako, Denmark 1:350 Trypsin 
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Figure 4.1: Anatomy of the pulvinar.  
The anteromedial (dashes) and lateral (dots) pulvinar are illustrated in successive coronal sections. Scale bar = 3 mm.
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4.2.3 Densitometry 
The anterior, medial and lateral nuclei were analysed using quantitative 
neuropathological techniques. Although the anterior and medial pulvinar border 
could not be reliably identified for stereological analysis, where the entire structure 
along its antero-posterior extent is required, it was possible to identify the individual 
structures for analysis of neuropathology if the section which contained the 
emergence of the anterior pole of the pulvinar was used to represent the anterior 
pulvinar. The medial and lateral pulvinar were assessed by densitometric analysis of 
the region at which both structures were at their maximal area on coronal section, as 
the anterior pulvinar is not present at this point  (Mai et al., 2016), combined with the 
section prior to the last section coronally on which they were present, to better 
represent the whole structure than a single section.  
To quantify neuropathological lesions, images of the sub-nuclei of the pulvinar were 
taken on a Zeiss AxioVision Z.1 microscope using a JVC 3-chip CCD true colour 
camera. Stereologer software was used to delineate a region of interest with a 2.5x 
objective, prior to placement of disector frames in a uniform, random arrangement. 
This method prevented the introduction of sampling bias by giving every area of the 
region of interest an equal probability of being analysed. Disector frames were 
captured at 10x objective for amyloid-β and tau, and at 20x objective for α-synuclein 
pathology, CD68 and GFAP, on the basis of the relative particle size and distribution 
of the structures measured. Images were taken within the disector frames and 
analysed using ImagePro Plus v.4.1 image analysis system. Using previously 
published techniques (Perry et al., 2012), the mean percentage area of 
immunoreactivity was determined by standardizing RGB thresholds per antibody and 
applying to all sections per case. Each case thus had a mean value generated per 
antibody across all sections analysed.  
 
4.2.4 Statistical analyses 
Inspection of Q-Q plots and Shapiro-Wilk tests suggested that a normal distribution 
could be assumed for the stereological data. However, visual inspection of 
regression lines of stereological data with age and PM interval indicated that 
homogeneity of regression slopes could not be assumed for all analyses. Therefore, 
ANOVA was conducted on stereological data, with Tukey’s HSD as the post-hoc test 
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if data had homogeneity of variance. Data that did not have homogeneity of variance 
were assessed using Games-Howell. Densitometric data were not normally 
distributed so Kruskal-Wallis tests with post-hoc Mann-Whitney U tests were used for 
these data. 
   
4.3 Results 
4.3.1 Demographics 
There was no significant difference in age (F=0.478, p=0.627), post-mortem interval 
(F=0.881, p=0.429) or gender (χ²=0.336, p=0.845) between experimental groups 
(Table 4.1). 
Final MMSE scores were available for 14/24 cases (five control, five DLB, four AD) 
and there was no significant difference between groups in the interval from last 
MMSE assessment to death. As expected, MMSE scores were significantly lower in 
DLB (p<0.01, d=1.80) and AD (p<0.01, d=1.74) patients, compared to controls, but 
there was no significant difference between AD and DLB.  
 
4.3.2 Stereology  
In the anteromedial pulvinar, no significant main effect of diagnosis on neuronal or 
glial number was found, and the volume of the structure was not significantly 
different across groups (Fig. 4.2).  
In the lateral pulvinar, a significant main effect of diagnosis on neuronal number was 
found (F=14.219, p<0.01). Post-hoc tests using Tukey’s HSD showed a significant 
decrease in neuronal number in DLB cases compared to controls (p<0.01, d=1.82) 
and a significant decrease in AD cases compared to controls (p=0.02, d=0.99). 
There was a trend toward a significant reduction in neuronal number in DLB versus 
AD cases (p=0.06, d=0.83). No significant differences in glial cell number or lateral 
pulvinar volume were found across groups (Fig. 4.2). 
In the anteromedial pulvinar, there was a trend towards a significant main effect of 
diagnosis on the ratio of glia to neurons but was not statistically significant (F=3.432, 
p=0.051). In the lateral pulvinar, a significant main effect of diagnosis on the ratio of 
glia to neurons was found (F=7.855, p=0.003). DLB cases had a significant increase 
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in glia relative to neurons compared to control (p=0.002) and AD (p=0.038). There 
was no significant difference between control and AD.  
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Figure 4.2: Stereological data.  
Dot plots illustrate stereological data from the pulvinar nuclei, lines represent the mean, *p<0.05 
compared to control. 
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4.3.3 Densitometry 
Graphical summaries of densitometric data can be found in Fig. 4.3. 
α-synuclein pathology was found in the pulvinar of all DLB cases, more frequently as 
Lewy neurites and dot-like profiles (dot-like profiles have been identified previously 
with the 5G4 antibody (Kovacs et al., 2012)), than as Lewy bodies (Fig. 4.4A). There 
was a significant main effect of diagnosis on α-synuclein pathology in the anterior 
(χ²=15.53, p<0.001), medial (χ²=15.54, p<0.001) and lateral (χ²=14.37, p=0.001) 
pulvinar. DLB cases had greater α-synuclein pathology in the anterior pulvinar than 
control (U=1.0, p=0.001, d=1.47) and AD cases (U=1.0, p=0.001, d=1.47). DLB 
cases had greater α-synculein pathology in the medial pulvinar than control (U=0.0, 
p=0.001, d=1.66) and AD cases (U=0.0, p=0.001, d=1.65). DLB cases had greater α-
synuclein pathology in the lateral pulvinar than control (U=1.0, p=0.001, d=1.55) and 
AD cases (U=3.0, p=0.002, d=1.47).  
In all three regions analysed, α-synuclein was significantly higher in DLB cases when 
compared to control and AD cases (Fig. 4.3). In DLB cases, the medial pulvinar was 
invariably more severely affected by α-synuclein pathology than the lateral (Z=2.524, 
p=0.012, d=0.62) or anterior nuclei (Z=2.857, p=0.004, d=0.48), and no significant 
difference in expression was found between anterior and lateral nuclei.  
Tau pathology was rarely present as neurofibrillary tangles in the pulvinar in non-AD 
cases. DLB cases typically had small patches of neuropil threads (Fig. 4.4B). There 
was a significant main effect of diagnosis on tau pathology in the anterior (χ²=15.83, 
p<0.001), medial (χ²=11.60, p=0.003) and lateral (χ²=14.60, p=0.001) pulvinar. AD 
had greater tau pathology in the anterior pulvinar than control cases (U=0.0, p=0.001, 
d=1.20) and DLB (U=3.0, p=0.002, d=1.18). There was no significant difference in 
tau pathology between DLB and control cases in the anterior pulvinar. AD had 
greater amyloid-β pathology in the medial pulvinar than control cases (U=2.0, 
p=0.002, d=1.24) and DLB (U=12.0, p=0.04, d=1.17). There was no significant 
difference in tau pathology between DLB and control cases in the medial pulvinar. 
AD cases had greater amyloid-β pathology in the lateral pulvinar than control (U=1.0, 
p=0.001, d=1.31) and DLB (U=7.0, p=0.008, d=1.23). There was no significant 
difference in tau pathology between DLB and control cases in the lateral pulvinar.  
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Amyloid-β pathology was variable in the pulvinar, with diffuse and focal deposits 
observed in varying quantities between the disease groups (Fig. 4.4C). There was a 
significant main effect of diagnosis on amyloid-β pathology in the anterior (F=5.571, 
p=0.011), medial (F=5.206, p=0.015) and lateral (F=7.379, p=0.004) pulvinar. AD 
had greater amyloid-β pathology in the anterior pulvinar than control cases (p=0.003, 
d=1.31) and DLB (p=0.040, d=1.12). There were no significant differences in 
amyloid-β levels in the anterior pulvinar between DLB and control cases. AD cases 
had greater amyloid-β pathology in the medial pulvinar than control (p=0.011, 
d=1.38). There was no significant difference between amyloid-β levels in the medial 
pulvinar between DLB and control cases or AD and DLB cases. AD cases had 
greater amyloid-β pathology in the lateral pulvinar than control (p=0.003, d=1.50). 
There was no significant difference between amyloid-β levels in the lateral pulvinar 
between DLB and control or AD and DLB cases.   
The GFAP antibody intensely labelled astrocytic profiles and processes throughout 
the pulvinar nuclei in all cases (Fig. 4.4D). There was a significant main effect of 
diagnosis on GFAP expression in the anterior (F=10.23, p=0.001), medial (F=6.26, 
p=0.008) and lateral (F=6.19, p=0.008) pulvinar. DLB cases had greater GFAP 
expression in the anterior pulvinar than control cases (p=0.009, d=1.27). AD cases 
had greater GFAP expression in the anterior pulvinar than control cases (p=0.001, 
d=1.58). There was no significant difference in GFAP expression between DLB and 
AD in the anterior pulvinar. DLB had greater GFAP expression in the medial pulvinar 
than control cases (p=0.038, d=1.13). AD had greater GFAP expression in the 
medial pulvinar than control cases (p=0.009, d=1.37). There was no significant 
difference in GFAP expression between DLB and AD in the medial pulvinar. DLB 
had greater GFAP expression in the lateral pulvinar than control cases (p=0.045, 
d=1.10). AD had greater GFAP expression in the lateral pulvinar than control cases 
(p=0.009, d=1.38). There was no significant difference in GFAP expression between 
DLB and AD cases in the lateral pulvinar.  
The CD68 antibody labelled microglial profiles in the pulvinar nuclei (Fig. 4.4E). No 
significant differences were found between groups in the microglial marker CD68 in 
any pulvinar sub-region (Fig. 4.3). 
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Figure 4.3: Densitometric analysis of the pulvinar nuclei.  
Bars represent mean and error bars represent standard deviation. *p<0.05 compared to control, 
**p<0.05 compared to control and AD, ***p<0.05 compared to control and DLB. 
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Figure 4.4: Pathology in the lateral pulvinar.  
Photomicrographs of the lateral pulvinar of a DLB case stained with 5G4 anti-α-synuclein (A), AT8 anti-phosphorylated tau (B), 4G8 anti-amyloid-β peptide 
(C), anti-GFAP (D) and anti-CD68 (E). Bar (A) = 50 μm, (B-E) = 100 μm, inset picture (A) is x2 the original image, (B-E) are x4 the original image. 
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4.3.4 Relationships between stereological and densitometric data 
There was a negative relationship between tau and neuronal number in the 
anteromedial pulvinar of DLB cases (rho=-0.98, p<0.01; Fig. 4.5). There was a 
negative relationship between α-synuclein and neuronal number in the lateral 
pulvinar of DLB cases (rho=-0.88, p<0.01; Fig. 4.5). 
There was a negative relationship between GFAP and neuronal number in the lateral 
pulvinar of AD cases (rho=-0.76, p=0.02; Fig. 4.5). There was no relationship 
between neuronal number and any densitometric variable in the anteromedial 
pulvinar of AD cases. 
No relationships were found between any neuropathological and stereological 
variables in the anteromedial or lateral pulvinar in control cases. Age was not 
significantly correlated with any neuropathological or stereological variable in any 
region. No significant correlations were found between GFAP percentage area 
stained and total glial number or mean glial density in any pulvinar sub-region.  
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Figure 4.5: Correlations between stereological and densitometric variables. 
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4.4 Discussion 
The present study found a significant reduction in neuronal number in the lateral but 
not anteromedial pulvinar in DLB, compared to control, and a trend toward a 
decrease in neuronal number in DLB, compared to AD, cases. A significant increase 
in α-synuclein pathology and astrocyte immunoreactivity was also found in the 
pulvinar in DLB compared to control cases but no significant difference in astrocyte 
expression was found in DLB compared to AD cases.  
A previous study has shown the pulvinar nucleus is vulnerable to Lewy body 
pathology, in comparison to another visual region of the thalamus, the LGN 
(Yamamoto et al., 2006). This is in broad agreement with the findings outlined in this 
study, as well as our previous findings in Chapter 3. However, the present study 
extended these findings by demonstrating a specific pattern of neuronal loss in the 
lateral pulvinar, and no change in neuronal number in the anteromedial pulvinar 
mirroring the findings in the LGN. In contrast, AD cases had significant neuronal loss 
in the LGN (Chapter 3) and less marked loss in the lateral pulvinar, when compared 
to DLB. Taken together, these findings suggest that neuronal loss in the visual 
thalamus in DLB is specific to the lateral pulvinar, where neuronal loss is more 
severe than that observed in AD. This is a notable finding as it is not common for 
stereological studies conducted in regions outside of the mid-brain to find neuronal 
reductions in DLB that exceed those in AD (for a review see (Erskine and Khundakar, 
2016)).   
The lateral pulvinar is known to receive prominent innervation from visual cortical 
areas (Kaas and Lyon, 2007) and to be functionally involved in regulating cortical 
activity in vision-related pathways (Bridge et al., 2015). As the lateral pulvinar has 
been shown to have a strong regulatory influence on the functioning of the primary 
visual cortex (Purushothaman et al., 2012), its degeneration in DLB may lead to 
altered functioning of the visual cortex and contribute to hallucinogenesis. In primate 
visual area V4, deactivation of the lateral pulvinar leads to reduced frequency of 
cortical oscillations similar to those observed during inattention or sleep (Zhou et al., 
2016). Lesion studies of the lateral pulvinar in non-human primates have 
demonstrated behavioural changes indicative of perceptual neglect, such as 
reluctance to grasp target stimuli with the contralateral limb (Wilke et al., 2010). As 
impaired visual attentional function is thought to contribute to the manifestation of 
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visual hallucinations in DLB (Collerton et al., 2005b; Diederich et al., 2005), neuronal 
loss observed in the lateral pulvinar in the present study may contribute to visual 
attentional dysfunction, which may relate to the occurrence of visual hallucinations.  
Previous neuroimaging findings have shown increased mean diffusivity in posterior 
thalamic regions that project to occipital and parietal regions in DLB (Delli Pizzi et al., 
2014). The degree of increased diffusivity in the posterior thalamic regions 
corresponding to the pulvinar have been demonstrated to relate to clinical markers of 
visual hallucination frequency and severity, suggesting a relationship between 
degeneration of pulvinar sub-nuclei that project to occipital regions and the 
occurrence of visual hallucinations (Delli Pizzi et al., 2014). Whilst the 
cytoarchitectonic parcellation of the pulvinar into anterior, medial, lateral and inferior 
sub-regions is not fully compatible with segregation based on physiology and 
connectivity (Shipp, 2003), areas corresponding to the lateral pulvinar project to 
occipital and parietal regions (Soares et al., 2001; Kaas and Lyon, 2007). This 
suggests the present finding of neuronal loss in the lateral pulvinar shares some 
consistencies with that reported from neuroimaging studies and may provide 
independent neuropathological verification of these findings (Delli Pizzi et al., 2014).  
The medial pulvinar, which possessed the greatest burden of α-synuclein pathology 
among the pulvinar nuclei examined in DLB cases (Fig. 4.2), has substantial 
reciprocal connectivity with the amygdala (Romanski et al., 1997). Despite its higher 
burden of Lewy body pathology, the medial pulvinar did not evidence neuronal loss 
in DLB, suggesting neuronal loss is not the result of Lewy body pathology in isolation. 
The pathway from the medial pulvinar to the amygdala may underlie affective 
blindsight, where blind individuals respond appropriately to emotional facial 
expressions, without conscious perception. Lesioning of the medial pulvinar leads to 
impairments in emotional facial processing (Ward et al., 2007). This pathway has 
been suggested to be dysfunctional in PD and may relate to impaired perception of 
fear in observed faces in Lewy body disease (Saenz et al., 2013). Deficits in affective 
blindsight have previously been discussed in the context of wider impairments to 
blindsight pathways that may contribute to visual hallucinations in Lewy body 
disease (Diederich et al., 2014).  
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The lateral and anterior pulvinar receive input from early visual (Benarroch, 2015) 
and somatosensory cortical areas (Jones et al., 1979), respectively. These regions 
are often affected at later stages of Lewy body pathology than the amygdala and 
cingulate which connect with the medial pulvinar (McKeith et al., 2005) and may be 
consistent with the emerging view suggesting α-synuclein pathology may spread in a 
manner reminiscent of prion protein (Herva and Spillantini, 2015; McCann et al., 
2016). 
GFAP is an astrocytic intermediate filament protein that serves as an astrocytic 
marker that is up-regulated in neurodegenerative diseases and ageing (Middeldorp 
and Hol, 2011). Activated astrocytes may have a role in neuroprotection and repair 
and may be present in higher levels in tissues undergoing degenerative changes 
(Sofroniew, 2009). Therefore, the present finding of increased GFAP 
immunoreactivity throughout the pulvinar complex in DLB and AD may reflect a 
reactive, compensatory response to neurodegenerative insults. Although one study 
has demonstrated elevated GFAP in the cerebrospinal fluid of DLB patients (Ishiki et 
al., 2016), another study did not, and also found no significant increase in GFAP-
immunoreactive astrocytes in the frontal cortex in DLB, nor a relationship with Lewy 
body pathology (van den Berge et al., 2012). Therefore, the present finding of 
reactive astrogliosis in the pulvinar in DLB may not simply reflect a stereotyped 
response seen throughout the brain in DLB. In contrast, astrogliosis is observed in 
many brain regions in AD and it is related to AD-type pathology (Garwood et al., 
2016). 
Microglial activation, as seen by CD68 staining, was not found to differ from control 
cases in the hippocampus of DLB cases (Bachstetter et al., 2015). Therefore, it is 
perhaps unsurprising the present study did not demonstrate changes in CD68 
immunoreactivity in DLB cases. Previous studies have suggested microglia show 
less of a tendency to co-localise with Lewy body pathology (Mackenzie, 2000) than 
they do with AD-type pathology (Arends et al., 2000). However, enrichment of 
proteins implicated in inflammation were found in transcriptomic analysis of the 
pulvinar (detailed in Chapter 5). Therefore, an activated microglial marker was used 
in the present study to investigate whether microglial activation is related to the 
inflammatory changes identified in a different group of DLB cases. Considering the 
relationship between microglia and AD-type pathology, it is more surprising that the 
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present study did not reveal changes in CD68 immunoreactivity in AD cases. 
However, one study has shown CD68 immunoreactivity is regionally variable, even 
in AD, with low levels of CD68 found in some brain regions, even when high AD-type 
pathology is present (Henstridge et al., 2015). This suggests microglial activation is 
not a uniform response across all brain regions, even in conditions such as AD.  
The negative relationship between α-synuclein immunoreactivity in the lateral 
pulvinar and neuronal number may indicate neuronal losses reflect more advanced 
levels of α-synuclein pathology. Such an effect may reflect an inherent maladaptive 
effect of α-synuclein aggregation, either through a loss of normal α-synuclein 
function or a toxic gain of function, or both (Cookson, 2006). Alternatively, α-
synuclein level within the lateral pulvinar may increase as a product of increasing 
global α-synuclein burden. Therefore, neuronal loss in the lateral pulvinar may be the 
result of global degenerative influences, of which local α-synuclein levels are a proxy 
measure. Relating these findings to quantitative measures of α-synuclein pathology 
throughout the brain would allow further investigation of these proposals.  
The negative relationship between tau levels in the medial pulvinar and neuronal 
number in DLB indicates local tau levels increase at a level commensurate with 
neuronal loss. As with α-synuclein in the lateral pulvinar, this may reflect global 
neuropathological burden. However, AD cases which had more widespread tau 
pathology throughout the brain, and were found to have higher levels of tau 
pathology in the anterior and medial pulvinar, did not have significant neuronal loss 
in the anteromedial pulvinar. Therefore, it is difficult to understand how tau pathology 
and neuronal loss could be directly related in the pulvinar in DLB.  
The specific pattern of neuronal loss seen in the lateral pulvinar in DLB patients has 
also been demonstrated in stereological studies of schizophrenic patients (Highley et 
al., 2003). Although visual hallucinations are relatively uncommon in schizophrenia 
(Mueser et al., 1990), schizophrenic and DLB patients often experience visual 
attentional deficits (Luck and Gold, 2008; Armstrong, 2012) and impairments in 
smooth pursuit eye movements (Armstrong, 2012; Gracitelli et al., 2015), which can 
occur as a result of attentional dysfunction (Yee, 1983). Considering the putative role 
of the lateral pulvinar in modulating visual cortical activity based on attentional 
demands (Purushothaman et al., 2012; Bridge et al., 2015; Zhou et al., 2016), these 
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findings may highlight a common neurodegenerative change that promotes 
attentional dysfunction in both disorders. In DLB, visual attentional deficits may act in 
concert with dysfunction or degeneration of other brain regions to elicit hallucinations. 
Considering the clinical and pathological overlap between PD and DLB, and the 
potential involvement of pulvinar dysfunction in blindsight pathways implicated in PD 
(Diederich et al., 2014), this may be a shared pattern of degeneration with PD. 
Future studies may investigate whether Lewy body pathology and neuronal loss also 
occur in the pulvinar in PD.   
In summary, the present study has shown specific patterns of degeneration in the 
DLB pulvinar and that these changes are of greater magnitude than those observed 
in AD. Whilst speculative, the putative role of the lateral pulvinar in modifying the 
response properties of visual cortical neurons may suggest its degeneration 
contributes to alterations in cortical activity, which has previously been related to 
visual hallucinations in DLB (Taylor et al., 2011). Additionally, the results of the 
current study offer broad neuropathological support for neuroimaging findings 
implicating the degeneration of particular pulvinar sub-regions in visual hallucinations 
in DLB (Delli Pizzi et al., 2014).  
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Chapter 5: Molecular studies in the pulvinar nucleus 
5.1 Introduction 
The previous chapter detailed the results of a histological study of the pulvinar in 
DLB which reported Lewy body pathology and astrogliosis in all pulvinar sub-regions, 
with neuronal loss restricted to the lateral pulvinar. The pulvinar has a role in visual 
attention and target selection (Benarroch, 2015), and exerts a powerful modulatory 
influence on visual cortical functioning (Kaas and Lyon, 2007; Purushothaman et al., 
2012). As visual attentional mechanisms (Collerton et al., 2005b; Diederich et al., 
2005) and altered activity in the primary visual cortex (Taylor et al., 2011; Khundakar 
et al., 2016) have both been postulated to create a vulnerability to visual 
hallucination, these results may indicate a pathological basis for visual hallucinations 
in DLB. 
The neuronal loss identified in the lateral pulvinar, and the higher levels of α-
synuclein pathology in the medial pulvinar, suggest that these two large pulvinar sub-
regions are functionally altered in DLB. Whilst histological analysis is valuable in 
ascertaining gross cellular morphometric changes and vulnerability to Lewy body 
formation, little information was provided regarding intracellular processing or 
neuronal functioning. Fixed-brain post-mortem tissue precludes the assessment of 
potential physiological changes that may have occurred as a result of morphological 
and pathological changes to neurons. Proteomic information could enable greater 
understanding of the potential impact of structural changes in visual thalamic circuitry    
and how they contribute to the clinical phenotype of DLB. 
This chapter therefore aimed to elaborate on the findings of the previous chapter by 
identifying potential changes at the molecular level. Firstly, tissue from the pulvinar 
was homogenised for RNA isolation and sent to a collaborator for sequencing and 
bioinformatics analysis to ascertain whether gene expression changes occur in DLB 
compared to aged control cases. Relative RNA expression levels were compared to 
identify significantly altered transcripts between groups. Gene ontology (GO) 
software was employed by our collaborator to identify biological processes, 
molecular function and cellular component annotations to establish systems 
associated with DLB in the pulvinar. Based on the resulting list of altered transcripts 
and pathways, this chapter outlines a series of western blot experiments used to 
assess levels of protein expression in the pulvinar.  
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5.1.1 Aims 
These studies used frozen post-mortem pulvinar tissue obtained from hallucinating 
DLB cases compared to cognitively normal, non-hallucinating, control cases. This 
study aims to: 
1) Investigate significantly altered transcripts to compile a list of protein targets.  
2) Assess protein expression changes based on identified changes in 
transcription and in specific biological pathways.  
 
5.2 Methods 
5.2.1 Tissue acquisition 
The pulvinar was identified as approximately the most posterior 5 mm of the 
thalamus, protruding into the lateral ventricle (Jones, 2007). 14 control and 14 DLB 
were included in the present study based on the intial criteria of low post-mortem 
interval and preserved pH for optimal neurochemical analysis (Table 5.1). However, 
since conducting this study, it has become apparent that low post-mortem interval is 
less important than tissue pH in selecting frozen brain tissue (Robinson et al., 2016). 
DLB cases were selected due to the presence of well-formed visual hallucinations, 
and a clinical and pathological diagnosis of DLB. Approximately 50 mg of tissue was 
removed from the posterior pole of the thalamus using a cooled scalpel and 
homogenised in 0.2M TEAB buffer, combined with protease inhibitor tablets (see 
Section 2.6.2). 
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Table 5.1: Demographic information for cases used in the molecular pulvinar study.  
‘PM interval’ is the interval between death and post-mortem examination, ‘Braak NFT’ represents global neurofibrillary pathology stage as outlined in (Braak 
et al., 2006), ‘McKeith LB’ represents global Lewy body pathology stage, as outlined in (McKeith et al., 2005), ‘clinico-path diagnosis’ represents the overall 
diagnosis reached by case-note review and neuropathological examination by senior clinicians and a consultant neuropathologist. ‘ND’ means ‘not 
determined’. 
Case ID Gender 
Age at death 
(years) 
Tissue pH 
PM interval 
(hours) 
Braak NFT McKeith LB 
Clinico-path 
diagnosis 
C5 M 73 6.45 25 0 None Control 
C11 F 84 6.55 7 3 None Control 
C12 F 88 6.39 21 3 None Control 
C13 F 74 ND 28 1 None Control 
C14 F 76 6.07 10 1 None Control 
C15 M 72 6.25 31 2 None Control 
C16 M 71 ND 15 ND ND Control 
C17 M 67 ND 38 1 None Control 
C18 M 85 ND 24 2 None Control 
C19 M 66 6.66 9 ND ND Control 
C20 F 79 ND 26 3 None Control 
C21 F 82 6.57 26 0 None Control 
C6 M 80 ND 16 3 Brainstem Control 
Mean±SD  76.7±7 6.4±0.2 21.2±9 1.8±1   
D13 M 75 6.45 18 3 Neocortical DLB 
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D14 M 78 6.40 8 4 Neocortical DLB 
D15 M 69 6.65 27 5 Neocortical DLB 
D16 M 78 6.46 23 4 Neocortical DLB 
D17 M 79 6.83 30 4 Neocortical DLB 
D18 F 77 6.24 23 3 Neocortical DLB 
D19 M 79 6.66 26 3 Neocortical DLB 
D20 M 77 6.50 38 ND ND DLB 
D21 M 76 ND 13 3 Neocortical DLB 
D22 F 81 6.02 4 5 Neocortical DLB 
D23 M 79 6.65 16 3 Neocortical DLB 
Mean±SD  77.1±3 6.5±0.2 20.5±10 3.7±1   
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5.2.2 RNA sequencing 
To investigate relative changes in RNA transcription in the pulvinar, RNA was 
extracted using a spin column method and treated with DNase. RNA concentration 
and integrity was subsequently determined before samples were dispatched to the 
laboratory of Professor Mark Cookson at the National Institutes of Health (NIH), 
Bethesda, MD, USA for RNA sequencing and bioinformatics analyses. 
Samples were analysed using DSEQ2 software with a general linear model 
assessing differences based on disease, with tissue pH, age, gender and PM 
interval used as covariates. Adjustments for multiple testing were employed with 
standard filters (Cook’s cutoff and automatic filters within the program). RNA 
sequencing data was analysed using GO software to assess pathways that may be 
dysfunctional or altered using a bioinformatics approach for large datasets. A 
detailed summary of analysis methods can be found in (Love et al., 2014).  
 
5.2.3 SDS-PAGE and Western blotting 
Protein homogenates of pulvinar tissue from control and DLB were prepared as 
described in Section 2.6.2. The total protein content of each sample was determined 
using the Bradford assay (Sigma-Aldrich, MO, USA). 10 μg of 1 µg/µl total protein 
was loaded into each well, with each well representing one case, of a polyacrylamide 
gel. The constituent proteins within the samples were separated using SDS-PAGE 
and transferred to nitrocellulose membranes for western blot analysis. Protein 
targets were identified from GO enrichment analysis of RNA sequencing data, and 
probed using antibodies (Tables 5.2 and 5.3).  Relative protein expression was 
determined between groups using semi-quantitative densitometric methods outlined 
in methods, and normalised relative to the housekeeping protein GAPDH.  
 
5.2.4 Statistics 
Variable changes, such as substrate exposure time, create difficulties in comparison 
between individual membranes. Densitometric analysis is a relative, independent, 
measure and, as a result, independent t-tests were performed on each protein target.    
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5.3 Results 
5.3.1 Demographics 
There was no significant difference in age at death (F=0.031, p=0.862), post-mortem 
interval (F=0.030, p=0.863) or gender (χ²=2.098, p=0.211) between experimental 
groups (Table 5.1). 
 
5.3.2 RNA sequencing 
One control and three DLB cases were excluded from the analysis due to low RNA 
integrity. The remaining group, 13 control and 11 DLB, showed some degree of 
separation in RNA profile between experimental groups but this was not absolute 
(Fig. 5.1). 
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Figure 5.1: Heat map of RNA sequencing data.  
Whilst many cases show clear separation from controls, there is overlap visible in the middle.  
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5.3.3 Selection of protein targets 
GO enrichment was conducted in the pulvinar samples following RNA sequencing. 
This showed significant enrichment for synaptic proteins and proteins involved in 
positive regulation of immune system process.  
Protein targets relating to synaptic functioning and immune system regulation were 
further investigated based on the identification of these pathways as altered in the 
GO analysis. Antibodies were often not available for altered protein targets identified 
using RNA sequencing analysis. In other cases, the expression of the protein was 
hypothesised to be low, based on relatively low levels of transcription. The pulvinar is 
a small region of the brain and, as a result, there was a limited amount of tissue 
available following RNA extraction. Work on previous studies has indicated that 
obtaining antibodies recognising their target epitope in human tissue is difficult, and 
optimisation of such antibodies often consumes large amounts of tissue (Khundakar 
et al., 2016). Therefore, the present study aimed to use antibodies that had 
previously been demonstrated to work in human post-mortem tissue.  
As a result, the choice of protein targets was based on: 
A) Availability of antibodies demonstrated to work in human tissue. 
B) A hypothetical link to synaptic or immune system functioning based on GO 
consortium pathways data. 
C) A significant quantity of the protein to make detection likely (a base mean > 
100 was used as an arbitrary cut-off point).  
Based on these criteria, the antibodies against synaptic proteins used in the present 
study are listed in Table 5.2.  
The antibodies against positive regulators of immune system functioning are listed in 
Table 5.3. GO analysis indicated that several markers of astrocytic sub-populations 
were elevated, such as GFAP and chitinase-3-like 1 (CHI3L1/YKL-40). Aldehyde 
dehydrogenase 1 family member L1 (ALDH1L1) is thought to be a more general 
marker of astrocytes and was therefore also included in this analysis (Cahoy et al., 
2008).    
In addition to the synaptic and immune system regulatory proteins listed, two 
GABAergic markers (glutamic acid decarboxylase 67; GAD67 and GABA type A 
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receptor-associated protein; GABARAP) were also assessed due to a previous 
finding of specific molecular GABAergic changes in the visual system in DLB, which 
occurred in the absence of histological GABAergic changes (Khundakar et al., 2016). 
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Table 5.2: Synaptic antibodies used in the present study, with the two additional GABAergic markers (GAD67 and GABARAP).  
In the instance of the protein having several transcript variants, the fold change and p-value are the isoform that showed the greatest change, as this was the 
justification for looking at the protein.  
Antibody Manufacturer Catalogue 
number 
Dilution Log2 fold change on 
RNAseq 
p value on RNAseq 
Gephyrin Synaptic systems 147111 1:1000 -0.8332 0.0105 
PSD-95 Santa Cruz sc-32290 1:500 -0.8392 0.0020 
Synaptophysin Millpore MAB368 1:20,000 -0.7153 0.0142 
SNAP-25 Santa Cruz sc-20038 1:2000 -0.8810 0.0054 
GAP43 Santa Cruz sc-135915 1:500 -0.8835 0.0056 
SV2B ProteinTech 14624-1-AP 1:500 -1.7425 <0.0001 
MAP2 Sigma Aldrich M4403 1:500 -0.7013 0.0104 
NSF Santa Cruz sc-15339 1:4000 -0.9992 0.0140 
GAD67 Santa Cruz sc-58531 1:1000 -0.6815 0.0160 
GABARAP Abcam ab109364 1:1000 +0.0318 0.8136 
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Table 5.3: Antibodies against positive regulators of immune system functioning.  
In the instance of the protein having several transcript variants, the fold change and p-value are the isoform that showed the greatest change, as this was the 
justification for looking at the protein. 
Antibody Manufacturer Catalogue 
number 
Dilution Log2 fold change on 
RNAseq 
p value on RNAseq 
ALDH1L1 Millipore MABN461 1:1000 +0.3893 0.1865 
SERPINH1/HSP47 Santa Cruz sc-13150 1:25 +1.9451 <0.0001 
HSPA1A GeneTex GTX111088 1:10,000 +1.4714 0.0002 
HSPA1B GeneTex GTX106148 1:5000 +1.2800 0.0005 
GFAP Santa Cruz sc-33673 1:500 +0.8315 0.0048 
CHI3L1/YKL-40 Abcam ab77528 1:1000 +2.0865 <0.0001 
C3 Abcam ab11862 1:2000 +1.2742 <0.0001 
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5.3.4 Western blotting of synaptic and GABAergic proteins 
Western blot analysis of synaptic proteins showed that, in comparison to control, 
DLB had several significant reductions.  
A single band at approximately 80 kDa was demonstrated for gephyrin (Fig. 5.2A), 
which corresponds with the canonical sequence (Uniprot: Q9NQX3). Gephyrin was 
significantly reduced in DLB compared to control (t=2.35, p=0.0350, d=0.78; Fig. 
5.2A).  
A single band at approximately 80 kDa was demonstrated for post-synaptic density 
protein 95 (PSD-95; Fig. 5.2B), which corresponds with the canonical sequence 
(Uniprot: P78352). PSD-95 was significantly reduced in DLB compared to control 
(t=2.63, p=0.0153, d=0.96; Fig. 5.2B). 
Two bands were demonstrated at approximately 39 kDa and 37 kDa for 
synaptophysin, subsequently described as isoforms 1 and 2, respectively (Fig. 5.2C). 
The canonical sequence of synaptophysin is 39 kDa (Jahn et al., 1985) but the only 
described variant of the canonical sequence of synaptophysin is 21 kDa (Uniprot: 
P08247-2). Synaptophysin isoform 1 was significantly reduced in DLB compared to 
control (t=2.62, p=0.0212, d=0.90; Fig. 5.2C). No significant difference was found in 
isoform 2 between DLB and control (Fig. 5.2C).     
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Figure 5.2: Western blotting of gephyrin, PSD-95 and synaptophysin.  
Gephyrin (A), PSD-95 (B) and synaptophysin (C) expression is compared between control and DLB. 
Bars demonstrate the mean and error bars represent standard deviation. *p<0.05. 
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A single band at approximately 24 kDa was demonstrated for SNAP-25 (Fig. 5.3A), 
which corresponds with the canonical sequence (Uniprot: P60880). SNAP-25 was 
not significantly different between DLB and control (p=0.0846; Fig. 5.3A). 
A single band at approximately 50 kDa was demonstrated for growth-associated 
protein 43 (GAP43; Fig. 5.3B), which does not correspond with the canonical 
sequence (Uniprot: P17677). The canonical sequence of GAP43 has a molecular 
mass of 25 kDa. As the observed bands are approximately twice the known 
molecular mass of the canonical sequence, one may speculate this is a dimer. 
GAP43 was not significantly different between DLB and control (p=0.1308; Fig. 5.3B). 
A single band at approximately 78 kDa was demonstrated for synaptic vesicle 
glycoprotein 2B (SV2B; Fig. 5.3C), which corresponds with the canonical sequence 
(Uniprot: Q7L1I2). SV2B was not significantly different between DLB and control 
(p=0.8770; Fig. 5.3C). 
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Figure 5.3: Western blotting of SNAP-25, GAP43 and SV2B.  
SNAP-25 (A), GAP43 (B) and SV2B (C) expression is compared between control and DLB. Bars 
demonstrate the mean and error bars represent standard deviation. 
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A single band at approximately 50 kDa was demonstrated for microtubule-associated 
protein 2 (MAP2; Fig. 5.4A), which does not correspond with the canonical sequence. 
It was not possible to detect the canonical sequence of MAP2, which has a relatively 
high molecular weight of 200 kDa (Uniprot: P11137). Instead, a known variant of the 
canonical sequence, isoform 2 (Uniprot: P11137-2), was detected at 50 kDa. MAP2 
was significantly reduced in DLB compared to control (t=2.40, p=0.0256, d=0.89; Fig. 
5.4A). 
A single band at approximately 82 kDa was demonstrated for N-ethylmaleimide 
sensitive fusion protein (NSF; Fig. 5.4B), which corresponds with the canonical 
sequence (Uniprot: P46459). NSF was significantly reduced in DLB compared to 
control (t=2.97, p=0.0070, d=1.04; Fig. 5.4B). 
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Figure 5.4: Western blotting of MAP2 and NSF.  
MAP2 (A) and NSF (B) expression is compared between control and DLB. Bars demonstrate the 
mean and error bars represent standard deviation. *p<0.05. 
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A single band at approximately 67 kDa was demonstrated for GAD67 (Fig. 5.5A), 
which corresponds with the canonical sequence (Uniprot: Q99259). GAD67 was 
significantly reduced in DLB compared to control (t=2.68, p=0.0171, d=0.92; Fig. 
5.5A).  
Two bands were demonstrated at approximately 16 kDa and 14 kDa for GABARAP 
(Fig. 5.5B), which will be subsequently referred to as GABARAP isoform 1 and 
GABARAP isoform 2, respectively. The only described sequence of GABARAP is 14 
kDa (Uniprot: O95166). The band at 16 kDa, which is qualitatively smaller, may 
represent a previously undescribed isoform of GABARAP. GABARAP isoform 1 was 
significantly reduced in DLB compared to control (t=2.20, p=0.0430, d=0.86; Fig. 
5.5B). However, GABARAP isoform 2 was not significantly different between DLB 
and control (p=0.0545; Fig. 5.5B). 
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Figure 5.5: Western blotting of GAD67 and GABARAP.  
GAD67 (A) and GABARAP (B) expression is compared between control and DLB. Bars demonstrate 
the mean and error bars represent standard deviation. *p<0.05.  
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5.3.5 Western blotting of proteins that regulate immune system functioning 
Two bands were demonstrated at approximately 100 kDa and 90 kDa for ALDH1L1, 
which will be subsequently described as isoforms 1 and 2, respectively (Fig. 5.6A). 
The former corresponds with the canonical sequence (Uniprot: O75891) and a 
known isoform has a molecular mass of 88 kDa (Uniprot: O75891-2), suggesting that 
isoform 2 is a known variant of ALDH1L1. ALDH1L1 isoform 1 was significantly 
increased in DLB compared to control (t=3.93, p=0.0007, d=1.25; Fig. 5.6A). No 
significant difference was found in isoform 2 between DLB and control (Fig. 5.6A). 
Isoform 1 was relatively increased, compared to isoform 2, in DLB compared to 
control (t=3.92, p=0.001, d=1.26).  
A single band at approximately 70 kDa was demonstrated for heat shock 70 kDa 
protein 1B (HSPA1B; Fig. 5.6B), which corresponds with the canonical sequence 
(Uniprot: P0DMV9). HSPA1B was significantly increased in DLB compared to control 
(t=2.99, p=0.0112, d=1.11; Fig. 5.6B). 
A single band at approximately 43 kDa was demonstrated for CHI3L1/YKL-40 (Fig. 
5.6C), which corresponds with the canonical sequence (Uniprot: P36222). 
CHI3L1/YKL-40 was significantly increased in DLB compared to control (t=2.40, 
p=0.0300, d=0.93; Fig. 5.6C). 
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Figure 5.6: Western blotting of ALDH1L1, HSPA1B and CHI3L1/YKL-40.  
ALDH1L1 (A), HSPA1B (B) and CHI3L1/YKL-40 (C) expression is compared between control and 
DLB. Bars demonstrate the mean and error bars represent standard deviation.*p<0.05 
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A single band at approximately 47 kDa was demonstrated for serine (or cysteine) 
proteinase inhibitor, clade H (heat shock protein 47), member 1 (SERPINH1/HSP47; 
Fig. 5.7A), which corresponds with the canonical sequence (Uniprot: P50454). 
SERPNH1/HSP47 was not significantly different between DLB and control (p=0.6368; 
Fig. 5.7A). 
A single band at approximately 70 kDa was demonstrated for heat shock protein 70 
kDa protein 1 (HSPA1A; Fig. 5.7B), which corresponds with the canonical sequence 
(Uniprot: P0DMV8). HSPA1A was not significantly different between DLB and control 
(p=0.6140; Fig. 5.7B). 
A single band was detected at approximately 100 kDa for complement component 3 
(C3; Fig. 5.7C), which does not correspond with the canonical sequence which has a 
molecular mass of 187 kDa (Uniprot: P01024). However, a molecular mass of 187 
kDa would not be detectable using the method employed and, therefore, the band at 
100 kDa was quantified. The 100 kDa band of C3 was not significantly different 
between DLB and control (p=0.1499; Fig. 5.7C). 
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Figure 5.7: Western blotting of SERPINH1/HSP47, HSPA1A and C3.  
SERPINH1/HSP47 (A), HSPA1A (B) and C3 (C) is compared between control and DLB. Bars 
demonstrate the mean and error bars represent standard deviation. 
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Several bands were demonstrated between 40 and 50 kDa for GFAP (Fig. 5.8), 
though all previously described isoforms of GFAP have an approximate molecular 
mass of 50 kDa (Uniprot: P14136). The additional bands below 50 kDa may reflect 
degradation products. The top, middle and bottom bands were analysed and will 
subsequently be referred to as GFAP isoforms 1, 2 and 3, respectively. GFAP 
isoform 1 was not significantly different between DLB and control (p=0.5107; Fig. 
5.8). GFAP isoform 2 was not significantly different between DLB and control 
(p=0.7234; Fig. 5.8). GFAP isoform 3 was not significantly different between DLB 
and control (p=0.1122; Fig. 5.8). 
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Figure 5.8: Western blotting of GFAP.  
GFAP isoform expression is compared between control and DLB. Bars demonstrate the mean and 
error bars represent standard deviation.   
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5.3.6 Relationships between synaptic markers 
Post-mortem interval was previously demonstrated to relate to decreases in some 
synaptic proteins, such as PSD-95 (Siew et al., 2004; Sinclair et al., 2015). However, 
a study published subsequent to the completion of this work has demonstrated post-
mortem interval has little impact on proteomic analysis, with most changes driven by 
tissue pH (Robinson et al., 2016). For this reason, post-mortem interval and tissue 
pH (when available) were related to all synaptic proteins. The only significant 
correlation was between tissue pH and SNAP-25 (rho=0.486, p=0.048).  
A correlation matrix was constructed between presynaptic markers (Table 5.4). This 
matrix suggested similar patterns of expression between synaptophysin, NSF, 
SNAP-25, GAP43 and dynamin. However, SV2B showed no significant correlations 
with other presynaptic markers. 
A correlation matrix was constructed between postsynaptic markers (Table 5.5). This 
matrix suggested similar patterns of expression between PSD-95, gephyrin and 
GABARAP. However, MAP2 was only significantly correlated with GABARAP 
isoform 2. 
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Table 5.4: Correlation matrix demonstrating correlations between presynaptic markers.  
All cases were used for this analysis. *p<0.05. 
 SYP NSF SNAP-25 GAP43 SV2B 
Synaptophysin  0.69* 0.46* 0.59* 0.31 
NSF 0.69*  0.25 0.57* 0.13 
SNAP-25 0.46* 0.25  0.52* -0.10 
GAP43 0.59* 0.57* 0.52*  0.11 
SV2B 0.31 0.13 -0.10 0.11  
 
 
 
Table 5.5: Correlation matrix demonstrating correlations between postsynaptic markers.  
All cases were used for this analysis. *p<0.05. 
 PSD-95 Gephyrin GABARAP1 GABARAP2 MAP2 
PSD-95  0.55* 0.79* 0.77* 0.27 
Gephyrin 0.55*  0.61* 0.53* 0.27 
GABARAP1 0.79* 0.61*  0.94* 0.40 
GABARAP2 0.77* 0.53* 0.94*  0.44* 
MAP2 0.27 0.27 0.40 0.44*  
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Table 5.9: Correlation matrix demonstrating correlations between astrocytic markers.  
All cases were used for this analysis. *p<0.05. 
 ALDH1L1 1 ALDH1L1 2 GFAP 1 GFAP 2 GFAP 3 CHI3L1 
ALDH1L1 1  0.79* 0.17 0.31 0.39 0.47* 
ALDH1L1 2 0.79*  -0.17 0.00 0.16 0.32 
GFAP 1 0.17 -0.16  0.65* 0.16 0.06 
GFAP 2 0.31 0.00 0.65*  0.71* 0.26 
GFAP3 0.39 0.16 0.16 0.71*  0.36 
CHI3L1 0.47* 0.32 0.06 0.26 0.36  
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5.3.7 Relationships between inflammatory markers 
A correlation matrix was constructed between all astroglial markers (Table 5.6). 
ALDH1L1 did not correlate with GFAP but positively correlated with CHI3L1/YKL-40. 
No GFAP isoform was related to ALDH1L1 or CHI3L1/YKL-40. 
 
5.3.8 Relationships between astroglial and synaptic markers 
To investigate potential relationships between synaptic and astroglial markers, the 
synaptic markers synaptophysin, NSF, SNAP-25, GAP43, dynamin, PSD-95, 
gephyrin and GABARAP were correlated with the astroglial markers ALDH1L1, 
GFAP and CHI3L1/YKL-40. The synaptic markers were selected based on the 
substantial interrelationships with other synaptic markers. The three astroglial 
markers were selected based on the evidential base linking them to astrocytic 
patterns of expression, and the previous observation of astrocytic increases in the 
pulvinar in DLB described in Chapter 4. As these analyses were not directly 
hypothesis-driven, Bonferroni corrections were applied to these results.  
ALDH1L1 isoform 1 was significantly negatively correlated with GAP43 (rho=-0.576, 
corrected p=0.033) and dynamin (rho=-0.623, corrected p=0.011). No significant 
correlations were found between ALDH1L1 isoform 1 and synaptophysin, NSF, 
SNAP-25, PSD-95, gephyrin, GABARAP isoform 1 and GABARAP isoform 2. All 
significant correlations between ALDH1L1 isoform 1 and synaptic markers are 
illustrated in Fig. 5.10. 
All GFAP isoforms and the ALDH1L1 isoform 2 were not significantly correlated with 
any synaptic markers after Bonferroni correction.  
CHI3L1/YKL-40 was significantly negatively correlated with NSF (rho=-0.578, 
p=0.033), GAP43 (rho=-0.612, p=0.011), PSD-95 (rho=-0.599, p=0.022), GABARAP 
isoform 1 (rho=-0.712, p=0.001) and GABARAP isoform 2 (rho=-0.672, p=0.001). No 
significant correlations were found between CHI3L1/YKL-40 and synaptophysin, 
SNAP-25 and gephyrin. Scatterplots of all significant correlations between 
CHI3L1/YKL-40 and synaptic markers are illustrated in Fig. 5.10. 
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Figure 5.10: Correlations between synaptic and astrocytic markers.  
Scatterplots illustrating significant correlations between ALDH1L1 and CHI3L1/YKL-40 with synaptic 
markers. 
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5.4 Discussion 
RNA sequencing data provided by a collaborator demonstrated synaptic and 
inflammatory changes in the pulvinar nucleus in DLB at the transcriptional level. The 
present study elaborated on these findings by demonstrating corresponding 
alterations in protein expression. Previous studies have shown that the pulvinar is 
vulnerable to Lewy body pathology (Yamamoto et al., 2006) unlike other thalamic 
visual structures, such as the LGN (Erskine et al., 2016). However, this is the first 
study to investigate the pulvinar at the molecular level in DLB. These findings 
indicate that beyond neuronal loss and astrogliosis identified using histopathological 
approaches in the previous chapter, the pulvinar undergoes molecular changes 
suggestive of synaptic loss and inflammation in DLB. Furthermore, there was a 
significant negative relationship between some astroglial markers and synaptic loss, 
indicating reductions in synaptic marker expression are commensurate with 
increases in astroglial markers.  
 
5.4.1 Selective reductions in synaptic markers 
Information transfer between neurons in the central nervous system is predominantly 
carried out at chemical synapses by neurotransmitters, which enable the fast 
passage of information between neurons (Hudspeth et al., 2013). Secretion of 
neurotransmitters into the synapse is induced by the opening of voltage-gated 
calcium channels, as a result of neuronal membrane depolarisation (Ramakrishnan 
et al., 2012). Neurotransmitter-containing vesicles fuse with the pre-synaptic 
membrane to release neurotransmitters (Sudhof, 2004), which may then bind to 
post-synaptic receptors, initiating (or inhibiting) intracellular processes in the post-
synaptic neuron (Hudspeth et al., 2013).  
Synaptic vesicles are typically clustered in regions termed ‘active zones’ in axonal 
boutons, close to the sites where vesicles are released from the pre-synaptic neuron 
into the synapse (Fig. 5.11A) (Fowler and Staras, 2015). Vesicle fusion with the pre-
synaptic membrane is facilitated by the SNARE protein family, which are present on 
both the synaptic vesicle and the pre-synaptic membrane (Ramakrishnan et al., 
2012). SNARE proteins tether the synaptic vesicle to the pre-synaptic membrane, 
thus facilitating synaptic vesicle fusion (Fig. 5.11B-D). SNAP-25 and SV2B are 
integral components of the pre-synaptic SNARE complex, which interact and 
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facilitate synaptic vesicle fusion and exocytosis (Sutton et al., 1998; Lazzell et al., 
2004). SNAP-25 is expressed on the pre-synaptic membrane, where it is vital for 
vesicle fusion and exocytosis (Ramakrishnan et al., 2012). Deletion of SNAP-25 from 
mice leads to profound dysfunction in calcium-mediated neurotransmitter exocytosis 
(Washbourne et al., 2002). GAP43 is not directly associated with the SNARE 
complex but is predominantly expressed on pre-synaptic membranes, where it may 
influence the growth state of the presynaptic terminal (Benowitz and Routtenberg, 
1997).  
SNAP-25, GAP43 and SV2B were not significantly different in DLB compared to 
control. This was unexpected for SV2B, which had the fifth greatest fold reduction in 
the RNA sequencing analysis. SV2B is a synaptic vesicle protein that is 
predominantly expressed on glutamatergic synapses (Bragina et al., 2011). Amyloid-
β toxicity may be mediated by SV2B as knock-out of SV2B in amyloid-β 
overexpressing mice is protective against cognitive decline (Detrait et al., 2014). One 
may speculate that reduced transcription of SV2B may reflect an attempt to 
attenuate SV2B-mediated amyloid-β toxicity. However, at the protein level, SV2B is 
not significantly different from control. A previous study has demonstrated amyloid-β 
may alter the translation of SV2B by acting upon a transcript variant, SV2Bb (Heese 
et al., 2001). Therefore, one may speculate the discrepancy between transcription 
and expression may result from the presence of amyloid-β in the pulvinar, which may 
alter translation of SV2B.    
The pre-synaptic proteins synaptophysin and NSF were significantly reduced in DLB 
compared to control. Synaptophysin and NSF both associate with the pre-synaptic 
SNARE complex to facilitate synaptic vesicle exocytosis (Calakos and Scheller, 1994; 
Rothman, 1994). The primary role of synaptophysin is thought to be in regulating 
neurotransmitter release and improving exocytotic efficiency (Gordon et al., 2016). 
NSF contributes to disassembling the SNARE complex following membrane fusion 
and exocytosis (Fig. 5.11E) (Rizo and Xu, 2015). In contrast to SNAP-25 and SV2B, 
synaptophysin and NSF are not necessary for vesicle exocytosis at synapses but aid 
efficiency of neurotransmitter release and turnover of vesicles following exocytosis 
(Fig. 5.11E-F) (Rizo and Xu, 2015). Therefore, in the present study, pre-synaptic 
proteins necessary for synaptic vesicle exocytosis were not altered in DLB compared 
to control. In contrast, reductions were found in pre-synaptic proteins that aid 
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efficient neurotransmitter release and turnover of synaptic vesicles. Alterations to 
proteins related to synaptic efficiency may be the result of α-synuclein pathology in 
pre-synaptic regions, which may alter synaptic efficiency without eliminating the 
ability of neurons to communicate through synapses. A previous in vitro report 
demonstrated the addition of recombinant α-synuclein to cultured cortical neurons 
reduced the rate of synaptic vesicle recycling (Bate et al., 2010). The pre-synaptic 
proteins altered in the present study are involved in the efficient recycling of synaptic 
vesicles, suggesting such alterations may be related to α-synuclein pathology.  
Compared to control, DLB had significant reductions in all post-synaptic proteins 
assessed: PSD-95, gephyrin, both isoforms of GABARAP and MAP2. PSD-95 is 
located on the postsynaptic membrane of glutamatergic synapses (Hunt et al., 1996), 
where it anchors neurotransmitter receptors and adhesion molecules (Keith and El-
Husseini, 2008). Gephyrin has a similar role to PSD-95 on the postsynaptic 
membrane of inhibitory synapses, acting as a scaffold to anchor GABAergic and 
glycinergic receptors to the cytoskeleton (Levi et al., 2004). GABARAP interacts with 
gephyrin and aids transport of GABAergic receptors to the post-synaptic membrane 
(Kneussel et al., 2000). MAP2 is localised on dendritic spines, upon which 
postsynaptic receptors are located (Caceres et al., 1983). The present results 
indicate reductions in post-synaptic receptor markers irrespective of their 
neurochemical composition, as excitatory and inhibitory post-synaptic markers are 
reduced.  
The reductions in synaptic marker expression at the protein level are broadly 
consistent with those identified at the transcriptional level by RNA sequencing, and 
may reflect synaptic loss in the pulvinar. Pre-synaptic changes in protein expression 
are limited to proteins involved in the efficient recycling of synaptic vesicles following 
exocytosis, thus contributing to reduced refractory periods following exocytosis and 
correspondingly increased neuronal firing. However, the necessary components for 
exocytosis remain intact. In contrast, more widespread changes were observed in 
post-synaptic receptors. As necessary components for neurotransmitter exocytosis, 
such as SNAP-25 and SV2B, are intact, synaptic dysfunction appears more likely 
than generalised synaptic loss.
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Figure 5.11: The SNARE complex.  
Pre-synaptic vesicles reside in the pre-synaptic bouton (A); vesicles move toward to pre-synaptic membrane (B); and are tethered by the SNARE complex (C); 
SNAP-25 aids vesicle fusion with the pre-synaptic membrane and contents are expelled into the synapse (D); NSF helps break down the SNARE complex (E); 
the vesicle is released from the pre-synaptic membrane and recycled (F).
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5.4.2 GABAergic marker reductions  
GABARAP and GAD67 are markers of the inhibitory neurotransmitter GABA and 
were significantly reduced in DLB compared to control, despite no changes to 
GABARAP transcription on RNA sequencing, as reported in Table 5.2. GABARAP 
interacts with gephyrin and transports GABAergic receptors to the postsynaptic 
membrane (Kneussel et al., 2000). GAD67 is one of two enzymes that catalyse the 
synthesis of GABA from glutamate (Fenalti et al., 2007). The expression of GAD67 is 
regulated in an activity-dependent manner (Lau and Murthy, 2012) and reductions 
have been demonstrated to decrease inhibitory network activity in cortical regions 
(Lazarus et al., 2015). Taken together, these results demonstrate general reductions 
in markers of GABAergic neurotransmission. Therefore, the present results support 
previous findings suggesting GABAergic dysfunction in the visual system in DLB as 
a potential mechanism underlying visual hallucinations (Khundakar et al., 2016; 
Taylor et al., 2016). 
 
5.4.3 Selective increases in positive regulators of immune system functioning 
The immune system protects the organism from a variety of diverse harm-causing 
agents, in addition to promoting repair and clearance of damaged tissues (Proserpio 
and Mahata, 2016). Positive regulators of immune system serve to activate or 
enhance the response of the immune system. The immune response in the brain is 
primarily conducted by microglia (Rivest, 2009), though astrocytes have also been 
demonstrated to modulate inflammation and can act to sustain inflammatory 
conditions (Farina et al., 2007). In the context of neurodegenerative disorders, 
neuroinflammation is an intrinsic cellular response to neurodegenerative insult 
initiated to isolate and clear damaged tissues (Lopez-Valdes and Martinez-Coria, 
2016).  
ALDH1L1, GFAP and CHI3L1/YKL-40 are expressed on astroglia (Cahoy et al., 
2008). In the brain, CHI3L1/YKL-40 is predominantly expressed in astrocytes and 
does not co-localise with the microglial marker LN-3 (Craig-Schapiro et al., 2010). 
However, CHI3L1/YKL-40 is specifically expressed in macrophages in the periphery 
(Rehli et al., 2003; Coffman, 2008). Therefore, it is impossible to discount the 
possibility that the presently reported elevations in CHI3L1/YKL-40 result from 
infiltrating macrophages resulting from tissue damage or neuronal insult in DLB. 
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ALDH1L1, a more general astrocytic marker than GFAP or CHI3L1/YKL-40 (Cahoy 
et al., 2008), was not elevated on RNA sequencing (Table 5.3) but was increased at 
the protein level. The increased protein expression but absence of increased 
transcription may suggest changes in the translation of ALDH1L1. DLB had a relative 
24% increase in isoform 1 relative to isoform 2, perhaps suggesting ALDH1L1 is 
transcribed or translated differently in DLB compared to control. GFAP was 
increased on RNA sequencing analysis (Table 5.3) but did not show any differences 
between groups at the protein level. However, western blot of GFAP demonstrated 
numerous bands between 40 kDa and 50 kDa which made densitometric analysis 
difficult, and likely affected the quantification of this protein. It is notable that Chapter 
4 reported increased density of GFAP-immunoreactive astrocytic profiles in a 
separate cohort of DLB cases compared to control. CHI3L1/YKL-40, a marker of a 
sub-population of astrocytes induced in inflammatory conditions (Bonneh-Barkay et 
al., 2010a), was significantly elevated in DLB compared to control. This was 
consistent with the RNA sequencing data, which suggested CHI3L1/YKL-40 was the 
second greatest fold increase in DLB.  
These findings indicate specific inflammatory changes in the pulvinar in DLB. 
CHI3L1/YKL-40 was negatively correlated with a number of synaptic markers. This 
may reflect inflammation as a result of synaptic dysfunction or vice-versa, though it is 
difficult to establish the direction of this relationship. CHI3L1/YKL-40 is a putative 
marker of inflammation (Coffman, 2008; Lee et al., 2011) that is up-regulated in 
numerous disease states characterised by inflammation, including rheumatoid 
arthritis (Johansen et al., 1999), active phases of inflammatory bowel diseases (Vind 
et al., 2003), and the acute inflammatory phase of traumatic brain injury (Bonneh-
Barkay et al., 2010b). Therefore, the elevated expression of CHI3L1/YKL-40, and its 
association with synaptic protein loss, may indicate inflammatory conditions with 
associated synaptic loss in the pulvinar in DLB.  
CHI3L1/YKL-40 has been previously shown to be decreased in the cerebrospinal 
fluid (CSF) of PD, MSA and DLB patients, in comparison to increased levels in 
tauopathy cases, which was interpreted as the result of reduced astroglial activation 
in synucleinopathies compared to tauopathies (Olsson et al., 2013; Janelidze et al., 
2016). Although CSF protein levels are not necessarily representative of cerebral 
protein expression, these findings may indicate that CHI3L1/YKL-40 elevations are 
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not a global phenomenon in DLB but may be regionally specific. Therefore, the 
present findings may suggest inflammatory conditions in the pulvinar that are not 
representative of the rest of the brain in DLB. Several hypotheses have suggested 
the manifestation of visual hallucinations could reflect the relative selectivity of brain 
regions pathologically affected by changes in DLB (Collerton et al., 2005b; Diederich 
et al., 2014; Carter and Ffytche, 2015). Therefore, the identification of the pulvinar as 
a region with elevated levels of an inflammatory astroglial marker may indicate a 
selective region of impairment that may contribute to the clinical phenotype. However, 
as the present study only assessed the pulvinar, it is impossible to establish whether 
this change is selective for this region. Future studies may investigate whether other 
regions of the thalamus, and the brain generally, have similar elevations in 
CHI3L1/YKL-40 in DLB, as the relationship between CHI3L1/YKL-40 and 
neuroinflammation makes it a potential therapeutic target. However, further work is 
necessary to evaluate the role of CHI3L1/YKL-40 and inflammation in DLB.   
Despite the increased transcription of complement component C3 on RNA 
sequencing, C3 was not changed at the protein level. The complement pathway is 
part of the immune system that amplifies the immune response and is implicated in 
several cytoprotective roles, including clearance of foreign pathogens, cell integrity 
and modulation of the intensity of immune responses (Holers, 2014). The cleavage 
of complement component C3 is a central event in the activation of the complement 
cascade and, therefore, in a pro-inflammatory response (Kemper and Atkinson, 
2007). Complement C3 is expressed in a range of cells within the mouse brain, 
including a subset of pyramidal neurons in hippocampal regions (Yu et al., 2002), 
and may be expressed in astrocytes (Zhou et al., 2008). In human tissues, some 
fragments of complement C3 have previously been described as a component of 
amyloid-β plaques (Eikelenboom and Stam, 1984), suggesting they are activated, 
perhaps as a response to amyloid-β deposition (Eikelenboom et al., 1988). 
Complement fragments co-localise with Lewy bodies in neurons in the substantia 
nigra in PD (Yamada et al., 1992) but are only co-expressed with amyloid-β plaques 
in the neocortex in DLB, and not neocortical Lewy bodies (Rozemuller et al., 2000). 
Increased transcription of complement C3 is, therefore, likely a pro-inflammatory 
response occurring as a result of pathological protein deposition in the pulvinar, as 
reported in Chapter 4.   
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Heat shock proteins bind to damaged or partially unfolded polypeptides under 
conditions of widespread damage to cellular proteins, such as with heat (De Maio, 
1999). Under normal physiological conditions, most heat shock proteins serve to 
ensure the proper folding of proteins (Sherman and Goldberg, 2001). 
SERPNH1/HSP47 is relatively understudied but appears to be expressed in 
astrocytes following excitotoxic lesions and may enhance glial cell protection under 
adverse conditions (Acarin et al., 2002). HSPA1A and HSPA1B belong to the heat 
shock protein 70 kDa (HSP70) family of heat shock proteins. The HSP70 family are 
chaperones, which promote correct folding of polypeptides upon their emergence 
from ribosomes under normal physiological conditions (Frydman and Hartl, 1996; 
Hartl and Hayer-Hartl, 2002). Under pathological conditions, HSP70 chaperones 
promote protein degradation through the ubiquitin-proteasome pathway (Pratt et al., 
2015) and may, therefore, contribute to the degradation of protein aggregates that 
are commonly found in neurodegenerative disorders (Sherman and Goldberg, 2001). 
In Lewy body disease, HSP70 chaperones co-localise with α-synuclein aggregates 
and may protect neurons from α-synuclein-mediated toxicity by inhibiting aggregation 
(Chaari et al., 2013). Disaggregase components of the HSP70 protein class have 
been demonstrated to disassemble α-synuclein fibrils into monomers (Gao et al., 
2015). Therefore, the increased transcription of HSPA1A and HSPA1B may reflect a 
stereotyped, protective mechanism to toxic protein assemblies, such as those found 
in Lewy body disease. In the present study, only HSPA1B was increased at the 
protein level, indicating a discrepancy between HSPA1A transcription and 
expression, or a lack of sensitive methods to detect a change at the protein level.  
 
5.4.4 General discussion 
Reductions in post-synaptic proteins, without corresponding loss of pre-synaptic 
proteins necessary for exocytosis, may suggest neuronal loss in the pulvinar is 
responsible for the reduction in post-synaptic proteins (Chapter 4). The preservation 
of pre-synaptic proteins vital for exocytosis may indicate greater numbers of afferent 
connections synapse upon individual pulvinar neurons. This is possibly an adaptive 
mechanism to compensate for neuronal loss, though it likely reduces the sensitivity 
of individual pulvinar neurons. Reductions in pre-synaptic markers implicated in 
maintaining efficient synaptic exocytosis and vesicle recycling may suggest input to 
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the pulvinar is altered. Therefore, it is also possible post-synaptic protein reductions 
are the result of altered input due to altered pre-synaptic functioning. Equally, input 
to the pulvinar may be altered as a result of changes to the constituent neuronal 
population. 
One hypothesis suggests altered retinal input, possibly secondary to pathology 
(Beach et al., 2014), induces compensatory decreases in inhibition in the primary 
visual cortex (Manford and Andermann, 1998; Khundakar et al., 2016; Taylor et al., 
2016). A study employing transcranial magnetic stimulation has demonstrated 
increased visual cortical excitability related to the occurrence of visual hallucinations 
in DLB (Taylor et al., 2011). On the molecular level, decreased GABAergic 
transcription has been identified, which may be a stereotyped response to altered 
visual input (Khundakar et al., 2016). The inferior and lateral pulvinar are directly 
connected to the primary visual cortex (Kaas and Lyon, 2007) and increased pulvinar 
excitability has been demonstrated to lead to increased primary visual cortical 
activity, without altering the physiology of the LGN (Purushothaman et al., 2012). 
Increased excitability of the pulvinar, as a result of reduced GABAergic activity, may 
contribute to increased visual cortical activity in DLB. However, as the present study 
did not assess neurotransmitter symptoms other than GABA, it is not possible to say 
whether these deficits are specific. It is possible the reported GABAergic losses 
reflect more widespread neurotransmitter reductions in the pulvinar, possibly as a 
result of neuronal loss or synaptic changes, as outlined previously (Chapter 4). 
The present findings on targets that positively regulate immune system functioning 
indicate increases in some astrocytic markers which, particularly in the case of 
CHI3L1/YKL-40, may suggest neuroinflammatory conditions in the pulvinar in DLB. 
The negative relationship between CHI3L1/YKL-40 and several synaptic proteins 
indicates inflammatory responses may be a response to, or potentially a potentiating 
factor in, the observed synaptic changes. However, it is difficult to establish the 
direction of these relationships. Increased levels of CHI3L1/YKL-40 have not 
previously been demonstrated in α-synucleinopathies, suggesting that the increase 
in CHI3L1/YKL-40 in the pulvinar may reflect a specific region of vulnerability in DLB. 
However, as the present study only investigated the pulvinar, future studies would 
need to address the specificity of these changes by assessing other brain regions. 
The up-regulation of heat shock proteins may reflect an adaptive response to protein 
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aggregates, which were identified and described in the histological analysis in 
Chapter 4. 
Taken together, these results indicate synaptic and inflammatory changes in the 
pulvinar in DLB. Neuronal loss in the pulvinar may be responsible for the uniform 
reduction in post-synaptic markers, whilst pre-synaptic proteins necessary for vesicle 
exocytosis were preserved. The putative inflammatory marker CHI3L1/YKL-40 is 
found in quantities proportional to the severity of damage to the brain in studies of 
traumatic brain injury (Wiley et al., 2015). Therefore, the most parsimonious 
explanation of these findings is that the expression of CHI3L1/YKL-40 is the result of 
neuronal or synaptic damage. This proposition is supported by the negative 
correlations between an array of synaptic markers and the astrocytic marker 
CHI3L1/YKL-40. Whether CHI3L1/YKL-40 expression is an adaptive response 
mechanism, a factor that exacerbates neuronal damage, or both, is an empirical 
question that cannot be answered by the present data.  
Irrespective of the causative mechanism and the temporal sequence of the synaptic 
changes and inflammatory marker expression in the pulvinar, these results may 
indicate that the pulvinar is functionally altered in DLB. The relationship between the 
hypothesised pulvinar dysfunction in DLB and the manifestation of visual 
hallucinations may be through impaired visual attention. Impaired visual attention is 
thought to contribute a vulnerability to visual hallucination in DLB (Collerton et al., 
2005b; Diederich et al., 2005; Shine et al., 2011; Factor et al., 2014) and focused 
attention upon the subject of visual hallucinations has been demonstrated to promote 
the disappearance of the hallucinated object (Diederich et al., 2003). Therefore, the 
present findings of pulvinar synaptic loss and inflammation in the pulvinar in DLB, 
may relate to visual hallucinations through attentional dysfunction. Equally, altered 
excitability in the pulvinar, as a result of GABAergic dysfunction, may also alter the 
excitability of the primary visual cortex. Increased visual cortical excitability has 
previously been linked to visual hallucinations in DLB (Taylor et al., 2011; Khundakar 
et al., 2016; Taylor et al., 2016). Both propositions are not mutually exclusive, and it 
is possible that the reported changes to the pulvinar mediate hallucinogenesis 
through both dysfunctional attentional mechanisms and impaired modulation of 
visual cortical excitability.   
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A weakness of the present study is that the small sample size may limit the 
generalisability of these findings. Pulvinar tissue with a short post-mortem interval 
was particularly difficult to obtain, though a recent study has indicated that employing 
this criterion in case selection may have unnecessarily limited the available tissue 
(Robinson et al., 2016). The present study compared DLB to control cases and, 
unlike previous chapters, did not include AD as a disease control group. Therefore, it 
is difficult to ascertain whether the presently reported changes are simply related to 
neurodegeneration generally, or specifically related to clinical features of DLB, such 
as visual hallucinations. RNAseq is an expensive technique and the addition of 
further cases to represent an AD group would have been prohibitive for the purposes 
of the present analysis. An additional concern is that transcriptional changes 
identified from RNA sequencing did not always correspond with the expression of the 
protein on western blotting. In some instances, explanations have been offered for 
specific proteins having an evidential basis explaining transcription and expression 
may be discrepant. Densitometric analysis of western blot membranes has been 
applied in a quantitative manner in the present study. However, western blotting 
does not allow the quantification of absolute levels of a particular protein within a 
matrix, instead relying on relative comparison of the size and intensity of bands. 
Absolute measures of protein concentrations within samples would have been 
possible using more quantitative analytical techniques, such as ELISA. However, 
initial pilot studies in developing ELISA for the present project indicated that the 
volume of tissue required for each individual protein was typically much higher than 
that required for western blotting. Considering the small volume of tissue available 
per case, this would limit the number of protein targets that could be assessed. 
Therefore, western blot analysis was used to ensure a larger array of proteins could 
be investigated.  
Glial markers such as GFAP, ALDH1L1 and CHI3L1 were normalised to GAPDH, a 
ubiquitously expressed cellular housekeeping protein. However, to evaluate whether 
any observed changes reflected increases in total numbers of astrocytes or 
increased expression of the assessed antigen within the glial population, a glial cell-
specific transcript may have been used. ALDH1L1 is thought to be a superior pan-
astrocytic marker than GFAP, and may have been a useful additional measure 
(Cahoy et al., 2008). Similarly, neuron-specific markers such as GAD67 were also 
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normalised to GAPDH and evaluation of expression relative to a neuron-specific 
marker, such as NeuN (Cahoy et al., 2008), may have enabled assessment of 
whether the assessed antigens were altered in expression whilst controlling for the 
confounding effects of neuronal loss as reported in chapter 4. A future study may 
wish to consider using cell-specific transcripts to evaluate changes in epitope 
expression independently of changes to cell number.  
In conclusion, the present study has demonstrated reductions in synaptic proteins 
and increased inflammatory markers in the pulvinar of DLB patients. Synaptic 
changes likely alter synaptic functioning and inflammatory markers may indicate 
tissue damage or insult. The role of inflammation in either protecting neurons and 
synapses, or accentuating the damage to them, requires further study. However, the 
likely effect of the synaptic and inflammatory changes is that normal functioning of 
the pulvinar is altered. As a major function of the pulvinar is in the coordination of 
visual attention, this may become deficient as a result of pulvinar degeneration. 
Visual attentional dysfunction is a widely reported phenomenon in DLB and may 
contribute a vulnerability to visual hallucination. Therefore, the observed molecular 
changes in the pulvinar are consistent with the proposition that it is functionally 
altered in DLB, contributing to a vulnerability to hallucination, potentially through 
deficient visual attentional mechanisms.      
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Chapter 6: Histological studies in the superior colliculus 
6.1 Introduction 
The superior colliculus is thought to play a vital role in orienting movements of the 
eyes and head to support shifts of visuo-spatial attention (Gandhi and Katnani, 2011). 
However, it is becoming increasingly evident that the superior colliculus has 
attentional functions beyond the execution of motor commands to support attention, 
such as target selection and the filtering of distracting stimuli (Krauzlis et al., 2013).  
The medial temporal visual area (area V5/MT) receives input from the inferior 
pulvinar in a pathway thought to originate in the superficial laminae of superior 
colliculus (Stepniewska et al., 1999; Stepniewska et al., 2000). The tectal-pulvinar-
V5/MT pathway has a role in the relay of information to the cortex regarding recently 
executed eye movements (Bridge et al., 2015). Patients with Lewy body disease 
have eye movement difficulties (Trick et al., 1994; Terao et al., 2011), which may be 
the result of impairment of the superior colliculus.  
Impairments in attentional shifting, resulting from superior colliculus dysfunction, 
have been suggested to contribute to the manifestation of visual hallucinations in 
Lewy body disease (Diederich et al., 2014). Difficulty in engaging the dorsal 
attentional network to attend to ambiguous visual stimuli has been suggested to 
contribute to the manifestation of visual hallucinations in DLB, with the superior 
colliculus directly implicated (Shine et al., 2014). Therefore, the present study aimed 
to investigate the three grey matter laminae of the superior colliculus, with the aim of 
identifying neuropathological changes that may contribute to hallucinations in DLB.     
 
6.1.1 Aims 
Formalin-fixed post-mortem superior colliculus tissue obtained from DLB patients 
was compared with aged cognitively normal control and AD cases. This study aimed 
to: 
1) Evaluate the density of neurons and glia in the individual laminae of the 
superior colliculus and compare these across experimental groups. 
2) Compare the burden of neuropathological lesions in the different laminae of 
the superior colliculus across experimental groups. 
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3) Relate morphometric and neuropathological findings to neuropsychological 
data from life, where available. 
 
6.2 Methods  
6.2.1 Tissue acquisition and sampling 
The superior colliculus is located on the posterior aspect of the midbrain, bordering 
the lateral aspects of the periaqueductal grey (Fig. 2.3) (Krauzlis et al., 2013). As 
thalamic and midbrain blocks are cut on two different planes, and midbrain tissue is 
valuable in DLB cases, it was not possible to sample the entirety of the structure for 
stereological determination of total neuron number. Therefore, a modified protocol 
was used where the density of neurons was determined, as a proxy of neuronal 
number, on three adjacent sections.  
Three groups of cases were included in this study: DLB, AD and aged control cases 
with low or absent levels of neurodegenerative pathology. Where possible, cases 
with detailed neuropsychological information from life were included to relate with 
pathological findings. To better evaluate relationships between neuropathological 
changes and visual hallucinations, two cases without a clinical history of visual 
hallucinations were also included. Demographic information is listed in Table 6.1.  
The superior colliculus is typically divided into three grey matter laminae, the SGS, 
SGI and SGP, which are interspersed with predominantly fibre-rich laminae. 
Analyses of neuronal and glial density and neuropathology were conducted on the 
individual grey matter layers to enable determination of any likely physiological 
changes resulting from the specific degeneration of one or more particular layers, as 
demonstrated in Fig. 6.1. 
Fixed tissue blocks containing the superior colliculus were sectioned into a series of 
three adjacent 30 μm-thick sections from a random starting point and stained with 
cresyl violet for stereological analysis. 6 μm-thick sections were obtained from three 
adjacent sections for densitometric analysis of protein deposits. Stereological 
analyses were conducted on 30 μm-thick sections stained with cresyl fast. 6 μm-
thick sections were stained with antibodies against a range of protein targets (Table 
6.2) using Menarini Menapath Polymer detection kits (Menarini, Berkshire, UK), as 
per manufacturer’s instructions.  
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Table 6.1: Demographic information for cases used in the superior colliculus study.  
‘PM interval’ represents post-mortem interval, the interval between death and post-mortem examination, ‘Braak NFT’ represents the neurofibrillary pathology 
stage outlined in (Braak et al., 2006), ‘McKeith LB’ represents Lewy body pathology stage outlined in (McKeith, 2006), ‘clinico-path diagnosis’ represents the 
diagnosis reached for each individual patients by senior clinicians and a neuropathologist, with consideration given to clinical and pathological features, 
‘NPI(hall)’ represents the hallucinations subscale of the NPI, outlined in (Cummings et al., 1994), ‘UPDRS III’ represents the motor subscale of the UPDRS, 
outlined in (Fahn and Elotion, 1987). 
Case ID Gender Age at 
death 
(years) 
PM 
interval 
(hours) 
Braak 
NFT 
McKeith 
LB 
Clinico-
path 
diagnosis 
NPI 
(hall) 
NPI 
interval 
to death 
(months) 
UPDRS 
III 
UPDRS 
interval 
to death 
(months) 
C5 M 73 25 0 None Control - - - - 
C22 F 80 25 2 None Control - - - - 
C23 F 90 63 2 None Control - - 7 21 
C24 M 91 72 1 None Control - - 12 15 
C25 M 83 112 2 None Control - - - - 
C26 M 71 25 1 None Control - - - - 
C27 M 79 39 2 None Control - - - - 
C28 F 93 12 3 None Control - - - - 
C29 M 94 25 2 None Control - - 16 8 
C30 F 81 75 2 None Control - - - - 
C31 M 84 45 2 None Control - - - - 
C32 M 78 64 2 Brainstem Control - - - - 
C33 F 63 16 2 None Control - - - - 
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Mean±SD  81.5±9 46.0±29 1.8±1   N/A N/A 11.7±5 14.7±6 
D13 M 75 18 2 Limbic DLB - - - - 
D24 M 77 29 2 Neocortical DLB 1 2 58 14 
D6 F 78 96 3 Neocortical DLB 6 1 14 1 
D25 F 91 84 5 Limbic DLB 9 5 24 29 
D21 M 76 13 2 Neocortical DLB 0 2 36 37 
D26 M 74 42 4 Neocortical DLB 4 9 31 36 
D27 F 73 99 3 Neocortical DLB 0 27 30 - 
D28 M 71 22 3 Neocortical DLB 2 10 4 25 
D29 F 87 90 2 Neocortical DLB 3 - 26 1 
D30 M 74 60 2 Neocortical DLB - - 53 6 
Mean±SD  77.6±6 55.3±35 2.8±1   3.1±3 7.8±9 30.7±17 18.5±15 
A2 M 91 22 5 None AD 0 16 35 148 
A9 M 68 24 6 None AD - - - - 
A13 M 80 39 6 None AD - - 3 31 
A14 M 87 21 6 None AD 0 11 5 11 
A15 F 80 10 6 Amygdala AD 0 8 - - 
A16 M 82 12 6 Amygdala AD 0 - - - 
A10 F 86 123 6 Brainstem AD - - - - 
A17 F 58 70 6 None AD - - - - 
A18 M 84 40 6 None AD 2 10 17 14 
A19 F 89 11 6 None AD - - - - 
Mean±SD  80.5±10 37.2±35 5.9±0   0.4±1 11.1±3 15.0±15 53.2±64 
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Figure 6.1: Anatomy of the superior colliculus. 
Photomicrograph of the superior colliculus stained with cresyl violet. The stratum griseum superficiale 
(SGS), stratum griseum intermedium (SGI) and stratum griseum profundum (SGP) of the superior 
colliculus have a distinctive laminar organisation. The periaqueductal grey (PAG) is proximal, located 
on the anteromedial aspect of the midbrain relative to the superior colliculus. Scale bar = 1.5 mm. 
 
 
 
 
 
Table 6.2: Antibodies used in the superior colliculus study. 
Antibody Manufacturer Dilution Antigen retrieval 
KM51 α-synuclein Leica Biosystems, 
UK 
1:250 EDTA pH 8.0 
 AT8 phospho-tau Autogen, MA, USA 1:4000 Citrate pH 6.0 
4G8 amyloid-β Covance, NJ, USA 1:15000 Formic acid 
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6.2.2 Stereological determination of neuronal density 
The SGS, SGI and SGP were identified based on their laminar location using a brain 
atlas (Paxinos and Huang, 2013), and each lamina was analysed individually to 
assess neuronal and glial cell density. Regions of interest were demarcated at 2.5x 
objective and cell counts were conducted at 63x oil-immersion objective using the 
optical disector probe. Neuronal cell counts were conducted in disector frames of 
3500 μm2 and glial cell counts were conducted in disector frames of 1900 μm2. 
Section thickness did not vary across disease groups in any lamina. Mean CE values 
reached acceptable levels of accuracy (<0.15) in all laminae (Herculano-Houzel et al., 
2015).    
 
6.2.3 Neuropathology 
The SGS, SGI and SGP were analysed using quantitative neuropathological 
techniques. To quantify neuropathological lesions, images of representative parts of 
each lamina were taken on a Zeiss AxioVision Z.1 microscope using a Zeiss 3-chip 
CCD true colour camera. Stereologer software was used to delineate a region of 
interest with a 2.5x objective, prior to placement of disector frames in a uniform, 
random arrangement. This method prevented the introduction of bias by giving every 
area of the region of interest an equal probability of being sampled for analysis. 
Disector frames were captured at 10x objective for amyloid-β and tau, and at 20x 
objective for α-synuclein pathology, different magnifications were used based on the 
relative particle size and distribution of the structures measured. Images were taken 
within the disector frames and analysed using ImagePro Plus v.4.1 image analysis 
system. Using previously published techniques (Perry et al., 2012; Erskine et al., 
2016), the mean percentage area of immunopositivity was determined by 
standardising RGB thresholds per antibody and applying to all sections per case. 
Each case thus had a mean value generated per antibody across each strata 
analysed.  
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6.2.4 Clinico-pathological relationships 
To determine the relationships between neuropathological data and clinical features, 
correlational analyses were conducted with neuropsychological data obtained during 
life. DLB patients had been recruited for clinical research, during which they received 
serial assessments of cognition, motor function and visual hallucination severity and 
frequency at regular intervals until death (Burn et al., 2003; Mosimann et al., 2006). 
Fewer control and AD cases had been assessed for motor impairment and visual 
hallucinations, as these are not characteristic features of either AD or normal ageing.   
The SGI and SGP have a well-described role in coordinating oculomotor functions 
(Krauzlis et al., 2013). To investigate whether collicular degeneration is related to 
general motor decline, neuronal density and pathological burden in the SGI and SGP 
were correlated with Unified Parkinson’s Disease Rating Scale Part III (UPDRS III) 
scores (Fahn and Elotion, 1987) in DLB cases. Only DLB cases were used for this 
analysis as motor features are not typically found in AD or normal ageing so no such 
relationship could be assessed in these groups. UPDRS Part III was available for 
9/10 DLB cases. The mean interval between final UPDRS Part III and death was 
20.34±6.45 months.  
Due to the hypothesised role of the superior colliculus in the manifestation of visual 
hallucinations in Lewy body disease (Diederich et al., 2014), neuronal density and 
pathological burden in all laminae of the superior colliculus were correlated with final 
NPI (hall) score (Cummings et al., 1994) in DLB cases. Only DLB cases were used 
for this analysis as, again, visual hallucinations are not typically found in AD or 
normal ageing and so no relationship can be assessed. Final NPI (hall) scores were 
available for 8/10 DLB cases. The mean interval from final NPI assessment to death 
was 7.81±3.45 months.  
 
6.2.5 Statistical analysis 
Inspection of Q-Q plots and Shapiro-Wilk tests suggested that stereological and 
neuropathological data were either not normally distributed or did not have 
homogeneity of variance. Therefore, Kruskal-Wallis tests with post-hoc Mann-
Whitney U tests were employed for all data.  
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6.3 Results 
6.3.1 Demographics 
There was no significant difference in age at death (F=0.591, p=0.560), post-mortem 
interval (F=0.761, p=0.476) or gender (χ²=0.008, p=0.996) between experimental 
groups (Table 6.1).  
 
6.3.2 Stereology  
Graphical representations of stereological data are contained in Fig. 6.2.  
In the SGS, there was a significant main effect of diagnosis on neuronal density 
(χ²=6.58, p=0.037). Post-hoc tests showed no significant difference between control 
and DLB. However, AD cases had a significant reduction in neuronal density 
compared to control (U=27.000, p=0.018, d=1.014). There was no significant 
difference between DLB and AD. However, there was a trend towards a significant 
reduction in AD compared to DLB (p=0.070). There was no significant main effect of 
diagnosis on glial density. However, there was a significant main effect of diagnosis 
on the ratio of glia to neurons in the SGS (χ²=10.461, p=0.005). Post-hoc tests 
showed no significant difference between DLB and control or AD. AD cases had a 
significant increase in glia relative to neurons compared to control (U=13.000, 
p=0.001, d=1.32).  
In the SGI, there was a significant main effect of diagnosis on neuronal density 
(χ²=13.05, p=0.001). Post-hoc tests showed DLB cases had a significant reduction in 
neuronal density compared to control (U=18.500, p=0.003, d=1.08). AD cases had a 
significant reduction in neuronal density compared to control (U=13.5, p=0.001, 
d=1.24). There was no significant difference between AD and DLB. There was no 
significant main effect of diagnosis on glial density. However, there was a significant 
main effect of diagnosis on the ratio of glia to neurons in the SGI (χ²=11.242, 
p=0.004). Post-hoc tests showed a significant increase in glia relative to neurons in 
DLB compared to control (U=22.000, p=0.008, d=1.09). AD cases also had a 
significant increase in glia relative to neurons compared to control (U=17.000, 
p=0.003, d=1.19). There was no significant difference in the ratio of glia to neurons 
between DLB and AD in the SGI. 
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In the SGP, there was a significant main effect of diagnosis on neuronal density 
(χ²=6.60, p=0.037). Post-hoc tests showed no significant difference between control 
and DLB. However, AD cases had a significant reduction in neuronal density 
compared to control (U=27.000, p=0.018, d=1.12). There was no significant 
difference between DLB and AD. However, there was a trend toward a significant 
reduction in AD compared to DLB (U=27.000, p=0.080, d=0.50). There was no 
significant main effect of diagnosis on glial density. However, there was a significant 
main effect of diagnosis on the ratio of glia to neurons in the SGP (χ²=6.381, 
p=0.041). Post-hoc tests showed no significant difference between DLB and control 
or AD. AD cases had a significant increase in glia relative to neurons compared to 
control (U=25.000, p=0.012, d=1.14).  
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Figure 6.2: Dot plots illustrating stereological results in the superior colliculus.  
Stereological measures of neuronal and glial density across the three grey matter laminae of the superior colliculus. *p<0.05 compared to control. 
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6.3.3 Neuropathology 
α-synuclein pathology was present in all DLB cases. Typically, Lewy bodies and 
neurites were only found in the SGI and SGP, with the SGS largely spared (Fig. 
6.3A-C). Significant main effects of diagnosis on α-synuclein pathology were found in 
the SGS (χ²=16.871, p<0.001), SGI (χ²=26.218, p<0.001) and SGP (χ²=18.426, 
p<0.001; Fig. 6.4). In the SGS, post-hoc analyses showed DLB cases had a greater 
degree of α-synuclein pathology compared to control (U=19.000, p=0.003, d=1.35) 
and AD (U=12.000, p=0.003, d=1.41). In the SGI, DLB cases had a greater degree 
of α-synuclein pathology compared to control (U=1.000, p<0.001, d=1.85) and AD 
(U=0.000, p<0.001, d=1.92). In the SGP, DLB cases had a greater degree of α-
synuclein pathology in the SGP compared to control (U=15.500, p=0.001, d=1.27) 
and AD (U=27.000, p<0.001, d=1.45). α-synuclein pathology did not significantly 
correlate with neuronal density in the SGS (p=0.444), SGI (p=0.533) or SGP 
(p=0.649). 
One control case, C32, had α-synuclein pathology consisting of Lewy bodies and 
neurites. This case also had global Lewy body pathology corresponding to the 
brainstem stage of the McKeith criteria (McKeith et al., 2005) and Lewy body Braak 
stage 3 (midbrain stage) (Braak et al., 2004). In contrast, no AD cases had any 
detectable α-synuclein pathology in the superior colliculus, despite one case (A10) 
having brainstem stage Lewy body pathology in the McKeith criteria (McKeith, 2006). 
However, under the Braak classification of Lewy body pathology, this corresponded 
to stage 1 (medulla oblongata) (Braak et al., 2004). Therefore, α-synuclein pathology 
may develop in the superior colliculus at the same stage as the development of Lewy 
body pathology in other regions of the midbrain.     
Tau pathology was observed in most cases (8/13 control, 9/10 DLB, 10/10 AD), 
typically in the form of neuropil threads in non-AD cases, though the pathological 
burden was highly variable across cases. Amyloid-β pathology was present as focal 
and diffuse deposits in many cases (2/13 control, 7/10 DLB, 10/10 AD), and 
appeared to affect all laminae of the superior colliculus (Fig. 6.3G-I). As expected on 
the basis of their neuropathological diagnosis, and demonstrated in Fig. 6.4, AD 
cases had greater levels of tau and amyloid-β than control in all laminae of the 
superior colliculus. DLB cases exceeded control only in tau burden in the SGI and 
amyloid-β burden in the SGP. Tau pathology was significantly negatively correlated 
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with neuronal density in the SGI (rho=-0.404, p=0.022; Fig. 6.6) and SGP (rho=-
0.451, p=0.009; Fig. 6.6).   
In DLB cases, there was a significant difference in the degree of α-synuclein 
pathology across the three laminae (χ²=12.600, p=0.002; Fig. 6.3A-C, Fig. 6.5). Post-
hoc Wilcoxon signed-rank tests showed the SGI had a greater burden of α-synuclein 
pathology than the SGS (Z=2.803, p=0.005, d=0.85) and the SGP had a greater 
burden of α-synuclein pathology than the SGS (Z=2.497, p=0.013, d=1.09). There 
was no significant difference in the burden of α-synuclein pathology between the SGI 
and SGP. There were no significant correlations between α-synuclein pathology and 
neuronal density in any experimental group.   
There was a significant difference in the degree of tau pathology across the three 
laminae (χ²=26.375, p<0.001; Fig. 6.3D-F, Fig. 6.5). Post-hoc tests showed the SGI 
had a greater burden of tau pathology than the SGS (Z=4.330, p<0.001, d=0.32) and 
the SGP had a greater burden of tau pathology than the SGS (Z=4.031, p<0.001, 
d=0.46). There was no significant difference in the burden of tau pathology between 
the SGI and SGP. There were no significant correlations between tau pathology and 
neuronal density in any experimental group. There was no significant difference in 
amyloid-β expression across the three laminae of the superior colliculus (Fig. 6.5). 
There were no significant correlations between amyloid-β pathology and neuronal 
density in any experimental group.  
In summary, Lewy body pathology was highest across all laminae in DLB cases, and 
AD-type pathology was highest across all laminae in AD cases (Fig. 6.4). Lewy body 
and tau pathology showed distinct patterns of expression, with the SGI and SGP 
affected more severely than the SGS (Fig. 6.3, 6.5). Amyloid-β did not show the 
same topography, with all laminae affected to a similar degree (Fig. 6.3, 6.5). 
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Figure 6.3: Neuropathology in the superior colliculus.  
Neuropathology in the different laminae of the superior colliculus in DLB case D6. α-synuclein pathology is  less severe in the stratum griseum superficiale 
(SGS; A) than the stratum griseum intermedium (SGI; B) and stratum griseum profundum (SGP; C). Tau pathology is minimal throughout but less severe in 
the SGS (D) than in the SGI (E) and SGP (F). Amyloid-β is observed in the SGS (G), SGI (H) and SGP (I) and shows less regional specificity than α-synuclein 
and tau. Scale bar = 50 μm.   
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Figure 6.4: Densitometric analysis of the superior colliculus.  
Bars represent means and error bars represent standard deviation. *p<0.05 compared to control, **p<0.05 compared to control and AD, ***p<0.05 compared 
to control and DLB.
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Figure 6.5: Laminar distribution of pathology in the superior colliculus. 
Bar charts illustrate the percentage area stained in each lamina of the superior colliculus, with bars 
representing means and error bars representing standard deviations. *p<0.05 compared to stratum 
griseum superficiale (SGS). 
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6.3.4 Clinico-pathological correlations 
There were no significant correlations between age at death, post-mortem interval 
and neuronal density in any lamina of the superior colliculus. 
In DLB cases, UPDRS III was negatively correlated with tau pathological burden in 
the SGS (rho=-0.720, p=0.029), SGI (rho=-0.683, p=0.042) and SGP (rho=-0.700, 
p=0.036). However, Braak neurofibrillary pathology stage did not correlate with 
UPDRS III. One outlier was found to be responsible for the initial correlations and 
removal of this case from the analysis removed all correlations between UPDRS III 
and tau. UPDRS III was not significantly correlated with α-synuclein pathology in the 
SGS (p=0.764), SGI (p=0.606) or SGP (p=0.932). No other stereological or 
pathological variables correlated with UPDRS III score in DLB cases.  
In DLB cases, NPI (hall) score was positively correlated with neuronal density in the 
SGS (rho=0.874, p=0.005; Fig. 6.6). No other stereological or pathological variables 
correlated with NPI (hall) score in DLB cases. 
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Figure 6.6: Relationships between pathology and neuronal number and clinical features. 
Scatterplots demonstrating the relationships between tau and neuronal density in the stratum griseum 
intermedium (SGI) and stratum griseum profundum (SGP), and between stratum griseum superficiale 
(SGS) neuronal density and NPI(hall) score. 
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6.4 Discussion 
The superior colliculus has been the subject of one previous neuropathological study 
that demonstrated DLB cases had moderate Lewy body pathology and mild to 
moderate AD-type pathology (Sierra et al., 2016). However, no previous study has 
conducted quantitative analysis of individual laminae of the superior colliculus in the 
context of visual hallucinations in DLB. As the superior colliculus has been directly 
implicated in the visual manifestations of Lewy body disease (Diederich et al., 2014; 
Shine et al., 2014), the present study aimed to investigate whether DLB is marked by 
degeneration of the superior colliculus. The key findings emerging from the present 
study are that DLB cases have reductions in neuronal density in the SGI, in contrast 
to the more widespread reductions observed in all laminae in AD. Distinct 
topographic patterns of deposition were observed for α-synuclein and tau pathology, 
with the SGI and SGP affected more severely than the SGS. Lewy body pathology 
was not related to cellular density in any lamina in DLB but tau pathology was 
inversely related to neuronal density in the SGI and SGP across all cases. Motor 
dysfunction, as assessed by UPDRS III, was not related to any neuropathological 
variable in the superior colliculus. There was no relationship between Lewy body 
pathology and hallucination severity and frequency, as assessed by NPI (hall). 
However, neuronal density in the SGS was positively correlated with the severity and 
frequency of visual hallucinations in DLB cases. 
Approximately 10% of retinal ganglion cells directly innervate the SGS (Perry and 
Cowey, 1984). Extra-retinal inputs to the SGS have not been examined in primates, 
though studies in the cat have suggested cholinergic modulation from the 
parabigeminal nucleus (Sherk, 1979). The medial temporal visual area (area V5/MT) 
receives input from the inferior pulvinar in a pathway originating in the SGS 
(Stepniewska et al., 1999; Stepniewska et al., 2000). This pathway may be involved 
in the non-conscious perception of motion (Lanyon et al., 2009) as some neurons 
within the primate SGS are motion sensitive (Inayat et al., 2015). There is 
speculation that the colliculo-pulvinar pathway may be important in saccadic 
suppression, the inhibition of activity in the LGN and visual cortex during the 
execution of saccadic eye movements (Wurtz et al., 2011). The SGS also projects to 
other regions receiving retinal innervation, including the LGN and the pretectal nuclei 
(Benevento and Fallon, 1975).  
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The SGI and SGP are increasingly viewed as being functionally and anatomically 
independent from the SGS (Krauzlis et al., 2013). In contrast to the predominantly 
retinal input of the SGS, these laminae receive inputs from wide-ranging cortical and 
sub-cortical regions. Inputs include motor and association sensory cortices, the 
hypothalamus, zona incerta, substantia nigra pars reticulata, locus coeruleus, dorsal 
raphe, pendunclopontine and deep cerebellar nuclei (Sparks and Hartwich-Young, 
1989). The SGI and SGP contain retinotopic maps of the visual field and are thought 
to have an important role in the selection of visual targets (Sparks, 1999). However, 
auditory and somatosensory maps have been demonstrated in the deeper laminae 
of the cat superior colliculus, in addition to multi-sensory neurons that respond to 
input from more than one sensory modality (Wallace et al., 1993). Neurons within the 
retinotopic area corresponding to the target of an upcoming saccade show 
heightened activity prior to the initiation of the saccade, suggesting the SGI and SGP 
are involved in the selection of saccadic targets (Glimcher and Sparks, 1992). 
However, neurons within the SGI also predict the target of upcoming pursuit eye 
movements, further indicating a role in pursuit target selection (Krauzlis and Dill, 
2002). Outputs from the SGI to the mediodorsal nucleus of the thalamus, projecting 
to the frontal eye fields, may serve to stabilise the visual field during saccadic eye 
movements (Wurtz et al., 2011).   
Within the superior colliculus, neuropathological lesions occurred in a stereotypical 
manner, with higher levels of α-synuclein and tau found in the SGI and SGP 
compared to the SGS. Structures connected to the SGI and SGP, such as the dorsal 
raphe, locus coeruleus and pedunculopontine nucleus, are vulnerable to the 
accumulation of Lewy body and tau pathology (Rub et al., 2000; Dugger et al., 2012). 
The SGS receives predominant afferent and efferent innervation from the primary 
visual pathway (Krauzlis et al., 2013), which does not appear to accumulate 
significant Lewy body or tau pathology in AD or Lewy body disease (Beach et al., 
2014; Ho et al., 2014; Khundakar et al., 2016). As tau and α-synuclein may spread 
throughout the brain in a manner reminiscent of prion protein, these distinct patterns 
of deposition may reflect greater connectivity with areas vulnerable to 
neuropathological lesion formation (Goedert, 2015).    
The present study demonstrated neuronal loss in the superior colliculus only in the 
SGI in DLB. This was in contrast to AD, where neuronal density reductions were 
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found in all strata of the superior colliculus. The SGI has a role in selecting targets of 
saccadic eye movements and initiating saccades (Glimcher and Sparks, 1992; 
Sparks, 1999) and projects to the lateral pulvinar, where specific neuronal loss was 
identified in DLB and AD (chapter 4) (Benevento and Standage, 1983). In 
comparison to AD, DLB patients have increased saccadic latency and are more 
likely to perform saccades that fall short of their target (Mosimann et al., 2005). 
Specific lesioning of the SGI in primates has been shown to increase saccadic 
latency and the likelihood of saccades falling short of their target (Aizawa and Wurtz, 
1998). Therefore, one could speculate that the presently reported degeneration of 
the SGI may contribute to saccadic abnormalities in DLB. However, as no difference 
was observed in neuronal density in the SGI between DLB and AD, and saccadic 
functioning was not tested in these cases, it is difficult to definitively determine 
whether neuronal density reductions were specifically related to saccadic dysfunction.   
Although the SGI and SGP have important roles in oculomotor function, the present 
study did not find the motor subscale of the UPDRS was related to neuronal density 
or Lewy body pathology in any lamina of the superior colliculus. This suggests 
degeneration of the superior colliculus is not related to parkinsonian motor 
dysfunction in DLB. A previous study has shown there is no relationship between 
UPDRS III and oculomotor dysfunction in PD, citing the potential role of non-
dopaminergic pathways in oculomotor dysfunction (Pinkhardt et al., 2012). Therefore, 
in the present study, superior colliculus degeneration may occur independently of the 
dopaminergic pathways that characterise the parkinsonism motor phenotype.  
The significant positive correlation between neuronal density in the SGS and the 
severity and frequency of visual hallucinations was an unexpected finding. It is 
possible, however, that sparing of this lamina, perhaps in conjunction with 
degeneration elsewhere, contributes to a vulnerability to hallucinations. Previous 
studies in the LGN and primary visual cortex (Erskine et al., 2016; Khundakar et al., 
2016) have suggested the visual system in AD shows more widespread 
neurodegenerative changes than in DLB. Despite this, visual hallucinations are more 
commonly encountered in DLB than AD (Armstrong and Kergoat, 2015), perhaps 
indicating the specificity of neurodegeneration in DLB may be crucial for the 
manifestation of visual hallucinations. However, this correlation was demonstrated in 
a relatively small number of DLB cases, meaning it is difficult to draw strong 
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conclusions about the relationship between neuronal density in the SGS and visual 
hallucinations.  
It is possible that a dysfunctional pathway routed through the SGS contributes to 
visual hallucinations. The SGS is modulated by the SGI (Isa and Hall, 2009), which 
enhances or inhibits visual system activity in response to visual targets (Isa and Hall, 
2009; Ghitani et al., 2014). Specific SGI neuronal loss has been shown to lead to 
compensatory increases in neuronal receptive field size (Aizawa and Wurtz, 1998). 
As SGI neurons receive auditory, somatosensory and multisensory input, it is 
possible that increased receptive field sizes lead to misidentification of sensory input 
from other modalities. Misidentified sensory information, when fed back to the SGS, 
could lead to altered activity, artificially enhancing activity in particular spatial 
locations of the visual field. Such a proposition would be dependent upon the 
intactness of the SGS to facilitate the enhancement of visual responses. However, it 
was beyond the scope of the present study to assess receptive field sizes or the 
impact of SGI neuronal loss on the functional capacity of the pathway through the 
SGS.  
The superior colliculus was not completely sampled as it is routinely dissected on 
two different planes, thus total neuronal number could not be estimated. The 
correlations between visual hallucinations and neuropathological variables also used 
small numbers of cases due to the small number of cases with NPI data obtained 
during life. 
In summary, the present study revealed specific changes in the superior colliculus 
that may contribute to visual hallucinations and saccadic abnormalities. By 
demonstrating neuronal density reductions in the SGI in DLB, compared to 
reductions in all strata in AD, this study has added to the previous chapters by 
showing that DLB have relatively selective neuronal loss in the visual system 
compared to AD. Therefore, visual hallucinations may result from the topography of 
degeneration in DLB, and the resulting physiological changes to visual processing at 
the network level. Understanding such changes is beyond the scope of a post-
mortem study. However, physiological studies may help establish the functional 
consequences of the pathological changes found here. 
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Chapter 7: Discussion 
7.1 Introduction 
DLB is a progressive neurodegenerative dementia marked by three core symptoms 
of fluctuating cognition, parkinsonism and complex visual hallucinations (McKeith, 
2006). Neuropathologically, DLB is characterised by Lewy body pathology in 
brainstem, limbic and neocortical regions, though intermediate levels of AD-type 
pathology are variably present (Attems et al., 2013). 60-80% of DLB patients 
experience complex visual hallucinations, yet their pathological aetiology remains 
unknown (Burghaus et al., 2012). Visual hallucinations are associated with reduced 
quality of life and increased rates of institutionalisation for DLB patients (Bostrom et 
al., 2007), which contribute to caregiver distress (Ricci et al., 2009).  
The subcortical visual nuclei comprising the visual thalamus and superior colliculus 
have been implicated in several hypotheses of visual hallucinations in DLB. The 
cortical release hypothesis suggests a lack of input to the primary visual cortex 
induces compensatory increases in activity and could prime the cortical visual 
system for hallucination (Manford and Andermann, 1998). Deficient visual attention 
mechanisms have also been implicated in the manifestation of visual hallucinations 
in DLB (Collerton et al., 2005b; Shine et al., 2014). The LGN, pulvinar and superior 
colliculus have also been implicated in blindsight pathways suggested to be 
dysfunctional in PD, and may therefore contribute to visual hallucinations in Lewy 
body disease generally (Diederich et al., 2014).  
 
7.2 The lateral geniculate nucleus is relatively preserved in dementia with 
Lewy bodies 
This study demonstrated the LGN did not exhibit α-synuclein or tau pathology in DLB, 
and amyloid-β did not differ significantly from control cases. Stereological analysis of 
neuronal and glial populations did not identify any changes in DLB cases compared 
to controls. In contrast, AD cases had significant increases in amyloid-β and tau 
pathology, accompanied with significant reductions in parvocellular neurons and 
gliosis in magnocellular laminae compared to controls. 
The relative preservation of the LGN indicates a lack of involvement in visual 
hallucinations in DLB, at least at a gross structural level, though knowledge of its 
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functional capacity remains beyond the scope of this study. However, consistent with 
the present findings of histological preservation of the LGN, physiological studies in 
PDD (Murphy et al.) and DLB (Erskine et al., 2016) have not revealed significant 
changes compared to control patients. Therefore, it is probable that degeneration in 
other brain regions is necessary to create a propensity toward visual hallucination. 
Subtle physiological changes to the retina, relayed by an intact LGN, may contribute 
a vulnerability to hallucination. Alternatively, a critical level of visual input may be 
necessary for altered mechanisms elsewhere in the brain to elicit visual 
hallucinations.  
In AD, degeneration of the LGN may perhaps counter-intuitively prevent the 
generation of hallucinations by not supplying a required critical level of visual input 
for hallucinations to occur. Substantial neuronal loss and tau pathology was only 
observed in AD cases with the most severe degree of global pathological burden, 
perhaps indicating the LGN is affected at a relatively late stage in the progression of 
AD pathology. 
 
7.3 The pulvinar nucleus exhibits neuronal and synaptic loss Lewy body 
pathology and astrogliosis in dementia with Lewy bodies  
In contrast to the LGN, Lewy body pathology was present throughout the pulvinar 
whilst neuronal loss was restricted to the lateral sub-region. Western blot 
assessment of synaptic and inflammatory markers in the pulvinar, based on pathway 
changes identified by RNA sequencing, demonstrated reductions in synaptic 
markers in DLB cases compared to controls. These changes correlated with 
increases in inflammatory markers, particularly astrocytic proteins. In AD, neuronal 
loss was also identified in the lateral pulvinar. The medial sub-region of the pulvinar 
did not show neuronal loss in DLB but did have the highest α-synuclein pathology. In 
AD cases, the medial pulvinar was more severely affected by tau pathology.   
The pulvinar has a vital role in controlling activity in the primary visual cortex 
(Purushothaman et al., 2012) and visual area V4 (Zhou et al., 2016) on the basis of 
attentional and behavioural demands. Visual attentional impairments have been 
suggested to create a vulnerability to visual hallucinations in DLB (Collerton et al., 
2005b; Shine et al., 2014). The connectivity between the pulvinar and amygdala is 
175 
 
thought to underlie unconscious affective facial perception (Ward et al., 2007) which 
is impaired in PD (Saenz et al., 2013; Diederich et al., 2014). The present findings of 
α-synuclein pathology, neuronal and synaptic loss and astrogliosis likely indicate 
altered functioning of the pulvinar in DLB. Altered visual attentional modulation may 
force dependence upon the self-referential default mode network, thus biasing the 
individual towards top-down influences in the prediction of visual stimuli (Shine et al., 
2014). Impaired affective facial perception circuitry may indicate wider impairments 
in blindsight pathways, forcing visual information to travel through the slower primary 
visual pathways (Diederich et al., 2014). Longer latencies in visual processing may 
similarly bias the individual toward top-down expectancies during visual perception.  
Similar to the findings from the LGN, the described changes in the pulvinar may not 
be solely responsible for visual hallucinations in DLB. It is likely the identified 
changes in the pulvinar act in concert with changes elsewhere in the brain. For 
example, an inherent bias toward top-down expectations may not induce visual 
hallucinations in isolation. Hallucinations may be dependent upon other changes to 
act in tandem with those identified in the pulvinar, such as altered top-down 
processes. Changes to the fusiform gyrus, for example, may contribute toward 
deficient proto-object selection, thus biasing the individual not just to top-down visual 
processing but also towards the selection of erroneous top-down visual objects. Our 
studies in the temporal lobe indicate a rostro-caudal gradient of Lewy body pathology 
in the fusiform gyrus in DLB, consistent with the suggestion that more complex 
object perception areas are impaired as a result of neurodegenerative pathology 
(Dey, 2015).    
 
7.4 The superior colliculus has specific neuronal loss and a unique 
topography of α-synuclein pathology 
In contrast to the LGN, Lewy body pathology was found in the superior colliculus in 
DLB, and neuronal loss specifically in the SGI. In DLB cases, neuronal density in the 
SGS was significantly correlated with clinical measures of hallucination severity and 
frequency. In contrast to DLB cases, neuronal loss was found in every lamina of the 
superior colliculus in AD. α-synuclein pathology was more severe in the SGI and 
SGP, with the SGS relatively spared in DLB. Tau pathology had a similar pattern of 
expression to α-synuclein, with the SGI and SGP more severely affected than the 
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SGS across all cases. In contrast, amyloid-β did not show significant lamina-specific 
variation in deposition in any disease group. 
The superior colliculus has an important role in motion perception, visuospatial 
attention, visual target selection and sensory integration (Krauzlis et al., 2013), which 
are suggested to be deficient in Lewy body disease and may contribute to the 
manifestation of visual hallucinations (Diederich et al., 2014). Additionally, the 
superior colliculus is thought to be vital in switching between different neural 
networks. This process may be dysfunctional in DLB and contribute a vulnerability to 
visual hallucinations by forcing reliance on the self-referential default mode network 
(Shine et al., 2014). As with previous findings, the changes to the superior colliculus 
are unlikely to elicit visual hallucinations in isolation, but likely interact with 
dysfunction in other regions to create a vulnerability to them. 
 
7.5 Distinct vulnerability across subcortical visual structures and their 
relationship to visual hallucinations in dementia with Lewy bodies 
The present series of studies has suggested neuronal loss and Lewy body pathology 
is more specific in the visual system in DLB than in AD. In particular, the secondary, 
rather than the primary, visual pathway is more severely affected. This is consistent 
with a previous study of Lewy body pathology in DLB (Yamamoto et al., 2006). 
However, the present series of studies have also demonstrated Lewy body 
pathology and neuronal loss have a specific topographical distribution in secondary 
visual pathway structures. The LGN is a relay structure for afferent visual input, 
whilst the pulvinar and superior colliculus are implicated in the modulation of visual 
information. Therefore, the present results in DLB showing greater pathological 
changes in modulatory structures are consistent with physiological studies in PDD, 
which indicate bottom-up influences, including those routed through the LGN, are 
substantially less perturbed than top-down influences (Murphy et al.). 
Neuronal loss was only found in the lateral region of the pulvinar and the SGI of the 
superior colliculus in DLB. The affected regions are implicated in modulating visual 
system activity based on salience of observed visual stimuli and impairments to 
these functions may contribute to the clinical phenotype in DLB. In contrast, neuronal 
loss was recorded in the parvocellular laminae of the LGN, the lateral region of the 
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pulvinar and all laminae of the superior colliculus in AD. As AD cases showed a 
more widespread pattern of neuronal loss, if visual hallucinations were to result 
purely from neuronal loss in vulnerable regions one could speculate they would be 
observed at least as frequently as in DLB. However, visual hallucinations are not a 
prominent clinical feature of AD (Burghaus et al., 2012), perhaps suggesting 
preservation of some regions, in combination with degeneration elsewhere, may both 
be necessary for their manifestation.  
The pulvinar and superior colliculus exhibited Lewy body pathology, which was not 
found in the LGN. Additionally, the pulvinar expressed increased transcription of the 
astrocytic marker CHI3L1/YKL-40, which has not been described in Lewy body 
disorders previously, and was inversely related to several synaptic markers. As 
CHI3L1/YKL-40 has not been previously described as elevated in DLB, it may relate 
to a pathological process specific to this region, rather than a global cerebral 
phenomenon. The relative specificity of pathological changes to the visual system in 
DLB compared to AD, combined with an increase in an astrocytic marker not 
previously described in Lewy body disorders, may suggest specific changes to the 
pulvinar. The specificity of such changes, in contrast to the more widespread 
degenerative changes in AD, may contribute to the distinct clinical phenotype of DLB, 
including visual hallucinations.   
With respect to the hypotheses underlying visual hallucinations in DLB, these 
findings contribute new insights into the mechanisms underlying this phenomenon. 
The cortical release hypothesis (Manford and Andermann, 1998) suggests visual 
cortical regions become disinhibited as a result of diminished input. Whilst cortical 
excitability is consistent with several studies in DLB (Taylor et al., 2011; Khundakar 
et al., 2016; Taylor et al., 2016), the present study may suggest visual cortical 
changes are not the result of altered afferent visual input through the LGN. It should 
be emphasised that lack of histological changes does not necessarily mean the LGN 
is functionally preserved. However, functional MRI in response to visual stimuli has 
demonstrated no changes in activity of DLB patients compared to controls (Erskine 
et al., 2016). However, it remains possible that retinal alterations, faithfully relayed by 
an intact LGN, create gaps in the visual field requiring ‘filling in’ by higher visual 
structures. Retinal pathology transmitted by an intact LGN, in combination with 
deficient visual attention mechanisms resulting from pulvinar degeneration, may be 
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consistent with the perceptual and attentional deficit model (Collerton et al., 2005b). 
Gaps in visual perception or corrupted visual input, relayed by an intact LGN, may 
contribute to incorrect proto-object selection which is then held in visual awareness 
by dysfunctional visual attentional mechanisms resulting from pulvinar pathology. In 
AD, LGN degeneration may prevent faithful relaying of visual input and thus gate 
against such an effect.  
α-synuclein pathology and neuronal loss in the lateral pulvinar and SGI of the 
superior colliculus, regions involved in visual attention and target selection, appear 
more consistent with the hypothesis that impairments in engaging the dorsal 
attentional network (Shine et al., 2014) contribute to visual hallucinations in DLB. 
Difficulty in engaging the dorsal attentional network in attending to ambiguous stimuli 
would force reliance on the default mode network, a self-referential system 
incorporating elements of memory. Therefore, in the presence of an ambiguous 
stimulus, instead of directing visual attention, the individual is reliant on previous 
experience and expectations. Such a shift toward greater top-down visual control 
may incorrectly match expectations with the observed stimulus, ultimately generating 
a hallucinatory percept. In AD, more widespread changes, particularly to regions 
involved in memory, may inhibit reliance upon self-referential aspects of the default 
mode network. In support of this proposition, a previous study has demonstrated AD 
patients have greater impairments in default mode network function than DLB 
(Franciotti et al., 2013). Therefore, although AD cases manifested greater 
neuropathological changes to the visual thalamic circuitry than DLB, greater 
alterations to the default mode network may prevent visual hallucinations.  
The present findings also correspond with the suggestion that individuals with Lewy 
body disease are ‘blind’ to blindsight (Diederich et al., 2014). The superior colliculus 
and pulvinar are both components of blindsight pathways implicated in visual 
hallucinations in Lewy body disease. However, this hypothesis suggests the SGS, 
which directly projects to the inferior pulvinar, is impaired. Whilst this was not what 
was found in the present study, preservation of the SGS was significantly associated 
with clinical markers of visual hallucinations. Preservation of the SGS, combined with 
neuronal loss and pathology in the deeper modulatory laminae, may indicate this 
pathway is dysfunctional rather than degenerated. Dysfunction of the short latency 
blindsight pathways may force reliance upon the longer latency primary visual 
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pathway, thus biasing the individual toward top-down influence on visual perception. 
Dysfunctional top-down visual mechanisms, resulting from pathology elsewhere, 
may inaccurately predict the observed visual stimulus, which is then perceived as a 
hallucinatory percept.       
 
7.6 Study strengths and limitations 
7.6.1 Study strengths  
Where possible, this study employed a rigorous stereological approach to estimate 
neuronal morphology. As tissue was sampled and cut according to stereological 
principles, estimates could be determined in a mathematical, rather than an 
assumption-based, manner. This meant that absolute measures of number could be 
established, rather than relying on the proxy measure of numerical density (number 
per area of tissue), which is vulnerable to bias resulting from factors such as tissue 
processing and orientation (Erskine and Khundakar, 2016).  
All included cases were characterised on the basis of both clinical and 
neuropathological findings, thus ensuring atypical cases were not included. The 
NBTR dissection protocol ensures the entire brain is fixed, processed and embedded 
for histology, not just the blocks necessary for neuropathological diagnosis. This is a 
considerable strength as the LGN and pulvinar are not located on sections typically 
needed for neuropathological diagnosis and, were they not already processed, the 
tissue would likely have been fixed for a long period of time, potentially affecting 
antigenicity. The use of a disease-control group (AD) was also an advantage, aiding 
identification of specific changes in DLB, particularly those that may relate to visual 
hallucinations. This enabled assessment of the relative specificity of the topography 
of Lewy body pathology and neuronal loss in DLB, which is likely to be an important 
contributor to the manifestation of visual hallucinations.  
Cases included in the molecular study were selectively chosen to be optimal for 
neurochemical analysis, ensuring the results were not affected by artefacts due to 
agonal state or post-mortem factors. The molecular analysis of the pulvinar 
employed whole-genome RNA sequencing, an atheoretical approach to determine 
relative changes in transcription. Analysis of transcriptional changes using a 
bioinformatics approach identified altered biological pathways without any a priori 
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hypothesis, ensuring changes were identified in an unbiased manner, irrespective of 
hypothesis. As the pulvinar is a relatively small structure, a limited amount of tissue 
was available for protein expression comparison studies. The use of western blot 
rather than ELISA enabled comparison of a wider range of protein targets, adding 
greater breadth to the study.       
 
7.6.2 Study limitations 
The present studies were limited by the relatively small sample sizes used. The 
advantages of stereological protocol, where whole structures are required to be 
sampled for analysis, were counterbalanced by many cases being rejected due to an 
incomplete sampling region. Human tissue is a valuable resource in dementia 
research though the fact that tissue is obtained at autopsy means that tissue is not 
active. Therefore, physiological changes as a result of pathology may only be 
inferred on the basis of known function, rather than by observation of changes in 
comparison to normal functioning. 
A related limitation was the use of differing case cohorts in the different studies, thus 
precluding comparisons within cases across all structures. Only three cases (two AD 
and one DLB) were histologically assessed in all three regions. As before, this was 
typically the result of tissue availability and many cases with complete tissue for one 
region did not have complete tissue for another region. In the pulvinar, molecular and 
histological analyses were conducted on two different cohorts, with only one control 
case used for both analyses, thus limiting comparisons between both studies. This 
was the result of controlling post-mortem interval and tissue pH for neurochemical 
analyses. Furthermore, with the exception of the superior colliculus cohort, most of 
the cases had not received serial neuropsychological assessment during life, thus 
precluding comparison of the results with quantitative data on the severity and 
frequency of visual hallucinations. The limited number of cases with both in-depth 
neuropsychological test results resulted from the need for intact tissue for 
stereological sampling. The necessity of whole and intact structures for stereological 
analysis was the primary factor that limited the number of cases used, and also the 
quality of clinical information available. In the present  studies, only few cases were 
found that had both intact tissue and serial neuropsychological data. Therefore, 
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whilst stereological analysis increased the precision of estimates of neuronal number, 
it also limited the ability to relate neuropathological changes to clinical features. The 
lack of quantitative neuropsychological data to relate to neuropathological findings, 
combined with the relatively small sample size, limits the generalisability of these 
findings to explain hallucinations in the wider DLB population. 
AD cases may not have been the most appropriate disease control group, with non-
hallucinating DLB cases a more suitable alternative. However, the presence of visual 
hallucinations as a core feature of DLB severely restricted the number of cases 
meeting this criterion. It was not possible to obtain enough DLB cases without a 
clinical history of visual hallucinations who also had complete tissue for stereological 
analysis. Therefore, the present results may relate more to idiosyncratic changes in 
DLB in general, rather than changes specific to visual hallucinations in particular. 
One exception was the superior colliculus study (Chapter 6) where full stereological 
protocol was not used, increasing the availability of cases and facilitating the 
inclusion of non-hallucinating DLB cases to determine relationships between 
neuropathological and clinical variables.  
Molecular studies conducted in the pulvinar were conducted on the whole structure, 
rather than individual sub-nuclei. Although α-synuclein pathology and astrogliosis 
was found throughout the entire pulvinar, neuronal loss was only found in the lateral 
sub-nucleus. The sub-nuclei of the pulvinar are small and not obvious on gross 
visual inspection meaning sub-dissection of these structures was not possible. 
Furthermore, the small size of these structures would also have vastly reduced the 
amount of tissue available for subsequent protein expression analysis. Relative 
protein expression levels were assessed using western blot methodology. As noted 
in Chapter 5, western blot is not a directly quantitative technique, and relative 
assessments of the size and intensity of bands must be made. Quantitative data 
would have been more easily obtained using a technique such as ELISA. However, 
initial pilot studies indicated the use of ELISA in assessment of desired targets would 
require considerably more tissue than could be acquired.  
Molecular studies were only conducted on the pulvinar, largely because of its size 
and its central role in visual function. As the LGN and superior colliculus are 
comparatively small structures, limiting the amount of available tissue and restricting 
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the breadth of analyses, we assessed these structures using purely histological 
methods.  
 
7.7 Future directions 
It is notable that the present significant results of neuronal loss using stereological 
sampling and rigid adherence to protocol would have been obtained even if neuronal 
density measures had been employed. Considering the limitations outlined in the 
previous section (7.6.2), if this study was to be conducted again one should focus 
upon obtaining a large number of cases with good clinical information rather than 
ensuring tissue is sufficient for stereological protocol. This would provide a better 
balance between the desire for accurate analysis and making results more 
applicable to the wider DLB population, whilst also enabling comparison between 
neuropathological and quantitative clinical information to evaluate clinico-
pathological correlations. 
As the present study has identified pathological alterations to regions that may 
contribute to the manifestation of visual hallucinations in DLB, further studies may 
examine the nature of such changes. For example, neuronal loss in the lateral 
pulvinar and SGI may affect particular sub-classes of neurons with specific 
neurochemical profiles. Identification of such specific neuronal vulnerability would aid 
further understanding of disease mechanisms in Lewy body disorders and potentially 
highlight therapeutic options based on neurochemical changes.  
Considering the interconnected nature of the brain, neuronal loss in one structure is 
likely to have a resulting impact upon regions substantially interconnected with it. As 
a result, further investigation of regions with substantial connections with the lateral 
pulvinar and SGI of the superior colliculus, such as visual area V4 and the substantia 
nigra pars reticulata, would be useful in determining further visual system changes in 
DLB. Such studies would likely further our understanding of the vulnerability of the 
visual system to the neurodegenerative process in DLB, and the pathophysiology of 
visual hallucinations.  
It is unlikely that neuronal loss in the lateral pulvinar and SGI are sufficient to cause 
visual hallucinations on their own. As noted previously, assessment of regions with 
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substantial connectivity with the pulvinar and superior colliculus would aid an 
understanding of the pathways involved in visual hallucinations. Additionally, a 
recurring theme of the present study is that perturbed top-down influences on vision 
may contribute to the phenomenon of visual hallucinations. In this regard, 
assessment of regions implicated in these functions, such as the frontal eye fields, 
cingulate gyrus and insula, which are typically affected by Lewy body pathology in 
DLB should be pursued. As discussed previously, the pulvinar and superior colliculus 
may contribute to visual hallucinations through pathways to the dorsal visual stream, 
particularly area V5/MT. If neuropathological changes were also found in the dorsal 
visual stream, it would provide further evidence for the hypotheses used to explain 
visual hallucinations presently, and would further implicate the tectal-pulvinar-V5/MT 
pathway in this phenomenon.    
Cholinergic dysfunction has been described in DLB and is thought to relate to the 
occurrence of visual hallucinations (Perry and Perry, 1995). Therefore, future studies 
may wish to investigate whether neuronal loss of Lewy pathology in cholinergic 
nuclei is related to clinical measures of hallucinations frequency and severity. The 
nucleus basalis of Meynert was initially investigated as a potential part of the present 
study. However, in many cases the thalamic sections cut for the present study were 
too posterior to include the nucleus basalis of Meynert and thus this study was not 
conducted.    
As indicated in the study limitations (7.6), the lack of stereological changes in the 
LGN does not necessarily indicate functional preservation. Similarly, the preservation 
of the SGS but association with visual hallucination severity and frequency, may 
indicate physiological changes. One way to assess these changes would be the use 
of molecular analyses, though the small size of these structures would likely limit 
such studies. However, a hypothesis-driven technique requiring less tissue, such as 
autoradiography or in-situ hybridisation, may be useful in this regard. Both regions 
receive substantial cholinergic innervation and, as a neurotransmitter typically 
reduced in DLB, such a study may provide useful insights into the role of the 
cholinergic system in visual hallucinations. Alternatively, physiological studies in DLB 
patients may also provide information on functional changes in the superior colliculus, 
notwithstanding the difficulties in resolving such small structures using imaging 
techniques. Such an approach has already identified the LGN does not manifest 
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functional changes in response to visual stimuli in DLB patients compared to control 
participants (Erskine et al., 2016).   
CHI3L1/YKL-40 protein expression was increased in the pulvinar in DLB and was 
inversely related to the expression of several synaptic markers. Despite previous 
studies finding no change in expression of this astrocytic marker in the CSF of Lewy 
body disorder patients (Wennstrom et al., 2015), it was elevated in the pulvinar in the 
present study. A key finding from the present project is the relative specificity of 
Lewy body pathology and neuronal loss in the visual system in DLB compared to AD. 
Stereological studies typically report neuronal loss as being more specific throughout 
the brain in DLB compared to AD (Erskine and Khundakar, 2016). Therefore, one 
may speculate CHI3L1/YKL-40 increases are not found throughout the brain in DLB 
but may also be region-specific. Future studies may examine the expression of this 
astrocytic marker throughout the brain in DLB cases, in comparison to AD. An 
association between expression of CHI3L1/YKL-40 and synaptic or neuronal loss 
may indicate its utility as a therapeutic target in DLB.     
The present study employed end-stage cases and demonstrated some regions did 
not show neurodegenerative changes in DLB. Therefore, a key question is why 
some regions did not manifest pathological changes, even after many years of 
symptoms. The prion-like spread hypothesis suggests misfolded α-synuclein can 
spread through the brain in a transsynaptic manner similar to that described 
previously for prion protein (Das and Zou, 2016). It is noteworthy that the retina and 
primary visual cortex, with which the LGN is primarily connected, do not manifest 
high burdens of Lewy body pathology, and the patient may die prior to pathology 
spreading to these regions. However, it is also possible that some neurons have 
reduced vulnerability to α-synuclein pathology than others. The prion-like spread 
hypothesis suggests α-synuclein prions are able to template the misfolding of the 
physiological protein into the pathogenic conformation. However, this proposal 
requires the normal physiological protein to be present in sufficient quantities to be 
templated into the pathogenic conformation. There is some evidence to indicate that 
regions which do not typically manifest Lewy body pathology, such as the cerebellum 
and visual cortex, typically express relatively low levels of physiological α-synuclein 
under normal conditions (Braak et al., 2000). Therefore, a future direction of the 
present study would be to determine whether cells within the regions and sub-
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regions without significant Lewy body pathology contain lower levels of physiological 
α-synuclein under normal conditions.  
A key criticism of studies employing post-mortem tissue is that physiological changes 
cannot be observed. Future studies may wish to examine how visual functioning is 
perturbed in laboratory animals with α-synuclein pathology, particularly with regard to 
supportive visual structures in the secondary visual pathway, such as the pulvinar 
and superior colliculus. Murine species would not be suitable for this purpose, as 
they do not possess a pulvinar (Jones, 2012) and do not perform saccadic eye 
movements, with the superior colliculus being the primary target of retinal innervation, 
rather than the LGN (Hofbauer and Drager, 1985). This would indicate that non-
human primates would be a better choice, despite the ethical issues related to their 
use. The model system used in non-human primates would also have to be carefully 
chosen as α-synuclein-inducing toxins, such as rotenone, act primarily on 
mitochondrial respiration (Xiong et al., 2012). As the visual system has high 
metabolic demands (Chhetri and Gueven, 2016), using mitochondrial toxins would 
impair visual structures at an early stage (Normando et al., 2016), which may not 
accurately reflect the clinical course of α-synucleinopathies. Therefore, a more 
appropriate model may be the injection of misfolded α-synuclein to pathological 
predilection sites, such as the dorsal motor nucleus of vagus or amygdala.  
It was suggested in Chapter 6 neuronal loss in the SGI of the superior colliculus may 
create conditions where sensory inputs from non-visual modalities are misidentified 
as visual information. As the SGI is used to modulate visual information through the 
SGS, and ultimately the LGN and visual cortex, these changes may alter visual 
activity based on non-visual input. This hypothesis could be tested in DLB patients 
by asking patients to observe controlled visual fields, perhaps on a tablet computer. 
Incorporating other sensory stimuli, such as auditory and somatosensory information, 
alongside the visual information and subsequent patient interview of perceived 
images, would enable determination of whether non-visual stimuli influenced visual 
hallucinations or misidentification. Such work would undoubtedly be useful in 
verifying the present interpretation of results, and could provide novel insights into 
visual hallucinations.   
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7.8 Conclusions 
The subcortical visual system shows relatively specific patterns of neuropathological 
change in DLB compared to AD. Specifically, more neurodegeneration was found in 
the pulvinar and superior colliculus than the LGN in DLB. Overall, these findings 
indicate specific impairments in structures involved in adjunctive visual functions, 
such as visual attention and target selection, with relative preservation of basic 
structures necessary for visual sensation. These findings provide anatomical 
evidence and support for several prominent hypotheses of visual hallucinations. 
  
187 
 
Chapter 8: References 
 
Aarsland, D., Andersen, K., Larsen, J.P., Lolk, A. and Kragh-Sorensen, P. (2003) 'Prevalence and 
characteristics of dementia in Parkinson disease: an 8-year prospective study', Arch Neurol, 60(3), pp. 
387-92. 
Aarsland, D., Ballard, C., McKeith, I., Perry, R.H. and Larsen, J.P. (2001) 'Comparison of 
extrapyramidal signs in dementia with Lewy bodies and Parkinson's disease', J Neuropsychiatry Clin 
Neurosci, 13(3), pp. 374-9. 
Aarsland, D., Perry, R., Larsen, J.P., McKeith, I.G., O'Brien, J.T., Perry, E.K., Burn, D. and Ballard, C.G. 
(2005) 'Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias', J Clin Psychiatry, 
66(5), pp. 633-7. 
Aarsland, D., Tandberg, E., Larsen, J.P. and Cummings, J.L. (1996) 'Frequency of dementia in 
Parkinson disease', Arch Neurol, 53(6), pp. 538-42. 
Abdelnour, C., van Steenoven, I., Londos, E., Blanc, F., Auestad, B., Kramberger, M.G., Zetterberg, H., 
Mollenhauer, B., Boada, M. and Aarsland, D. (2016) 'Alzheimer's disease cerebrospinal fluid 
biomarkers predict cognitive decline in lewy body dementia', Mov Disord, 31(8), pp. 1203-8. 
Acarin, L., Paris, J., Gonzalez, B. and Castellano, B. (2002) 'Glial expression of small heat shock 
proteins following an excitotoxic lesion in the immature rat brain', Glia, 38(1), pp. 1-14. 
Aizawa, H. and Wurtz, R.H. (1998) 'Reversible inactivation of monkey superior colliculus. I. Curvature 
of saccadic trajectory', J Neurophysiol, 79(4), pp. 2082-96. 
Alladi, S., Xuereb, J., Bak, T., Nestor, P., Knibb, J., Patterson, K. and Hodges, J.R. (2007) 'Focal cortical 
presentations of Alzheimer's disease', Brain, 130(Pt 10), pp. 2636-45. 
Allen, R.L., Walker, Z., D'Ath, P.J. and Katona, C.L. (1995) 'Risperidone for psychotic and behavioural 
symptoms in Lewy body dementia', Lancet, 346(8968), p. 185. 
American Psychiatric, A. (2013) Diagnostic and statistical manual of mental disorders (DSM-5®). 
American Psychiatric Pub. 
Arai, M., Arai, R., Kani, K. and Jacobowitz, D.M. (1992) 'Immunohistochemical localization of 
calretinin in the rat lateral geniculate nucleus and its retino-geniculate projection', Brain Res, 596(1-
2), pp. 215-22. 
Arakawa, K., Tobimatsu, S., Kato, M. and Kira, J. (1999) 'Parvocellular and magnocellular visual 
processing in spinocerebellar degeneration and Parkinson's disease: an event-related potential 
study', Clinical Neurophysiology, 110(6), pp. 1048-57. 
Archibald, N.K., Clarke, M.P., Mosimann, U.P. and Burn, D.J. (2011) 'Visual symptoms in Parkinson's 
disease and Parkinson's disease dementia', Mov Disord, 26(13), pp. 2387-95. 
Arends, Y.M., Duyckaerts, C., Rozemuller, J.M., Eikelenboom, P. and Hauw, J.J. (2000) 'Microglia, 
amyloid and dementia in alzheimer disease. A correlative study', Neurobiol Aging, 21(1), pp. 39-47. 
Armstrong, M.J., Litvan, I., Lang, A.E., Bak, T.H., Bhatia, K.P., Borroni, B., Boxer, A.L., Dickson, D.W., 
Grossman, M., Hallett, M., Josephs, K.A., Kertesz, A., Lee, S.E., Miller, B.L., Reich, S.G., Riley, D.E., 
Tolosa, E., Troster, A.I., Vidailhet, M. and Weiner, W.J. (2013) 'Criteria for the diagnosis of 
corticobasal degeneration', Neurology, 80(5), pp. 496-503. 
Armstrong, R. and Kergoat, H. (2015) 'Oculo-visual changes and clinical considerations affecting older 
patients with dementia', Ophthalmic Physiol Opt, 35(4), pp. 352-76. 
Armstrong, R.A. (2012) 'Visual signs and symptoms of dementia with Lewy bodies', Clinical & 
experimental optometry : journal of the Australian Optometrical Association, 95(6), pp. 621-30. 
Asplund, C.L., Todd, J.J., Snyder, A.P. and Marois, R. (2010) 'A central role for the lateral prefrontal 
cortex in goal-directed and stimulus-driven attention', Nat Neurosci, 13(4), pp. 507-12. 
Attems, J., Jellinger, K.A., Dening, T. and Thomas, A. (2013) 'Neuropathology', Oxford textbook of old 
age psychiatry, 2, pp. 87-105. 
188 
 
Baba, M., Nakajo, S., Tu, P.H., Tomita, T., Nakaya, K., Lee, V.M., Trojanowski, J.Q. and Iwatsubo, T. 
(1998) 'Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia 
with Lewy bodies', Am J Pathol, 152(4), pp. 879-84. 
Bachstetter, A.D., Van Eldik, L.J., Schmitt, F.A., Neltner, J.H., Ighodaro, E.T., Webster, S.J., Patel, E., 
Abner, E.L., Kryscio, R.J. and Nelson, P.T. (2015) 'Disease-related microglia heterogeneity in the 
hippocampus of Alzheimer's disease, dementia with Lewy bodies, and hippocampal sclerosis of 
aging', Acta Neuropathol Commun, 3, p. 32. 
Ballard, C., McKeith, I., Harrison, R., O'Brien, J., Thompson, P., Lowery, K., Perry, R. and Ince, P. (1997) 
'A detailed phenomenological comparison of complex visual hallucinations in dementia with Lewy 
bodies and Alzheimer's disease', International Psychogeriatrics, 9(4), pp. 381-8. 
Ballard, C.G., Aarsland, D., McKeith, I., O'Brien, J., Gray, A., Cormack, F., Burn, D., Cassidy, T., 
Starfeldt, R., Larsen, J.P., Brown, R. and Tovee, M. (2002) 'Fluctuations in attention: PD dementia vs 
DLB with parkinsonism', Neurology, 59(11), pp. 1714-20. 
Bancher, C., Brunner, C., Lassmann, H., Budka, H., Jellinger, K., Wiche, G., Seitelberger, F., Grundke-
Iqbal, I., Iqbal, K. and Wisniewski, H.M. (1989) 'Accumulation of abnormally phosphorylated tau 
precedes the formation of neurofibrillary tangles in Alzheimer's disease', Brain Res, 477(1-2), pp. 90-
9. 
Barber, R., Scheltens, P., Gholkar, A., Ballard, C., McKeith, I., Ince, P., Perry, R. and O'Brien, J. (1999) 
'White matter lesions on magnetic resonance imaging in dementia with Lewy bodies, Alzheimer's 
disease, vascular dementia, and normal aging', J Neurol Neurosurg Psychiatry, 67(1), pp. 66-72. 
Barbur, J.L. (2004) ''Double-blindsight' revealed through the processing of color and luminance 
contrast defined motion signals', Prog Brain Res, 144, pp. 243-59. 
Barker, R.A. and Williams-Gray, C.H. (2016) 'Review: The spectrum of clinical features seen with 
alpha synuclein pathology', Neuropathol Appl Neurobiol, 42(1), pp. 6-19. 
Bartels, T., Choi, J.G. and Selkoe, D.J. (2011) 'alpha-Synuclein occurs physiologically as a helically 
folded tetramer that resists aggregation', Nature, 477(7362), pp. 107-10. 
Bate, C., Gentleman, S. and Williams, A. (2010) 'alpha-synuclein induced synapse damage is 
enhanced by amyloid-beta1-42', Mol Neurodegener, 5, p. 55. 
Beach, T.G., Carew, J., Serrano, G., Adler, C.H., Shill, H.A., Sue, L.I., Sabbagh, M.N., Akiyama, H. and 
Cuenca, N. (2014) 'Phosphorylated alpha-synuclein-immunoreactive retinal neuronal elements in 
Parkinson's disease subjects', Neurosci Lett, 571, pp. 34-8. 
Benarroch, E.E. (2015) 'Pulvinar: associative role in cortical function and clinical correlations', 
Neurology, 84(7), pp. 738-47. 
Bendor, J.T., Logan, T.P. and Edwards, R.H. (2013) 'The function of alpha-synuclein', Neuron, 79(6), 
pp. 1044-66. 
Benevento, L.A. and Fallon, J.H. (1975) 'The ascending projections of the superior colliculus in the 
rhesus monkey (Macaca mulatta)', J Comp Neurol, 160(3), pp. 339-61. 
Benevento, L.A. and Standage, G.P. (1983) 'The organization of projections of the retinorecipient and 
nonretinorecipient nuclei of the pretectal complex and layers of the superior colliculus to the lateral 
pulvinar and medial pulvinar in the macaque monkey', J Comp Neurol, 217(3), pp. 307-36. 
Benowitz, L.I. and Routtenberg, A. (1997) 'GAP-43: an intrinsic determinant of neuronal 
development and plasticity', Trends Neurosci, 20(2), pp. 84-91. 
Berg, D., Postuma, R.B., Bloem, B., Chan, P., Dubois, B., Gasser, T., Goetz, C.G., Halliday, G.M., Hardy, 
J., Lang, A.E., Litvan, I., Marek, K., Obeso, J., Oertel, W., Olanow, C.W., Poewe, W., Stern, M. and 
Deuschl, G. (2014) 'Time to redefine PD? Introductory statement of the MDS Task Force on the 
definition of Parkinson's disease', Mov Disord, 29(4), pp. 454-62. 
Berman, R.A. and Wurtz, R.H. (2010) 'Functional Identification of a Pulvinar Path from Superior 
Colliculus to Cortical Area MT', Journal of Neuroscience, 30(18), pp. 6342-6354. 
Bertram, K. and Williams, D.R. (2012) 'Visual hallucinations in the differential diagnosis of 
parkinsonism', J Neurol Neurosurg Psychiatry, 83(4), pp. 448-52. 
189 
 
Beyer, M.K., Larsen, J.P. and Aarsland, D. (2007) 'Gray matter atrophy in Parkinson disease with 
dementia and dementia with Lewy bodies', Neurology, 69(8), pp. 747-54. 
Bisley, J.W. and Goldberg, M.E. (2010) 'Attention, intention, and priority in the parietal lobe', Annu 
Rev Neurosci, 33, pp. 1-21. 
Blanc, F., Noblet, V., Philippi, N., Cretin, B., Foucher, J., Armspach, J.P., Rousseau, F. and Alzheimer's 
Disease Neuroimaging, I. (2014) 'Right anterior insula: core region of hallucinations in cognitive 
neurodegenerative diseases', PLoS One, 9(12), p. e114774. 
Bodis-Wollner, I., Kozlowski, P.B., Glazman, S. and Miri, S. (2014) 'alpha-synuclein in the inner retina 
in parkinson disease', Ann Neurol, 75(6), pp. 964-6. 
Boeve, B.F. (2013) 'Idiopathic REM sleep behaviour disorder in the development of Parkinson's 
disease', The Lancet Neurology, 12(5), pp. 469-482. 
Boeve, B.F., Silber, M.H., Ferman, T.J., Lin, S.C., Benarroch, E.E., Schmeichel, A.M., Ahlskog, J.E., 
Caselli, R.J., Jacobson, S., Sabbagh, M., Adler, C., Woodruff, B., Beach, T.G., Iranzo, A., Gelpi, E., 
Santamaria, J., Tolosa, E., Singer, C., Mash, D.C., Luca, C., Arnulf, I., Duyckaerts, C., Schenck, C.H., 
Mahowald, M.W., Dauvilliers, Y., Graff-Radford, N.R., Wszolek, Z.K., Parisi, J.E., Dugger, B., Murray, 
M.E. and Dickson, D.W. (2013) 'Clinicopathologic correlations in 172 cases of rapid eye movement 
sleep behavior disorder with or without a coexisting neurologic disorder', Sleep Med, 14(8), pp. 754-
62. 
Boeve, B.F., Silber, M.H., Ferman, T.J., Lucas, J.A. and Parisi, J.E. (2001) 'Association of REM sleep 
behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy', Mov 
Disord, 16(4), pp. 622-30. 
Bohr, I.J., Ray, M.A., McIntosh, J.M., Chalon, S., Guilloteau, D., McKeith, I.G., Perry, R.H., Clementi, F., 
Perry, E.K., Court, J.A. and Piggott, M.A. (2005) 'Cholinergic nicotinic receptor involvement in 
movement disorders associated with Lewy body diseases. An autoradiography study using 
[(125)I]alpha-conotoxinMII in the striatum and thalamus', Exp Neurol, 191(2), pp. 292-300. 
Bonneh-Barkay, D., Wang, G., Starkey, A., Hamilton, R.L. and Wiley, C.A. (2010a) 'In vivo CHI3L1 (YKL-
40) expression in astrocytes in acute and chronic neurological diseases', J Neuroinflammation, 7, p. 
34. 
Bonneh-Barkay, D., Zagadailov, P., Zou, H., Niyonkuru, C., Figley, M., Starkey, A., Wang, G., Bissel, S.J., 
Wiley, C.A. and Wagner, A.K. (2010b) 'YKL-40 expression in traumatic brain injury: an initial analysis', 
J Neurotrauma, 27(7), pp. 1215-23. 
Boot, B. (2013) 'The incidence and prevalence of dementia with Lewy bodies is underestimated', 
Psychol Med, 43(12), pp. 2687-8. 
Bostrom, F., Jonsson, L., Minthon, L. and Londos, E. (2007) 'Patients with dementia with lewy bodies 
have more impaired quality of life than patients with Alzheimer disease', Alzheimer Dis Assoc Disord, 
21(2), pp. 150-4. 
Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H. and Del Tredici, K. (2006) 'Staging of Alzheimer 
disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry', Acta 
Neuropathol, 112(4), pp. 389-404. 
Braak, H. and Braak, E. (1991) 'Alzheimer's disease affects limbic nuclei of the thalamus', Acta 
Neuropathol, 81(3), pp. 261-8. 
Braak, H., Del Tredici, K., Gai, W.P. and Braak, E. (2000) 'Alpha-synuclein is not a requisite component 
of synaptic boutons in the adult human central nervous system', J Chem Neuroanat, 20(3-4), pp. 245-
52. 
Braak, H., Del Tredici, K., Rub, U., de Vos, R.A., Jansen Steur, E.N. and Braak, E. (2003) 'Staging of 
brain pathology related to sporadic Parkinson's disease', Neurobiol Aging, 24(2), pp. 197-211. 
Braak, H., Ghebremedhin, E., Rub, U., Bratzke, H. and Del Tredici, K. (2004) 'Stages in the 
development of Parkinson's disease-related pathology', Cell Tissue Res, 318(1), pp. 121-34. 
Bradshaw, J., Saling, M., Hopwood, M., Anderson, V. and Brodtmann, A. (2004) 'Fluctuating cognition 
in dementia with Lewy bodies and Alzheimer's disease is qualitatively distinct', J Neurol Neurosurg 
Psychiatry, 75(3), pp. 382-7. 
190 
 
Bragina, L., Fattorini, G., Giovedi, S., Melone, M., Bosco, F., Benfenati, F. and Conti, F. (2011) 
'Analysis of Synaptotagmin, SV2, and Rab3 Expression in Cortical Glutamatergic and GABAergic Axon 
Terminals', Front Cell Neurosci, 5, p. 32. 
Bridge, H., Leopold, D.A. and Bourne, J.A. (2015) 'Adaptive Pulvinar Circuitry Supports Visual 
Cognition', Trends Cogn Sci. 
Brooks, D. and Halliday, G.M. (2009) 'Intralaminar nuclei of the thalamus in Lewy body diseases', 
Brain Res Bull, 78(2-3), pp. 97-104. 
Burghaus, L., Eggers, C., Timmermann, L., Fink, G.R. and Diederich, N.J. (2012) 'Hallucinations in 
neurodegenerative diseases', CNS Neurosci Ther, 18(2), pp. 149-59. 
Burn, D.J. and Jaros, E. (2001) 'Multiple system atrophy: cellular and molecular pathology', Mol 
Pathol, 54(6), pp. 419-26. 
Burn, D.J., Rowan, E.N., Allan, L.M., Molloy, S., O'Brien, J.T. and McKeith, I.G. (2006) 'Motor subtype 
and cognitive decline in Parkinson's disease, Parkinson's disease with dementia, and dementia with 
Lewy bodies', J Neurol Neurosurg Psychiatry, 77(5), pp. 585-9. 
Burn, D.J., Rowan, E.N., Minett, T., Sanders, J., Myint, P., Richardson, J., Thomas, A., Newby, J., Reid, 
J., O'Brien, J.T. and McKeith, I.G. (2003) 'Extrapyramidal features in Parkinson's disease with and 
without dementia and dementia with Lewy bodies: A cross-sectional comparative study', Mov Disord, 
18(8), pp. 884-9. 
Burre, J., Sharma, M., Tsetsenis, T., Buchman, V., Etherton, M.R. and Sudhof, T.C. (2010) 'Alpha-
synuclein promotes SNARE-complex assembly in vivo and in vitro', Science, 329(5999), pp. 1663-7. 
Burton, E.J., McKeith, I.G., Burn, D.J., Williams, E.D. and O'Brien, J.T. (2004) 'Cerebral atrophy in 
Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia 
with Lewy bodies and controls', Brain, 127(Pt 4), pp. 791-800. 
Burton, H. and Jones, E.G. (1976) 'The posterior thalamic region and its cortical projection in New 
World and Old World monkeys', J Comp Neurol, 168(2), pp. 249-301. 
Caceres, A., Payne, M.R., Binder, L.I. and Steward, O. (1983) 'Immunocytochemical localization of 
actin and microtubule-associated protein MAP2 in dendritic spines', Proc Natl Acad Sci U S A, 80(6), 
pp. 1738-42. 
Cagnin, A., Gnoato, F., Jelcic, N., Favaretto, S., Zarantonello, G., Ermani, M. and Dam, M. (2013) 
'Clinical and cognitive correlates of visual hallucinations in dementia with Lewy bodies', J Neurol 
Neurosurg Psychiatry, 84(5), pp. 505-10. 
Cahoy, J.D., Emery, B., Kaushal, A., Foo, L.C., Zamanian, J.L., Christopherson, K.S., Xing, Y., Lubischer, 
J.L., Krieg, P.A., Krupenko, S.A., Thompson, W.J. and Barres, B.A. (2008) 'A transcriptome database 
for astrocytes, neurons, and oligodendrocytes: a new resource for understanding brain development 
and function', J Neurosci, 28(1), pp. 264-78. 
Calakos, N. and Scheller, R.H. (1994) 'Vesicle-associated membrane protein and synaptophysin are 
associated on the synaptic vesicle', J Biol Chem, 269(40), pp. 24534-7. 
Caminiti, S.P., Tettamanti, M., Sala, A., Presotto, L., Iannaccone, S., Cappa, S.F., Magnani, G., Perani, 
D. and Alzheimer's Disease Neuroimaging, I. (2016) 'Metabolic connectomics targeting brain 
pathology in dementia with Lewy bodies', J Cereb Blood Flow Metab. 
Carter, R. and Ffytche, D.H. (2015) 'On visual hallucinations and cortical networks: a trans-diagnostic 
review', J Neurol, 262(7), pp. 1780-90. 
Ceravolo, R., Volterrani, D., Gambaccini, G., Rossi, C., Logi, C., Manca, G., Berti, C., Mariani, G., Murri, 
L. and Bonuccelli, U. (2003) 'Dopaminergic degeneration and perfusional impairment in Lewy body 
dementia and Alzheimer's disease', Neurol Sci, 24(3), pp. 162-3. 
Chaari, A., Hoarau-Vechot, J. and Ladjimi, M. (2013) 'Applying chaperones to protein-misfolding 
disorders: molecular chaperones against alpha-synuclein in Parkinson's disease', Int J Biol Macromol, 
60, pp. 196-205. 
Chang, C.C., Liu, J.S., Chang, Y.Y., Chang, W.N., Chen, S.S. and Lee, C.H. (2008) '(99m)Tc-ethyl 
cysteinate dimer brain SPECT findings in early stage of dementia with Lewy bodies and Parkinson's 
disease patients: a correlation with neuropsychological tests', Eur J Neurol, 15(1), pp. 61-5. 
191 
 
Chaudhary, H., Stefanovic, A.N., Subramaniam, V. and Claessens, M.M. (2014) 'Membrane 
interactions and fibrillization of alpha-synuclein play an essential role in membrane disruption', FEBS 
Lett, 588(23), pp. 4457-63. 
Cheong, S.K., Tailby, C., Martin, P.R., Levitt, J.B. and Solomon, S.G. (2011) 'Slow intrinsic rhythm in 
the koniocellular visual pathway', Proc Natl Acad Sci U S A, 108(35), pp. 14659-63. 
Chhetri, J. and Gueven, N. (2016) 'Targeting mitochondrial function to protect against vision loss', 
Expert Opin Ther Targets, 20(6), pp. 721-36. 
Chiu, P.Y., Tsai, C.T., Chen, P.K., Chen, W.J. and Lai, T.J. (2016) 'Neuropsychiatric Symptoms in 
Parkinson's Disease Dementia Are More Similar to Alzheimer's Disease than Dementia with Lewy 
Bodies: A Case-Control Study', PLoS One, 11(4), p. e0153989. 
Chorostecki, J., Seraji-Bozorgzad, N., Shah, A., Bao, F., Bao, G., George, E., Gorden, V., Caon, C., 
Frohman, E., Bhatti, M.T. and Khan, O. (2015) 'Characterization of retinal architecture in Parkinson's 
disease', J Neurol Sci, 355(1-2), pp. 44-8. 
Claassen, D.O., Lowe, V.J., Peller, P.J., Petersen, R.C. and Josephs, K.A. (2011) 'Amyloid and glucose 
imaging in dementia with Lewy bodies and multiple systems atrophy', Parkinsonism Relat Disord, 
17(3), pp. 160-5. 
Clark, W.E. (1932) 'A MORPHOLOGICAL STUDY OF THE LATERAL GENICULATE BODY', Br J Ophthalmol, 
16(5), pp. 264-84. 
Coffman, F.D. (2008) 'Chitinase 3-Like-1 (CHI3L1): a putative disease marker at the interface of 
proteomics and glycomics', Crit Rev Clin Lab Sci, 45(6), pp. 531-62. 
Collerton, D., Burn, D., McKeith, I. and O'Brien, J. (2003) 'Systematic review and meta-analysis show 
that dementia with Lewy bodies is a visual-perceptual and attentional-executive dementia', Dement 
Geriatr Cogn Disord, 16(4), pp. 229-37. 
Collerton, D., Perry, E. and McKeith, I. (2005a) 'Still PADing along: Perception and attention remain 
key factors in understanding complex visual hallucinations', Behavioral and Brain Sciences, 28(6), pp. 
776-794. 
Collerton, D., Perry, E. and McKeith, L. (2005b) 'Why people see things that are not there: A novel 
Perception and Attention Deficit model for recurrent complex visual hallucinations', Behavioral and 
Brain Sciences, 28(6), pp. 737-+. 
Colloby, S.J., Fenwick, J.D., Williams, E.D., Paling, S.M., Lobotesis, K., Ballard, C., McKeith, I. and 
O'Brien, J.T. (2002) 'A comparison of (99m)Tc-HMPAO SPET changes in dementia with Lewy bodies 
and Alzheimer's disease using statistical parametric mapping', Eur J Nucl Med Mol Imaging, 29(5), pp. 
615-22. 
Conway, K.A., Harper, J.D. and Lansbury, P.T., Jr. (2000a) 'Fibrils formed in vitro from alpha-synuclein 
and two mutant forms linked to Parkinson's disease are typical amyloid', Biochemistry, 39(10), pp. 
2552-63. 
Conway, K.A., Lee, S.J., Rochet, J.C., Ding, T.T., Williamson, R.E. and Lansbury, P.T., Jr. (2000b) 
'Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein 
mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy', Proc 
Natl Acad Sci U S A, 97(2), pp. 571-6. 
Cookson, M.R. (2006) 'Hero versus antihero: the multiple roles of alpha-synuclein in 
neurodegeneration', Exp Neurol, 199(2), pp. 238-42. 
Corbetta, M. and Shulman, G.L. (2002) 'Control of goal-directed and stimulus-driven attention in the 
brain', Nat Rev Neurosci, 3(3), pp. 201-15. 
Corneil, B.D., Olivier, E. and Munoz, D.P. (2002) 'Neck muscle responses to stimulation of monkey 
superior colliculus. II. Gaze shift initiation and volitional head movements', J Neurophysiol, 88(4), pp. 
2000-18. 
Corripio, I., Escarti, M.J., Portella, M.J., Perez, V., Grasa, E., Sauras, R.B., Alonso, A., Safont, G., 
Camacho, M.V., Duenas, R., Arranz, B., San, L., Catafau, A.M., Carrio, I. and Alvarez, E. (2011) 'Density 
of striatal D2 receptors in untreated first-episode psychosis: an I123-IBZM SPECT study', Eur 
Neuropsychopharmacol, 21(12), pp. 861-6. 
192 
 
Court, J., Spurden, D., Lloyd, S., McKeith, I., Ballard, C., Cairns, N., Kerwin, R., Perry, R. and Perry, E. 
(1999) 'Neuronal nicotinic receptors in dementia with Lewy bodies and schizophrenia: alpha-
bungarotoxin and nicotine binding in the thalamus', J Neurochem, 73(4), pp. 1590-7. 
Court, J.A., Ballard, C.G., Piggott, M.A., Johnson, M., O'Brien, J.T., Holmes, C., Cairns, N., Lantos, P., 
Perry, R.H., Jaros, E. and Perry, E.K. (2001) 'Visual hallucinations are associated with lower alpha 
bungarotoxin binding in dementia with Lewy bodies', Pharmacol Biochem Behav, 70(4), pp. 571-9. 
Cowey, A. and Stoerig, P. (1989) 'Projection patterns of surviving neurons in the dorsal lateral 
geniculate nucleus following discrete lesions of striate cortex: implications for residual vision', Exp 
Brain Res, 75(3), pp. 631-8. 
Craig-Schapiro, R., Perrin, R.J., Roe, C.M., Xiong, C., Carter, D., Cairns, N.J., Mintun, M.A., Peskind, 
E.R., Li, G., Galasko, D.R., Clark, C.M., Quinn, J.F., D'Angelo, G., Malone, J.P., Townsend, R.R., Morris, 
J.C., Fagan, A.M. and Holtzman, D.M. (2010) 'YKL-40: a novel prognostic fluid biomarker for 
preclinical Alzheimer's disease', Biol Psychiatry, 68(10), pp. 903-12. 
Cremades, N., Cohen, S.I., Deas, E., Abramov, A.Y., Chen, A.Y., Orte, A., Sandal, M., Clarke, R.W., 
Dunne, P., Aprile, F.A., Bertoncini, C.W., Wood, N.W., Knowles, T.P., Dobson, C.M. and Klenerman, D. 
(2012) 'Direct observation of the interconversion of normal and toxic forms of alpha-synuclein', Cell, 
149(5), pp. 1048-59. 
Crick, F. (1984) 'Function of the thalamic reticular complex: the searchlight hypothesis', Proc Natl 
Acad Sci U S A, 81(14), pp. 4586-90. 
Culo, S., Mulsant, B.H., Rosen, J., Mazumdar, S., Blakesley, R.E., Houck, P.R. and Pollock, B.G. (2010) 
'Treating neuropsychiatric symptoms in dementia with Lewy bodies: a randomized controlled-trial', 
Alzheimer Dis Assoc Disord, 24(4), pp. 360-4. 
Cummings, J.L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D.A. and Gornbein, J. (1994) 
'The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia', 
Neurology, 44(12), pp. 2308-14. 
Cusick, C.G., Scripter, J.L., Darensbourg, J.G. and Weber, J.T. (1993) 'Chemoarchitectonic subdivisions 
of the visual pulvinar in monkeys and their connectional relations with the middle temporal and 
rostral dorsolateral visual areas, MT and DLr', J Comp Neurol, 336(1), pp. 1-30. 
DaDalt, O. and Coughlin, J.F. (2016) 'Managing Financial Well-Being in the Shadow of Alzheimer’s 
Disease', Public Policy & Aging Report, 26(1), pp. 36-38. 
Danzer, K.M., Haasen, D., Karow, A.R., Moussaud, S., Habeck, M., Giese, A., Kretzschmar, H., 
Hengerer, B. and Kostka, M. (2007) 'Different species of alpha-synuclein oligomers induce calcium 
influx and seeding', J Neurosci, 27(34), pp. 9220-32. 
Das, A.S. and Zou, W.Q. (2016) 'Prions: Beyond a Single Protein', Clin Microbiol Rev, 29(3), pp. 633-58. 
de Jong, L.W., van der Hiele, K., Veer, I.M., Houwing, J.J., Westendorp, R.G., Bollen, E.L., de Bruin, 
P.W., Middelkoop, H.A., van Buchem, M.A. and van der Grond, J. (2008) 'Strongly reduced volumes 
of putamen and thalamus in Alzheimer's disease: an MRI study', Brain, 131(Pt 12), pp. 3277-85. 
De Maio, A. (1999) 'Heat shock proteins: facts, thoughts, and dreams', Shock, 11(1), pp. 1-12. 
De Reuck, J., Deramecourt, V., Cordonnier, C., Leys, D., Pasquier, F. and Maurage, C.A. (2013) 
'Prevalence of cerebrovascular lesions in patients with Lewy body dementia: a neuropathological 
study', Clin Neurol Neurosurg, 115(7), pp. 1094-7. 
Delli Pizzi, S., Franciotti, R., Taylor, J.P., Esposito, R., Tartaro, A., Thomas, A., Onofrj, M. and Bonanni, 
L. (2015a) 'Structural Connectivity is Differently Altered in Dementia with Lewy Body and Alzheimer's 
Disease', Front Aging Neurosci, 7, p. 208. 
Delli Pizzi, S., Franciotti, R., Taylor, J.P., Thomas, A., Tartaro, A., Onofrj, M. and Bonanni, L. (2015b) 
'Thalamic Involvement in Fluctuating Cognition in Dementia with Lewy Bodies: Magnetic Resonance 
Evidences', Cereb Cortex, 25(10), pp. 3682-9. 
Delli Pizzi, S., Maruotti, V., Taylor, J.P., Franciotti, R., Caulo, M., Tartaro, A., Thomas, A., Onofrj, M. 
and Bonanni, L. (2014) 'Relevance of subcortical visual pathways disruption to visual symptoms in 
dementia with Lewy bodies', Cortex, 59, pp. 12-21. 
193 
 
Denison, R.N., Vu, A.T., Yacoub, E., Feinberg, D.A. and Silver, M.A. (2014) 'Functional mapping of the 
magnocellular and parvocellular subdivisions of human LGN', Neuroimage, 102 Pt 2, pp. 358-69. 
Derrington, A.M. and Lennie, P. (1984) 'Spatial and temporal contrast sensitivities of neurones in 
lateral geniculate nucleus of macaque', J Physiol, 357, pp. 219-40. 
Desgent, S. and Ptito, M. (2012) 'Cortical GABAergic interneurons in cross-modal plasticity following 
early blindness', Neural Plast, 2012, p. 590725. 
Detrait, E., Maurice, T., Hanon, E., Leclercq, K. and Lamberty, Y. (2014) 'Lack of synaptic vesicle 
protein SV2B protects against amyloid-beta(2)(5)(-)(3)(5)-induced oxidative stress, cholinergic deficit 
and cognitive impairment in mice', Behav Brain Res, 271, pp. 277-85. 
Devos, D., Tir, M., Maurage, C.A., Waucquier, N., Defebvre, L., Defoort-Dhellemmes, S. and Destee, A. 
(2005) 'ERG and anatomical abnormalities suggesting retinopathy in dementia with Lewy bodies', 
Neurology, 65(7), pp. 1107-10. 
Dey, M., Erskine, D., Singh, P., Tsefou, E., Taylor, J.P., McKeith, I.G., Attems, J., Thomas, A.J., 
Khundakar, A.A., Morris, C.M., Patterson, L., Hiskett, I., Gordon, D., Hook, R., Hanson, P.S., Rushton, 
S., O'Brien, J.T. (2015) 'Does Abnormal Ventral Visual Stream Function Underlie Recurrent Complex 
Visual Hallucinations in Dementia with Lewy Bodies?', American Journal of Neurodegenerative 
Diseases, 4((S1)). 
Diederich, N.J., Goetz, C.G., Raman, R., Pappert, E.J., Leurgans, S. and Piery, V. (1998) 'Poor visual 
discrimination and visual hallucinations in Parkinson's disease', Clin Neuropharmacol, 21(5), pp. 289-
95. 
Diederich, N.J., Goetz, C.G. and Stebbins, G.T. (2005) 'Repeated visual hallucinations in Parkinson's 
disease as disturbed external/internal perceptions: Focused review and a new integrative model', 
Movement Disorders, 20(2), pp. 130-140. 
Diederich, N.J., Pieri, V. and Goetz, C.G. (2003) 'Coping strategies for visual hallucinations in 
Parkinson's disease', Movement Disorders, 18(7), pp. 831-832. 
Diederich, N.J., Stebbins, G., Schiltz, C. and Goetz, C.G. (2014) 'Are patients with Parkinson's disease 
blind to blindsight?', Brain, 137(Pt 6), pp. 1838-49. 
Donaghy, P., Thomas, A.J. and O'Brien, J.T. (2015) 'Amyloid PET Imaging in Lewy body disorders', Am 
J Geriatr Psychiatry, 23(1), pp. 23-37. 
Donnemiller, E., Heilmann, J., Wenning, G.K., Berger, W., Decristoforo, C., Moncayo, R., Poewe, W. 
and Ransmayr, G. (1997) 'Brain perfusion scintigraphy with 99mTc-HMPAO or 99mTc-ECD and 123I-
beta-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy 
body disease', Eur J Nucl Med, 24(3), pp. 320-5. 
Dorph-Petersen, K.-A., Caric, D., Saghafi, R., Zhang, W., Sampson, A.R. and Lewis, D.A. (2009) 
'Volume and neuron number of the lateral geniculate nucleus in schizophrenia and mood disorders', 
Acta Neuropathologica, 117(4), pp. 369-384. 
Dubois, B., Feldman, H.H., Jacova, C., Hampel, H., Molinuevo, J.L., Blennow, K., DeKosky, S.T., 
Gauthier, S., Selkoe, D., Bateman, R., Cappa, S., Crutch, S., Engelborghs, S., Frisoni, G.B., Fox, N.C., 
Galasko, D., Habert, M.O., Jicha, G.A., Nordberg, A., Pasquier, F., Rabinovici, G., Robert, P., Rowe, C., 
Salloway, S., Sarazin, M., Epelbaum, S., de Souza, L.C., Vellas, B., Visser, P.J., Schneider, L., Stern, Y., 
Scheltens, P. and Cummings, J.L. (2014) 'Advancing research diagnostic criteria for Alzheimer's 
disease: the IWG-2 criteria', Lancet Neurol, 13(6), pp. 614-29. 
Dugger, B.N., Murray, M.E., Boeve, B.F., Parisi, J.E., Benarroch, E.E., Ferman, T.J. and Dickson, D.W. 
(2012) 'Neuropathological analysis of brainstem cholinergic and catecholaminergic nuclei in relation 
to rapid eye movement (REM) sleep behaviour disorder', Neuropathol Appl Neurobiol, 38(2), pp. 
142-52. 
Dugger, B.N., Tu, M., Murray, M.E. and Dickson, D.W. (2011) 'Disease specificity and pathologic 
progression of tau pathology in brainstem nuclei of Alzheimer's disease and progressive 
supranuclear palsy', Neurosci Lett, 491(2), pp. 122-6. 
Eikelenboom, P., Hack, C.E., Rozemuller, J.M. and Stam, F.C. (1988) 'Complement activation in 
amyloid plaques in Alzheimer’s dementia', Virchows Archiv B, 56(1), pp. 259-262. 
194 
 
Eikelenboom, P. and Stam, F.C. (1984) 'An immunohistochemical study on cerebral vascular and 
senile plaque amyloid in Alzheimer's dementia', Virchows Arch B Cell Pathol Incl Mol Pathol, 47(1), 
pp. 17-25. 
Eliezer, D., Kutluay, E., Bussell, R., Jr. and Browne, G. (2001) 'Conformational properties of alpha-
synuclein in its free and lipid-associated states', J Mol Biol, 307(4), pp. 1061-73. 
Erickson, S.L., Melchitzky, D.S. and Lewis, D.A. (2004) 'Subcortical afferents to the lateral 
mediodorsal thalamus in cynomolgus monkeys', Neuroscience, 129(3), pp. 675-90. 
Erskine, D. and Khundakar, A.A. (2016) 'Stereological approaches to dementia research using human 
brain tissue', J Chem Neuroanat. 
Erskine, D., Taylor, J.P., Firbank, M.J., Patterson, L., Onofrj, M., O'Brien, J.T., McKeith, I.G., Attems, J., 
Thomas, A.J., Morris, C.M. and Khundakar, A.A. (2016) 'Changes to the lateral geniculate nucleus in 
Alzheimer's disease but not dementia with Lewy bodies', Neuropathol Appl Neurobiol, 42(4), pp. 
366-76. 
Eugene, C., Laghaei, R. and Mousseau, N. (2014) 'Early oligomerization stages for the non-amyloid 
component of alpha-synuclein amyloid', J Chem Phys, 141(13), p. 135103. 
Eustache, P., Nemmi, F., Saint-Aubert, L., Pariente, J. and Peran, P. (2016) 'Multimodal Magnetic 
Resonance Imaging in Alzheimer's Disease Patients at Prodromal Stage', J Alzheimers Dis, 50(4), pp. 
1035-50. 
Factor, S.A., Scullin, M.K., Sollinger, A.B., Land, J.O., Wood-Siverio, C., Zanders, L., Freeman, A., 
Bliwise, D.L., McDonald, W.M. and Goldstein, F.C. (2014) 'Cognitive correlates of hallucinations and 
delusions in Parkinson's disease', J Neurol Sci, 347(1-2), pp. 316-21. 
Fahn, S. and Elotion, R. (1987) 'UPDRS Program Members. Unified Parkinson’s disease rating scale. 
vol 2. Florham Park'. NJ: Macmillan Healthcare Information. 
Farina, C., Aloisi, F. and Meinl, E. (2007) 'Astrocytes are active players in cerebral innate immunity', 
Trends Immunol, 28(3), pp. 138-45. 
Fauvet, B., Mbefo, M.K., Fares, M.B., Desobry, C., Michael, S., Ardah, M.T., Tsika, E., Coune, P., 
Prudent, M., Lion, N., Eliezer, D., Moore, D.J., Schneider, B., Aebischer, P., El-Agnaf, O.M., Masliah, E. 
and Lashuel, H.A. (2012) 'alpha-Synuclein in central nervous system and from erythrocytes, 
mammalian cells, and Escherichia coli exists predominantly as disordered monomer', J Biol Chem, 
287(19), pp. 15345-64. 
Fenalti, G., Law, R.H., Buckle, A.M., Langendorf, C., Tuck, K., Rosado, C.J., Faux, N.G., Mahmood, K., 
Hampe, C.S., Banga, J.P., Wilce, M., Schmidberger, J., Rossjohn, J., El-Kabbani, O., Pike, R.N., Smith, 
A.I., Mackay, I.R., Rowley, M.J. and Whisstock, J.C. (2007) 'GABA production by glutamic acid 
decarboxylase is regulated by a dynamic catalytic loop', Nat Struct Mol Biol, 14(4), pp. 280-6. 
Fenelon, G., Mahieux, F., Huon, R. and Ziegler, M. (2000) 'Hallucinations in Parkinson's disease: 
prevalence, phenomenology and risk factors', Brain, 123 ( Pt 4), pp. 733-45. 
Ffytche, D.H. (2005) 'Visual hallucinations and the Charles Bonnet syndrome', Curr Psychiatry Rep, 
7(3), pp. 168-79. 
ffytche, D.H. (2009) 'Visual hallucinations in eye disease', Curr Opin Neurol, 22(1), pp. 28-35. 
Fischer, J. and Whitney, D. (2012) 'Attention gates visual coding in the human pulvinar', Nat Commun, 
3, p. 1051. 
Fowler, M.W. and Staras, K. (2015) 'Synaptic vesicle pools: Principles, properties and limitations', Exp 
Cell Res, 335(2), pp. 150-6. 
Franciotti, R., Falasca, N.W., Bonanni, L., Anzellotti, F., Maruotti, V., Comani, S., Thomas, A., Tartaro, 
A., Taylor, J.P. and Onofrj, M. (2013) 'Default network is not hypoactive in dementia with fluctuating 
cognition: an Alzheimer disease/dementia with Lewy bodies comparison', Neurobiol Aging, 34(4), pp. 
1148-58. 
Frederick, J.M., Rayborn, M.E., Laties, A.M., Lam, D.M. and Hollyfield, J.G. (1982) 'Dopaminergic 
neurons in the human retina', J Comp Neurol, 210(1), pp. 65-79. 
Frydman, J. and Hartl, F.U. (1996) 'Principles of chaperone-assisted protein folding: differences 
between in vitro and in vivo mechanisms', Science, 272(5267), pp. 1497-502. 
195 
 
Fujishiro, H., Iseki, E., Kasanuki, K., Chiba, Y., Ota, K., Murayama, N. and Sato, K. (2013) 'A follow up 
study of non-demented patients with primary visual cortical hypometabolism: prodromal dementia 
with Lewy bodies', J Neurol Sci, 334(1-2), pp. 48-54. 
Gallagher, D.A., Parkkinen, L., O'Sullivan, S.S., Spratt, A., Shah, A., Davey, C.C., Bremner, F.D., Revesz, 
T., Williams, D.R., Lees, A.J. and Schrag, A. (2011) 'Testing an aetiological model of visual 
hallucinations in Parkinson's disease', Brain, 134(Pt 11), pp. 3299-309. 
Galvin, J.E., Giasson, B., Hurtig, H.I., Lee, V.M. and Trojanowski, J.Q. (2000) 'Neurodegeneration with 
brain iron accumulation, type 1 is characterized by alpha-, beta-, and gamma-synuclein 
neuropathology', Am J Pathol, 157(2), pp. 361-8. 
Gandhi, N.J. and Katnani, H.A. (2011) 'Motor functions of the superior colliculus', Annu Rev Neurosci, 
34, pp. 205-31. 
Gao, X., Carroni, M., Nussbaum-Krammer, C., Mogk, A., Nillegoda, N.B., Szlachcic, A., Guilbride, D.L., 
Saibil, H.R., Mayer, M.P. and Bukau, B. (2015) 'Human Hsp70 Disaggregase Reverses Parkinson's-
Linked alpha-Synuclein Amyloid Fibrils', Mol Cell, 59(5), pp. 781-93. 
Garwood, C.J., Ratcliffe, L.E., Simpson, J.E., Heath, P.R., Ince, P.G. and Wharton, S.B. (2016) 'Review: 
Astrocytes in Alzheimer's disease and other age-associated dementias; a supporting player with a 
central role', Neuropathol Appl Neurobiol. 
Gattass, R., Galkin, T.W., Desimone, R. and Ungerleider, L.G. (2014) 'Subcortical Connections of Area 
V4 in the Macaque', Journal of Comparative Neurology, 522(8), pp. 1941-1965. 
Ghitani, N., Bayguinov, P.O., Vokoun, C.R., McMahon, S., Jackson, M.B. and Basso, M.A. (2014) 
'Excitatory synaptic feedback from the motor layer to the sensory layers of the superior colliculus', J 
Neurosci, 34(20), pp. 6822-33. 
Giasson, B.I., Uryu, K., Trojanowski, J.Q. and Lee, V.M. (1999) 'Mutant and wild type human alpha-
synucleins assemble into elongated filaments with distinct morphologies in vitro', J Biol Chem, 
274(12), pp. 7619-22. 
Gibb, W.R. and Lees, A.J. (1988) 'A comparison of clinical and pathological features of young- and 
old-onset Parkinson's disease', Neurology, 38(9), pp. 1402-6. 
Gilman, S., Wenning, G.K., Low, P.A., Brooks, D.J., Mathias, C.J., Trojanowski, J.Q., Wood, N.W., 
Colosimo, C., Durr, A., Fowler, C.J., Kaufmann, H., Klockgether, T., Lees, A., Poewe, W., Quinn, N., 
Revesz, T., Robertson, D., Sandroni, P., Seppi, K. and Vidailhet, M. (2008) 'Second consensus 
statement on the diagnosis of multiple system atrophy', Neurology, 71(9), pp. 670-6. 
Glimcher, P.W. and Sparks, D.L. (1992) 'Movement selection in advance of action in the superior 
colliculus', Nature, 355(6360), pp. 542-5. 
Gnanalingham, K.K., Byrne, E.J., Thornton, A., Sambrook, M.A. and Bannister, P. (1997) 'Motor and 
cognitive function in Lewy body dementia: comparison with Alzheimer's and Parkinson's diseases', J 
Neurol Neurosurg Psychiatry, 62(3), pp. 243-52. 
Goasdoue, K., Awabdy, D., Bjorkman, S.T. and Miller, S. (2016) 'Standard loading controls are not 
reliable for Western blot quantification across brain development or in pathological conditions', 
Electrophoresis, 37(4), pp. 630-4. 
Goedert, M. (2015) 'NEURODEGENERATION. Alzheimer's and Parkinson's diseases: The prion 
concept in relation to assembled Abeta, tau, and alpha-synuclein', Science, 349(6248), p. 1255555. 
Gomez-Isla, T., Price, J.L., McKeel, D.W., Jr., Morris, J.C., Growdon, J.H. and Hyman, B.T. (1996) 
'Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease', J 
Neurosci, 16(14), pp. 4491-500. 
Gomperts, S.N. (2014) 'Imaging the role of amyloid in PD dementia and dementia with Lewy bodies', 
Curr Neurol Neurosci Rep, 14(8), p. 472. 
Gonzalez, D., Satriotomo, I., Miki, T., Lee, K.Y., Yokoyama, T., Touge, T., Matsumoto, Y., Li, H.P., 
Kuriyama, S. and Takeuchi, Y. (2006) 'Changes of parvalbumin immunoreactive neurons and GFAP 
immunoreactive astrocytes in the rat lateral geniculate nucleus following monocular enucleation', 
Neurosci Lett, 395(2), pp. 149-54. 
196 
 
Gordon, S.L., Harper, C.B., Smillie, K.J. and Cousin, M.A. (2016) 'A Fine Balance of Synaptophysin 
Levels Underlies Efficient Retrieval of Synaptobrevin II to Synaptic Vesicles', PLoS One, 11(2), p. 
e0149457. 
Gracitelli, C.P., Abe, R.Y., Diniz-Filho, A., Vaz-de-Lima, F.B., Paranhos, A., Jr. and Medeiros, F.A. (2015) 
'Ophthalmology issues in schizophrenia', Curr Psychiatry Rep, 17(5), p. 28. 
Grinberg, L.T. and Thal, D.R. (2010) 'Vascular pathology in the aged human brain', Acta Neuropathol, 
119(3), pp. 277-90. 
Grothe, M.J., Schuster, C., Bauer, F., Heinsen, H., Prudlo, J. and Teipel, S.J. (2014) 'Atrophy of the 
cholinergic basal forebrain in dementia with Lewy bodies and Alzheimer's disease dementia', J 
Neurol, 261(10), pp. 1939-48. 
Gundersen, H.J. and Jensen, E.B. (1987) 'The efficiency of systematic sampling in stereology and its 
prediction', J Microsc, 147(Pt 3), pp. 229-63. 
Gunderson, C.H. and Hoyt, W.F. (1971) 'Geniculate hemianopia: incongruous homonymous field 
defects in two patients with partial lesions of the lateral geniculate nucleus', J Neurol Neurosurg 
Psychiatry, 34(1), pp. 1-6. 
Gurry, T., Ullman, O., Fisher, C.K., Perovic, I., Pochapsky, T. and Stultz, C.M. (2013) 'The dynamic 
structure of alpha-synuclein multimers', J Am Chem Soc, 135(10), pp. 3865-72. 
Harding, A.J., Broe, G.A. and Halliday, G.M. (2002) 'Visual hallucinations in Lewy body disease relate 
to Lewy bodies in the temporal lobe', Brain, 125(Pt 2), pp. 391-403. 
Harting, J.K., Huerta, M.F., Hashikawa, T. and van Lieshout, D.P. (1991) 'Projection of the mammalian 
superior colliculus upon the dorsal lateral geniculate nucleus: organization of tectogeniculate 
pathways in nineteen species', J Comp Neurol, 304(2), pp. 275-306. 
Hartl, F.U. and Hayer-Hartl, M. (2002) 'Molecular chaperones in the cytosol: from nascent chain to 
folded protein', Science, 295(5561), pp. 1852-8. 
Haug, H., Kuhl, S., Mecke, E., Sass, N.L. and Wasner, K. (1984) 'The significance of morphometric 
procedures in the investigation of age changes in cytoarchitectonic structures of human brain', J 
Hirnforsch, 25(4), pp. 353-74. 
Heese, K., Nagai, Y. and Sawada, T. (2001) 'Identification of a new synaptic vesicle protein 2B mRNA 
transcript which is up-regulated in neurons by amyloid beta peptide fragment (1-42)', Biochem 
Biophys Res Commun, 289(5), pp. 924-8. 
Heidebrink, J.L. (2002) 'Is dementia with Lewy bodies the second most common cause of dementia?', 
J Geriatr Psychiatry Neurol, 15(4), pp. 182-7. 
Heitz, C., Noblet, V., Cretin, B., Philippi, N., Kremer, L., Stackfleth, M., Hubele, F., Armspach, J.P., 
Namer, I. and Blanc, F. (2015) 'Neural correlates of visual hallucinations in dementia with Lewy 
bodies', Alzheimers Res Ther, 7(1), p. 6. 
Hely, M.A., Reid, W.G., Adena, M.A., Halliday, G.M. and Morris, J.G. (2008) 'The Sydney multicenter 
study of Parkinson's disease: the inevitability of dementia at 20 years', Mov Disord, 23(6), pp. 837-44. 
Henderson, J.M., Carpenter, K., Cartwright, H. and Halliday, G.M. (2000) 'Loss of thalamic 
intralaminar nuclei in progressive supranuclear palsy and Parkinson's disease: clinical and 
therapeutic implications', Brain, 123 ( Pt 7), pp. 1410-21. 
Henderson, T., Georgiou-Karistianis, N., White, O., Millist, L., Williams, D.R., Churchyard, A. and 
Fielding, J. (2011) 'Inhibitory control during smooth pursuit in Parkinson's disease and Huntington's 
disease', Mov Disord, 26(10), pp. 1893-9. 
Hendry, S.H. and Reid, R.C. (2000) 'The koniocellular pathway in primate vision', Annu Rev Neurosci, 
23, pp. 127-53. 
Henstridge, C.M., Jackson, R.J., Kim, J.M., Herrmann, A.G., Wright, A.K., Harris, S.E., Bastin, M.E., 
Starr, J.M., Wardlaw, J., Gillingwater, T.H., Smith, C., McKenzie, C.A., Cox, S.R., Deary, I.J. and Spires-
Jones, T.L. (2015) 'Post-mortem brain analyses of the Lothian Birth Cohort 1936: extending lifetime 
cognitive and brain phenotyping to the level of the synapse', Acta Neuropathol Commun, 3, p. 53. 
Hepp, D.H., Ruiter, A.M., Galis, Y., Voorn, P., Rozemuller, A.J., Berendse, H.W., Foncke, E.M. and van 
de Berg, W.D. (2013) 'Pedunculopontine cholinergic cell loss in hallucinating Parkinson disease 
197 
 
patients but not in dementia with Lewy bodies patients', J Neuropathol Exp Neurol, 72(12), pp. 1162-
70. 
Herculano-Houzel, S., von Bartheld, C.S., Miller, D.J. and Kaas, J.H. (2015) 'How to count cells: the 
advantages and disadvantages of the isotropic fractionator compared with stereology', Cell Tissue 
Res, 360(1), pp. 29-42. 
Hernowo, A.T., Boucard, C.C., Jansonius, N.M., Hooymans, J.M. and Cornelissen, F.W. (2011) 
'Automated morphometry of the visual pathway in primary open-angle glaucoma', Invest 
Ophthalmol Vis Sci, 52(5), pp. 2758-66. 
Herva, M.E. and Spillantini, M.G. (2015) 'Parkinson's disease as a member of Prion-like disorders', 
Virus Res, 207, pp. 38-46. 
Hickey, T.L. and Guillery, R.W. (1979) 'Variability of laminar patterns in the human lateral geniculate 
nucleus', J Comp Neurol, 183(2), pp. 221-46. 
Higashi, S., Iseki, E., Yamamoto, R., Minegishi, M., Hino, H., Fujisawa, K., Togo, T., Katsuse, O., 
Uchikado, H., Furukawa, Y., Kosaka, K. and Arai, H. (2007) 'Concurrence of TDP-43, tau and alpha-
synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies', Brain Res, 
1184, pp. 284-94. 
Highley, J.R., Walker, M.A., Crow, T.J., Esiri, M.M. and Harrison, P.J. (2003) 'Low medial and lateral 
right pulvinar volumes in schizophrenia: a postmortem study', Am J Psychiatry, 160(6), pp. 1177-9. 
Hirai, T. and Jones, E.G. (1989) 'A new parcellation of the human thalamus on the basis of 
histochemical staining', Brain Res Brain Res Rev, 14(1), pp. 1-34. 
Ho, C.Y., Troncoso, J.C., Knox, D., Stark, W. and Eberhart, C.G. (2014) 'Beta-Amyloid, Phospho-Tau 
and Alpha-Synuclein Deposits Similar to Those in the Brain Are Not Identified in the Eyes of 
Alzheimer's and Parkinson's Disease Patients', Brain Pathology, 24(1), pp. 25-32. 
Hof, P.R. and Morrison, J.H. (1990) 'Quantitative analysis of a vulnerable subset of pyramidal 
neurons in Alzheimer's disease: II. Primary and secondary visual cortex', J Comp Neurol, 301(1), pp. 
55-64. 
Hofbauer, A. and Drager, U.C. (1985) 'Depth segregation of retinal ganglion cells projecting to mouse 
superior colliculus', J Comp Neurol, 234(4), pp. 465-74. 
Holers, V.M. (2014) 'Complement and its receptors: new insights into human disease', Annu Rev 
Immunol, 32, pp. 433-59. 
Howlett, D.R., Whitfield, D., Johnson, M., Attems, J., O'Brien, J.T., Aarsland, D., Lai, M.K., Lee, J.H., 
Chen, C., Ballard, C., Hortobagyi, T. and Francis, P.T. (2015) 'Regional Multiple Pathology Scores Are 
Associated with Cognitive Decline in Lewy Body Dementias', Brain Pathol, 25(4), pp. 401-8. 
Hudspeth, A.J., Jessell, T.M., Kandel, E.R., Schwartz, J.H. and Siegelbaum, S.A. (2013) Principles of 
neural science. 
Hugo, J. and Ganguli, M. (2014) 'Dementia and cognitive impairment: epidemiology, diagnosis, and 
treatment', Clin Geriatr Med, 30(3), pp. 421-42. 
Hunt, C.A., Schenker, L.J. and Kennedy, M.B. (1996) 'PSD-95 is associated with the postsynaptic 
density and not with the presynaptic membrane at forebrain synapses', J Neurosci, 16(4), pp. 1380-8. 
Hurd, M.D., Martorell, P., Delavande, A., Mullen, K.J. and Langa, K.M. (2013) 'Monetary costs of 
dementia in the United States', New England Journal of Medicine, 368(14), pp. 1326-1334. 
Hyman, B.T., Phelps, C.H., Beach, T.G., Bigio, E.H., Cairns, N.J., Carrillo, M.C., Dickson, D.W., 
Duyckaerts, C., Frosch, M.P., Masliah, E., Mirra, S.S., Nelson, P.T., Schneider, J.A., Thal, D.R., Thies, B., 
Trojanowski, J.Q., Vinters, H.V. and Montine, T.J. (2012) 'National Institute on Aging-Alzheimer's 
Association guidelines for the neuropathologic assessment of Alzheimer's disease', Alzheimers & 
Dementia, 8(1), pp. 1-13. 
Imamura, T., Ishii, K., Hirono, N., Hashimoto, M., Tanimukai, S., Kazuai, H., Hanihara, T., Sasaki, M. 
and Mori, E. (1999) 'Visual hallucinations and regional cerebral metabolism in dementia with Lewy 
bodies (DLB)', Neuroreport, 10(9), pp. 1903-7. 
Imamura, T., Ishii, K., Sasaki, M., Kitagaki, H., Yamaji, S., Hirono, N., Shimomura, T., Hashimoto, M., 
Tanimukai, S., Kazui, H. and Mori, E. (1997) 'Regional cerebral glucose metabolism in dementia with 
198 
 
Lewy bodies and Alzheimer's disease: a comparative study using positron emission tomography', 
Neurosci Lett, 235(1-2), pp. 49-52. 
Inayat, S., Barchini, J., Chen, H., Feng, L., Liu, X. and Cang, J. (2015) 'Neurons in the most superficial 
lamina of the mouse superior colliculus are highly selective for stimulus direction', J Neurosci, 35(20), 
pp. 7992-8003. 
Irwin, D.J. (2016) 'Tauopathies as clinicopathological entities', Parkinsonism Relat Disord, 22 Suppl 1, 
pp. S29-33. 
Isa, T. and Hall, W.C. (2009) 'Exploring the superior colliculus in vitro', J Neurophysiol, 102(5), pp. 
2581-93. 
Ishii, K., Hosokawa, C., Hyodo, T., Sakaguchi, K., Usami, K., Shimamoto, K., Hosono, M., Yamazoe, Y. 
and Murakami, T. (2015) 'Regional glucose metabolic reduction in dementia with Lewy bodies is 
independent of amyloid deposition', Ann Nucl Med, 29(1), pp. 78-83. 
Ishii, K., Imamura, T., Sasaki, M., Yamaji, S., Sakamoto, S., Kitagaki, H., Hashimoto, M., Hirono, N., 
Shimomura, T. and Mori, E. (1998) 'Regional cerebral glucose metabolism in dementia with Lewy 
bodies and Alzheimer's disease', Neurology, 51(1), pp. 125-30. 
Ishiki, A., Kamada, M., Kawamura, Y., Terao, C., Shimoda, F., Tomita, N., Arai, H. and Furukawa, K. 
(2016) 'Glial fibrillar acidic protein in the cerebrospinal fluid of Alzheimer's disease, dementia with 
Lewy bodies, and frontotemporal lobar degeneration', J Neurochem, 136(2), pp. 258-61. 
Jahn, R., Schiebler, W., Ouimet, C. and Greengard, P. (1985) 'A 38,000-dalton membrane protein 
(p38) present in synaptic vesicles', Proc Natl Acad Sci U S A, 82(12), pp. 4137-41. 
Janelidze, S., Hertze, J., Zetterberg, H., Landqvist Waldo, M., Santillo, A., Blennow, K. and Hansson, O. 
(2016) 'Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer's disease', Ann Clin 
Transl Neurol, 3(1), pp. 12-20. 
Janzen, J., van 't Ent, D., Lemstra, A.W., Berendse, H.W., Barkhof, F. and Foncke, E.M. (2012) 'The 
pedunculopontine nucleus is related to visual hallucinations in Parkinson's disease: preliminary 
results of a voxel-based morphometry study', J Neurol, 259(1), pp. 147-54. 
Jayakumar, J., Dreher, B. and Vidyasagar, T.R. (2013) 'Tracking blue cone signals in the primate brain', 
Clin Exp Optom, 96(3), pp. 259-66. 
Jeffries, A.M., Killian, N.J. and Pezaris, J.S. (2014) 'Mapping the primate lateral geniculate nucleus: a 
review of experiments and methods', J Physiol Paris, 108(1), pp. 3-10. 
Jellinger, K., Danielczyk, W., Fischer, P. and Gabriel, E. (1990) 'Clinicopathological analysis of 
dementia disorders in the elderly', J Neurol Sci, 95(3), pp. 239-58. 
Jellinger, K.A. (2003) 'Neuropathological spectrum of synucleinopathies', Mov Disord, 18 Suppl 6, pp. 
S2-12. 
Jellinger, K.A. and Attems, J. (2007) 'Neuropathological evaluation of mixed dementia', J Neurol Sci, 
257(1-2), pp. 80-7. 
Jellinger, K.A. and Attems, J. (2008) 'Prevalence and impact of vascular and Alzheimer pathologies in 
Lewy body disease', Acta Neuropathol, 115(4), pp. 427-36. 
Jellinger, K.A. and Attems, J. (2015) 'Challenges of multimorbidity of the aging brain: a critical 
update', J Neural Transm (Vienna), 122(4), pp. 505-21. 
Jembrek, M.J. and Vlainic, J. (2015) 'GABA Receptors: Pharmacological Potential and Pitfalls', Curr 
Pharm Des, 21(34), pp. 4943-59. 
Johansen, J.S., Stoltenberg, M., Hansen, M., Florescu, A., Horslev-Petersen, K., Lorenzen, I. and Price, 
P.A. (1999) 'Serum YKL-40 concentrations in patients with rheumatoid arthritis: relation to disease 
activity', Rheumatology (Oxford), 38(7), pp. 618-26. 
Jones, E.G. (1998) 'A new view of specific and nonspecific thalamocortical connections', Adv Neurol, 
77, pp. 49-71; discussion 72-3. 
Jones, E.G. (2007) The Thalamus. Second edn. Cambridge: Cambridge University Press. 
Jones, E.G. (2012) The thalamus. Springer Science & Business Media. 
Jones, E.G. and Hendry, S.H. (1989) 'Differential Calcium Binding Protein Immunoreactivity 
Distinguishes Classes of Relay Neurons in Monkey Thalamic Nuclei', Eur J Neurosci, 1(3), pp. 222-246. 
199 
 
Jones, E.G., Wise, S.P. and Coulter, J.D. (1979) 'Differential thalamic relationships of sensory-motor 
and parietal cortical fields in monkeys', J Comp Neurol, 183(4), pp. 833-81. 
Jorm, A.F. and Jolley, D. (1998) 'The incidence of dementia: a meta-analysis', Neurology, 51(3), pp. 
728-33. 
Josephs, K.A., Murray, M.E., Whitwell, J.L., Parisi, J.E., Petrucelli, L., Jack, C.R., Petersen, R.C. and 
Dickson, D.W. (2014) 'Staging TDP-43 pathology in Alzheimer's disease', Acta Neuropathol, 127(3), 
pp. 441-50. 
Josephs, K.A., Murray, M.E., Whitwell, J.L., Tosakulwong, N., Weigand, S.D., Petrucelli, L., Liesinger, 
A.M., Petersen, R.C., Parisi, J.E. and Dickson, D.W. (2016) 'Updated TDP-43 in Alzheimer's disease 
staging scheme', Acta Neuropathol, 131(4), pp. 571-85. 
Josephson, S.A. and Kirsch, H.E. (2006) 'Complex visual hallucinations as post-ictal cortical release 
phenomena', Neurocase, 12(2), pp. 107-10. 
Kaas, J.H. and Lyon, D.C. (2007) 'Pulvinar contributions to the dorsal and ventral streams of visual 
processing in primates', Brain Res Rev, 55(2), pp. 285-96. 
Kalia, L.V. and Kalia, S.K. (2015) 'alpha-Synuclein and Lewy pathology in Parkinson's disease', Curr 
Opin Neurol, 28(4), pp. 375-81. 
Kantarci, K., Avula, R., Senjem, M.L., Samikoglu, A.R., Zhang, B., Weigand, S.D., Przybelski, S.A., 
Edmonson, H.A., Vemuri, P., Knopman, D.S., Ferman, T.J., Boeve, B.F., Petersen, R.C. and Jack, C.R., Jr. 
(2010) 'Dementia with Lewy bodies and Alzheimer disease: neurodegenerative patterns 
characterized by DTI', Neurology, 74(22), pp. 1814-21. 
Kao, A.W., Racine, C.A., Quitania, L.C., Kramer, J.H., Christine, C.W. and Miller, B.L. (2009) 'Cognitive 
and neuropsychiatric profile of the synucleinopathies: Parkinson disease, dementia with Lewy bodies, 
and multiple system atrophy', Alzheimer Dis Assoc Disord, 23(4), pp. 365-70. 
Karnath, H.O., Himmelbach, M. and Rorden, C. (2002) 'The subcortical anatomy of human spatial 
neglect: putamen, caudate nucleus and pulvinar', Brain, 125(Pt 2), pp. 350-60. 
Kasai, T., Tokuda, T., Yamaguchi, N., Watanabe, Y., Kametani, F., Nakagawa, M. and Mizuno, T. (2008) 
'Cleavage of normal and pathological forms of alpha-synuclein by neurosin in vitro', Neurosci Lett, 
436(1), pp. 52-6. 
Kastner, S., O'Connor, D.H., Fukui, M.M., Fehd, H.M., Herwig, U. and Pinsk, M.A. (2004) 'Functional 
imaging of the human lateral geniculate nucleus and pulvinar', J Neurophysiol, 91(1), pp. 438-48. 
Keith, D. and El-Husseini, A. (2008) 'Excitation Control: Balancing PSD-95 Function at the Synapse', 
Front Mol Neurosci, 1, p. 4. 
Kemper, C. and Atkinson, J.P. (2007) 'T-cell regulation: with complements from innate immunity', 
Nat Rev Immunol, 7(1), pp. 9-18. 
Khundakar, A., Morris, C., Oakley, A., McMeekin, W. and Thomas, A.J. (2009) 'Morphometric analysis 
of neuronal and glial cell pathology in the dorsolateral prefrontal cortex in late-life depression', Br J 
Psychiatry, 195(2), pp. 163-9. 
Khundakar, A.A., Hanson, P.S., Erskine, D., Lax, N.Z., Roscamp, J., Karyka, E., Tsefou, E., Singh, P., 
Cockell, S.J., Gribben, A., Ramsay, L., Blain, P.G., Mosimann, U.P., Lett, D.J., Elstner, M., Turnbull, 
D.M., Xiang, C.C., Brownstein, M.J., O'Brien, J.T., Taylor, J.P., Attems, J., Thomas, A.J., McKeith, I.G. 
and Morris, C.M. (2016) 'Analysis of primary visual cortex in dementia with Lewy bodies indicates 
GABAergic involvement associated with recurrent complex visual hallucinations', Acta Neuropathol 
Commun, 4(1), p. 66. 
Kim, H.J., Jeon, B.S. and Jellinger, K.A. (2015) 'Diagnosis and differential diagnosis of MSA: boundary 
issues', J Neurol, 262(8), pp. 1801-13. 
Kim, H.J., Lee, J.E., Shin, S.J., Sohn, Y.H. and Lee, P.H. (2011) 'Analysis of the substantia innominata 
volume in patients with Parkinson's disease with dementia, dementia with lewy bodies, and 
Alzheimer's disease', J Mov Disord, 4(2), pp. 68-72. 
Kneussel, M., Haverkamp, S., Fuhrmann, J.C., Wang, H., Wassle, H., Olsen, R.W. and Betz, H. (2000) 
'The gamma-aminobutyric acid type A receptor (GABAAR)-associated protein GABARAP interacts 
200 
 
with gephyrin but is not involved in receptor anchoring at the synapse', Proc Natl Acad Sci U S A, 
97(15), pp. 8594-9. 
Knopman, D.S., Parisi, J.E., Salviati, A., Floriach-Robert, M., Boeve, B.F., Ivnik, R.J., Smith, G.E., 
Dickson, D.W., Johnson, K.A., Petersen, L.E., McDonald, W.C., Braak, H. and Petersen, R.C. (2003) 
'Neuropathology of cognitively normal elderly', J Neuropathol Exp Neurol, 62(11), pp. 1087-95. 
Kodama, T. and Honda, Y. (1996) 'Acetylcholine releases of mesopontine PGO-on cells in the lateral 
geniculate nucleus in sleep-waking cycle and serotonergic regulation', Prog Neuropsychopharmacol 
Biol Psychiatry, 20(7), pp. 1213-27. 
Kovacs, G.G., Alafuzoff, I., Al-Sarraj, S., Arzberger, T., Bogdanovic, N., Capellari, S., Ferrer, I., Gelpi, E., 
Kovari, V., Kretzschmar, H., Nagy, Z., Parchi, P., Seilhean, D., Soininen, H., Troakes, C. and Budka, H. 
(2008) 'Mixed brain pathologies in dementia: the BrainNet Europe consortium experience', Dement 
Geriatr Cogn Disord, 26(4), pp. 343-50. 
Kovacs, G.G., Wagner, U., Dumont, B., Pikkarainen, M., Osman, A.A., Streichenberger, N., Leisser, I., 
Verchere, J., Baron, T., Alafuzoff, I., Budka, H., Perret-Liaudet, A. and Lachmann, I. (2012) 'An 
antibody with high reactivity for disease-associated alpha-synuclein reveals extensive brain 
pathology', Acta Neuropathol, 124(1), pp. 37-50. 
Kovari, E., Horvath, J. and Bouras, C. (2009) 'Neuropathology of Lewy body disorders', Brain Res Bull, 
80(4-5), pp. 203-10. 
Krauzlis, R. and Dill, N. (2002) 'Neural correlates of target choice for pursuit and saccades in the 
primate superior colliculus', Neuron, 35(2), pp. 355-63. 
Krauzlis, R.J., Lovejoy, L.P. and Zenon, A. (2013) 'Superior colliculus and visual spatial attention', 
Annu Rev Neurosci, 36, pp. 165-82. 
Kromer, R., Buhmann, C., Hidding, U., Keseru, M., Keseru, D., Hassenstein, A. and Stemplewitz, B. 
(2016) 'Evaluation of Retinal Vessel Morphology in Patients with Parkinson's Disease Using Optical 
Coherence Tomography', PLoS One, 11(8), p. e0161136. 
Kruger, R., Vieira-Saecker, A.M., Kuhn, W., Berg, D., Muller, T., Kuhnl, N., Fuchs, G.A., Storch, A., 
Hungs, M., Woitalla, D., Przuntek, H., Epplen, J.T., Schols, L. and Riess, O. (1999) 'Increased 
susceptibility to sporadic Parkinson's disease by a certain combined alpha-synuclein/apolipoprotein 
E genotype', Ann Neurol, 45(5), pp. 611-7. 
Kuljis, R.O. (1994) 'Lesions in the pulvinar in patients with Alzheimer's disease', J Neuropathol Exp 
Neurol, 53(2), pp. 202-11. 
Kuruva, C.S. and Reddy, P.H. (2016) 'Amyloid beta modulators and neuroprotection in Alzheimer's 
disease: a critical appraisal', Drug Discov Today. 
Kusumi, I., Boku, S. and Takahashi, Y. (2015) 'Psychopharmacology of atypical antipsychotic drugs: 
From the receptor binding profile to neuroprotection and neurogenesis', Psychiatry Clin Neurosci, 
69(5), pp. 243-58. 
Langkammer, C., Ropele, S., Pirpamer, L., Fazekas, F. and Schmidt, R. (2014) 'MRI for iron mapping in 
Alzheimer's disease', Neurodegener Dis, 13(2-3), pp. 189-91. 
Lanyon, L.J., Giaschi, D., Young, S.A., Fitzpatrick, K., Diao, L., Bjornson, B.H. and Barton, J.J. (2009) 
'Combined functional MRI and diffusion tensor imaging analysis of visual motion pathways', J 
Neuroophthalmol, 29(2), pp. 96-103. 
Lau, C.G. and Murthy, V.N. (2012) 'Activity-dependent regulation of inhibition via GAD67', J Neurosci, 
32(25), pp. 8521-31. 
Lazarus, M.S., Krishnan, K. and Huang, Z.J. (2015) 'GAD67 deficiency in parvalbumin interneurons 
produces deficits in inhibitory transmission and network disinhibition in mouse prefrontal cortex', 
Cereb Cortex, 25(5), pp. 1290-6. 
Lazzell, D.R., Belizaire, R., Thakur, P., Sherry, D.M. and Janz, R. (2004) 'SV2B regulates synaptotagmin 
1 by direct interaction', J Biol Chem, 279(50), pp. 52124-31. 
Lee, B.B., Creutzfeldt, O.D. and Elepfandt, A. (1979) 'The responses of magno- and parvocellular cells 
of the monkey's lateral geniculate body to moving stimuli', Exp Brain Res, 35(3), pp. 547-57. 
201 
 
Lee, C.G., Da Silva, C.A., Dela Cruz, C.S., Ahangari, F., Ma, B., Kang, M.J., He, C.H., Takyar, S. and Elias, 
J.A. (2011) 'Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling, 
and injury', Annu Rev Physiol, 73, pp. 479-501. 
Lee, H.G., Jo, J., Hong, H.H., Kim, K.K., Park, J.K., Cho, S.J. and Park, C. (2016) 'State-of-the-art 
housekeeping proteins for quantitative western blotting: Revisiting the first draft of the human 
proteome', Proteomics, 16(13), pp. 1863-7. 
Lee, J.E., Park, H.J., Park, B., Song, S.K., Sohn, Y.H., Lee, J.D. and Lee, P.H. (2010) 'A comparative 
analysis of cognitive profiles and white-matter alterations using voxel-based diffusion tensor imaging 
between patients with Parkinson's disease dementia and dementia with Lewy bodies', Journal of 
Neurology Neurosurgery and Psychiatry, 81(3), pp. 320-326. 
Leuba, G. and Saini, K. (1995) 'Pathology of subcortical visual centres in relation to cortical 
degeneration in Alzheimer's disease', Neuropathol Appl Neurobiol, 21(5), pp. 410-22. 
Levi, S., Logan, S.M., Tovar, K.R. and Craig, A.M. (2004) 'Gephyrin is critical for glycine receptor 
clustering but not for the formation of functional GABAergic synapses in hippocampal neurons', J 
Neurosci, 24(1), pp. 207-17. 
Li, J.C., Sampson, G.P. and Vidyasagar, T.R. (2007) 'Interactions between luminance and colour 
channels in visual search and their relationship to parallel neural channels in vision', Exp Brain Res, 
176(3), pp. 510-8. 
Lippa, C.F., Smith, T.W. and Perry, E. (1999) 'Dementia with Lewy bodies: choline acetyltransferase 
parallels nucleus basalis pathology', J Neural Transm (Vienna), 106(5-6), pp. 525-35. 
Litvan, I., Goldman, J.G., Troster, A.I., Schmand, B.A., Weintraub, D., Petersen, R.C., Mollenhauer, B., 
Adler, C.H., Marder, K., Williams-Gray, C.H., Aarsland, D., Kulisevsky, J., Rodriguez-Oroz, M.C., Burn, 
D.J., Barker, R.A. and Emre, M. (2012) 'Diagnostic criteria for mild cognitive impairment in 
Parkinson's disease: Movement Disorder Society Task Force guidelines', Mov Disord, 27(3), pp. 349-
56. 
Lobotesis, K., Fenwick, J.D., Phipps, A., Ryman, A., Swann, A., Ballard, C., McKeith, I.G. and O'Brien, 
J.T. (2001) 'Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD', Neurology, 
56(5), pp. 643-9. 
Lopez-Valdes, H.E. and Martinez-Coria, H. (2016) 'The Role of Neuroinflammation in Age-Related 
Dementias', Rev Invest Clin, 68(1), pp. 40-8. 
Love, M.I., Huber, W. and Anders, S. (2014) 'Moderated estimation of fold change and dispersion for 
RNA-seq data with DESeq2', Genome Biol, 15(12), p. 550. 
Love, S. and Miners, J.S. (2016) 'Cerebral Hypoperfusion and the Energy Deficit in Alzheimer's 
Disease', Brain Pathology, 26(5), pp. 607-17. 
Lu, Z.L. and Dosher, B.A. (1998) 'External noise distinguishes attention mechanisms', Vision Res, 38(9), 
pp. 1183-98. 
Luck, S.J. and Gold, J.M. (2008) 'The construct of attention in schizophrenia', Biol Psychiatry, 64(1), 
pp. 34-9. 
Luco, C., Hoppe, A., Schweitzer, M., Vicuna, X. and Fantin, A. (1992) 'Visual field defects in vascular 
lesions of the lateral geniculate body', J Neurol Neurosurg Psychiatry, 55(1), pp. 12-5. 
Lysakowski, A., Standage, G.P. and Benevento, L.A. (1986) 'Histochemical and architectonic 
differentiation of zones of pretectal and collicular inputs to the pulvinar and dorsal lateral geniculate 
nuclei in the macaque', J Comp Neurol, 250(4), pp. 431-48. 
Mackenzie, I.R. (2000) 'Activated microglia in dementia with Lewy bodies', Neurology, 55(1), pp. 132-
4. 
Madras, B.K. (2013) 'History of the discovery of the antipsychotic dopamine D2 receptor: a basis for 
the dopamine hypothesis of schizophrenia', J Hist Neurosci, 22(1), pp. 62-78. 
Mai, J.K., Majtanik, M. and Paxinos, G. (2016) Atlas of the human brain. Academic Press. 
Makin, S.M., Redman, J., Mosimann, U.P., Dudley, R., Clarke, M.P., Colbourn, C. and Collerton, D. 
(2013) 'Complex visual hallucinations and attentional performance in eye disease and dementia: a 
test of the Perception and Attention Deficit model', Int J Geriatr Psychiatry, 28(12), pp. 1232-8. 
202 
 
Mandelkow, E.M. and Mandelkow, E. (2012) 'Biochemistry and cell biology of tau protein in 
neurofibrillary degeneration', Cold Spring Harb Perspect Med, 2(7), p. a006247. 
Mandler, M., Walker, L., Santic, R., Hanson, P., Upadhaya, A.R., Colloby, S.J., Morris, C.M., Thal, D.R., 
Thomas, A.J., Schneeberger, A. and Attems, J. (2014) 'Pyroglutamylated amyloid-beta is associated 
with hyperphosphorylated tau and severity of Alzheimer's disease', Acta Neuropathol, 128(1), pp. 
67-79. 
Manford, M. and Andermann, F. (1998) 'Complex visual hallucinations. Clinical and neurobiological 
insights', Brain, 121 ( Pt 10), pp. 1819-40. 
Marra, C., Quaranta, D., Profice, P., Pilato, F., Capone, F., Iodice, F., Di Lazzaro, V. and Gainotti, G. 
(2012) 'Central cholinergic dysfunction measured "in vivo" correlates with different behavioral 
disorders in Alzheimer's disease and dementia with Lewy body', Brain Stimul, 5(4), pp. 533-8. 
Martin, P.R., Blessing, E.M., Buzas, P., Szmajda, B.A. and Forte, J.D. (2011) 'Transmission of colour 
and acuity signals by parvocellular cells in marmoset monkeys', J Physiol, 589(Pt 11), pp. 2795-812. 
Masland, R.H. (2012) 'The neuronal organization of the retina', Neuron, 76(2), pp. 266-80. 
Masliah, E., Rockenstein, E., Veinbergs, I., Sagara, Y., Mallory, M., Hashimoto, M. and Mucke, L. 
(2001) 'beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a 
transgenic mouse model linking Alzheimer's disease and Parkinson's disease', Proc Natl Acad Sci U S 
A, 98(21), pp. 12245-50. 
Maurage, C.A., Ruchoux, M.M., de Vos, R., Surguchov, A. and Destee, A. (2003) 'Retinal involvement 
in dementia with Lewy bodies: a clue to hallucinations?', Ann Neurol, 54(4), pp. 542-7. 
May, P.J. (2006) 'The mammalian superior colliculus: laminar structure and connections', Prog Brain 
Res, 151, pp. 321-78. 
Mazoyer, B., Zago, L., Mellet, E., Bricogne, S., Etard, O., Houde, O., Crivello, F., Joliot, M., Petit, L. and 
Tzourio-Mazoyer, N. (2001) 'Cortical networks for working memory and executive functions sustain 
the conscious resting state in man', Brain Res Bull, 54(3), pp. 287-98. 
McAleese, K.E., Walker, L., Erskine, D., Thomas, A.J., McKeith, I.G. and Attems, J. (2016) 'TDP-43 
pathology in Alzheimer's disease, dementia with Lewy bodies and ageing', Brain Pathol. 
McCann, H., Cartwright, H. and Halliday, G.M. (2016) 'Neuropathology of alpha-synuclein 
propagation and braak hypothesis', Mov Disord, 31(2), pp. 152-60. 
McKeith, I., Fairbairn, A., Perry, R., Thompson, P. and Perry, E. (1992) 'Neuroleptic sensitivity in 
patients with senile dementia of Lewy body type', Bmj, 305(6855), pp. 673-8. 
McKeith, I., Mintzer, J., Aarsland, D., Burn, D., Chiu, H., Cohen-Mansfield, J., Dickson, D., Dubois, B., 
Duda, J.E., Feldman, H., Gauthier, S., Halliday, G., Lawlor, B., Lippa, C., Lopez, O.L., Carlos Machado, J., 
O'Brien, J., Playfer, J., Reid, W. and International Psychogeriatric Association Expert Meeting on, 
D.L.B. (2004) 'Dementia with Lewy bodies', Lancet Neurol, 3(1), pp. 19-28. 
McKeith, I., O'Brien, J., Walker, Z., Tatsch, K., Booij, J., Darcourt, J., Padovani, A., Giubbini, R., 
Bonuccelli, U., Volterrani, D., Holmes, C., Kemp, P., Tabet, N., Meyer, I. and Reininger, C. (2007) 
'Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with 
Lewy bodies: a phase III, multicentre study', Lancet Neurol, 6(4), pp. 305-13. 
McKeith, I., Taylor, J.P., Thomas, A., Donaghy, P. and Kane, J. (2016) 'Revisiting DLB Diagnosis: A 
Consideration of Prodromal DLB and of the Diagnostic Overlap With Alzheimer Disease', J Geriatr 
Psychiatry Neurol, 29(5), pp. 249-53. 
McKeith, I.G. (2000) 'Clinical Lewy body syndromes', Ann N Y Acad Sci, 920, pp. 1-8. 
McKeith, I.G. (2006) 'Consensus guidelines for the clinical and pathologic diagnosis of dementia with 
Lewy bodies (DLB): report of the Consortium on DLB International Workshop', J Alzheimers Dis, 9(3 
Suppl), pp. 417-23. 
McKeith, I.G., Ballard, C.G., Perry, R.H., Ince, P.G., O'Brien, J.T., Neill, D., Lowery, K., Jaros, E., Barber, 
R., Thompson, P., Swann, A., Fairbairn, A.F. and Perry, E.K. (2000) 'Prospective validation of 
consensus criteria for the diagnosis of dementia with Lewy bodies', Neurology, 54(5), pp. 1050-8. 
McKeith, I.G., Dickson, D.W., Lowe, J., Emre, M., O'Brien, J.T., Feldman, H., Cummings, J., Duda, J.E., 
Lippa, C., Perry, E.K., Aarsland, D., Arai, H., Ballard, C.G., Boeve, B., Burn, D.J., Costa, D., Del Ser, T., 
203 
 
Dubois, B., Galasko, D., Gauthier, S., Goetz, C.G., Gomez-Tortosa, E., Halliday, G., Hansen, L.A., Hardy, 
J., Iwatsubo, T., Kalaria, R.N., Kaufer, D., Kenny, R.A., Korczyn, A., Kosaka, K., Lee, V.M., Lees, A., 
Litvan, I., Londos, E., Lopez, O.L., Minoshima, S., Mizuno, Y., Molina, J.A., Mukaetova-Ladinska, E.B., 
Pasquier, F., Perry, R.H., Schulz, J.B., Trojanowski, J.Q. and Yamada, M. (2005) 'Diagnosis and 
management of dementia with Lewy bodies: third report of the DLB Consortium', Neurology, 65(12), 
pp. 1863-72. 
McKeith, I.G., Galasko, D., Kosaka, K., Perry, E.K., Dickson, D.W., Hansen, L.A., Salmon, D.P., Lowe, J., 
Mirra, S.S., Byrne, E.J., Lennox, G., Quinn, N.P., Edwardson, J.A., Ince, P.G., Bergeron, C., Burns, A., 
Miller, B.L., Lovestone, S., Collerton, D., Jansen, E.N., Ballard, C., de Vos, R.A., Wilcock, G.K., Jellinger, 
K.A. and Perry, R.H. (1996) 'Consensus guidelines for the clinical and pathologic diagnosis of 
dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop', 
Neurology, 47(5), pp. 1113-24. 
McKeith, I.G., Rowan, E., Askew, K., Naidu, A., Allan, L., Barnett, N., Lett, D., Mosimann, U.P., Burn, D. 
and O'Brien, J.T. (2006) 'More severe functional impairment in dementia with lewy bodies than 
Alzheimer disease is related to extrapyramidal motor dysfunction', Am J Geriatr Psychiatry, 14(7), pp. 
582-8. 
McKhann, G.M., Knopman, D.S., Chertkow, H., Hyman, B.T., Jack, C.R., Kawas, C.H., Klunk, W.E., 
Koroshetz, W.J., Manly, J.J., Mayeux, R., Mohs, R.C., Morris, J.C., Rossor, M.N., Scheltens, P., Carrillo, 
M.C., Thies, B., Weintraub, S. and Phelps, C.H. (2011) 'The diagnosis of dementia due to Alzheimer's 
disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups 
on diagnostic guidelines for Alzheimer's disease', Alzheimers & Dementia, 7(3), pp. 263-269. 
Mega, M.S., Lee, L., Dinov, I.D., Mishkin, F., Toga, A.W. and Cummings, J.L. (2000) 'Cerebral 
correlates of psychotic symptoms in Alzheimer's disease', J Neurol Neurosurg Psychiatry, 69(2), pp. 
167-71. 
Meppelink, A.M., Koerts, J., Borg, M., Leenders, K.L. and van Laar, T. (2008) 'Visual object recognition 
and attention in Parkinson's disease patients with visual hallucinations', Mov Disord, 23(13), pp. 
1906-12. 
Merigan, W.H. and Maunsell, J.H. (1993) 'How parallel are the primate visual pathways?', Annu Rev 
Neurosci, 16, pp. 369-402. 
Metzler-Baddeley, C., Baddeley, R.J., Lovell, P.G., Laffan, A. and Jones, R.W. (2010) 'Visual 
impairments in dementia with Lewy bodies and posterior cortical atrophy', Neuropsychology, 24(1), 
pp. 35-48. 
Middeldorp, J. and Hol, E.M. (2011) 'GFAP in health and disease', Prog Neurobiol, 93(3), pp. 421-443. 
Miners, J.S., Renfrew, R., Swirski, M. and Love, S. (2014a) 'Accumulation of alpha-synuclein in 
dementia with Lewy bodies is associated with decline in the alpha-synuclein-degrading enzymes 
kallikrein-6 and calpain-1', Acta Neuropathol Commun, 2, p. 164. 
Miners, S., Moulding, H., de Silva, R. and Love, S. (2014b) 'Reduced vascular endothelial growth 
factor and capillary density in the occipital cortex in dementia with Lewy bodies', Brain Pathol, 24(4), 
pp. 334-43. 
Minoshima, S., Foster, N.L., Sima, A.A., Frey, K.A., Albin, R.L. and Kuhl, D.E. (2001) 'Alzheimer's 
disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy 
confirmation', Ann Neurol, 50(3), pp. 358-65. 
Mondon, K., Gochard, A., Marque, A., Armand, A., Beauchamp, D., Prunier, C., Jacobi, D., de Toffol, 
B., Autret, A., Camus, V. and Hommet, C. (2007) 'Visual recognition memory differentiates dementia 
with Lewy bodies and Parkinson's disease dementia', J Neurol Neurosurg Psychiatry, 78(7), pp. 738-
41. 
Montero, V.M. (2000) 'Attentional activation of the visual thalamic reticular nucleus depends on 
'top-down' inputs from the primary visual cortex via corticogeniculate pathways', Brain Res, 864(1), 
pp. 95-104. 
Monti, J.M. (2011) 'Serotonin control of sleep-wake behavior', Sleep Med Rev, 15(4), pp. 269-81. 
204 
 
Montine, T.J., Phelps, C.H., Beach, T.G., Bigio, E.H., Cairns, N.J., Dickson, D.W., Duyckaerts, C., Frosch, 
M.P., Masliah, E., Mirra, S.S., Nelson, P.T., Schneider, J.A., Thal, D.R., Trojanowski, J.Q., Vinters, H.V. 
and Hyman, B.T. (2012) 'National Institute on Aging-Alzheimer's Association guidelines for the 
neuropathologic assessment of Alzheimer's disease: a practical approach', Acta Neuropathol, 123(1), 
pp. 1-11. 
Moon, W.J., Kim, H.J., Roh, H.G., Choi, J.W. and Han, S.H. (2012) 'Fluid-attenuated inversion recovery 
hypointensity of the pulvinar nucleus of patients with Alzheimer disease: its possible association 
with iron accumulation as evidenced by the t2(*) map', Korean J Radiol, 13(6), pp. 674-83. 
Moreno-Ramos, T., Benito-Leon, J., Villarejo, A. and Bermejo-Pareja, F. (2013) 'Retinal nerve fiber 
layer thinning in dementia associated with Parkinson's disease, dementia with Lewy bodies, and 
Alzheimer's disease', J Alzheimers Dis, 34(3), pp. 659-64. 
Morris, J.C. and Cummings, J. (2005) 'Mild cognitive impairment (MCI) represents early-stage 
Alzheimer's disease', J Alzheimers Dis, 7(3), pp. 235-9; discussion 255-62. 
Mosimann, U.P., Mather, G., Wesnes, K.A., O'Brien, J.T., Burn, D.J. and McKeith, I.G. (2004) 'Visual 
perception in Parkinson disease dementia and dementia with Lewy bodies', Neurology, 63(11), pp. 
2091-6. 
Mosimann, U.P., Muri, R.M., Burn, D.J., Felblinger, J., O'Brien, J.T. and McKeith, I.G. (2005) 'Saccadic 
eye movement changes in Parkinson's disease dementia and dementia with Lewy bodies', Brain, 
128(Pt 6), pp. 1267-76. 
Mosimann, U.P., Rowan, E.N., Partington, C.E., Collerton, D., Littlewood, E., O'Brien, J.T., Burn, D.J. 
and McKeith, I.G. (2006) 'Characteristics of visual hallucinations in Parkinson disease dementia and 
dementia with lewy bodies', Am J Geriatr Psychiatry, 14(2), pp. 153-60. 
Mouton, P.R. (2011) Unbiased stereology: a concise guide. JHU Press. 
Mouton, P.R. (2013) Neurostereology: unbiased stereology of neural systems. John Wiley & Sons. 
Mueser, K.T., Bellack, A.S. and Brady, E.U. (1990) 'Hallucinations in schizophrenia', Acta Psychiatr 
Scand, 82(1), pp. 26-9. 
Mukaetova-Ladinska, E.B., Andras, A., Milne, J., Abdel-All, Z., Borr, I., Jaros, E., Perry, R.H., Honer, 
W.G., Cleghorn, A., Doherty, J., McIntosh, G., Perry, E.K., Kalaria, R.N. and McKeith, I.G. (2013) 
'Synaptic proteins and choline acetyltransferase loss in visual cortex in dementia with Lewy bodies', J 
Neuropathol Exp Neurol, 72(1), pp. 53-60. 
Muller, J.R., Philiastides, M.G. and Newsome, W.T. (2005) 'Microstimulation of the superior colliculus 
focuses attention without moving the eyes', Proc Natl Acad Sci U S A, 102(3), pp. 524-9. 
Munhoz, R.P. and Teive, H.A. (2014) 'REM sleep behaviour disorder: how useful is it for the 
differential diagnosis of parkinsonism?', Clin Neurol Neurosurg, 127, pp. 71-4. 
Munkle, M.C., Waldvogel, H.J. and Faull, R.L. (2000) 'The distribution of calbindin, calretinin and 
parvalbumin immunoreactivity in the human thalamus', J Chem Neuroanat, 19(3), pp. 155-73. 
Murphy, N., Killen, A., Graziadio, S., Peraza-Rodriguez, L., Baker, M., Elder, G.J., Thomas, A., McKeith, 
I., Rochester, L. and Taylor, J.-P. 'Early Bottom-up Visual Information Processing in Hallucinating 
Patients with Parkinson’s Disease with Dementia: A preliminary visual evoked potential study', 
American Journal of Neurodegenerative Disease: Proceedings of the International Dementia with 
Lewy Bodies Conference 2015  
Nagahama, Y., Okina, T., Suzuki, N. and Matsuda, M. (2010) 'Neural correlates of psychotic 
symptoms in dementia with Lewy bodies', Brain, 133(Pt 2), pp. 557-67. 
Nakagawa, S. and Tanaka, S. (1984) 'Retinal projections to the pulvinar nucleus of the macaque 
monkey: a re-investigation using autoradiography', Exp Brain Res, 57(1), pp. 151-7. 
Nedelska, Z., Schwarz, C.G., Boeve, B.F., Lowe, V.J., Reid, R.I., Przybelski, S.A., Lesnick, T.G., Gunter, 
J.L., Senjem, M.L., Ferman, T.J., Smith, G.E., Geda, Y.E., Knopman, D.S., Petersen, R.C., Jack, C.R., Jr. 
and Kantarci, K. (2015) 'White matter integrity in dementia with Lewy bodies: a voxel-based analysis 
of diffusion tensor imaging', Neurobiol Aging, 36(6), pp. 2010-7. 
205 
 
Nelson, P.T., Jicha, G.A., Kryscio, R.J., Abner, E.L., Schmitt, F.A., Cooper, G., Xu, L.O., Smith, C.D. and 
Markesbery, W.R. (2010) 'Low sensitivity in clinical diagnoses of dementia with Lewy bodies', J 
Neurol, 257(3), pp. 359-66. 
Neumann, M., Adler, S., Schluter, O., Kremmer, E., Benecke, R. and Kretzschmar, H.A. (2000) 'Alpha-
synuclein accumulation in a case of neurodegeneration with brain iron accumulation type 1 (NBIA-1, 
formerly Hallervorden-Spatz syndrome) with widespread cortical and brainstem-type Lewy bodies', 
Acta Neuropathol, 100(5), pp. 568-74. 
Neuropathology Group. Medical Research Council Cognitive, F. and Aging, S. (2001) 'Pathological 
correlates of late-onset dementia in a multicentre, community-based population in England and 
Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study 
(MRC CFAS)', Lancet, 357(9251), pp. 169-75. 
Nordstrom, A.L., Farde, L., Eriksson, L. and Halldin, C. (1995) 'No elevated D2 dopamine receptors in 
neuroleptic-naive schizophrenic patients revealed by positron emission tomography and [11C]N-
methylspiperone', Psychiatry Res, 61(2), pp. 67-83. 
Normando, E.M., Davis, B.M., De Groef, L., Nizari, S., Turner, L.A., Ravindran, N., Pahlitzsch, M., 
Brenton, J., Malaguarnera, G., Guo, L., Somavarapu, S. and Cordeiro, M.F. (2016) 'The retina as an 
early biomarker of neurodegeneration in a rotenone-induced model of Parkinson's disease: evidence 
for a neuroprotective effect of rosiglitazone in the eye and brain', Acta Neuropathol Commun, 4(1), p. 
86. 
Nowacka, B., Lubinski, W., Honczarenko, K., Potemkowski, A. and Safranow, K. (2015) 'Bioelectrical 
function and structural assessment of the retina in patients with early stages of Parkinson's disease 
(PD)', Doc Ophthalmol, 131(2), pp. 95-104. 
O'Brien, J.T., Colloby, S.J., Pakrasi, S., Perry, E.K., Pimlott, S.L., Wyper, D.J., McKeith, I.G. and Williams, 
E.D. (2008) 'Nicotinic alpha4beta2 receptor binding in dementia with Lewy bodies using 123I-5IA-
85380 SPECT demonstrates a link between occipital changes and visual hallucinations', Neuroimage, 
40(3), pp. 1056-63. 
O'Connor, D.H., Fukui, M.M., Pinsk, M.A. and Kastner, S. (2002) 'Attention modulates responses in 
the human lateral geniculate nucleus', Nat Neurosci, 5(11), pp. 1203-9. 
Ogren, M. and Hendrickson, A. (1976) 'Pathways between striate cortex and subcortical regions in 
Macaca mulatta and Saimiri sciureus: evidence for a reciprocal pulvinar connection', Exp Neurol, 
53(3), pp. 780-800. 
Oikawa, T., Nonaka, T., Terada, M., Tamaoka, A., Hisanaga, S.I. and Hasegawa, M. (2016) 'alpha-
Synuclein fibrils exhibit gain-of-toxic-function, promoting tau aggregation and inhibiting microtubule 
assembly', J Biol Chem. 
Olsson, B., Constantinescu, R., Holmberg, B., Andreasen, N., Blennow, K. and Zetterberg, H. (2013) 
'The glial marker YKL-40 is decreased in synucleinopathies', Mov Disord, 28(13), pp. 1882-5. 
Onofrj, M., Taylor, J.P., Monaco, D., Franciotti, R., Anzellotti, F., Bonanni, L., Onofrj, V. and Thomas, A. 
(2013) 'Visual hallucinations in PD and Lewy body dementias: old and new hypotheses', Behav 
Neurol, 27(4), pp. 479-93. 
Pachalska, M., Bidzan, L., Bidzan, M. and Goral-Polrola, J. (2015) 'Vascular Factors and Cognitive 
Dysfunction in Alzheimer Disease', Med Sci Monit, 21, pp. 3483-9. 
Papapetropoulos, S., McCorquodale, D.S., Gonzalez, J., Jean-Gilles, L. and Mash, D.C. (2006) 'Cortical 
and amygdalar Lewy body burden in Parkinson's disease patients with visual hallucinations', 
Parkinsonism Relat Disord, 12(4), pp. 253-6. 
Paskavitz, J.F., Lippa, C.F., Hamos, J.E., Pulaski-Salo, D. and Drachman, D.A. (1995) 'Role of the 
dorsomedial nucleus of the thalamus in Alzheimer's disease', J Geriatr Psychiatry Neurol, 8(1), pp. 
32-7. 
Paslawski, W., Andreasen, M., Nielsen, S.B., Lorenzen, N., Thomsen, K., Kaspersen, J.D., Pedersen, J.S. 
and Otzen, D.E. (2014) 'High stability and cooperative unfolding of alpha-synuclein oligomers', 
Biochemistry, 53(39), pp. 6252-63. 
206 
 
Pasquier, J., Michel, B.F., Brenot-Rossi, I., Hassan-Sebbag, N., Sauvan, R. and Gastaut, J.L. (2002) 
'Value of (99m)Tc-ECD SPET for the diagnosis of dementia with Lewy bodies', Eur J Nucl Med Mol 
Imaging, 29(10), pp. 1342-8. 
Patterson, B.W., Elbert, D.L., Mawuenyega, K.G., Kasten, T., Ovod, V., Ma, S., Xiong, C., Chott, R., 
Yarasheski, K., Sigurdson, W., Zhang, L., Goate, A., Benzinger, T., Morris, J.C., Holtzman, D. and 
Bateman, R.J. (2015) 'Age and amyloid effects on human central nervous system amyloid-beta 
kinetics', Ann Neurol, 78(3), pp. 439-53. 
Paxinos, G. and Huang, X.-F. (2013) Atlas of the human brainstem. Elsevier. 
Percival, K.A., Koizumi, A., Masri, R.A., Buzas, P., Martin, P.R. and Grunert, U. (2014) 'Identification of 
a pathway from the retina to koniocellular layer K1 in the lateral geniculate nucleus of marmoset', J 
Neurosci, 34(11), pp. 3821-5. 
Perneczky, R., Drzezga, A., Boecker, H., Forstl, H., Kurz, A. and Haussermann, P. (2008) 'Cerebral 
metabolic dysfunction in patients with dementia with Lewy bodies and visual hallucinations', 
Dement Geriatr Cogn Disord, 25(6), pp. 531-8. 
Perriol, M.P., Dujardin, K., Derambure, P., Marcq, A., Bourriez, J.L., Laureau, E., Pasquier, F., Defebvre, 
L. and Destee, A. (2005) 'Disturbance of sensory filtering in dementia with Lewy bodies: comparison 
with Parkinson's disease dementia and Alzheimer's disease', J Neurol Neurosurg Psychiatry, 76(1), pp. 
106-8. 
Perry, E.K., Haroutunian, V., Davis, K.L., Levy, R., Lantos, P., Eagger, S., Honavar, M., Dean, A., 
Griffiths, M., McKeith, I.G. and et al. (1994) 'Neocortical cholinergic activities differentiate Lewy body 
dementia from classical Alzheimer's disease', Neuroreport, 5(7), pp. 747-9. 
Perry, E.K., Johnson, M., Ekonomou, A., Perry, R.H., Ballard, C. and Attems, J. (2012) 'Neurogenic 
abnormalities in Alzheimer's disease differ between stages of neurogenesis and are partly related to 
cholinergic pathology', Neurobiol Dis, 47(2), pp. 155-62. 
Perry, E.K. and Perry, R.H. (1995) 'Acetylcholine and hallucinations: disease-related compared to 
drug-induced alterations in human consciousness', Brain Cogn, 28(3), pp. 240-58. 
Perry, E.K., Smith, C.J., Court, J.A. and Perry, R.H. (1990a) 'Cholinergic nicotinic and muscarinic 
receptors in dementia of Alzheimer, Parkinson and Lewy body types', J Neural Transm Park Dis 
Dement Sect, 2(3), pp. 149-58. 
Perry, R.H., Irving, D., Blessed, G., Fairbairn, A. and Perry, E.K. (1990b) 'Senile dementia of Lewy body 
type. A clinically and neuropathologically distinct form of Lewy body dementia in the elderly', J 
Neurol Sci, 95(2), pp. 119-39. 
Perry, V.H. and Cowey, A. (1984) 'Retinal ganglion cells that project to the superior colliculus and 
pretectum in the macaque monkey', Neuroscience, 12(4), pp. 1125-37. 
Petrova, M., Mehrabian-Spasova, S., Aarsland, D., Raycheva, M. and Traykov, L. (2015) 'Clinical and 
Neuropsychological Differences between Mild Parkinson's Disease Dementia and Dementia with 
Lewy Bodies', Dement Geriatr Cogn Dis Extra, 5(2), pp. 212-20. 
Pievani, M., de Haan, W., Wu, T., Seeley, W.W. and Frisoni, G.B. (2011) 'Functional network 
disruption in the degenerative dementias', Lancet Neurol, 10(9), pp. 829-43. 
Piggott, M.A., Ballard, C.G., Dickinson, H.O., McKeith, I.G., Perry, R.H. and Perry, E.K. (2007) 'Thalamic 
D2 receptors in dementia with Lewy bodies, Parkinson's disease, and Parkinson's disease dementia', 
Int J Neuropsychopharmacol, 10(2), pp. 231-44. 
Piggott, M.A., Marshall, E.F., Thomas, N., Lloyd, S., Court, J.A., Jaros, E., Burn, D., Johnson, M., Perry, 
R.H., McKeith, I.G., Ballard, C. and Perry, E.K. (1999) 'Striatal dopaminergic markers in dementia with 
Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution', Brain, 122 ( Pt 8), pp. 
1449-68. 
Pinkhardt, E.H., Jurgens, R., Lule, D., Heimrath, J., Ludolph, A.C., Becker, W. and Kassubek, J. (2012) 
'Eye movement impairments in Parkinson's disease: possible role of extradopaminergic mechanisms', 
BMC Neurol, 12, p. 5. 
Plassman, B.L., Langa, K.M., Fisher, G.G., Heeringa, S.G., Weir, D.R., Ofstedal, M.B., Burke, J.R., Hurd, 
M.D., Potter, G.G., Rodgers, W.L., Steffens, D.C., Willis, R.J. and Wallace, R.B. (2007) 'Prevalence of 
207 
 
dementia in the United States: the aging, demographics, and memory study', Neuroepidemiology, 
29(1-2), pp. 125-32. 
Polymeropoulos, M.H., Lavedan, C., Leroy, E., Ide, S.E., Dehejia, A., Dutra, A., Pike, B., Root, H., 
Rubenstein, J., Boyer, R., Stenroos, E.S., Chandrasekharappa, S., Athanassiadou, A., Papapetropoulos, 
T., Johnson, W.G., Lazzarini, A.M., Duvoisin, R.C., Di Iorio, G., Golbe, L.I. and Nussbaum, R.L. (1997) 
'Mutation in the alpha-synuclein gene identified in families with Parkinson's disease', Science, 
276(5321), pp. 2045-7. 
Popken, G.J., Leggio, M.G., Bunney, W.E. and Jones, E.G. (2002) 'Expression of mRNAs related to the 
GABAergic and glutamatergic neurotransmitter systems in the human thalamus: normal and 
schizophrenic', Thalamus & Related Systems, 1(4), pp. 349-369. 
Postuma, R.B., Berg, D., Stern, M., Poewe, W., Olanow, C.W., Oertel, W., Obeso, J., Marek, K., Litvan, 
I., Lang, A.E., Halliday, G., Goetz, C.G., Gasser, T., Dubois, B., Chan, P., Bloem, B.R., Adler, C.H. and 
Deuschl, G. (2015) 'MDS clinical diagnostic criteria for Parkinson's disease', Mov Disord, 30(12), pp. 
1591-601. 
Pratt, W.B., Gestwicki, J.E., Osawa, Y. and Lieberman, A.P. (2015) 'Targeting Hsp90/Hsp70-based 
protein quality control for treatment of adult onset neurodegenerative diseases', Annu Rev 
Pharmacol Toxicol, 55, pp. 353-71. 
Price, J.L., Davis, P.B., Morris, J.C. and White, D.L. (1991) 'The distribution of tangles, plaques and 
related immunohistochemical markers in healthy aging and Alzheimer's disease', Neurobiol Aging, 
12(4), pp. 295-312. 
Prince, M., Guerchet, M. and Prina, M. (2013) The global impact of dementia 2013-2050. Alzheimer's 
Disease International. 
Proserpio, V. and Mahata, B. (2016) 'Single-cell technologies to study the immune system', 
Immunology, 147(2), pp. 133-40. 
Prusiner, S.B. and Kingsbury, D.T. (1985) 'Prions - Infectious Pathogens Causing the Spongiform 
Encephalopathies', Crc Critical Reviews in Clinical Neurobiology, 1(3), pp. 181-200. 
Purushothaman, G., Marion, R., Li, K. and Casagrande, V.A. (2012) 'Gating and control of primary 
visual cortex by pulvinar', Nat Neurosci, 15(6), pp. 905-12. 
Rabinovici, G.D., Jagust, W.J., Furst, A.J., Ogar, J.M., Racine, C.A., Mormino, E.C., O'Neil, J.P., Lal, R.A., 
Dronkers, N.F., Miller, B.L. and Gorno-Tempini, M.L. (2008) 'Abeta amyloid and glucose metabolism 
in three variants of primary progressive aphasia', Ann Neurol, 64(4), pp. 388-401. 
Rahimi, J. and Kovacs, G.G. (2014) 'Prevalence of mixed pathologies in the aging brain', Alzheimers 
Res Ther, 6(9), p. 82. 
Rahimi, J., Milenkovic, I. and Kovacs, G.G. (2015) 'Patterns of Tau and α-Synuclein Pathology in the 
Visual System', J Parkinsons Dis, 5(2), pp. 333-340. 
Ramakrishnan, N.A., Drescher, M.J. and Drescher, D.G. (2012) 'The SNARE complex in neuronal and 
sensory cells', Mol Cell Neurosci, 50(1), pp. 58-69. 
Ray, M., Bohr, I., McIntosh, J.M., Ballard, C., McKeith, I., Chalon, S., Guilloteau, D., Perry, R., Perry, E., 
Court, J.A. and Piggott, M. (2004) 'Involvement of alpha6/alpha3 neuronal nicotinic acetylcholine 
receptors in neuropsychiatric features of Dementia with Lewy bodies: [(125)I]-alpha-conotoxin MII 
binding in the thalamus and striatum', Neurosci Lett, 372(3), pp. 220-5. 
Reese, B.E. (2011) 'Development of the retina and optic pathway', Vision research, 51(7), pp. 613-32. 
Rehli, M., Niller, H.H., Ammon, C., Langmann, S., Schwarzfischer, L., Andreesen, R. and Krause, S.W. 
(2003) 'Transcriptional regulation of CHI3L1, a marker gene for late stages of macrophage 
differentiation', J Biol Chem, 278(45), pp. 44058-67. 
Respondek, G., Roeber, S., Kretzschmar, H., Troakes, C., Al-Sarraj, S., Gelpi, E., Gaig, C., Chiu, W.Z., 
van Swieten, J.C., Oertel, W.H. and Hoglinger, G.U. (2013) 'Accuracy of the National Institute for 
Neurological Disorders and Stroke/Society for Progressive Supranuclear Palsy and neuroprotection 
and natural history in Parkinson plus syndromes criteria for the diagnosis of progressive 
supranuclear palsy', Mov Disord, 28(4), pp. 504-9. 
208 
 
Ricci, M., Guidoni, S.V., Sepe-Monti, M., Bomboi, G., Antonini, G., Blundo, C. and Giubilei, F. (2009) 
'Clinical findings, functional abilities and caregiver distress in the early stage of dementia with Lewy 
bodies (DLB) and Alzheimer's disease (AD)', Arch Gerontol Geriatr, 49(2), pp. e101-4. 
Richard, I.H., Papka, M., Rubio, A. and Kurlan, R. (2002) 'Parkinson's disease and dementia with Lewy 
bodies: one disease or two?', Mov Disord, 17(6), pp. 1161-5. 
Rivest, S. (2009) 'Regulation of innate immune responses in the brain', Nat Rev Immunol, 9(6), pp. 
429-39. 
Rizo, J. and Xu, J. (2015) 'The Synaptic Vesicle Release Machinery', Annu Rev Biophys, 44, pp. 339-67. 
Robertson, A.D., Messner, M.A., Shirzadi, Z., Kleiner-Fisman, G., Lee, J., Hopyan, J., Lang, A.E., Black, 
S.E., MacIntosh, B.J. and Masellis, M. (2016) 'Orthostatic hypotension, cerebral hypoperfusion, and 
visuospatial deficits in Lewy body disorders', Parkinsonism Relat Disord, 22, pp. 80-6. 
Robinson, A.C., Palmer, L., Love, S., Hamard, M., Esiri, M., Ansorge, O., Lett, D., Attems, J., Morris, C., 
Troakes, C., Selvackadunco, S., King, A., Al-Sarraj, S. and Mann, D.M. (2016) 'Extended post-mortem 
delay times should not be viewed as a deterrent to the scientific investigation of human brain tissue: 
a study from the Brains for Dementia Research Network Neuropathology Study Group, UK', Acta 
Neuropathol, 132(5), pp. 753-755. 
Romanski, L.M., Giguere, M., Bates, J.F. and Goldman-Rakic, P.S. (1997) 'Topographic organization of 
medial pulvinar connections with the prefrontal cortex in the rhesus monkey', J Comp Neurol, 379(3), 
pp. 313-32. 
Rothman, J.E. (1994) 'Intracellular membrane fusion', Adv Second Messenger Phosphoprotein Res, 29, 
pp. 81-96. 
Rothman, K.J. (1990) 'No adjustments are needed for multiple comparisons', Epidemiology, 1(1), pp. 
43-6. 
Rozemuller, A.J., Eikelenboom, P., Theeuwes, J.W., Jansen Steur, E.N. and de Vos, R.A. (2000) 
'Activated microglial cells and complement factors are unrelated to cortical Lewy bodies', Acta 
Neuropathol, 100(6), pp. 701-8. 
Rub, U., Del Tredici, K., Schultz, C., Ghebremedhin, E., de Vos, R.A., Jansen Steur, E. and Braak, H. 
(2002) 'Parkinson's disease: the thalamic components of the limbic loop are severely impaired by 
alpha-synuclein immunopositive inclusion body pathology', Neurobiol Aging, 23(2), pp. 245-54. 
Rub, U., Del Tredici, K., Schultz, C., Thal, D.R., Braak, E. and Braak, H. (2000) 'The evolution of 
Alzheimer's disease-related cytoskeletal pathology in the human raphe nuclei', Neuropathol Appl 
Neurobiol, 26(6), pp. 553-67. 
Ruffmann, C., Calboli, F.C., Bravi, I., Gveric, D., Curry, L.K., de Smith, A., Pavlou, S., Buxton, J.L., 
Blakemore, A.I., Takousis, P., Molloy, S., Piccini, P., Dexter, D.T., Roncaroli, F., Gentleman, S.M. and 
Middleton, L.T. (2016) 'Cortical Lewy bodies and Abeta burden are associated with prevalence and 
timing of dementia in Lewy body diseases', Neuropathol Appl Neurobiol, 42(5), pp. 436-50. 
Rye, D.B. (1997) 'Contributions of the pedunculopontine region to normal and altered REM sleep', 
Sleep, 20(9), pp. 757-88. 
Saalmann, Y.B., Pinsk, M.A., Wang, L., Li, X. and Kastner, S. (2012) 'The Pulvinar Regulates 
Information Transmission Between Cortical Areas Based on Attention Demands', Science, 337(6095), 
pp. 753-756. 
Saenz, A., Doe de Maindreville, A., Henry, A., de Labbey, S., Bakchine, S. and Ehrle, N. (2013) 
'Recognition of facial and musical emotions in Parkinson's disease', Eur J Neurol, 20(3), pp. 571-7. 
Saito, Y., Kawai, M., Inoue, K., Sasaki, R., Arai, H., Nanba, E., Kuzuhara, S., Ihara, Y., Kanazawa, I. and 
Murayama, S. (2000) 'Widespread expression of alpha-synuclein and tau immunoreactivity in 
Hallervorden-Spatz syndrome with protracted clinical course', J Neurol Sci, 177(1), pp. 48-59. 
Saito, Y., Ruberu, N.N., Sawabe, M., Arai, T., Kazama, H., Hosoi, T., Yamanouchi, H. and Murayama, S. 
(2004) 'Lewy body-related alpha-synucleinopathy in aging', J Neuropathol Exp Neurol, 63(7), pp. 742-
9. 
209 
 
Sartucci, F., Borghetti, D., Bocci, T., Murri, L., Orsini, P., Porciatti, V., Origlia, N. and Domenici, L. 
(2010) 'Dysfunction of the magnocellular stream in Alzheimer's disease evaluated by pattern 
electroretinograms and visual evoked potentials', Brain Res Bull, 82(3-4), pp. 169-76. 
Sato, T., Hanyu, H., Hirao, K., Shimizu, S., Kanetaka, H. and Iwamoto, T. (2007) 'Deep gray matter 
hyperperfusion with occipital hypoperfusion in dementia with Lewy bodies', Eur J Neurol, 14(11), pp. 
1299-301. 
Schall, J.D. (1995) 'Neural basis of saccade target selection', Rev Neurosci, 6(1), pp. 63-85. 
Scharre, D.W., Chang, S.I., Nagaraja, H.N., Park, A., Adeli, A., Agrawal, P., Kloos, A., Kegelmeyer, D., 
Linder, S., Fritz, N., Kostyk, S.K. and Kataki, M. (2016) 'Paired Studies Comparing Clinical Profiles of 
Lewy Body Dementia with Alzheimer's and Parkinson's Diseases', J Alzheimers Dis, 54(3), pp. 995-
1004. 
Schmeichel, A.M., Buchhalter, L.C., Low, P.A., Parisi, J.E., Boeve, B.W., Sandroni, P. and Benarroch, 
E.E. (2008) 'Mesopontine cholinergic neuron involvement in Lewy body dementia and multiple 
system atrophy', Neurology, 70(5), pp. 368-73. 
Schmid, M.C., Mrowka, S.W., Turchi, J., Saunders, R.C., Wilke, M., Peters, A.J., Ye, F.Q. and Leopold, 
D.A. (2010) 'Blindsight depends on the lateral geniculate nucleus', Nature, 466(7304), pp. 373-7. 
Schneider, J.A., Arvanitakis, Z., Bang, W. and Bennett, D.A. (2007) 'Mixed brain pathologies account 
for most dementia cases in community-dwelling older persons', Neurology, 69(24), pp. 2197-204. 
Schneider, K.A. and Kastner, S. (2009) 'Effects of sustained spatial attention in the human lateral 
geniculate nucleus and superior colliculus', J Neurosci, 29(6), pp. 1784-95. 
Seidel, K., Mahlke, J., Siswanto, S., Kruger, R., Heinsen, H., Auburger, G., Bouzrou, M., Grinberg, L.T., 
Wicht, H., Korf, H.W., den Dunnen, W. and Rub, U. (2015) 'The brainstem pathologies of Parkinson's 
disease and dementia with Lewy bodies', Brain Pathology, 25(2), pp. 121-35. 
Selemon, L.D. and Begovic, A. (2007) 'Stereologic analysis of the lateral geniculate nucleus of the 
thalamus in normal and schizophrenic subjects', Psychiatry Res, 151(1-2), pp. 1-10. 
Sharma, M., Burre, J. and Sudhof, T.C. (2011) 'CSPalpha promotes SNARE-complex assembly by 
chaperoning SNAP-25 during synaptic activity', Nat Cell Biol, 13(1), pp. 30-9. 
Sherk, H. (1979) 'Connections and visual-field mapping in cat's tectoparabigeminal circuit', J 
Neurophysiol, 42(6), pp. 1656-68. 
Sherman, M.Y. and Goldberg, A.L. (2001) 'Cellular defenses against unfolded proteins: a cell biologist 
thinks about neurodegenerative diseases', Neuron, 29(1), pp. 15-32. 
Shimizu, S., Hanyu, H., Hirao, K., Sato, T., Iwamoto, T. and Koizumi, K. (2008) 'Value of analyzing deep 
gray matter and occipital lobe perfusion to differentiate dementia with Lewy bodies from 
Alzheimer's disease', Ann Nucl Med, 22(10), pp. 911-6. 
Shine, J.M., Halliday, G.M., Naismith, S.L. and Lewis, S.J. (2011) 'Visual misperceptions and 
hallucinations in Parkinson's disease: dysfunction of attentional control networks?', Mov Disord, 
26(12), pp. 2154-9. 
Shine, J.M., O'Callaghan, C., Halliday, G.M. and Lewis, S.J. (2014) 'Tricks of the mind: Visual 
hallucinations as disorders of attention', Prog Neurobiol, 116, pp. 58-65. 
Shipp, S. (2003) 'The functional logic of cortico-pulvinar connections', Philos Trans R Soc Lond B Biol 
Sci, 358(1438), pp. 1605-24. 
Sierra, M., Gelpi, E., Marti, M.J. and Compta, Y. (2016) 'Lewy- and Alzheimer-type pathologies in 
midbrain and cerebellum across the Lewy body disorders spectrum', Neuropathol Appl Neurobiol, 
42(5), pp. 451-62. 
Siew, L.K., Love, S., Dawbarn, D., Wilcock, G.K. and Allen, S.J. (2004) 'Measurement of pre- and post-
synaptic proteins in cerebral cortex: effects of post-mortem delay', J Neurosci Methods, 139(2), pp. 
153-9. 
Silva, M.F., Faria, P., Regateiro, F.S., Forjaz, V., Januario, C., Freire, A. and Castelo-Branco, M. (2005) 
'Independent patterns of damage within magno-, parvo- and koniocellular pathways in Parkinson's 
disease', Brain, 128(Pt 10), pp. 2260-71. 
210 
 
Sincich, L.C., Park, K.F., Wohlgemuth, M.J. and Horton, J.C. (2004) 'Bypassing V1: a direct geniculate 
input to area MT', Nat Neurosci, 7(10), pp. 1123-8. 
Sinclair, L.I., Tayler, H.M. and Love, S. (2015) 'Synaptic protein levels altered in vascular dementia', 
Neuropathol Appl Neurobiol, 41(4), pp. 533-43. 
Soares, J.G., Gattass, R., Souza, A.P., Rosa, M.G., Fiorani, M., Jr. and Brandao, B.L. (2001) 
'Connectional and neurochemical subdivisions of the pulvinar in Cebus monkeys', Vis Neurosci, 18(1), 
pp. 25-41. 
Sofroniew, M.V. (2009) 'Molecular dissection of reactive astrogliosis and glial scar formation', Trends 
Neurosci, 32(12), pp. 638-47. 
Sommer, M.A. and Wurtz, R.H. (2004) 'What the brain stem tells the frontal cortex. I. Oculomotor 
signals sent from superior colliculus to frontal eye field via mediodorsal thalamus', J Neurophysiol, 
91(3), pp. 1381-402. 
Sosa-Ortiz, A.L., Acosta-Castillo, I. and Prince, M.J. (2012) 'Epidemiology of dementias and 
Alzheimer's disease', Arch Med Res, 43(8), pp. 600-8. 
Sparks, D.L. (1999) 'Conceptual issues related to the role of the superior colliculus in the control of 
gaze', Curr Opin Neurobiol, 9(6), pp. 698-707. 
Sparks, D.L. and Hartwich-Young, R. (1989) 'The deep layers of the superior colliculus', Rev Oculomot 
Res, 3, pp. 213-255. 
Spillantini, M.G., Schmidt, M.L., Lee, V.M., Trojanowski, J.Q., Jakes, R. and Goedert, M. (1997) 'Alpha-
synuclein in Lewy bodies', Nature, 388(6645), pp. 839-40. 
Sprague, J.M. (1966) 'Interaction of cortex and superior colliculus in mediation of visually guided 
behavior in the cat', Science, 153(3743), pp. 1544-7. 
Sprengelmeyer, R., Young, A.W., Mahn, K., Schroeder, U., Woitalla, D., Buttner, T., Kuhn, W. and 
Przuntek, H. (2003) 'Facial expression recognition in people with medicated and unmedicated 
Parkinson's disease', Neuropsychologia, 41(8), pp. 1047-1057. 
Stepniewska, I., Qi, H.X. and Kaas, J.H. (1999) 'Do superior colliculus projection zones in the inferior 
pulvinar project to MT in primates?', Eur J Neurosci, 11(2), pp. 469-80. 
Stepniewska, I., Ql, H.X. and Kaas, J.H. (2000) 'Projections of the superior colliculus to subdivisions of 
the inferior pulvinar in New World and Old World monkeys', Vis Neurosci, 17(4), pp. 529-49. 
Steriade, M. (1996) 'Arousal: revisiting the reticular activating system', Science, 272(5259), pp. 225-6. 
Steriade M, J.E., McCormick DA (1997) Thalamus. Oxford: Elsevier. 
Stoerig, P. and Cowey, A. (1997) 'Blindsight in man and monkey', Brain, 120 ( Pt 3), pp. 535-59. 
Streiner, D.L. and Norman, G.R. (2011) 'Correction for multiple testing: is there a resolution?', Chest, 
140(1), pp. 16-8. 
Sudhof, T.C. (2004) 'The synaptic vesicle cycle', Annu Rev Neurosci, 27, pp. 509-47. 
Sudhof, T.C. (2013) 'Neurotransmitter release: the last millisecond in the life of a synaptic vesicle', 
Neuron, 80(3), pp. 675-90. 
Sutton, R.B., Fasshauer, D., Jahn, R. and Brunger, A.T. (1998) 'Crystal structure of a SNARE complex 
involved in synaptic exocytosis at 2.4 A resolution', Nature, 395(6700), pp. 347-53. 
Taipa, R., Pinho, J. and Melo-Pires, M. (2012) 'Clinico-pathological correlations of the most common 
neurodegenerative dementias', Front Neurol, 3, p. 68. 
Tamietto, M. and de Gelder, B. (2010) 'Neural bases of the non-conscious perception of emotional 
signals', Nat Rev Neurosci, 11(10), pp. 697-709. 
Taylor, J.P., Firbank, M., Barnett, N., Pearce, S., Livingstone, A., Mosimann, U., Eyre, J., McKeith, I.G. 
and O'Brien, J.T. (2011) 'Visual hallucinations in dementia with Lewy bodies: transcranial magnetic 
stimulation study', Br J Psychiatry, 199(6), pp. 492-500. 
Taylor, J.P., Firbank, M. and O'Brien, J.T. (2016) 'Visual cortical excitability in dementia with Lewy 
bodies', Br J Psychiatry, 208(5), pp. 497-8. 
Taylor, J.P., Firbank, M.J., He, J.B., Barnett, N., Pearce, S., Livingstone, A., Vuong, Q., McKeith, I.G. 
and O'Brien, J.T. (2012) 'Visual cortex in dementia with Lewy bodies: magnetic resonance imaging 
study', British Journal of Psychiatry, 200(6), pp. 491-498. 
211 
 
Teaktong, T., Piggott, M.A., McKeith, I.G., Perry, R.H., Ballard, C.G. and Perry, E.K. (2005) 'Muscarinic 
M2 and M4 receptors in anterior cingulate cortex: relation to neuropsychiatric symptoms in 
dementia with Lewy bodies', Behav Brain Res, 161(2), pp. 299-305. 
Terao, Y., Fukuda, H., Yugeta, A., Hikosaka, O., Nomura, Y., Segawa, M., Hanajima, R., Tsuji, S. and 
Ugawa, Y. (2011) 'Initiation and inhibitory control of saccades with the progression of Parkinson's 
disease - changes in three major drives converging on the superior colliculus', Neuropsychologia, 
49(7), pp. 1794-806. 
Thal, D.R., Rub, U., Orantes, M. and Braak, H. (2002) 'Phases of A beta-deposition in the human brain 
and its relevance for the development of AD', Neurology, 58(12), pp. 1791-1800. 
Tiraboschi, P., Hansen, L.A., Alford, M., Merdes, A., Masliah, E., Thal, L.J. and Corey-Bloom, J. (2002) 
'Early and widespread cholinergic losses differentiate dementia with Lewy bodies from Alzheimer 
disease', Arch Gen Psychiatry, 59(10), pp. 946-51. 
Tiraboschi, P., Salmon, D.P., Hansen, L.A., Hofstetter, R.C., Thal, L.J. and Corey-Bloom, J. (2006) 'What 
best differentiates Lewy body from Alzheimer's disease in early-stage dementia?', Brain, 129(Pt 3), 
pp. 729-35. 
Tofaris, G.K. and Spillantini, M.G. (2007) 'Physiological and pathological properties of alpha-
synuclein', Cell Mol Life Sci, 64(17), pp. 2194-201. 
Tosto, G., Monsell, S.E., Hawes, S.E., Bruno, G. and Mayeux, R. (2015) 'Progression of Extrapyramidal 
Signs in Alzheimer's Disease: Clinical and Neuropathological Correlates', J Alzheimers Dis, 49(4), pp. 
1085-93. 
Trick, G.L., Kaskie, B. and Steinman, S.B. (1994) 'Visual impairment in Parkinson's disease: deficits in 
orientation and motion discrimination', Optom Vis Sci, 71(4), pp. 242-5. 
Uchiyama, M., Nishio, Y., Yokoi, K., Hosokai, Y., Takeda, A. and Mori, E. (2015) 'Pareidolia in 
Parkinson's disease without dementia: A positron emission tomography study', Parkinsonism Relat 
Disord, 21(6), pp. 603-9. 
Ungerleider, L.G., Galkin, T.W., Desimone, R. and Gattass, R. (2014) 'Subcortical Projections of Area 
V2 in the Macaque', Journal of Cognitive Neuroscience, 26(6), pp. 1220-1233. 
Ungerleider LG, M.M. (1982) 'Two cortical visual streams', in Inge DJ, G.M.M.R. (ed.) Analysis of 
visual behaviour. Cambridge, MA: MIT Press,  pp. 549-586. 
United Nations. Department of, E. (2010) World population ageing 2009. United Nations Publications. 
Urwyler, P., Nef, T., Killen, A., Collerton, D., Thomas, A., Burn, D., McKeith, I. and Mosimann, U.P. 
(2014) 'Visual complaints and visual hallucinations in Parkinson's disease', Parkinsonism Relat Disord, 
20(3), pp. 318-22. 
Urwyler, P., Nef, T., Muri, R., Archibald, N., Makin, S.M., Collerton, D., Taylor, J.P., Burn, D., McKeith, 
I. and Mosimann, U.P. (2016) 'Visual Hallucinations in Eye Disease and Lewy Body Disease', Am J 
Geriatr Psychiatry, 24(5), pp. 350-8. 
van den Berge, S.A., Kevenaar, J.T., Sluijs, J.A. and Hol, E.M. (2012) 'Dementia in Parkinson's Disease 
Correlates with alpha-Synuclein Pathology but Not with Cortical Astrogliosis', Parkinsons Dis, 2012, p. 
420957. 
Vann Jones, S.A. and O'Brien, J.T. (2014) 'The prevalence and incidence of dementia with Lewy 
bodies: a systematic review of population and clinical studies', Psychol Med, 44(4), pp. 673-83. 
Vind, I., Johansen, J.S., Price, P.A. and Munkholm, P. (2003) 'Serum YKL-40, a potential new marker 
of disease activity in patients with inflammatory bowel disease', Scand J Gastroenterol, 38(6), pp. 
599-605. 
von Gunten, A., Kovari, E., Bussiere, T., Rivara, C.B., Gold, G., Bouras, C., Hof, P.R. and 
Giannakopoulos, P. (2006) 'Cognitive impact of neuronal pathology in the entorhinal cortex and CA1 
field in Alzheimer's disease', Neurobiol Aging, 27(2), pp. 270-7. 
Wakabayashi, K., Hayashi, S., Yoshimoto, M., Kudo, H. and Takahashi, H. (2000) 'NACP/α-synuclein-
positive filamentous inclusions in astrocytes and oligodendrocytes of Parkinson’s disease brains', 
Acta Neuropathologica, 99(1), pp. 14-20. 
212 
 
Wakabayashi, K., Yoshimoto, M., Fukushima, T., Koide, R., Horikawa, Y., Morita, T. and Takahashi, H. 
(1999) 'Widespread occurrence of alpha-synuclein/NACP-immunoreactive neuronal inclusions in 
juvenile and adult-onset Hallervorden-Spatz disease with Lewy bodies', Neuropathol Appl Neurobiol, 
25(5), pp. 363-8. 
Walker, M.P., Ayre, G.A., Cummings, J.L., Wesnes, K., McKeith, I.G., O'Brien, J.T. and Ballard, C.G. 
(2000a) 'The Clinician Assessment of Fluctuation and the One Day Fluctuation Assessment Scale. Two 
methods to assess fluctuating confusion in dementia', Br J Psychiatry, 177, pp. 252-6. 
Walker, M.P., Ayre, G.A., Cummings, J.L., Wesnes, K., McKeith, I.G., O'Brien, J.T. and Ballard, C.G. 
(2000b) 'Quantifying fluctuation in dementia with Lewy bodies, Alzheimer's disease, and vascular 
dementia', Neurology, 54(8), pp. 1616-25. 
Walker, Z., Costa, D.C., Janssen, A.G., Walker, R.W., Livingstone, G. and Katona, C.L. (1997) 
'Dementia with lewy bodies: a study of post-synaptic dopaminergic receptors with iodine-123 
iodobenzamide single-photon emission tomography', Eur J Nucl Med, 24(6), pp. 609-14. 
Walker, Z., McKeith, I., Rodda, J., Qassem, T., Tatsch, K., Booij, J., Darcourt, J. and O'Brien, J. (2012) 
'Comparison of cognitive decline between dementia with Lewy bodies and Alzheimer's disease: a 
cohort study', BMJ open, 2, p. e000380. 
Wallace, M.T., Meredith, M.A. and Stein, B.E. (1993) 'Converging influences from visual, auditory, 
and somatosensory cortices onto output neurons of the superior colliculus', J Neurophysiol, 69(6), pp. 
1797-809. 
Ward, R., Calder, A.J., Parker, M. and Arend, I. (2007) 'Emotion recognition following human pulvinar 
damage', Neuropsychologia, 45(8), pp. 1973-8. 
Ward, R., Danziger, S., Owen, V. and Rafal, R. (2002) 'Deficits in spatial coding and feature binding 
following damage to spatiotopic maps in the human pulvinar', Nat Neurosci, 5(2), pp. 99-100. 
Warren, N.M., Piggott, M.A., Lees, A.J. and Burn, D.J. (2007) 'Muscarinic receptors in the thalamus in 
progressive supranuclear palsy and other neurodegenerative disorders', J Neuropathol Exp Neurol, 
66(5), pp. 399-404. 
Washbourne, P., Thompson, P.M., Carta, M., Costa, E.T., Mathews, J.R., Lopez-Bendito, G., Molnar, Z., 
Becher, M.W., Valenzuela, C.F., Partridge, L.D. and Wilson, M.C. (2002) 'Genetic ablation of the t-
SNARE SNAP-25 distinguishes mechanisms of neuroexocytosis', Nat Neurosci, 5(1), pp. 19-26. 
Watson, R., Blamire, A.M., Colloby, S.J., Wood, J.S., Barber, R., He, J. and O'Brien, J.T. (2012) 
'Characterizing dementia with Lewy bodies by means of diffusion tensor imaging', Neurology, 79(9), 
pp. 906-14. 
Watson, R., Blamire, A.M. and O'Brien, J.T. (2009) 'Magnetic resonance imaging in lewy body 
dementias', Dement Geriatr Cogn Disord, 28(6), pp. 493-506. 
Weber, T., Zemelman, B.V., McNew, J.A., Westermann, B., Gmachl, M., Parlati, F., Sollner, T.H. and 
Rothman, J.E. (1998) 'SNAREpins: minimal machinery for membrane fusion', Cell, 92(6), pp. 759-72. 
Weddell, R.A. (2004) 'Subcortical modulation of spatial attention including evidence that the Sprague 
effect extends to man', Brain Cogn, 55(3), pp. 497-506. 
Wennstrom, M., Surova, Y., Hall, S., Nilsson, C., Minthon, L., Hansson, O. and Nielsen, H.M. (2015) 
'The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer's 
but Not Parkinson's Disease or Dementia with Lewy Bodies', PLoS One, 10(8), p. e0135458. 
Whitwell, J.L., Weigand, S.D., Shiung, M.M., Boeve, B.F., Ferman, T.J., Smith, G.E., Knopman, D.S., 
Petersen, R.C., Benarroch, E.E., Josephs, K.A. and Jack, C.R., Jr. (2007) 'Focal atrophy in dementia 
with Lewy bodies on MRI: a distinct pattern from Alzheimer's disease', Brain, 130(Pt 3), pp. 708-19. 
Wiley, C.A., Bonneh-Barkay, D., Dixon, C.E., Lesniak, A., Wang, G., Bissel, S.J. and Kochanek, P.M. 
(2015) 'Role for mammalian chitinase 3-like protein 1 in traumatic brain injury', Neuropathology, 
35(2), pp. 95-106. 
Wilke, M., Turchi, J., Smith, K., Mishkin, M. and Leopold, D.A. (2010) 'Pulvinar Inactivation Disrupts 
Selection of Movement Plans', Journal of Neuroscience, 30(25), pp. 8650-8659. 
Winner, B., Jappelli, R., Maji, S.K., Desplats, P.A., Boyer, L., Aigner, S., Hetzer, C., Loher, T., Vilar, M., 
Campioni, S., Tzitzilonis, C., Soragni, A., Jessberger, S., Mira, H., Consiglio, A., Pham, E., Masliah, E., 
213 
 
Gage, F.H. and Riek, R. (2011) 'In vivo demonstration that alpha-synuclein oligomers are toxic', Proc 
Natl Acad Sci U S A, 108(10), pp. 4194-9. 
Wolfe, J.M., Butcher, S.J., Lee, C. and Hyle, M. (2003) 'Changing your mind: on the contributions of 
top-down and bottom-up guidance in visual search for feature singletons', J Exp Psychol Hum 
Percept Perform, 29(2), pp. 483-502. 
Wong-Riley, M., Antuono, P., Ho, K.C., Egan, R., Hevner, R., Liebl, W., Huang, Z., Rachel, R. and Jones, 
J. (1997) 'Cytochrome oxidase in Alzheimer's disease: biochemical, histochemical, and 
immunohistochemical analyses of the visual and other systems', Vision Res, 37(24), pp. 3593-608. 
World Health, O. (2012) Dementia: a public health priority. World Health Organization. 
Wurtz, R.H., Joiner, W.M. and Berman, R.A. (2011) 'Neuronal mechanisms for visual stability: 
progress and problems', Philos Trans R Soc Lond B Biol Sci, 366(1564), pp. 492-503. 
Xiong, N., Long, X., Xiong, J., Jia, M., Chen, C., Huang, J., Ghoorah, D., Kong, X., Lin, Z. and Wang, T. 
(2012) 'Mitochondrial complex I inhibitor rotenone-induced toxicity and its potential mechanisms in 
Parkinson's disease models', Crit Rev Toxicol, 42(7), pp. 613-32. 
Xu, X., Ichida, J.M., Allison, J.D., Boyd, J.D., Bonds, A.B. and Casagrande, V.A. (2001) 'A comparison of 
koniocellular, magnocellular and parvocellular receptive field properties in the lateral geniculate 
nucleus of the owl monkey (Aotus trivirgatus)', J Physiol, 531(Pt 1), pp. 203-18. 
Xuereb, J.H., Perry, R.H., Candy, J.M., Perry, E.K., Marshall, E. and Bonham, J.R. (1991) 'Nerve cell loss 
in the thalamus in Alzheimer's disease and Parkinson's disease', Brain, 114 ( Pt 3), pp. 1363-79. 
Yamada, T., McGeer, P.L. and McGeer, E.G. (1992) 'Lewy bodies in Parkinson's disease are 
recognized by antibodies to complement proteins', Acta Neuropathol, 84(1), pp. 100-4. 
Yamamoto, R., Iseki, E., Marui, W., Togo, T., Katsuse, O., Kato, M., Isojima, D., Akatsu, H., Kosaka, K. 
and Arai, H. (2005) 'Non-uniformity in the regional pattern of Lewy pathology in brains of dementia 
with Lewy bodies', Neuropathology, 25(3), pp. 188-94. 
Yamamoto, R., Iseki, E., Murayama, N., Minegishi, M., Marui, W., Togo, T., Katsuse, O., Kato, M., 
Iwatsubo, T., Kosaka, K. and Arai, H. (2006) 'Investigation of Lewy pathology in the visual pathway of 
brains of dementia with Lewy bodies', J Neurol Sci, 246(1-2), pp. 95-101. 
Yamamoto, R., Iseki, E., Murayama, N., Minegishi, M., Marui, W., Togo, T., Katsuse, O., Kosaka, K., 
Kato, M., Iwatsubo, T. and Arai, H. (2007) 'Correlation in Lewy pathology between the claustrum and 
visual areas in brains of dementia with Lewy bodies', Neurosci Lett, 415(3), pp. 219-24. 
Yarnall, A.J., Breen, D.P., Duncan, G.W., Khoo, T.K., Coleman, S.Y., Firbank, M.J., Nombela, C., 
Winder-Rhodes, S., Evans, J.R., Rowe, J.B., Mollenhauer, B., Kruse, N., Hudson, G., Chinnery, P.F., 
O'Brien, J.T., Robbins, T.W., Wesnes, K., Brooks, D.J., Barker, R.A. and Burn, D.J. (2014) 
'Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE-PD study', 
Neurology, 82(4), pp. 308-16. 
Yee, R.D. (1983) 'Eye movement recording as a clinical tool', Ophthalmology, 90(3), pp. 211-22. 
Yi, H.A., Moller, C., Dieleman, N., Bouwman, F.H., Barkhof, F., Scheltens, P., van der Flier, W.M. and 
Vrenken, H. (2016) 'Relation between subcortical grey matter atrophy and conversion from mild 
cognitive impairment to Alzheimer's disease', J Neurol Neurosurg Psychiatry, 87(4), pp. 425-32. 
Yokota, O., Davidson, Y., Arai, T., Hasegawa, M., Akiyama, H., Ishizu, H., Terada, S., Sikkink, S., 
Pickering-Brown, S. and Mann, D.M. (2010) 'Effect of topographical distribution of alpha-synuclein 
pathology on TDP-43 accumulation in Lewy body disease', Acta Neuropathol, 120(6), pp. 789-801. 
Yoshizawa, H., Vonsattel, J.P. and Honig, L.S. (2013) 'Early neuropsychological discriminants for Lewy 
body disease: an autopsy series', J Neurol Neurosurg Psychiatry, 84(12), pp. 1326-30. 
Yu, J.X., Bradt, B.M. and Cooper, N.R. (2002) 'Constitutive expression of proinflammatory 
complement components by subsets of neurons in the central nervous system', J Neuroimmunol, 
123(1-2), pp. 91-101. 
Yucel, Y.H., Zhang, Q., Gupta, N., Kaufman, P.L. and Weinreb, R.N. (2000) 'Loss of neurons in 
magnocellular and parvocellular layers of the lateral geniculate nucleus in glaucoma', Arch 
Ophthalmol, 118(3), pp. 378-84. 
214 
 
Zahirovic, I., Wattmo, C., Torisson, G., Minthon, L. and Londos, E. (2016) 'Prevalence of Dementia 
With Lewy Body Symptoms: A Cross-Sectional Study in 40 Swedish Nursing Homes', J Am Med Dir 
Assoc. 
Zakharov, S.D., Hulleman, J.D., Dutseva, E.A., Antonenko, Y.N., Rochet, J.C. and Cramer, W.A. (2007) 
'Helical alpha-synuclein forms highly conductive ion channels', Biochemistry, 46(50), pp. 14369-79. 
Zhang, P., Zhou, H., Wen, W. and He, S. (2015) 'Layer-specific response properties of the human 
lateral geniculate nucleus and superior colliculus', Neuroimage, 111, pp. 159-66. 
Zhou, H., Schafer, R.J. and Desimone, R. (2016) 'Pulvinar-Cortex Interactions in Vision and Attention', 
Neuron, 89(1), pp. 209-20. 
Zhou, J., Fonseca, M.I., Pisalyaput, K. and Tenner, A.J. (2008) 'Complement C3 and C4 expression in 
C1q sufficient and deficient mouse models of Alzheimer's disease', J Neurochem, 106(5), pp. 2080-92. 
Zikou, A.K., Kitsos, G., Tzarouchi, L.C., Astrakas, L., Alexiou, G.A. and Argyropoulou, M.I. (2012) 
'Voxel-based morphometry and diffusion tensor imaging of the optic pathway in primary open-angle 
glaucoma: a preliminary study', AJNR Am J Neuroradiol, 33(1), pp. 128-34. 
Zinner-Feyerabend, M. and Braak, E. (1991) 'Glutamic acid decarboxylase (GAD)-immunoreactive 
structures in the adult human lateral geniculate nucleus', Anat Embryol (Berl), 183(2), pp. 111-7. 
 
 
 
 
